var title_f33_62_34784="Tenosynovial cyst puncture";
var content_f33_62_34784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Confirmation of a tenosynovial cyst by simple puncture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand is flat in a palm up position with the fingers extended. The point of entry is over the metacarpal head, proximal to the finger crease. Ethyl chloride is applied to the skin for anesthesia. A 5/8 inch, 25 gauge needle is inserted to a depth of 3/8 to 1/2 inch and 1/4 mL lidocaine is injected subcutaneously and at the flexor tendon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34784=[""].join("\n");
var outline_f33_62_34784=null;
var title_f33_62_34785="Anatomy of the ulnar nerve at the elbow";
var content_f33_62_34785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Anatomy of the ulnar nerve at the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the relationship between the ulnar nerve at the elbow and musculoskeletal anatomy. Note the position of the nerve relative to the medial epicondyle and the aponeurosis of the flexor carpi ulnaris which forms the roof of the true cubital tunnel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34785=[""].join("\n");
var outline_f33_62_34785=null;
var title_f33_62_34786="Langerhans histiocytosis skin 1";
var content_f33_62_34786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow-brown and erythematous papules, erosions, and crusts are present on this infant with Langerhans cell histiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34786=[""].join("\n");
var outline_f33_62_34786=null;
var title_f33_62_34787="Abdominal aortic aneurysm";
var content_f33_62_34787=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/62/34787/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34787/contributors\" id=\"au5205\">",
"       Emile R Mohler III, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/62/34787/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34787/contributors\" id=\"se3367\">",
"       John F Eidt, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34787/contributors\" id=\"se3365\">",
"       Joseph L Mills, Sr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/62/34787/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34787/contributors\" id=\"de2771\">",
"       Kathryn A Collins, MD, PhD, FACS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/62/34787?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ABDOMINAL AORTIC ANEURYSM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     An aortic aneurysm occurs when the walls of the main blood vessel that carries blood away from the heart (the aorta) bulge or dilate. An abdominal aortic aneurysm (AAA) is located in the abdominal area, near the navel (",
"     <a class=\"graphic graphic_figure graphicRef52216 \" href=\"mobipreview.htm?43/4/44098\">",
"      figure 1",
"     </a>",
"     ). Aneurysms can also occur in other areas of the aorta, but the abdomen is the most common site. Abdominal aortic aneurysms are",
"     <strong>",
"      not",
"     </strong>",
"     related to aneurysms of the blood vessels in the brain.",
"    </p>",
"    <p>",
"     Intact abdominal aortic aneurysms cause no health problems. However, large aneurysms can burst, or rupture, and cause heavy bleeding into the abdomen. A ruptured aortic aneurysm is a medical emergency requiring immediate treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ABDOMINAL AORTIC ANEURYSM RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Abdominal aortic aneurysms (AAA) are uncommon in people under the age of 60. About one person in 1000 develops an abdominal aortic aneurysm between the ages of 60 and 65, and this number continues to rise with age. Screening studies show that abdominal aortic aneurysms occur in 2 to 13 percent of men and 6 percent of women over the age of 65. However, almost 90 percent of the aneurysms identified by screening are small (less than 3.5 cm in diameter) and unlikely to burst.",
"    </p>",
"    <p>",
"     In addition to age, a number of other factors increase a person's risk of developing an abdominal aortic aneurysm:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Smoking markedly increases risk for AAA. The risk is directly related to number of years smoking and decreases in the years following smoking cessation.",
"      </li>",
"      <li>",
"       Men develop AAAs four to five times more often than women.",
"      </li>",
"      <li>",
"       People who are white develop aortic aneurysms more commonly than other groups.",
"      </li>",
"      <li>",
"       People with other medical conditions, such as coronary heart disease and peripheral vascular disease, are more likely to develop AAAs.",
"      </li>",
"      <li>",
"       A family history of abdominal aneurysm increases the risk of developing the condition and interacts with the risks associated with age and gender. The risk of developing an aneurysm among brothers of a person with a known aneurysm who are older than 60 years of age is as high as 18 percent.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Screening for AAA",
"     </span>",
"     &nbsp;&mdash;&nbsp;A screening test to determine if an AAA is present is recommended in certain groups of people [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/1\">",
"      1",
"     </a>",
"     ]. These recommendations are based upon the increased risk that older men, especially those who smoke or who have a family history of AAA, will develop an AAA.",
"    </p>",
"    <p>",
"     The test used most commonly to screen for AAA is abdominal ultrasonography. This test is painless and involves the use of a wand, which is applied to the abdomen and uses high frequency sound waves to create an image of the abdominal aorta; aneurysms or other abnormalities can be seen in the image.",
"    </p>",
"    <p>",
"     A screening test is recommended in the following groups:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Men who are ages 65 to 75 and who have ever smoked should be screened one time for AAA with abdominal ultrasonography. There is little benefit of repeat screening after a man has a single negative ultrasound. Men older than 75 are unlikely to benefit from screening.",
"      </li>",
"      <li>",
"       Men 60 years of age or older who have a sibling or parent with an AAA should have a physical examination and ultrasound screening.",
"      </li>",
"      <li>",
"       There is no recommendation to screen women for AAA. Women who are concerned about their risk of AAA, based upon their family history or other risk factors, should discuss their concerns with their healthcare provider.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ABDOMINAL AORTIC ANEURYSM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most abdominal aortic aneurysms are small and do not cause any symptoms. People without symptoms are usually unaware that they have an aneurysm.",
"    </p>",
"    <p>",
"     Some aneurysms cause a noticeable, small pulsating mass near the navel. This may not be noticed by the patient, but can be detected by a healthcare provider during a routine physical examination. Approximately 30 percent of asymptomatic abdominal aortic aneurysms are discovered in this manner. Other aneurysms are identified during imaging (ie, X-ray, ultrasound, CT scan, MRI) of the abdomen, done for other reasons.",
"    </p>",
"    <p>",
"     Some aneurysms can cause abdominal or back pain. Such aneurysms are typically detected during an evaluation for pain.",
"    </p>",
"    <p>",
"     Because blood can pool in the part of the aorta that is bulging, some people develop blood clots inside the aneurysm. If one of these clots breaks loose, it can end up clogging a blood vessel in one of the legs. This can lead to symptoms, such as pain, numbness, or tingling in the leg. In some cases, parts of the leg or foot may even turn pale and become cool to the touch.",
"    </p>",
"    <p>",
"     Most patients have little warning before rupture. Patients who develop abdominal pain or tenderness may have had a recent increase in aneurysm size, which may predict rupture.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ABDOMINAL AORTIC ANEURYSM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Approximately 15,000 deaths occur each year in the United States due to abdominal aortic aneurysms, usually because of rupture. Once rupture has occurred, the success rate of surgery is much lower than if surgery is performed electively, prior to rupture. The goal of therapy is to treat the aneurysm before rupture.",
"    </p>",
"    <p>",
"     Aneurysm repair is the primary treatment for aneurysms that are symptomatic or at a high risk for rupture. Repair, however, is associated with other risks and complications. The risk of elective repair must be balanced against the risk of complications or death from an untreated aneurysm. This decision requires understanding of the usual course in patients with untreated aneurysms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Risk of rupture",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of rupture of small aneurysms (smaller than 4.0 centimeters) is much less than the risk of rupture of large aneurysms (larger than 6.0 centimeters). In addition to size, the risk of rupture of an abdominal aortic aneurysm depends on the rate at which the aneurysm is expanding. The evidence suggests that aneurysms expand at an average rate of 0.3 to 0.4 centimeters per year (1 inch = 2.5 cm). The annual risk of rupture based upon aneurysm size is estimated as follows [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/2\">",
"      2",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Less than 4.0 cm in diameter = less than 0.5 percent",
"      </li>",
"      <li>",
"       Between 4.0 to 4.9 cm in diameter = 0.5 to 5 percent",
"      </li>",
"      <li>",
"       Between 5.0 to 5.9 cm in diameter = 3 to 15 percent",
"      </li>",
"      <li>",
"       Between 6.0 to 6.9 cm in diameter = 10 to 20 percent",
"      </li>",
"      <li>",
"       Between 7.0 to 7.9 cm in diameter = 20 to 40 percent",
"      </li>",
"      <li>",
"       Greater than or equal to 8.0 cm in diameter = 30 to 50 percent",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There can be significant variability in the rate of expansion, both from one patient to another and for a given patient from year to year. Many patients have long periods with little change in aneurysm size. Larger aneurysms tend to expand faster than smaller aneurysms.",
"    </p>",
"    <p>",
"     Aneurysms that expand rapidly (for example, more than 0.5 cm over six months) are at high risk of rupture. Growth tends to be more rapid in smokers, and less rapid in patients with peripheral artery disease or diabetes mellitus. Some aneurysms, for unclear reasons, remain relatively fixed in size for a period of time and then undergo rapid expansion. The risk of rupture of large aneurysms (&ge;5.0 cm) is significantly greater in women than men (18 versus 12 percent) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17517630\">",
"     <span class=\"h2\">",
"      Other aneurysm complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other complications of abdominal aortic aneurysm are less common and not as well recognized. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Inflammatory aneurysm, swelling and inflammation of the aneurysm wall that causes abdominal pain",
"      </li>",
"      <li>",
"       Aorto-venous fistula, an abnormal connection between the aorta and a vein",
"      </li>",
"      <li>",
"       Primary aortoenteric fistula, an abnormal connection between the aorta and the bowel",
"      </li>",
"      <li>",
"       Thromboembolism, blood clots or debris from the AAA that block blood flow to the legs [",
"       <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/4\">",
"        4",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Infected aneurysm",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These complications can be limb- and life-threatening, and, when diagnosed, indicate the need for repair.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      General treatment principles",
"     </span>",
"     &nbsp;&mdash;&nbsp;In all cases, the decision about whether and when to repair an asymptomatic aneurysm is based upon the risks associated with the aneurysm itself and the risks associated with the repair [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/5\">",
"      5",
"     </a>",
"     ]. Most people with an aneurysm less than 4.0 cm (1.6 inches) in diameter are advised not to have immediate surgery, but rather to follow the aneurysm over time; this is known as watchful waiting. Usually, this involves an ultrasound examination of the abdomen every six months to 3 years, depending on the size of the aneurysm. (See",
"     <a class=\"local\" href=\"#H256213461\">",
"      'Medical treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     On the other hand, most patients with an asymptomatic aneurysm greater than 5.5 cm (2.2 inches) in diameter or that expands more than 0.5 cm over a six-month period are advised to have repair. Repair may also be recommended for people with aneurysms that are greater than twice the size of a normal portion of the aorta.",
"    </p>",
"    <p>",
"     People with an aneurysm between 4.0 and 5.5 cm should discuss their options with a physician. The best approach will depend upon the risk of repair and the risk of aneurysm rupture in an individual patient. Features influencing this decision include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The size and rate of growth of the aneurysm.",
"      </li>",
"      <li>",
"       The development of symptoms. Patients with aneurysms that become tender to touch or are associated with abdominal or back pain may be advised to have repair even if rupture cannot be demonstrated. Other symptoms that develop that have no other cause and could be related to the aneurysm could be another reason why repair would be recommended.",
"      </li>",
"      <li>",
"       The presence of other aneurysms. Patients with aneurysms in other large arteries (such as the iliac, femoral or popliteal arteries of the leg) should have their abdominal aneurysm repaired, usually before, but sometimes at the same time as these other aneurysms.",
"      </li>",
"      <li>",
"       Surgical risk. The risk of surgery varies for each individual and the magnitude of risk may be estimated. Patients whose surgical risk is estimated to be high may do better with watchful waiting or less invasive aneurysm repair (see",
"       <a class=\"local\" href=\"#H17517696\">",
"        'Surgical risk'",
"       </a>",
"       below and",
"       <a class=\"local\" href=\"#H256213461\">",
"        'Medical treatment'",
"       </a>",
"       below and",
"       <a class=\"local\" href=\"#H17517760\">",
"        'Endovascular stent graft'",
"       </a>",
"       below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H256213461\">",
"     <span class=\"h2\">",
"      Medical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Small abdominal aortic aneurysms that are not expanding quickly are usually left alone and watched for changes in size, most often by ultrasound examination of the abdomen every six months. A small aneurysm that grows to be 5.5 cm or larger, or that expands more than 0.5 cm over a six-month period of time should probably be repaired surgically, if possible. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Surgical repair'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Patients being followed with ultrasound, those awaiting repair, or those who have an abdominal aortic aneurysm but whose doctor feels that surgery is too risky, are watched carefully and their medical problems carefully managed. Blood pressure is carefully controlled, and cigarette smoking should be stopped. Also, a medication called a beta blocker may be recommended to slow the rate of aneurysm growth. At least one clinical study showed that people who took beta blockers had a slower rate of growth of their AAA compared with people who took a placebo (0.36 versus 0.68 cm per year) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Patients should call their doctor if they develop abdominal tenderness or back pain. These symptoms may be signs of impending rupture.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Surgical repair",
"     </span>",
"     &nbsp;&mdash;&nbsp;Abdominal aortic aneurysms can be repaired either through &ldquo;open surgery&rdquo; or with the use of an &ldquo;endovascular stent graft&rdquo; (See",
"     <a class=\"local\" href=\"#H17517684\">",
"      'Open surgery'",
"     </a>",
"     below and",
"     <a class=\"local\" href=\"#H17517760\">",
"      'Endovascular stent graft'",
"     </a>",
"     below.) (",
"     <a class=\"graphic graphic_figure graphicRef57520 \" href=\"mobipreview.htm?33/0/33797\">",
"      figure 2",
"     </a>",
"     ). Repair of the aneurysm is recommended if it:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Causes symptoms,",
"      </li>",
"      <li>",
"       Is larger than 5.5 cm (2.2 inches) in diameter,",
"      </li>",
"      <li>",
"       Is rapidly expanding, or",
"      </li>",
"      <li>",
"       Occurs along with aneurysms in the iliac, femoral or popliteal arteries.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17517696\">",
"     <span class=\"h3\">",
"      Surgical risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery of any kind carries certain risks that vary from one person to another, depending upon the patient's general state of health. The surgical risk for repair of an abdominal aortic aneurysm increases with age and the presence of other health conditions. As examples, people who have other heart or lung diseases, and people who smoke are more likely to develop complications such as pneumonia and irregularities in their heart rates after surgery. In addition, older adults are more prone to develop problems (such as cardiac events and stroke) both during and after surgery.",
"    </p>",
"    <p>",
"     Coronary artery disease is common in people who have abdominal aortic aneurysms. If there are other risk factors for heart disease (such as smoking, diabetes, high blood pressure), the doctor may recommend an evaluation of the heart prior to considering aneurysm surgery. This evaluation may range from a simple exercise stress test to heart catheterization.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17517684\">",
"     <span class=\"h3\">",
"      Open surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Open surgical correction of an abdominal aortic aneurysm involves removing the section of the abdominal aorta that is dilated and replacing it with a prosthesis made of synthetic material (also known as a graft) that is sutured into place (",
"     <a class=\"graphic graphic_figure graphicRef57520 \" href=\"mobipreview.htm?33/0/33797\">",
"      figure 2",
"     </a>",
"     ). This will allow blood to flow normally and the artery wall is used to cover the graft. Planned or elective surgery reduces the risk of rupture of large asymptomatic abdominal aortic aneurysms, and graft failure is uncommon.",
"    </p>",
"    <p>",
"     Surgery is done in an operating room while the patient is under general anesthesia, and generally takes four to six hours. After surgery, a patient is taken to the intensive care unit for monitoring. Several catheters are used, including a urinary catheter (to drain the bladder), an arterial catheter (to monitor blood pressure), a central venous catheter (to monitor pressures in the heart), an epidural catheter (to give pain medicine), and a nasogastric tube (a tube from the stomach to the nose that is initially used to keep the stomach empty). Patients are generally able to go home after four to seven days, and are able to resume normal activities in about four weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17517760\">",
"     <span class=\"h3\">",
"      Endovascular stent graft",
"     </span>",
"     &nbsp;&mdash;&nbsp;A less invasive surgical procedure called an endovascular stent graft has shown success in repairing AAAs. It involves making an incision in the groin to expose the femoral artery, placing a wire in the vessel over which a variety of specialized catheters are used to pass a folded graft to the area of the aneurysm (",
"     <a class=\"graphic graphic_figure graphicRef57520 \" href=\"mobipreview.htm?33/0/33797\">",
"      figure 2",
"     </a>",
"     ). Dye is injected to guide the placement of a stent-graft device into the area of the aneurysm. Once the device is correctly positioned, the stent graft is unfolded and expanded with a balloon that pushes it up against the normal aortic wall. This type of graft is not sewn into place. Blood flows through the graft instead of the abnormally dilated aorta, which decreases the pulsations on the aortic wall.",
"    </p>",
"    <p>",
"     There is less experience and fewer data regarding endovascular stent grafts than surgery, and long-term outcomes are being studied. Stent grafts are primarily performed in older patients who have medical conditions that increase their risk for conventional open surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17517778\">",
"     <span class=\"h3\">",
"      Comparing two methods of repair",
"     </span>",
"     &nbsp;&mdash;&nbsp;Open surgery is a little riskier in the short term, but it fixes the problem for good. Endovascular repair is less risky in the short term, but it needs to be carefully followed. That&rsquo;s because endovascular grafts sometimes slip out of place causing an endoleak or kinking the graft. Fixing these problems usually involves a simpler procedure than the first one. If your doctor offers you a choice between the two options, ask:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       What are the risks of each procedure for me?",
"      </li>",
"      <li>",
"       What kind of follow-up will I need with each option?",
"      </li>",
"      <li>",
"       What is likely to happen if I do not have either treatment?",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     Most people with abdominal aortic aneurysms live healthy, symptom-free lives. The decision to undergo surgery involves weighing the risk of aneurysm rupture versus the risks of a surgical procedure. While some general guidelines are suggested based upon the aneurysm size and the rate at which it is enlarging, each treatment decision should be made on an individual basis. Patients should discuss their individual risk of surgery with an experienced healthcare provider to make an informed decision.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24482064\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24482072\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/39/22130?source=see_link\">",
"      Patient information: Abdominal aortic aneurysm (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/38/30307?source=see_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24482080\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=see_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Society for Vascular Surgery",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.vascularweb.org/vascularhealth/Pages/abdominal-aortic-aneurysm.aspx\">",
"        www.vascularweb.org/vascularhealth/Pages/abdominal-aortic-aneurysm.aspx",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Vascular Disease Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.vdf.org/\">",
"        vdf.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"        www.nhlbi.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Heart Association",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.americanheart.org/\">",
"        www.americanheart.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/62/34787/abstract/2,3,5-14\">",
"      2,3,5-14",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/62/34787?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/1\">",
"      U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: recommendation statement. Ann Intern Med 2005; 142:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/2\">",
"      Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg 2003; 37:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/3\">",
"      Norman PE, Powell JT. Abdominal aortic aneurysm: the prognosis in women is worse than in men. Circulation 2007; 115:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/4\">",
"      Bower TC, Cherry KJ Jr, Pairolero PC. Unusual manifestations of abdominal aortic aneurysms. Surg Clin North Am 1989; 69:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/5\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/6\">",
"      Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg 1994; 19:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/7\">",
"      United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/8\">",
"      Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 1998; 352:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/9\">",
"      Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med 1989; 321:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/10\">",
"      Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/11\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/12\">",
"      Newman AB, Arnold AM, Burke GL, et al. Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: the cardiovascular health study. Ann Intern Med 2001; 134:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/13\">",
"      Lederle FA, Simel DL. The rational clinical examination. Does this patient have abdominal aortic aneurysm? . JAMA 1999; 281:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34787/abstract/14\">",
"      Salo JA, Soisalon-Soininen S, Bondestam S, Mattila PS. Familial occurrence of abdominal aortic aneurysm. Ann Intern Med 1999; 130:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_62_34787=[""].join("\n");
var outline_f33_62_34787=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ABDOMINAL AORTIC ANEURYSM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ABDOMINAL AORTIC ANEURYSM RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ABDOMINAL AORTIC ANEURYSM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ABDOMINAL AORTIC ANEURYSM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/4/44098\" title=\"figure 1\">",
"           Abdominal aortic aneurysm anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/0/33797\" title=\"figure 2\">",
"           Abdominal aortic aneurysm repair PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34788="Pyrazinamide: An overview";
var content_f33_62_34788=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pyrazinamide: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34788/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34788/contributors\">",
"     Richard H Drew, PharmD, MS, BCPS, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34788/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34788/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34788/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34788/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/62/34788/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     Pyrazinamide",
"    </a>",
"    (PZA) is an antimicrobial agent that is most commonly used for treatment of active tuberculosis (TB) during the initial phase of therapy (generally the first two months of treatment), in combination with other agents. The spectrum of PZA is relatively narrow; it demonstrates clinically significant antibacterial activity only against Mycobacterium tuberculosis and M. africanum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to the clinical use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    will be reviewed here. Issues related to treatment of latent and active TB are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parent compound is metabolized via pyrazinamidase (PZase) to pyrazinoic acid; pyrazinoic acid is the active form of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/2\">",
"     2",
"    </a>",
"    ]. The mechanism of action for PZA is unknown. PZA and its analog, 5-chloro-PZA, may inhibit the fatty acid synthetase I (FASI) enzyme of M. tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. PZA is generally considered to be a bacteriostatic agent.",
"   </p>",
"   <p>",
"    PZA thought to be more active at an acidic pH (eg, within macrophages) and against dormant or semidormant microorganisms, although the role of PZA against intracellular organisms remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/5\">",
"     5",
"    </a>",
"    ]. In one study, pyrazinoic acid remained outside of M. tuberculosis cells at a neutral or alkaline pH but accumulated within cells at an acidic pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/6\">",
"     6",
"    </a>",
"    ]. In the same study, M. smegmatis (which is not susceptible to PZA) was found to convert PZA to pyrazinoic acid but due to an active efflux mechanism did to accumulate the metabolite, even at an acidic pH. Other mycobacterial strains appear to have natural resistance to PZA due to lack of PZase activity or absence of transport mechanisms to take up the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When used as part of combination therapy, PZA appears to accelerate the sterilizing effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/1\">",
"     1",
"    </a>",
"    ]. In selected populations this has enabled reduction in the duration of treatment infection due to susceptible M. tuberculosis isolates from nine to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;PZA is not used as monotherapy in the treatment of M. tuberculosis because of the rapid development of resistance to the drug. The major mechanism of resistance to PZA arises from mutations in the gene encoding PZase, pncA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/7\">",
"     7",
"    </a>",
"    ]. A number of different mutations in this gene have been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Resistance to PZA is seen most frequently in patients with multidrug-resistant TB (MDR-TB).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absorption of PZA is thought to be complete after oral administration, with peak serum concentrations achieved within one to two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. Relatively small changes in absorption are demonstrated when PZA is taken with meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/11\">",
"     11",
"    </a>",
"    ]. Serum concentrations have been reported to range from 30 to 50",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    after a 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PZA is thought to be widely distributed in many body tissues and fluids, with a volume of distribution estimated to be 0.6 to 0.7",
"    <span class=\"nowrap\">",
"     L/kg.",
"    </span>",
"    Intrapulmonary concentrations of PZA are high (4 to 40 times the reported MIC for PZA-susceptible strains in one study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/12\">",
"     12",
"    </a>",
"    ]. PZA distributes well into the cerebrospinal fluid, with concentrations reported to be similar to those observed in simultaneous serum samples. Intracellular PZA concentrations are similar to those of extracellular fluids. Children appear to have a larger volume of distribution and a slower absorption and clearance of PZA than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PZA undergoes extensive hepatic metabolism. Approximately 70 percent of the dose is excreted in the urine in the form of metabolites. The half-life is approximately 9 to 10 hours in patients with normal renal and hepatic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/1\">",
"     1",
"    </a>",
"    ]. The drug and its metabolites are removed by hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DOSING AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily doses are 15 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (up to a maximum of 2",
"    <span class=\"nowrap\">",
"     g/d)",
"    </span>",
"    in children and 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in adults (maximum of 2",
"    <span class=\"nowrap\">",
"     g/d)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef50514 \" href=\"mobipreview.htm?30/12/30923\">",
"     table 1",
"    </a>",
"    ). Intermittent dosing is performed as part of directly observed therapy (DOT). Adult DOT regimens consist of either 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 4",
"    <span class=\"nowrap\">",
"     g/dose)",
"    </span>",
"    twice weekly or 35 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 3",
"    <span class=\"nowrap\">",
"     g/dose)",
"    </span>",
"    three times per week (",
"    <a class=\"graphic graphic_table graphicRef50514 \" href=\"mobipreview.htm?30/12/30923\">",
"     table 1",
"    </a>",
"    ). Pediatric DOT consists of 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum of 2",
"    <span class=\"nowrap\">",
"     g/dose)",
"    </span>",
"    twice weekly&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small reductions in peak serum concentrations can be avoided by giving PZA in the fasting state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/11\">",
"     11",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;PZA dosing requires adjustment in patients with severe renal insufficiency. In patients with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or in patients with end-stage renal disease requiring hemodialysis, 25 to 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose should be administered three times a week after dialysis. Since PZA and pyrazinoic acid are removed by hemodialysis, doses should be administered after dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/16\">",
"     16",
"    </a>",
"    ]. PZA increases the risk of hyperuricemia in patients with renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Liver dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose adjustment may be required in patients with hepatic dysfunction, though there are no published guidelines available for administration of PZA to patients with significant liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most clinically significant adverse events associated with PZA administration are hepatotoxicity, gastrointestinal intolerance, nongouty polyarthralgias, and asymptomatic hyperuricemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity due to PZA can manifest as elevated aspartate aminotransferase (AST) concentration, jaundice, and liver tenderness. Hepatotoxicity appears to be dose-related and is infrequent at daily doses of &le;25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Prior liver disease, age over 60 years, and concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    appear to increase risk for development of hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Some reports have suggested that PZA may also potentiate hepatotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyrazinoic acid, the active metabolite of PZA, competes with uric acid for elimination via the kidneys, resulting in asymptomatic hyperuricemia and exacerbations of gout in susceptible individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/19\">",
"     19",
"    </a>",
"    ]. Gastrointestinal intolerance may result in nausea and vomiting. Dermatologic (maculopapular rash, urticaria, photosensitivity) and hematologic (thrombocytopenia, sideroblastic anemia) side effects have been described but are relatively rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving PZA (in combination with other antituberculous agents) should undergo baseline assessment and periodic monitoring of liver function. Serum uric acid measurements may be obtained in individuals who have a history of gout, who are receiving concomitant medications that alter uric acid excretion (such as loop diuretics), or who are at increased risk for hyperuricemia due to underlying renal dysfunction.",
"   </p>",
"   <p>",
"    PZA serum concentration monitoring is not routinely performed. However, a proposed therapeutic range two hours following administration has been reported to be 20 to 60",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34788/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    has been associated with severe and fatal hepatotoxic reactions. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     \"Pyrazinamide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2780382\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"       Pyrazinamide",
"      </a>",
"      (PZA) is an antimicrobial agent used for treatment of active tuberculosis (TB) during the initial phase of therapy (generally the first two months of treatment), in combination with other agents. PZA is not used as monotherapy in the treatment of M. tuberculosis because of rapid development of resistance to the drug. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of action for PZA is not fully understood; it may inhibit the fatty acid synthetase I enzyme of M. tuberculosis. PZA thought to be more active in acidic environments (eg, within macrophages). When administered as part of combination therapy PZA appears to accelerate the sterilizing effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PZA is thought to be widely distributed in many body tissues and fluids. Intrapulmonary concentrations of PZA are high. PZA also distributes well into the cerebrospinal fluid. PZA undergoes extensive hepatic metabolism; approximately 70 percent of the dose is excreted in the urine in the form of metabolites. The half-life is approximately 9 to 10 hours in patients with normal renal and hepatic function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dosing is summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef50514 \" href=\"mobipreview.htm?30/12/30923\">",
"       table 1",
"      </a>",
"      ). PZA dosing requires adjustment in patients with severe renal insufficiency and may also be required in patients with hepatic dysfunction. For patients on hemodialysis the PZA should be administered after dialysis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects associated with PZA administration include hepatotoxicity, gastrointestinal intolerance, nongouty polyarthralgias, and asymptomatic hyperuricemia. PZA increases the risk of hyperuricemia most commonly in the setting of renal insufficiency or with the use of concomitant medications, which decrease uric acid excretion. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving PZA should undergo baseline assessment and periodic monitoring of liver function. Serum uric acid measurements may be obtained in individuals who have a history of gout, who are receiving concomitant medications that decrease uric acid excretion (such as loop diuretics), or who are at increased risk for hyperuricemia due to underlying renal dysfunction. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Heifets L. Antimycobacterial agents: Pyrazinamide. In: Antimicrobial Therapy and Vaccines, Yu VL, Merigan TC, Barriere SL (Eds), Williams and Wilkins, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/2\">",
"      Raynaud C, Lan&eacute;elle MA, Senaratne RH, et al. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999; 145 ( Pt 6):1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/3\">",
"      Zimhony O, Cox JS, Welch JT, et al. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000; 6:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/4\">",
"      Ngo SC, Zimhony O, Chung WJ, et al. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob Agents Chemother 2007; 51:2430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/5\">",
"      Heifets L, Higgins M, Simon B. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 2000; 4:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/6\">",
"      Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999; 181:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/7\">",
"      Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/8\">",
"      Sachais BS, Nachamkindagger I I, Mills JK, Leonard DG. Novel pncA Mutations in Pyrazinamide-Resistant Isolates of Mycobacterium tuberculosis. Mol Diagn 1998; 3:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/9\">",
"      Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 1999; 43:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/10\">",
"      Marttila HJ, Marjam&auml;ki M, Vyshnevskaya E, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 1999; 43:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/11\">",
"      Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998; 18:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/12\">",
"      Conte JE Jr, Golden JA, Duncan S, et al. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 1999; 43:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/13\">",
"      Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis 1999; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/14\">",
"      Malone RS, Fish DN, Spiegel DM, et al. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999; 159:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/15\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/17\">",
"      Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/18\">",
"      Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/19\">",
"      Koumbaniou C, Nicopoulos C, Vassiliou M, et al. Is pyrazinamide really the third drug of choice in the treatment of tuberculosis? Int J Tuberc Lung Dis 1998; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     Campbell R, James C. National Tuberculosis Curriculum Consortium TB Drug Reference Sheet. National Heart, Lung &amp; Blood Institute, San Diego. file://ntcc.ucsd.edu/TB.drug.reference.sheet_final2007.pdf (Accessed on October 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34788/abstract/21\">",
"      Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 492 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34788=[""].join("\n");
var outline_f33_62_34788=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2780382\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DOSING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Liver dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2780382\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/12/30923\" title=\"table 1\">",
"      Pyrazinamide weight based dosing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=related_link\">",
"      Pyrazinamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34789="PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis";
var content_f33_62_34789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34789/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34789/contributors\">",
"     Angela M Caliendo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34789/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34789/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34789/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34789/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/62/34789/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although encephalitis is a rare complication of herpes simplex virus (HSV) infection, HSV is the most common cause of nonepidemic, sporadic, acute focal encephalitis in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The estimated frequency of HSV encephalitis (HSE) is between 1:250,000 and 1:500,000 persons per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/1\">",
"     1",
"    </a>",
"    ]. The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    reduces the mortality from approximately 70 percent in untreated infection to 19 to 28 percent; however, neurologic impairment is common (44 to 62 percent) in those who survive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link&amp;anchor=H19#H19\">",
"     \"Herpes simplex virus type 1 encephalitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the severity of the illness and the availability of effective therapy, there is a need for a rapid and accurate diagnostic test for HSV encephalitis (HSE). In adults, the infection is usually caused by HSV type 1 and may be due to primary infection or reactivation of latent infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal HSV infection occurs in 1:3500 to 1:5000 deliveries in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/2\">",
"     2",
"    </a>",
"    ]. It is usually acquired by intrapartum contact with infected maternal genital secretions, and is therefore most often due to HSV type 2. There are three general presentations of the disease: skin, eye, and mouth (45 percent); encephalitis (35 percent); and disseminated disease (20 percent), which is often associated with central nervous system (CNS) involvement. Thus, CNS disease occurs in approximately 50 percent of babies with neonatal HSV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STANDARD DIAGNOSTIC METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation does not distinguish HSE from encephalitis caused by other viruses such as St. Louis (flavivirus), Eastern equine (togavirus), and Epstein-Barr virus (EBV), or from Mycobacterium tuberculosis meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38968?source=see_link\">",
"     \"Viral encephalitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38023?source=see_link\">",
"     \"St. Louis encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Culture of HSV from the cerebrospinal fluid (CSF) of adults with HSE has a sensitivity of less than 10 percent. Better results are obtained with tests that measure HSV antigens or antibodies in the CSF; these tests are associated with sensitivity and specificity rates of 75 to 85 percent and 60 to 90 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"gold standard\" for the diagnosis of HSE has been brain biopsy, with identification of HSV in the tissue by cell culture or immunohistochemical staining. Although brain biopsy has a sensitivity of 99 percent and a specificity of 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/2\">",
"     2",
"    </a>",
"    ], it requires an invasive procedure, and the results may not be available for several days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these limitations, CSF polymerase chain reaction (PCR) testing has been evaluated as a diagnostic test for HSE. It is rapid and associated with a very high sensitivity and specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POLYMERASE CHAIN REACTION CLINICAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two largest studies compared CSF PCR to either brain biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] or intrathecal HSV antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/6\">",
"     6",
"    </a>",
"    ] in patients with suspected HSE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, 42 of 43 patients with biopsy-proven HSV encephalitis had CSF positive for HSV-1 DNA by PCR (all but one on the first CSF sample), while the CSF from 60 patients with non-HSV acute febrile focal encephalopathy were negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/6\">",
"       6",
"      </a>",
"      ]. The one false negative test occurred in a patient who had been treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      . PCR remained positive for as long as 27 days after the onset of symptoms.",
"     </li>",
"     <li>",
"      The second study compared PCR to brain biopsy in specimens from both HSV culture-positive and negative specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/7\">",
"       7",
"      </a>",
"      ]. HSV DNA was detected in the CSF in 53 of 54 patients (98 percent) with biopsy-proven HSV encephalitis compared with 3 of 47 patients (6 percent) whose brain tissue was culture-negative. Sensitivity was 98 percent and specificity was 94 percent. The three presumptive false-positive tests occurred when the site of the brain disease was not properly sampled or the brain tissue was not properly cultured; thus, the specificity of HSV PCR may approach 100 percent for the diagnosis of HSE. The sensitivity of the PCR assay was not significantly decreased until after the patient received greater than seven days of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PCR is positive early in the course of the illness (within the first 24 hours of onset of symptoms) and remains positive during the first week of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/8\">",
"     8",
"    </a>",
"    ]. In some cases, viral genomes persist in the CSF for two weeks or longer after the onset of antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR is also useful for the diagnosis of neonatal HSV infection. In one series, HSV DNA was detected in the CSF in 26 of 34 (76 percent) infants with CNS disease, 13 of 14 (94 percent) with disseminated infection, and 7 of 29 (24 percent) with skin, eye, or mouth involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/9\">",
"     9",
"    </a>",
"    ]. One of the seven patients in the last group subsequently developed severe neurologic impairment.",
"   </p>",
"   <p>",
"    Based upon these results, detection of HSV DNA in CSF by PCR has become the standard for the diagnosis of HSE and neonatal HSV infection involving the CNS. The primer pairs used in these studies identified HSV types 1 and 2 and did not cross react with other herpesviruses including cytomegalovirus (CMV), varicella-zoster virus (VZV), human herpesvirus-6, and EBV.",
"   </p>",
"   <p>",
"    The persistence of HSV DNA in the CSF of newborns for greater than one week after initiating therapy is associated with a poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specimen collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most HSV PCR assays require between 0.5 and 1 mL of CSF. An evaluation of the stability of HSV DNA in CSF containing lymphocytes and monocytes revealed little degradation of HSV DNA in specimens that were stored for 30 days at room temperature (20 to 23&ordm;C), refrigerated (2 to 8&ordm;C), or frozen (-20 to -70&ordm;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/11\">",
"     11",
"    </a>",
"    ]. Specimens can be transported at room temperature, although refrigeration or freezing may be recommended by reference laboratories. Specimens are stored refrigerated or frozen until the testing is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interpretation of the results",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV PCR results should be interpreted cautiously since neither the sensitivity nor specificity of the test is 100 percent. The test results should always be interpreted within the context of the clinical presentation of the patient. If testing results do not correlate with the clinical impression, repeat testing should be performed. As noted above, the sensitivity of the HSV PCR assay is not significantly decreased until after seven days of therapy.",
"   </p>",
"   <p>",
"    False-negative HSV PCR results may be due to low sensitivity of a particular assay. There is no standardized assay; rather most laboratories develop their own \"in-house\" testing. As a result, assay sensitivity may vary among laboratories. The presence of substances in the CSF that inhibit amplification (for example, blood) may also lead to false negative results. Thus, the assay should include a method to remove inhibitory substances from the CSF specimen or include an inhibition control for each specimen.",
"   </p>",
"   <p>",
"    One study has shown that neurologic disease with HSV is rarely seen in individuals with a normal CSF white blood cell count and protein concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/12\">",
"     12",
"    </a>",
"    ]. However, caution should be exercised in applying this generalization to immunocompromised patients as they may not mount a typical inflammatory response to HSV infection. One study validated that restricting HSV testing to samples that met criteria based on CSF values (white blood cell count of &gt;5",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or protein level &gt;50",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or host criteria (age &lt;2 years, HIV infection, or history of transplantation) was cost-effective and did not result in any missed HSV diagnoses. Two of the rejected specimens tested positive for HSV-2 DNA, but both met acceptance criteria, which had not been communicated to the laboratory. Successful implementation of a screening program requires good communication between clinicians and the laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False-positive HSV PCR results are most commonly due to contamination from carryover of amplified product or cross-contamination during specimen processing. Laboratories performing PCR should follow strict methods to minimize this risk. The use of real-time PCR testing has greatly reduced the risk of contamination due to carryover of amplified product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Availability of the test",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no commercial HSV PCR assays that have been cleared by the Food and Drug Administration (FDA). When choosing a reference laboratory that uses an HSV PCR assay that was developed in that laboratory, physicians should inquire about assay sensitivity, specificity, and the use of inhibition controls. Testing should be performed using a primer pair that detects HSV types 1 and 2 with equal sensitivity. The cost of the test varies among laboratories but usually ranges from $75 to $200.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HSV MENINGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV can cause aseptic meningitis, usually a self-limited disease that resolves without specific therapy; in a small subset of patients HSV can lead to recurrent lymphocytic meningitis over a period of many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. In adults, HSV-associated meningitis is usually caused by HSV type 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/2,14,15\">",
"     2,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on data demonstrating the relative performance characteristics of PCR testing compared with brain biopsy and culture in patients with encephalitis, and other data in patients with genital ulcerative disease, PCR testing is also the preferred diagnostic test of choice in patients with suspected HSV-2-associated meningitis. It is estimated that CSF viral culture has a sensitivity of only 50 percent in patients with HSV meningitis. Culture-based techniques for HSV meningitis may have low sensitivity because HSV DNA levels are generally lower among patients with clinical meningitis than encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/16\">",
"     16",
"    </a>",
"    ]. The clinical diagnosis may also be somewhat elusive since many patients do not have genital lesions at the time of presentation, particularly in the setting of recurrent meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, the absence of genital lesions should not deter the clinician from testing for HSV-2 infection in a patient with aseptic meningitis.",
"   </p>",
"   <p>",
"    PCR testing is recommended by the Centers for Disease Control for suspected HSV meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/19\">",
"     19",
"    </a>",
"    ], although data on the sensitivity and specificity of this diagnostic method in this setting are not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. One study assessed the etiology of aseptic meningitis in 144 patients using a comprehensive diagnostic approach using cultures, serology, and PCR testing on multiples specimens (eg, blood, CSF, urine, throat) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34789/abstract/17\">",
"     17",
"    </a>",
"    ]. An etiologic agent was identified in 66 percent of patients; the most common pathogen was enterovirus followed by HSV-2, as detected on PCR. However, none of these patients had confirmation of their diagnosis through culture, blood serologies, or detection of intrathecal antibody production; there were also no data on the clinical presentation. Thus, the sensitivity and specificity of PCR cannot be inferred from these data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19625151\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although encephalitis is a rare complication of herpes simplex virus (HSV) infection, HSV is the most common cause of nonepidemic, sporadic, acute focal encephalitis in the United States. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the wide availability of molecular testing methodology, brain biopsy was considered the \"gold standard\" for the diagnosis of herpes simplex virus encephalitis; HSV was identified in tissue by cell culture or immunohistochemical staining. Although brain biopsy has a sensitivity of 99 percent and a specificity of 100 percent, it remains an invasive procedure and the results may not be available for several days. Culture and serologic techniques are not good alternatives because they have lower sensitivity and specificity than brain biopsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Standard diagnostic methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymerase chain reaction (PCR) testing on cerebral spinal fluid offers rapid results with high sensitivity and specificity of 98 and 94 percent, respectively, when compared with brain biopsy specimens. Detection of HSV DNA in CSF by PCR has become the standard for the diagnosis of herpes simplex virus encephalitis in adults and neonates. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Polymerase chain reaction clinical studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCR testing is positive early in the course of the illness (within the first 24 hours of onset of symptoms) and remains positive during the first week of antiviral therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Polymerase chain reaction clinical studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most HSV PCR assays require between 0.5 and 1 mL of CSF for HSV testing. Specimens are stored refrigerated or frozen until testing is performed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Specimen collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV PCR results should always be interpreted within the context of the clinical presentation of the patient. If testing results do not correlate with the clinical impression, repeat testing should be performed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Interpretation of the results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV can also cause aseptic meningitis, a self-limited disease usually associated with HSV type 2 infection. The preferred diagnostic test for patients with suspected HSV meningitis is PCR testing on cerebral spinal fluid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HSV meningitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/1\">",
"      Whitley RJ. Viral encephalitis. N Engl J Med 1990; 323:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/2\">",
"      Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995; 20:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/3\">",
"      Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/4\">",
"      Sk&ouml;ldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 1984; 2:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/5\">",
"      Whitley RJ, Cobbs CG, Alford CA Jr, et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA 1989; 262:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/6\">",
"      Aurelius E, Johansson B, Sk&ouml;ldenberg B, et al. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 1991; 337:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/7\">",
"      Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995; 171:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/8\">",
"      Wildemann B, Ehrhart K, Storch-Hagenlocher B, et al. Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology 1997; 48:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/9\">",
"      Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1996; 174:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/10\">",
"      Malm G, Forsgren M. Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum. Arch Dis Child Fetal Neonatal Ed 1999; 81:F24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/11\">",
"      Wiedbrauk DL, Cunningham W. Stability of herpes simplex virus DNA in cerebrospinal fluid specimens. Diagn Mol Pathol 1996; 5:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/12\">",
"      Simko JP, Caliendo AM, Hogle K, Versalovic J. Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documented by detection of HSV DNA. Clin Infect Dis 2002; 35:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/13\">",
"      Hanson KE, Alexander BD, Woods C, et al. Validation of laboratory screening criteria for herpes simplex virus testing of cerebrospinal fluid. J Clin Microbiol 2007; 45:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/14\">",
"      Tedder DG, Ashley R, Tyler KL, Levin MJ. Herpes simplex virus infection as a cause of benign recurrent lymphocytic meningitis. Ann Intern Med 1994; 121:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/15\">",
"      Schlesinger Y, Tebas P, Gaudreault-Keener M, et al. Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis 1995; 20:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/16\">",
"      Murphy RF, Caliendo AM. Relative quantity of cerebrospinal fluid herpes simplex virus DNA in adult cases of encephalitis and meningitis. Am J Clin Pathol 2009; 132:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/17\">",
"      Kupila L, Vuorinen T, Vainionp&auml;&auml; R, et al. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology 2006; 66:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/18\">",
"      O'Sullivan CE, Aksamit AJ, Harrington JR, et al. Clinical spectrum and laboratory characteristics associated with detection of herpes simplex virus DNA in cerebrospinal fluid. Mayo Clin Proc 2003; 78:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34789/abstract/19\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8286 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-42B8F45CE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34789=[""].join("\n");
var outline_f33_62_34789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19625151\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STANDARD DIAGNOSTIC METHODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POLYMERASE CHAIN REACTION CLINICAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specimen collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interpretation of the results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Availability of the test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HSV MENINGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19625151\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38023?source=related_link\">",
"      St. Louis encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34790="Flupentixol: Drug information";
var content_f33_62_34790=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flupentixol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/5/24661?source=see_link\">",
"    see \"Flupentixol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fluanxol&reg;;",
"     </li>",
"     <li>",
"      Fluanxol&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psychotic symptoms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.M. (depot):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients naive to treatment with long-acting depot antipsychotics: Administer test dose of 5-20 mg (5 mg dose is recommended in elderly, frail, cachectic patients or patients with predisposition to extrapyramidal reactions). Closely monitor  therapeutic response and for the appearance of extrapyramidal symptoms over the following 5-10 days.  Oral antipsychotic  drugs may be continued, but dosage should be reduced during this overlapping period and eventually discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients with prior exposure and good tolerance of long-acting depot antipsychotics: 20-40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: 20-40 mg may be given 4-10 days after initial injection (if well tolerated), followed by usual maintenance dose of 20-40 mg every 2-3 weeks. Dose is individualized and titrated in maximum increments of &le;20 mg (doses &gt;80 mg are not usually necessary but have been used in some patients). Dose should be maintained at the lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 1 mg 3 times/day; dose must be individualized. May be increased by 1 mg every 2-3 days based on tolerance and control of symptoms. Usual maintenance dosage: 3-6 mg/day in divided doses (doses &ge;12 mg/day have been used in some patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from oral tablets to maintenance dosing with I.M. injection (decanoate):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     When transitioning to the depot injection, continue oral therapy at decreasing dosages for the first week following the initial injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If I.M administration every 2 weeks: Use decanoate dose equal to 4 times the total daily oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If I.M. administration every 4 weeks: Use decanoate dose equal to 8 times the total daily oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion from other antipsychotic depot formulations to I.M. flupentixol decanoate:",
"     </b>",
"     Conversion ratios to calculate the equivalent dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flupentixol decanoate 40 mg = fluphenazine decanoate 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flupentixol decanoate 40 mg = zuclopenthixol decanoate 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flupentixol decanoate 40 mg = haloperidol decanoate 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13456106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer&rsquo;s product labeling recommendations are unclear. Use in renal insufficiency is contraindicated however the labeling also suggests that dosage adjustments are not required in renal impairment; flupentixol systemic exposure is not likely to be influenced by renal impairment as the drug undergoes extensive hepatic metabolism and is primarily excreted in the feces.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13456105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling; flupentixol undergoes extensive hepatic metabolism. Use caution.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10241400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as decanoate [depot]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluanxol&reg;: 20 mg/mL (1 mL); 100 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dihydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluanxol&reg;: 0.5 mg, 3 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11233777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F172868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer by deep I.M. injection, preferably in the gluteus maximus; doses requiring more than 2 mL should be administered as divided doses between 2 injection sites.",
"     <b>",
"      Do not administer I.V.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Tablets may be taken with or without food. During initial therapy, may consider reducing evening dose in patients with sleep disturbance. Maintenance dose may be given as single morning dose. Missed doses should be taken at the next regularly scheduled time.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance therapy of chronic schizophrenic patients whose main manifestations do",
"     <b>",
"      not",
"     </b>",
"     include excitement, agitation, or hyperactivity",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not  always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Extrapyramidal effects (up to 30%; including akathisia, dystonia, pseudoparkinsonism, tardive dyskinesia), depression, dizziness, drowsiness, fainting, fatigue, headache, hypomania, insomnia, oculogyric crises, opisthotonos, psychomotor agitation, restlessness, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, eczema, erythema, exfoliative dermatitis, pruritus, rash, seborrhea, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, galactorrhea, gynecomastia, hyperprolactinemia, impotence, libido decreased/increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, paralytic ileus, salivation increased, weight changes, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperreflexia, hypertonia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, lens opacity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal pain, accommodation abnormal, amenorrhea,  dyspepsia, dyspnea, erectile dysfunction, glucose tolerance impaired, granulocytopenia, hot flashes, hyperglycemia, muscle rigidity, myalgia, neuroleptic malignant syndrome (NMS), neutropenia, priapism, QT prolongation, thrombocytopenia, torsade de pointes, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia, vomiting, weakness",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional adverse events associated with antipsychotics include agranulocytosis, arrhythmias, angioedema, asthma, cerebral edema, corneal deposits, CSF proteins altered,  CVA, ECG changes, EEG changes,  glaucoma, glycosuria, gynecomastia,  hemolytic anemia, hepatotoxicity, hypoglycemia, hypo/hypertension,  laryngeal edema, lenticular deposits, leukopenia, menstrual abnormalities, miosis, mydriasis, nonthrombocytopenic purpura,  pancytopenia, peripheral edema, photosensitivity, pigmentary retinopathy, skin pigmentation, SLE, sudden death, syncope, tachycardia, VTE",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flupentixol, thioxanthenes, or any component of the formulation; acute intoxication (ethanol, barbiturate, or opioid); CNS depression due to any cause; coma; severely-agitated psychotic  patients, psychoneurotic patients, or geriatric patients with confusion and/or agitation; suspected or established subcortical brain damage; cerebrovascular or renal insufficiency; severe cardiovascular disease/circulatory collapse;  liver damage; concomitant use with large doses of hypnotics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.  Avoid use in patients with underlying QT prolongation, in those taking medicines that prolong the QT interval, or cause polymorphic ventricular tachycardia; monitor ECG closely for dose-related QT effects. Adverse effects of decanoate may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, flupentixol has a low potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Antipsychotic use has been associated with agranulocytosis, neutropenia and granulocytopenia; obtain CBC prior to treatment and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Risk of tardive dyskinesia and potential for irreversibility often associated with total cumulative dose and therapy duration and may also be increased in elderly patients (particularly elderly women); antipsychotics may also mask signs/symptoms of tardive dyskinesia. Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS):",
"     <b>",
"      [Canadian Boxed Warning]: NMS has been associated with use of antipsychotic agents, including flupentixol;",
"     </b>",
"     monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia). Discontinue treatment immediately with onset of NMS; recurrence has been reported in patients rechallenged with antipsychotic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular: Lens opacity has been reported rarely with use. Similar drugs have been associated with pigmentary retinopathy, corneal and lenticular deposits, and photosensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating in some patients (flupentixol is associated with less sedative effects compared to other antipsychotics), use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Venous thromboembolism (VTE): VTE has been reported with antipsychotics; evaluate VTE risk prior to and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use is contraindicated in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Elderly patients with dementia-related psychosis who are treated with antipsychotics are at an increased risk of death compared to placebo. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (including fatalities) has been reported in elderly patients with dementia-related psychosis. Flupentixol is not approved for use in elderly patients with dementia or dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with known or suspected glaucoma (avoid use in patients with known or suspected  narrow-angle glaucoma); condition may be exacerbated by cholinergic blockade (flupentixol has weak anticholinergic properties compared to other antipsychotics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use is contraindicated in patients with liver damage. Has not been studied in hepatic impairment; flupentixol undergoes hepatic metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolactin-dependent tumors: Use with caution in patients with breast cancer or other prolactin-dependent tumors; elevates prolactin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: The manufacturer's labeling contraindicates use in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Surgical patients receiving high-dose flupentixol should be monitored closely for hypotension; dose reduction of anesthetic or CNS depressants may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not recommended for use in excitable, overactive, or manic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Therapy discontinuation: Avoid abrupt withdrawal in patients receiving maintenance therapy; withdrawal symptoms (eg, n/v, insomnia, restlessness, agitation) may appear 1-4 days after discontinuing therapy and subside within 7-14 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13456098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F172888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13456099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     At therapeutic doses, flupentixol is found at low concentrations in human breast milk. Adverse effects are not likely in a nursing infant when used within the therapeutic dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F172863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; hepatic function tests, lipid profile, CBC, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F172873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Depixol (GB);",
"     </li>",
"     <li>",
"      Fluanxol (AT, BE, BG, CH, CL, CN, CZ, DE, DK, EE, FI, GB, HK, IL, IN, NL, NO, NZ, PE, PH, PK, PL, PT, RU, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Fluanxol Depot (AT, AU, BG, CH, CL, CZ, DE, DK, EE, FI, HK, HN, IL, IN, MY, NO, PE, PH, SE, SG, TH, TW, ZA);",
"     </li>",
"     <li>",
"      Jexit (TW);",
"     </li>",
"     <li>",
"      Pentixol (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flupentixol is a thioxanthene-derivative antipsychotic which blocks postsynaptic dopamine receptors in the CNS, resulting in inhibition of dopamine-mediated effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: I.M. depot: 24-72 hours following injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M. depot: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~14 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via sulfoxidation and dealkylation; also undergoes glucuronidation; metabolites are inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: ~35 hours; I.M. depot: 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 3-8 hours; I.M. depot: 4-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Mostly feces (as metabolites); urine (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Psychiatric Association, \"Clinical Practice Guidelines. Treatment of Schizophrenia,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2005, 50(13 Suppl 1):7-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/62/34790/abstract-text/16529334/pubmed\" id=\"16529334\" target=\"_blank\">",
"        16529334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8783 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34790=[""].join("\n");
var outline_f33_62_34790=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172893\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172885\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062881\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13456106\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13456105\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241400\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233777\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172868\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172867\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172891\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172871\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172856\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299355\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172860\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13456098\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172888\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13456099\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172863\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172873\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172855\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172870\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8783|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/5/24661?source=related_link\">",
"      Flupentixol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34791="Approach to Gram stain and culture results in the microbiology laboratory";
var content_f33_62_34791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to Gram stain and culture results in the microbiology laboratory",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Joshua Freeman, MBChB, FRCPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Sally Roberts, MBChB, FRACP, FRCPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34791/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/62/34791/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical decisions regarding the management of infections are frequently based on the results of Gram stain and culture. Therefore, it is important that such studies are performed and interpreted correctly.",
"   </p>",
"   <p>",
"    Issues relating to the interpretation of Gram stain and culture results are discussed here. Issues relating to the management of specific infections are discussed in detail separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GRAM STAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gram stain is used to differentiate between different types of bacteria based on the biochemical properties of their cell walls. The method is named after Danish scientist Hans Christian Gram (1853 to 1938), who developed the technique in order to distinguish between two different bacterial causes of pneumonia (Streptococcus pneumoniae and Klebsiella pneumoniae)",
"   </p>",
"   <p>",
"    Gram staining of clinical specimens (including sterile and nonsterile body fluid specimens, biopsy specimens, and positive culture specimens) is useful for guiding empiric clinical management for bacterial infections pending definitive culture data",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecular data. Gram staining also allows visualization of yeast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performing a Gram stain consists of the following steps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare a heat-fixed smear of processed clinical specimen or a bacterial culture on a glass slide",
"     </li>",
"     <li>",
"      Apply the primary stain (crystal violet) to the slide; rinse with water.",
"     </li>",
"     <li>",
"      Immerse the slide in mordant (Gram's iodine).",
"     </li>",
"     <li>",
"      Perform rapid decolorization (a matter of seconds) with acetone or alcohol. The decolorization step is critical and it must be timed correctly; if the decolorizing agent is left on too long, crystal violet stain will be removed from Gram-positive cells as well as Gram-negative cells.",
"     </li>",
"     <li>",
"      Counterstain with safranin or basic fuchsin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, Gram staining allows categorization of observed microorganisms into two major groups: Gram-positive and Gram-negative. Gram-positive bacteria retain crystal violet and appear purple with Gram staining; Gram-negative bacteria do not retain crystal violet but take up safranin counterstain and thus appear pink. A few Gram-negative organisms tend to stain faintly with safranin (such as Campylobacter species), and thus an alternative counterstain such as carbol fuchsin may be preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some organisms are Gram-variable (ie, they may stain either negative or positive). Common Gram-variable organisms observed in clinical specimens include Gardnerella vaginalis and Mobiluncus species. These organisms are associated with bacterial vaginosis and are technically classified as \"Gram-positive.\" In addition, some Gram-negative organisms such as Acinetobacter species tend to retain crystal violet and may sometimes appear Gram-variable.",
"   </p>",
"   <p>",
"    Some bacterial species cannot be visualized by Gram stain because they either lack a cell wall (eg, Mycoplasma species) or because their cell wall structure does not retain Gram stain reagents (eg, Chlamydia and Mycobacterium species; the latter may have a \"beaded\" Gram-positive appearance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Some nonbacterial species also stain purple with Gram stain (such as Candida species) (",
"    <a class=\"graphic graphic_picture graphicRef70812 \" href=\"mobipreview.htm?34/21/35166\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Gram stained bacteria are described according to the morphology of individual bacteria (eg, spherical \"cocci\" or rod-shaped \"bacilli\"), their arrangement (eg, \"chains\" or \"clusters\"), and their size. The morphology of individual bacteria may occasionally be atypical if the patient has received antibiotics prior to specimen collection. For example, some Gram-negative bacteria may become longer and more filamentous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Specimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sterile sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterile sites refer to anatomic sites in which bacterial organisms are not present in the absence of infection. Fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue from these sites should be collected under sterile conditions (examples include cerebrospinal fluid, pleural fluid, pericardial fluid, synovial fluid and peritoneal fluid). Colonizing bacteria rarely contaminate specimens from sterile sites in sufficient quantities to be detected on Gram stain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any bacteria detected on Gram stain of a sterile site specimen should be considered significant, although a negative Gram stain does not exclude infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/5\">",
"     5",
"    </a>",
"    ]. For some sterile site specimens, the sensitivity of Gram stain may be increased by cytospin centrifugation prior to staining (particularly cerebrospinal fluid) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nonsterile sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsterile sites refer to anatomic sites in which colonizing organisms (\"normal flora\") may be present. Specimens from these sites are typically contaminated with colonizing bacteria (\"normal flora\"). Examples include sputum, throat swabs, wound swabs, and genital swabs (",
"    <a class=\"graphic graphic_picture graphicRef77934 \" href=\"mobipreview.htm?35/55/36720\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These specimens also generally contain human cells such as epithelial cells and white blood cells. Human cells are stained by the safranin (or carbol fuchsin) counterstain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/7\">",
"     7",
"    </a>",
"    ]. Human cells present in these specimens (such as neutrophils, lymphocytes, and epithelial cells) are reported \"semi-quantitatively\" (eg, 1+ to 4+ or rare-few-moderate-abundant). This information can be used to assess the quality of the specimen and whether inflammation is present. Note that white cells may be absent in the presence of infection if the patient is neutropenic. In addition, the presence of Gram-positive bacilli in the absence of white cells should raise suspicion for gas gangrene.",
"   </p>",
"   <p>",
"    A high quality sputum specimen has high numbers of white cells and few epithelial cells; a low quality specimen has high numbers of epithelial cells and low numbers of white cells. Low quality specimens may be rejected by the laboratory as unfit for culture; criteria for rejecting specimens differ between laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpretation of Gram stains from nonsterile sites requires experience and knowledge of the normal expected flora. A sputum specimen with a large number of bacteria of different morphologies may be consistent with normal oral colonizing bacteria. On the other hand, a high quality sputum specimen with large numbers of bacteria present on Gram stain demonstrating the typical morphology of a possible respiratory tract pathogen may be a useful clue as to the etiology of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gram-positive cocci",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clusters &mdash; Gram-positive cocci in clusters usually indicate Staphylococcus species, although Gram staining cannot differentiate S. aureus from other staphylococcal species. The coagulase test may be used classic for differentiating S. aureus from other staphylococcal species. Other less common species that manifest as Gram-positive cocci in clusters and occasionally appear in clinical specimens include Micrococcus, Pediococcus, Aerococcus, and Stomatococcus species (",
"      <a class=\"graphic graphic_picture graphicRef65118 \" href=\"mobipreview.htm?11/2/11298\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72812 \" href=\"mobipreview.htm?28/60/29633\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef65230 \" href=\"mobipreview.htm?35/42/36513\">",
"       picture 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/11\">",
"       11",
"      </a>",
"      ]. Yeast forms also stain Gram-positive and should not be mistaken for Gram-positive bacteria (",
"      <a class=\"graphic graphic_picture graphicRef70812 \" href=\"mobipreview.htm?34/21/35166\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Chains &mdash; Gram-positive cocci in chains usually indicates Streptococcus or Enterococcus species, although Gram staining cannot distinguish between viridans streptococci, hemolytic streptococci, or enterococci (",
"      <a class=\"graphic graphic_picture graphicRef53370 \" href=\"mobipreview.htm?19/58/20385\">",
"       picture 6",
"      </a>",
"      ). Other species manifesting as Gram-positive cocci in chains that very occasionally appear in clinical specimens include Leuconostoc, Abiotrophia, Granulicatella, and Gemella species other than G. haemolysans. Anaerobes such as Peptostreptococcus, Finegoldia, and Peptococcus spp also have this appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diplococci &mdash; The finding of Gram-positive diplococci (spheres in pairs) is pathognomonic for S. pneumoniae; this organism may also be arranged in short chains. Individual bacteria classically appear slightly elongated and arranged end to end (",
"      <a class=\"graphic graphic_picture graphicRef51986 \" href=\"mobipreview.htm?19/16/19720\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef70655 \" href=\"mobipreview.htm?39/44/40644\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72926 \" href=\"mobipreview.htm?10/49/11039\">",
"       picture 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,12\">",
"       2,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gram-negative cocci",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative cocci usually indicates Neisseria meningitidis or Neisseria gonorrhoeae. Typically these species are arranged as pairs (\"diplococci\") (",
"    <a class=\"graphic graphic_picture graphicRef57914 \" href=\"mobipreview.htm?23/57/24466\">",
"     picture 10",
"    </a>",
"    ). Other Gram-negative cocci include Moraxella catarrhalis, other Neisseria species and the anaerobic Veillonella species (",
"    <a class=\"graphic graphic_picture graphicRef58978 \" href=\"mobipreview.htm?35/27/36273\">",
"     picture 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Acinetobacter species may also have this appearance, though it may also retain crystal violet and thus appear Gram-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gram-positive rods",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coryneform (\"diphtheroid\") &mdash; Coryneform Gram-positive bacilli are usually pleomorphic or \"club-shaped\" and arranged in parallel (palisading) formations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in arrangements resembling \"Chinese letters\" (",
"      <a class=\"graphic graphic_picture graphicRef60691 \" href=\"mobipreview.htm?27/46/28389\">",
"       picture 12",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"       2,13",
"      </a>",
"      ]. This appearance is typical of Corynebacterium species; Propionibacterium and Listeria species may also have this appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Box-car\" shaped &mdash; Box-car shaped Gram-positive bacilli usually indicate anaerobic Clostridium species or aerobic Bacillus or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      species. These bacilli have a \"box-car\" shape with squared off ends and parallel sides (",
"      <a class=\"graphic graphic_picture graphicRef54494 \" href=\"mobipreview.htm?0/39/626\">",
"       picture 13",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef56042 \" href=\"mobipreview.htm?38/24/39310\">",
"       picture 14",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,12,13\">",
"       2,12,13",
"      </a>",
"      ]. The presence of Gram-positive or Gram-variable bacilli in soft tissue specimens without visible white cells should raise suspicion for gas gangrene.",
"     </li>",
"     <li>",
"      Branching &mdash; Branching Gram-positive bacilli usually indicates either the aerobic Nocardia species or the anaerobic Actinomyces species (",
"      <a class=\"graphic graphic_picture graphicRef56655 \" href=\"mobipreview.htm?5/30/5610\">",
"       picture 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69434 \" href=\"mobipreview.htm?18/63/19440\">",
"       picture 16",
"      </a>",
"      ). Streptomyces species may also have this appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"       2,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small Gram-positive coccobacilli &mdash; Small Gram-positive coccobacilli classically indicates Listeria species (",
"      <a class=\"graphic graphic_picture graphicRef70010 \" href=\"mobipreview.htm?10/6/10351\">",
"       picture 17",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef61238 \" href=\"mobipreview.htm?35/2/35887\">",
"       movie 1",
"      </a>",
"      ), although the Gram stain appearance of this organism may be highly variable (\"pleomorphic\") [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"       2,13",
"      </a>",
"      ]. The Gram stain appearance of Listeria spp may resemble S. pneumoniae, Corynebacterium species, or even Enterococcus species (",
"      <a class=\"graphic graphic_picture graphicRef60691 \" href=\"mobipreview.htm?27/46/28389\">",
"       picture 12",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gram-negative rods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram stain cannot reliably distinguish between most aerobic and anaerobic species of Gram-negative bacilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. However, some reports describe Gram-negative bacilli as fusiform, curved or small Gram-negative coccobacilli (",
"    <a class=\"graphic graphic_picture graphicRef82014 \" href=\"mobipreview.htm?3/19/3391\">",
"     picture 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70346 \" href=\"mobipreview.htm?20/4/20548\">",
"     picture 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73132 \" href=\"mobipreview.htm?33/50/34595\">",
"     picture 20",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fusiform &mdash; Gram-negative bacilli with tapered ends (a \"fusiform\" or filamentous appearance) include Fusobacterium nucleatum, an anaerobe, and Capnocytophaga species (",
"      <a class=\"graphic graphic_picture graphicRef52408 \" href=\"mobipreview.htm?6/1/6163\">",
"       picture 21",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"       2,13",
"      </a>",
"      ]. Some Gram-negative bacteria may become longer and more filamentous in the setting of antibiotic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Curved &mdash; Curved Gram-negative bacilli is a typical appearance of Vibrio species. Campylobacter and Helicobacter species may also appear curved or \"S-shaped\" (",
"      <a class=\"graphic graphic_picture graphicRef61365 \" href=\"mobipreview.htm?30/43/31415\">",
"       picture 22",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"       2,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small Gram-negative coccobacilli &mdash; Small Gram-negative coccobacilli corresponds to a number of organisms including Haemophilus and Brucella species [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"       2,13",
"      </a>",
"      ]. Haemophilus species may also appear as long filaments (",
"      <a class=\"graphic graphic_picture graphicRef72893 \" href=\"mobipreview.htm?22/39/23157\">",
"       picture 23",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef52680 \" href=\"mobipreview.htm?38/51/39743\">",
"       picture 24",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is a non-bacterial species that stains purple with Gram stain. Long \"pseudohyphae\" (elongated structures) may be present, as well as daughter yeast cells \"budding\" from larger parent yeast cells (",
"    <a class=\"graphic graphic_picture graphicRef72452 \" href=\"mobipreview.htm?18/40/19079\">",
"     picture 25",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CULTURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional diagnostic microbiology techniques rely on the growth of organisms on appropriate culture media. In general, specimens from sterile sites may be inoculated onto enriched all-purpose media such as blood or chocolate agar; most ordinary bacterial pathogens grow readily on these nonselective solid media. Specimens from nonsterile sites that contain mixed microbial flora should also be inoculated onto additional plates such as MacConkey or other selective media. Selective media are used to inhibit the growth of commensal colonizing bacteria.",
"   </p>",
"   <p>",
"    After bacteria have been isolated on solid agar media (for most organisms this occurs within 24 to 48 hours), colony morphology, growth requirements and rapid bench tests may allow for preliminary or presumptive identification. Confirmation of species identification usually takes additional hours or days. Colonies of interest selected from mixed cultures (such as those typically recovered from non-sterile site specimens) must be \"subcultured\" prior to identification in order to obtain a pure culture (",
"    <a class=\"graphic graphic_picture graphicRef66953 \" href=\"mobipreview.htm?38/44/39621\">",
"     picture 26",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bacteria initially cultured in broth medium (eg, blood cultures) are evaluated by Gram stain followed by inoculation of blood culture broth onto solid media.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Growth conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important growth conditions include temperature and atmospheric conditions. Most bacterial cultures are incubated at 35 to 37&ordm;C. Atmospheric conditions used in the microbiology laboratory include aerobic, anaerobic and 5 percent CO2. Many facultative anaerobic organisms such as streptococci grow well under anaerobic conditions. In general, however, anaerobic organisms do not grow readily under aerobic conditions. Capnocytophaga species require 5 percent CO2 such for optimal growth (\"capnophilic organisms\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Other microorganisms may also require specialized atmospheric conditions. For example, Campylobacter species grow most readily under \"microaerophilic conditions\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Culture media",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Blood agar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood agar supports the growth of many common human bacterial pathogens (with the exception of Haemophilus influenzae). Blood agar culture plates are also useful for observing hemolysis (the ability of bacterial colonies to break down red blood cells). The presence of and type of hemolysis is useful for classifying streptococcal species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha hemolysis (incomplete or partial hemolysis) is caused by bacterial production of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      , which in turn oxidizes hemoglobin (red) to methemoglobin (green) (",
"      <a class=\"graphic graphic_picture graphicRef59890 \" href=\"mobipreview.htm?33/33/34334\">",
"       picture 27",
"      </a>",
"      ). S. pneumoniae and viridans streptococci display alpha hemolysis.",
"     </li>",
"     <li>",
"      Beta hemolysis (complete red cell lysis) results in transparency in the normally red agar media. This transparency is typically present around and under the colonies (",
"      <a class=\"graphic graphic_picture graphicRef57140 \" href=\"mobipreview.htm?9/7/9343\">",
"       picture 28",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef68908 \" href=\"mobipreview.htm?15/33/15903\">",
"       picture 29",
"      </a>",
"      ). S. pyogenes and Listeria typically display beta hemolysis. Some weakly beta hemolytic species (eg, S. agalactiae and C. perfringens) may induce intense beta hemolysis when grown concurrently with S. aureus.",
"     </li>",
"     <li>",
"      Gamma hemolysis (no hemolysis) results in no change in the agar color around and under the colony. E. faecalis (formerly Group D streptococcus) displays gamma hemolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemolytic streptococci are further categorized by Lancefield grouping. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Lancefield grouping'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chocolate agar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chocolate agar is named for its brown color. It contains lysed red blood cells that have released growth factors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    (X factor) and NAD (V factor). These growth factors are necessary for the in vitro growth of Haemophilus influenzae (",
"    <a class=\"graphic graphic_picture graphicRef59330 \" href=\"mobipreview.htm?22/15/22783\">",
"     picture 30",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72828 \" href=\"mobipreview.htm?12/20/12623\">",
"     picture 31",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     MacConkey agar",
"    </span>",
"    &nbsp;&mdash;&nbsp;MacConkey agar is a selective medium designed to detect Gram-negative bacteria. Bile salts in MacConkey agar inhibit growth of Gram-positive bacteria. Lactose fermenting organisms produce pink colonies when grown on this media; non-lactose fermenting organisms produce colorless colonies (",
"    <a class=\"graphic graphic_picture graphicRef63042 \" href=\"mobipreview.htm?29/21/30046\">",
"     picture 32",
"    </a>",
"    ). Lactose fermenting organisms include E. coli, Enterobacter and Klebsiella. Non lactose fermenting organisms include Pseudomonas, Proteus, Salmonella, Shigella and Citrobacter.",
"   </p>",
"   <p>",
"    Certain Gram-negative species do not grow on MacConkey agar (so called \"fastidious\" Gram negatives). These include Bordetella, Brucella, Campylobacter, Haemophilus, Legionella, Pasteurella, Acinetobacter and Eikenella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Selective media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective media are primarily used for cultures of specimens collected from non-sterile sites. These selective media can help detect specific pathogenic organisms growing concurrently with normal colonizing bacteria. These selective media typically contain antibiotics. Pathogens that may be identified with selective media include Bordetella pertussis, Salmonella species, Shigella species and Neisseria gonorrhoeae and Legionella pneumophila (",
"    <a class=\"graphic graphic_picture graphicRef74516 \" href=\"mobipreview.htm?11/15/11506\">",
"     picture 33",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Colony morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colony morphology for a given organism may vary according to the agar medium used and the growth conditions. Colonies are described based on their texture, size, shape, and color [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      K. pneumoniae colonies frequently appear \"mucoid\" on blood agar",
"     </li>",
"     <li>",
"      Moraxella catarrhalis produces \"dry\" colonies that can be pushed across the agar.",
"     </li>",
"     <li>",
"      Yersinia enterocolitica manifests as \"pinpoint\" colonies on MacConkey agar",
"     </li>",
"     <li>",
"      Proteus species produce large \"swarming\" colonies on MacConkey agar",
"     </li>",
"     <li>",
"      S. pneumoniae produces colonies with have a central depression such that they resemble pieces used for the game of drafts (\"draftsmen\" appearance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although \"sniffing\" cultures is generally not encouraged, several common pathogens have distinctive odors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaerobic organisms are typically foul smelling",
"     </li>",
"     <li>",
"      P. aeruginosa has a \"grape-like\" or \"fruity\" odor",
"     </li>",
"     <li>",
"      H. influenzae is said to have a \"mousy\" odor",
"     </li>",
"     <li>",
"      Streptococcus intermedius group (also known as the Streptococcus milleri group or Streptococcus anginosus group) has a distinctive \"caramel\" or \"butterscotch\" odor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,12,13\">",
"       2,12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Eikenella has a \"bleach-like\" odor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bench tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following biochemical tests are commonly used to determine the species of a pathogen grown in culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Coagulase test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coagulase test is used to differentiate S. aureus from other staphylococci (",
"    <a class=\"graphic graphic_picture graphicRef77734 \" href=\"mobipreview.htm?27/24/28046\">",
"     picture 34",
"    </a>",
"    ). The test typically takes &le;4 hours but may take up to 24 hours. In many laboratories, the coagulase test has been replaced by commercially available rapid latex agglutination tests, which take several minutes and may be used for presumptive identification of S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Catalase test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catalase test is used to distinguish staphylococci from streptococci and enterococci. Catalase production is indicated by the presence of oxygen bubbles when bacterial colonies are exposed to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef80137 \" href=\"mobipreview.htm?18/43/19133\">",
"     picture 35",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2\">",
"     2",
"    </a>",
"    ]. This test can have false-positive results if colonies grown on blood agar are tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Oxidase test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxidase test is used to differentiate Gram-negative bacilli based on their production of certain cytochrome c oxidases. Bacterial colonies are inoculated onto strips impregnated with oxidase reagent. This reagent appears purple when oxidized and colorless when reduced; a positive result is indicated by a purple color change that is detectable within a few seconds.",
"   </p>",
"   <p>",
"    Oxidase positive organisms include Pseudomonas aeruginosa, Pasteurella multocida, Vibrio and Aeromonas species. Oxidase negative organisms include Enterobacteriaceae (such as E. coli, K. pneumoniae, E. cloacae, Serratia spp) and Acinetobacter species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Lancefield grouping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lancefield grouping of hemolytic streptococci groups organisms based on specific carbohydrates in the bacterial cell wall which allow agglutination with particular antisera. Not all streptococci can be grouped; some species such as S. pneumoniae do not express Lancefield antigens.",
"   </p>",
"   <p>",
"    Lancefield grouping is usually used to identify beta hemolytic streptococci but may also be used to help identify other streptococci and enterococci. For example, Enterococcus species are usually group D; S. anginosus group are frequently group F but may be groups A, C, or G [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Bile solubility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile solubility testing is useful for rapid differentiation of S. pneumoniae (which are bile soluble) from other alpha hemolytic streptococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     PYR hydrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PYR hydrolysis is used primarily for further identification of Gram-positive cocci in chains. A positive test suggests S. pyogenes, Enterococcus, or",
"    <span class=\"nowrap\">",
"     Abiotrophia/Granulicatella",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34791/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     CORRELATING RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram stain findings must be correlated with culture results. A Gram stain demonstrating multiple bacterial species together with only one or two aerobic species isolated in culture, for example, can be an important clue to the presence of anaerobes. If the Gram stain is positive and the cultures are negative, possibilities include the presence of anaerobes, false-negative results reflecting prior antibiotic therapy, or a fastidious organism that cannot grow on routine media.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Gram stain is a laboratory technique used to differentiate between different types of bacteria based on the biochemical properties of their cell walls. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of bacteria in Gram stains of specimens collected from sterile sites should almost always be considered a significant finding. However, Gram stains of specimens from nonsterile sites must be interpreted with care. For these specimens, the number and types of human cells present provides information about the quality of the specimen and the presence of inflammation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sterile sites'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonsterile sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram staining allows categorization into two major groups: Gram-positive and Gram-negative. Gram-positive bacteria retain crystal violet and appear purple with Gram staining, whereas Gram-negative bacteria do not retain crystal violet but take up safranin counterstain and thus appear pink. Gram stained bacteria are described according to the morphology of individual bacteria (eg, spherical \"cocci\" or rod-shaped \"bacilli\"), their arrangement (eg, \"chains\" or \"clusters\") and size. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specimens from sterile sites should be inoculated onto enriched all-purpose media such as blood or chocolate agar; most ordinary bacterial pathogens grow readily on these nonselective solid media. Specimens from nonsterile sites that might contain mixed microbial flora should also be inoculated onto selective media such as MacConkey agar or other selective media. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Culture media'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of common organisms have characteristic morphologies; the colonial morphology of a given organism may vary according to the agar medium used and the growth conditions. Colonies are described based on their texture, size, shape, and color. Although sniffing cultures is generally not encouraged, several common pathogens have distinctive odors. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Colony morphology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bench tests are biochemical tools used for determining the species of a pathogen grown in culture. Common bench tests include the coagulase, catalase, and oxidase tests. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Bench tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kruczak-Filipov P, Shively R. Gram stain procedure. In: Clinical Microbiology Procedures Handbook, Isenberg HD (Ed), American Society for Microbiology, Washington, DC 1992. Vol 1.",
"    </li>",
"    <li>",
"     Manual of Clinical Microbiology, 6th ed, Murray PR, Baron EJ, Pfaller MA, et al (Eds), ASM Press, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/3\">",
"      Moulder JW. Looking at Chlamydiae without looking at their hosts. Am Soc Microbiol News 1984; 50:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/4\">",
"      Lorian V, Waluschka A, Kim Y. Abnormal morphology of bacteria in the sputa of patients treated with antibiotics. J Clin Microbiol 1982; 16:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/5\">",
"      Marton KI, Gean AD. The spinal tap: a new look at an old test. Ann Intern Med 1986; 104:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/6\">",
"      Shanholtzer CJ, Schaper PJ, Peterson LR. Concentrated gram stain smears prepared with a cytospin centrifuge. J Clin Microbiol 1982; 16:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/7\">",
"      McClelland R. Gram's stain: the key to microbiology. MLO Med Lab Obs 2001; 33:20.",
"     </a>",
"    </li>",
"    <li>",
"     Morin S, Tetrault J, James L, et al. Specimen acceptability: Evaluation of specimen quality. In: Clinical Microbiology Procedures Handbook, Isenberg HD (Ed), American Society for Microbiology, Washington, DC 1992. Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/9\">",
"      Bartlett RC, Tetreault J, Evers J, et al. Quality assurance of gram-stained direct smears. Am J Clin Pathol 1979; 72:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/10\">",
"      Reimer LG, Carroll KC. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis 1998; 26:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/11\">",
"      Ruoff KL. Miscellaneous catalase-negative, gram-positive cocci: emerging opportunists. J Clin Microbiol 2002; 40:1129.",
"     </a>",
"    </li>",
"    <li>",
"     Principles and practice of infectious diseases, 5th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000.",
"    </li>",
"    <li>",
"     Koneman EW, Allen SD, Janda WM, et al. Color atlas and textbook of diagnostic microbiology, Lippincott, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/14\">",
"      Buchner LH, Schneierson S. Clinical and laboratory aspects of Listeria monocytogenes infections. With a report of ten cases. Am J Med 1968; 45:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34791/abstract/15\">",
"      Nieman RE, Lorber B. Listeriosis in adults: a changing pattern. Report of eight cases and review of the literature, 1968-1978. Rev Infect Dis 1980; 2:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2746 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34791=[""].join("\n");
var outline_f33_62_34791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GRAM STAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Specimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sterile sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nonsterile sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gram-positive cocci",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gram-negative cocci",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gram-positive rods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gram-negative rods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Candida",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CULTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Growth conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Culture media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Blood agar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chocolate agar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - MacConkey agar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Selective media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Colony morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bench tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Coagulase test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Catalase test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Oxidase test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Lancefield grouping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Bile solubility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - PYR hydrolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CORRELATING RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2746|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35166\" title=\"picture 1\">",
"      Budding yeast Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/55/36720\" title=\"picture 2\">",
"      Normal vaginal flora",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/2/11298\" title=\"picture 3\">",
"      Gram positive cocci clusters 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/60/29633\" title=\"picture 4\">",
"      Gram positive cocci clusters 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/42/36513\" title=\"picture 5\">",
"      S aureus sputum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/58/20385\" title=\"picture 6\">",
"      Gram positive cocci chains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/16/19720\" title=\"picture 7\">",
"      S pneumoniae gram stains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/44/40644\" title=\"picture 8\">",
"      Gram positive diplococci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/49/11039\" title=\"picture 9\">",
"      S pneumoniae in CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/57/24466\" title=\"picture 10\">",
"      Gram negative diplococci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/27/36273\" title=\"picture 11\">",
"      Moraxella sputum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28389\" title=\"picture 12\">",
"      Coryneform bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/39/626\" title=\"picture 13\">",
"      C perfringens Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/24/39310\" title=\"picture 14\">",
"      Clostridium difficile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/30/5610\" title=\"picture 15\">",
"      Nocardia 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/63/19440\" title=\"picture 16\">",
"      Nocardia 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/6/10351\" title=\"picture 17\">",
"      Listeria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/19/3391\" title=\"picture 18\">",
"      Gram stain urine 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/4/20548\" title=\"picture 19\">",
"      K pneumoniae sputum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/50/34595\" title=\"picture 20\">",
"      Bacteroides fragilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/1/6163\" title=\"picture 21\">",
"      Fusobacterium nucleatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/43/31415\" title=\"picture 22\">",
"      Curved Gram negative bacilli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/39/23157\" title=\"picture 23\">",
"      Haemophilus 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/51/39743\" title=\"picture 24\">",
"      Haemophilus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/40/19079\" title=\"picture 25\">",
"      Candida images",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/44/39621\" title=\"picture 26\">",
"      Mixed flora on blood agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/33/34334\" title=\"picture 27\">",
"      Alpha hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/7/9343\" title=\"picture 28\">",
"      Beta hemolysis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/33/15903\" title=\"picture 29\">",
"      Beta hemolysis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/15/22783\" title=\"picture 30\">",
"      Haemophilus chocolate agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/20/12623\" title=\"picture 31\">",
"      X and V factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/21/30046\" title=\"picture 32\">",
"      MacConkey agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/15/11506\" title=\"picture 33\">",
"      Selective media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/24/28046\" title=\"picture 34\">",
"      Coagulase test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/43/19133\" title=\"picture 35\">",
"      Catalase test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2746|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?35/2/35887\" title=\"movie 1\">",
"      L monocytogenes tumbling motility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34792="Allergic reactions to local anesthetics";
var content_f33_62_34792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergic reactions to local anesthetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34792/contributors\">",
"     Michael Schatz, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34792/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34792/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/62/34792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics (LAs) have been used to provide anesthesia since the discovery of cocaine in 1884 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/1\">",
"     1",
"    </a>",
"    ]. They may be administered by topical, infiltrative, nerve block, epidural, or spinal routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse reactions to LAs are not uncommon and most are nonallergic in etiology. However, two different types of allergic reactions to LAs have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic contact dermatitis and delayed swelling at the site of administration: these types of reactions are well established.",
"     </li>",
"     <li>",
"      Urticaria and anaphylaxis: these types of reaction are rare and the data implicating LAs are limited to case reports.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suspected allergic reactions to LAs should be evaluated, because most patients can tolerate other local anesthetic agents. Simply advising a patient to avoid all local anesthetics is unnecessarily restrictive, and subjects that patient either to the pain of procedures performed without local anesthesia, or to the increased risks of general anesthesia. Patients with delayed cutaneous reactions may be referred to either dermatology or allergy specialists who perform patch testing, and patients with suspected anaphylaxis should be referred to allergy specialists.",
"   </p>",
"   <p>",
"    An approach to evaluation and management of patients with allergic reactions to local anesthetics will be reviewed here. A related topic, anaphylaxis in the setting of anesthesia or surgery, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=see_link\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=see_link\">",
"     \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of local anesthetics for infiltrative anesthesia and for topical anesthesia and a general approach to the management of pain and sedation in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CATEGORIES OF LOCAL ANESTHETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAs have been divided into two groups based upon their chemical structure (",
"    <a class=\"graphic graphic_table graphicRef57120 \" href=\"mobipreview.htm?17/47/18171\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group I: The benzoic acid ester agents, which include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"       benzocaine",
"      </a>",
"      , procaine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"       tetracaine",
"      </a>",
"     </li>",
"     <li>",
"      Group II: The amide agents, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       mepivacaine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cross-reactivity patterns among different agents and between groups with respect to allergic reactions are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTACT DERMATITIS OR DELAYED LOCAL SWELLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics can cause delayed swelling, localized dermatitis, or mucosal inflammation at the site of administration due to delayed-type (type IV) hypersensitivity (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute allergic contact dermatitis typically presents as a localized eczematous and pruritic rash appearing within 72 hours at the site of administration. Vesiculation, blistering, or weeping can occur. The area affected is limited to tissue that was in direct contact with the causal agent. LAs may also cause delayed onset swelling, with or without overlying dermatitis, at sites of injection. Mucosal reactions may blister and progress to sloughing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation usually consists of clinical history, patch testing, and possibly challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should review the medical procedure in detail and events immediately surrounding it for possible exposure to other contact allergens, such as topical antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] or suture materials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be asked about prior reactions to local anesthetics used in medical procedures and in over-the-counter products (preparations for hemorrhoids, vaginal irritation, sunburn, and other uses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other possible culprits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of localized swelling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermatitis at the site of LA injection includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive swelling due to operative trauma",
"     </li>",
"     <li>",
"      Local toxic effects or allergic contact dermatitis from other topical agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      and other topical agents used in wound dressings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Additives and preservatives in the local anesthetic itself, such as sulfites and parabens, although these are believed to be relatively uncommon culprits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/14-20\">",
"       14-20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LA preparations may contain sulfite (bisulfite or metabisulfite) which are included to stabilize added vasoconstrictors. A small number of case reports have described local reactions attributed to sulfite sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. One case described a woman with severe edema of the face and neck after receiving a LA for dental work, with a positive patch test to both the LA and metabisulfite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sulfite-sensitive asthmatics are not known to be at increased risk for reactions to sulfites in local anesthetics. One study found that doses of metabisulfite of up to 10 times the amount usually found in LA preparations did not cause symptoms when injected subcutaneously in a group of known sulfite-sensitive asthmatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parabens (either methyl- or propyl-) are added to many commercial preparations of LAs as preservatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/18\">",
"     18",
"    </a>",
"    ]. Parabens are an uncommon cause of contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch testing is a means of diagnosing type IV hypersensitivity reactions by exposing a small area of skin (usually the upper back) to the suspected allergen in a controlled manner (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"     table 2",
"    </a>",
"    ). The patient should not have applied topical glucocorticoids to the tested skin for at least one week, and should not have taken systemic glucocorticoids for at least one to two weeks prior to testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal concentration of LAs for use in patch testing has not been determined. In published studies, concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (in a petroleum vehicle) used for testing have ranged from 5 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/3,6,7,22,23\">",
"     3,6,7,22,23",
"    </a>",
"    ]. Testing can be performed using 10-mm Finn&reg; chambers on Scanpor&reg; tape (or equivalent products) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the standard T.R.U.E.&reg; test panel (Allerderm Lab, Phoenix, AZ) includes a \"caine mix,\" which contains",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    hydrochloride,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35410?source=see_link\">",
"     dibucaine",
"    </a>",
"    hydrochloride, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    , representing both group I and group II LAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/24\">",
"     24",
"    </a>",
"    ]. At the same time, patch testing with an alternative LA could be performed, or the evaluation could be done in steps.",
"   </p>",
"   <p>",
"    Patches are removed at 48 hours, readings are taken at 48 and 72 hours, and reactions are scored as detailed by the manufacturer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/25\">",
"     25",
"    </a>",
"    ]. A positive result varies from mild erythema and induration to severe vesiculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical history consistent with a delayed cutaneous reaction to an LA, combined with a positive patch test result, is sufficient for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have demonstrated type IV allergic reactions to one LA may tolerate other LAs. Management consists of identifying other agents that the patient tolerates. When evaluating patients for tolerance to other LAs, we suggest choosing an agent from the other chemical group (",
"    <a class=\"graphic graphic_table graphicRef57120 \" href=\"mobipreview.htm?17/47/18171\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cross-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about cross-reactivity (based upon patch testing) among LAs is limited, although there is evidence for cross-reactivity within each group of agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/26-28\">",
"     26-28",
"    </a>",
"    ] and minimal evidence for cross-reactivity between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, we suggest choosing one or more drugs from the other LA group as an alternative agent for patch testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     URTICARIA AND ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics have been implicated in IgE-mediated, type I hypersensitivity reactions (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"     table 2",
"    </a>",
"    ). These are also called immediate hypersensitivity reactions. Clinical manifestations of immediate allergic reactions include pruritus, urticaria, bronchospasm, angioedema of noncontiguous tissues, and anaphylaxis, typically occurring",
"    <strong>",
"     within one hour",
"    </strong>",
"    of an LA injection. However, the evidence for the existence of these reactions consists of a small number of case reports in which positive skin tests were demonstrated. Drug-specific IgE has not been demonstrated in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Case reports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports of type I reactions to LAs include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Multiple drugs",
"      </strong>",
"      : A well-substantiated report described a patient with pruritus of the palms and soles, followed by generalized urticaria, developing 20 minutes after injection of a local anesthetic for a procedure on the hand [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/29\">",
"       29",
"      </a>",
"      ]. The local anesthetic that elicited the reaction was not known. Immediate-type skin tests to preservative-free preparations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , mepivicaine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      (all group II) were strongly positive, with negative skin tests to procaine (group I). Double-blind placebo-controlled subcutaneous challenges elicited generalized urticaria with both 0.1 mL of undiluted mepivicaine and lidocaine, but were negative with procaine and placebo. However, in vitro tests could not identify drug-specific IgE in the serum.",
"     </li>",
"     <li>",
"      <strong>",
"       Articaine:",
"      </strong>",
"      Another case involved a woman who developed giant urticaria and a sensation of lightheadedness five minutes after an injection of articaine HCl (group II) for a dental procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/33\">",
"       33",
"      </a>",
"      ]. Skin tests for latex, methylparabens, and procaine (group I) were negative. Intradermal skin tests with the group II agents, xylocaine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      were all positive, indicating sensitivity to multiple group II agents. The patient then tolerated a challenge with procaine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      : A report described a woman with anaphylactic reactions to an unknown local anesthetic 20 years before, to lidocaine 12 years before, and large local urticaria in response to EMLA cream (containing lidocaine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      , and castor oil) 5 years before [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/34\">",
"       34",
"      </a>",
"      ]. Prick skin testing with undiluted lidocaine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       mepivacaine",
"      </a>",
"      were positive, and was negative to undiluted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"       ropivacaine",
"      </a>",
"      , but positive to intradermal testing with a 1:100 dilution of ropivacaine (all group I). Prick and intradermal skin tests to procaine (group II) were negative. The patient was then admitted to the intensive care unit, where she was tolerated injection challenge of 2 percent procaine. She was also challenged (single blind) with saline and then with 0.1 mL of subcutaneous preservative-free 0.2 percent ropivacaine, which induced anaphylaxis requiring",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      : Another case report described a patient with localized urticaria following the use of EMLA cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/30\">",
"       30",
"      </a>",
"      ]. Skin prick testing was positive to EMLA and lidocaine and negative to the other components.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      : A fourth report described a patient who received intralesional injections of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      suspension mixed with 1 percent lidocaine with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      for acne keloidalis nodules on the neck [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/31\">",
"       31",
"      </a>",
"      ]. The patient left the office shortly after the procedure and returned 15 minutes later with lightheadedness, periorbital swelling, and wheezing. He was treated successfully. Subsequently, skin testing to 1:10,000 dilution of 1 percent lidocaine given intradermally was positive, although skin testing to the triamcinolone preparation was not performed.",
"     </li>",
"     <li>",
"      <strong>",
"       Levobupivacaine and",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"       ropivacaine",
"      </a>",
"      : A 74 year old man suffered flushing, seizure, and cardiovascular collapse a few minutes after receiving levobupivacaine for a cervical plexus block [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/35\">",
"       35",
"      </a>",
"      ]. Anaphylaxis was not initially suspected and he underwent a procedure 15 days later, for which he was given ropivacaine. He again developed facial erythema and cardiovascular collapse and this time, serial serum histamine and tryptase measurements were performed, demonstrating increases in both mediators. Skin testing performed six weeks later was positive with 1:10 dilutions of 0.5 percent levobupivacaine and 0.5 percent ropivacaine by prick method. Intradermal testing was done with a 1:10,000 dilution of ropivacaine (which had a smaller prick test result), which yielded a large positive result. Prick and intradermal testing with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and articaine (1:1000 and 1:10 dilutions) and with latex (prick) were negative. He tolerated articaine challenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8361454\">",
"    <span class=\"h2\">",
"     Cross-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on available case reports of immediate reactions to LAs, there is evidence for cross-reactivity among group II agents, and lack of cross-reactivity between group I and II agents. This should be considered when choosing other LA to test as possible alternatives. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Skin testing and challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mimics of allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonallergic reactions to LAs are far more common than true allergic reactions. These pseudoallergic reactions include psychomotor or anxiety-related reactions, vasovagal syncope, sympathetic stimulation, and systemic toxic effects related to the pharmacologic properties of these agents.",
"   </p>",
"   <p>",
"    The clinical manifestations of nonallergic reactions can resemble aspects of allergic reactions. As examples, dyspnea, hypotension, light-headedness, and syncope are signs and symptoms that can be seen in both allergic and nonallergic reactions. However, the presence of wheezing, pruritus, urticaria, or angioedema strongly suggests true allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Psychomotor reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychomotor reactions or anxiety-related symptoms include hyperventilation (manifested by dyspnea and tachypnea), paresthesias in the fingers or peri-oral area, dizziness, palpitations, tachycardia, nausea, or simply \"not feeling good\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Vasovagal syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasovagal syncope is usually associated with bradycardia (rather than tachycardia) and pallor (rather than flushing). These differences can be helpful in distinguishing it from anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sympathetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia, hypertension, anxiety, and palpitations may be caused by the release of endogenous catecholamines in response to pain. In addition, the vasoconstrictor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is sometimes added to LA solutions for the purposes of reducing bleeding, potentiating the degree of local anesthesia achieved, limiting the total dose required, and minimizing systemic absorption of the LA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Although the amount of epinephrine in these preparations is too small to induce significant systemic responses in most normal subjects, or in those with heart disease, high blood pressure, hyperthyroidism, or on tricyclic anti-depressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], it is still possible that some patients are very sensitive to its actions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Systemic toxic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics can cause central nervous stimulation even at therapeutic levels, and patients differ in their sensitivity to these effects. Highly-sensitive individuals may experience anxiety, tremulousness, excitement, or even convulsions. At toxic doses, vasomotor collapse with hypotension, apnea, stupor, and myocardial dysfunction may occur.",
"   </p>",
"   <p>",
"    One of the newer agents, articaine, has been implicated in the development of persistent paresthesias due to nerve damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/41\">",
"     41",
"    </a>",
"    ]. The toxic effects of specific LAs are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient with a possible immediate allergic reaction following administration of a local anesthetic involves a detailed history, consideration of other possible allergens, skin testing, and challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should review the entire procedure and events surrounding it. As much information as possible regarding the patient's reaction(s) should be obtained, including the specific drug preparation used, the presence of added vasoconstrictor or preservatives, the time between administration and onset of the reaction, and the specific symptoms experienced. Any documented objective records should be ascertained and reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other potential allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential allergens often encountered during minor medical procedures include latex, antibiotics, and analgesics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latex from gloves or other medical equipment used during procedures (especially dental procedures) can be a source of allergic reactions. However, the incidence of latex reactions has declined dramatically with the widespread use of latex-free products. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotics, both topical and systemic, can act as allergens. Systemic antibiotics are a well established source of anaphylactic reactions. Topical antibiotic preparations, including neosporin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      , have also been implicated in anaphylaxis, particularly when applied to non-intact skin following minor procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/42-44\">",
"       42-44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) and opiates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/45\">",
"       45",
"      </a>",
"      ] are both capable of causing anaphylaxis or reactions resembling it in susceptible patients. Allergic reactions to NSAIDs are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parabens (either methyl- or propyl-) are added to many preparations of commonly used LAs as a preservative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/18\">",
"       18",
"      </a>",
"      ]. Parabens are structurally related to the benzoic acid ester LAs and are capable of producing immediate hypersensitivity reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/46\">",
"       46",
"      </a>",
"      ]. In several case reports, the apparent adverse reaction to an LA was actually due to immediate hypersensitivity to paraben [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/40,47-50\">",
"       40,47-50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Skin testing and challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for skin testing and challenge is a history of symptoms that could have been either IgE-mediated allergy or nonallergic (such as syncope or hypotension). Skin testing and challenge are performed to determine what alternative LAs the patient tolerates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the LA associated with the reaction is",
"      <strong>",
"       known",
"      </strong>",
"      , test a potential alternative LA from the other chemical group (",
"      <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"       table 2",
"      </a>",
"      ) or, if the culprit drug is an amide, consider an alternative amide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the LA associated with the reaction is",
"      <strong>",
"       unknown",
"      </strong>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      should be chosen, since it is commonly available and since there are cases of tolerance of lidocaine even in patients who reported previous reactions to lidocaine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preparations without vasoconstrictors (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    ) should be used for skin testing because the vasoconstrictor may mask a positive test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although paraben preservatives may occasionally be responsible for LA reactions, the wider availability of LA preparations containing parabens, as well as the infrequency of paraben reactions, suggests that initial skin tests may be performed with paraben-containing preparations. However, if skin testing is positive, paraben sensitivity must be considered. This can be evaluated by repeat testing with preservative-free preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669002\">",
"    <span class=\"h4\">",
"     Testing procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several approaches to skin testing and challenge with LAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The approach described herein is that of the author and has proven clinically useful (",
"    <a class=\"graphic graphic_table graphicRef80642 \" href=\"mobipreview.htm?11/3/11323\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51,56-58\">",
"     51,56-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prick (epicutaneous) testing with undiluted drug is performed initially.",
"     </li>",
"     <li>",
"      If prick testing is negative, intracutaneous (intradermal) testing should be performed with a 1:100 dilution of drug. Undiluted group I drugs have been reported to yield positive intradermal tests in up to 20 percent of subjects with no history of an adverse LA reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51\">",
"       51",
"      </a>",
"      ]. Use of 1:10 dilutions has not been extensively reported, although some guidelines do include this concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/54\">",
"       54",
"      </a>",
"      ]. However, we advocate the use of a maximum dilution of 1:100 for intradermal testing, since false positive skin tests have not been reported with this concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/58\">",
"       58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A general discussion of the techniques for allergen skin testing is provided elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"       \"Overview of skin testing for allergic disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H668976\">",
"    <span class=\"h4\">",
"     Skin test interpretation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive result - For the purposes of management, a positive result should be interpreted as possible allergy, unless a normal control subject has reacted to the same solution.",
"      <br/>",
"      <br/>",
"      If a paraben-containing preparation was used for testing, paraben sensitivity should be considered, as mentioned previously. Testing should be repeated with a paraben-free solution (ie, from a single-dose vial). If the paraben-free preparation also elicits a positive test, then that specific LA should be avoided.",
"     </li>",
"     <li>",
"      Negative result &ndash; In the case of LAs (like almost all other drugs), skin testing with the native drug cannot be considered absolutely conclusive in excluding IgE-mediated allergy, since the allergenic determinant(s) or hapten-carrier complex responsible for IgE-mediated allergic reactions to local anesthetics have not been identified. Despite this, case reports and extensive clinical experience suggest that a negative intradermal test is predictive of tolerance of that LA on challenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      \"False-negative\" skin tests have occurred in less than 1 percent of reported patients; these individuals reacted when challenged with a drug to which they were skin test negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51,59\">",
"       51,59",
"      </a>",
"      ]. However, these reactions were very mild and often were not suggestive of IgE-mediated reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/50,51,60\">",
"       50,51,60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If the prick and intradermal skin tests are negative, incremental challenge is performed next to confirm that the patient tolerates the drug in question.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     Challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A negative skin test to an LA should be confirmed with a subsequent incremental challenge before clinical use of that drug is recommended, because false-negative skin tests are rare, but possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Challenge should not be performed with a drug for which skin testing was positive. This has been reported at least once and the reaction was confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recommended protocol - Challenge procedures should be performed under careful observation, with experienced personnel and appropriate facilities immediately available to treat a potential adverse reaction. The patient is usually observed for at least one hour after the final challenge step.",
"      <br/>",
"      <br/>",
"      A widely-used protocol for subcutaneous incremental challenge involves injections, typically in the upper lateral arm, of gradually increasing volumes of a LA to which the patient is skin test-negative (",
"      <a class=\"graphic graphic_table graphicRef56788 \" href=\"mobipreview.htm?28/26/29099\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A single-blind saline step may be added (as the first step) in a patient whose prior reaction is strongly suspected of being anxiety-related in origin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51,60\">",
"       51,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After a negative skin test and a negative single blind saline challenge, we sometimes omit the 0.1 cc and 0.5 cc undiluted subcutaneous challenge steps, and proceed directly to a subcutaneous injection of 1.0 cc of undiluted LA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes - A challenge is considered positive if the patient develops a wheal and flare reaction at the site of injection, any acute-onset rash distant from the site of challenge, a 15 percent decrease in blood pressure, wheezing, or a 15 percent decrease in pulmonary function, occurring during the 20 minutes after administration of any challenge step [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an LA was tolerated on incremental challenge, adverse reactions to the next clinical use of that agent are uncommon and not likely to be IgE-mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34792/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Future use of local anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a specific LA has been tolerated in an incremental challenge, a report should be supplied to the referring clinician or dentist that includes the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The specific LA tolerated in challenge",
"     </li>",
"     <li>",
"      Its vasoconstrictor, preservative, and stabilizer content (or if a preservative-free preparation should be used)",
"     </li>",
"     <li>",
"      The total dose tolerated during challenge (which is useful for patients with toxic reactions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should not be at increased risk for experiencing an immediate allergic reaction if preparations with the same LA and additives as those given in the challenge are used in future procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Patients with past nonallergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies exist for the prevention of subsequent nonallergic reactions to LAs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with past psychomotor reactions and sympathetic stimulation, anxiety may be reduced by reassurance of the benign nature of these reactions, empiric use of a different LA, and, if necessary, premedication with an anxiolytic.",
"     </li>",
"     <li>",
"      For patients with toxic effects, the cumulative dose used in future procedures should be kept as low as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most idiosyncratic reactions to local anesthetics (LAs) are nonallergic in nature. However, these agents can cause contact dermatitis (type IV hypersensitivity) and have been implicated in rare cases of urticaria and anaphylaxis (type I hypersensitivity). Patients with suspected allergic reactions to LAs should be evaluated, because most can tolerate other local anesthetic agents. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical nonallergic reactions include psychomotor responses related to anxiety, sympathetic stimulation from pain or toxic effects attributable to heightened sensitivity to known properties of the drug. Several strategies are proposed for minimizing the recurrence of these reactions. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Mimics of allergic reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Patients with past nonallergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contact dermatitis and delayed-onset localized swelling are examples of type IV, delayed type hypersensitivity reactions. Symptoms develop one to three days after drug administration and can be evaluated with patch testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contact dermatitis or delayed local swelling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaphylaxis and immediate allergic reactions, which typically begin within one hour of drug administration, have been attributed to LAs in only a handful of case reports. An approach to safely precluding these reactions through skin testing and challenge has been developed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Urticaria and anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/1\">",
"      Eggleston ST, Lush LW. Understanding allergic reactions to local anesthetics. Ann Pharmacother 1996; 30:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/2\">",
"      Melamed J, Beaucher WN. Delayed-type hypersensitivity (type IV) reactions in dental anesthesia. Allergy Asthma Proc 2007; 28:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/3\">",
"      Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. Contact Dermatitis 1998; 39:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/4\">",
"      Garc&iacute;a F, Iparraguirre A, Blanco J, et al. Contact dermatitis from prilocaine with cross-sensitivity to pramocaine and bupivacaine. Contact Dermatitis 2007; 56:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/5\">",
"      P&eacute;rez-P&eacute;rez LC, Fern&aacute;ndez-Redondo V, Ginarte-Val M, et al. Allergic contact dermatitis from EMLA cream in a hemodialyzed patient. Dermatitis 2006; 17:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/6\">",
"      Mackley CL, Marks JG Jr, Anderson BE. Delayed-type hypersensitivity to lidocaine. Arch Dermatol 2003; 139:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/7\">",
"      Amado A, Sood A, Taylor JS. Contact allergy to lidocaine: a report of sixteen cases. Dermatitis 2007; 18:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/8\">",
"      Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermat 2003; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/9\">",
"      Grandinetti PJ, Fowler JF Jr. Simultaneous contact allergy to neomycin, bacitracin, and polymyxin. J Am Acad Dermatol 1990; 23:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/10\">",
"      Connolly M, Mehta A, Sansom JE, Dunnill MG. Allergic contact dermatitis from tetracaine in the beauty industry. Contact Dermatitis 2004; 51:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/11\">",
"      Villarreal LC, de Frutos FJ, Del Prado S&aacute;nchez Caminero M, Sebasti&aacute;n FV. Perineal allergic contact dermatitis due to tetracaine in a urological lubricant. Contact Dermatitis 2004; 51:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/12\">",
"      Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/13\">",
"      Gallenkemper G, Rabe E, Bauer R. Contact sensitization in chronic venous insufficiency: modern wound dressings. Contact Dermatitis 1998; 38:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/14\">",
"      Schwartz HJ, Sher TH. Bisulfite sensitivity manifesting as allergy to local dental anesthesia. J Allergy Clin Immunol 1985; 75:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/15\">",
"      Dooms-Goossens A, de Alam AG, Degreef H, Kochuyt A. Local anesthetic intolerance due to metabisulfite. Contact Dermatitis 1989; 20:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/16\">",
"      Fisher AA. Reactions to injectable local anesthetics. Part IV: Reactions to sulfites in local anesthetics. Cutis 1989; 44:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/17\">",
"      Goldfarb G, Simon R. Provocation of sulfite sensitive asthma (Abst). J Allergy Clin Immunol 1984; 73:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/18\">",
"      Ivy RS. Anesthetics and methylparaben. J Am Dent Assoc 1983; 106:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/19\">",
"      Cashman AL, Warshaw EM. Parabens: a review of epidemiology, structure, allergenicity, and hormonal properties. Dermatitis 2005; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/20\">",
"      Pratt MD, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis 2004; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/21\">",
"      Condie MW, Adams RM. Influence of oral prednisone on patch-test reactions to Rhus antigen. Arch Dermatol 1973; 107:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/22\">",
"      Kaufmann JM, Hale EK, Ashinoff RA, Cohen DE. Cutaneous lidocaine allergy confirmed by patch testing. J Drugs Dermatol 2002; 1:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/23\">",
"      Sanchez-Morillas L, Martinez JJ, Martos MR, et al. Delayed-type hypersensitivity to mepivacaine with cross-reaction to lidocaine. Contact Dermatitis 2005; 53:352.",
"     </a>",
"    </li>",
"    <li>",
"     www.truetest.com/PhysicianPDF/HCP8_TT_Rx_info.pdf (Accessed on November 21, 2008).",
"    </li>",
"    <li>",
"     www.truetest.com (Accessed on November 21, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/26\">",
"      Bircher AJ, Messmer SL, Surber C, Rufli T. Delayed-type hypersensitivity to subcutaneous lidocaine with tolerance to articaine: confirmation by in vivo and in vitro tests. Contact Dermatitis 1996; 34:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/27\">",
"      Curley RK, Macfarlane AW, King CM. Contact sensitivity to the amide anesthetics lidocaine, prilocaine, and mepivacaine. Case report and review of the literature. Arch Dermatol 1986; 122:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/28\">",
"      Klein CE, Gall H. Type IV allergy to amide-type local anesthetics. Contact Dermatitis 1991; 25:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/29\">",
"      Cuesta-Herranz J, de las Heras M, Fern&aacute;ndez M, et al. Allergic reaction caused by local anesthetic agents belonging to the amide group. J Allergy Clin Immunol 1997; 99:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/30\">",
"      Waton J, Boulanger A, Trechot PH, et al. Contact urticaria from Emla cream. Contact Dermatitis 2004; 51:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/31\">",
"      Haugen RN, Brown CW. Case reports: type I hypersensitivity to lidocaine. J Drugs Dermatol 2007; 6:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/32\">",
"      Chiu CY, Lin TY, Hsia SH, et al. Systemic anaphylaxis following local lidocaine administration during a dental procedure. Pediatr Emerg Care 2004; 20:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/33\">",
"      Warrington RJ, McPhillips S. Allergic reaction to local anesthetic agents of the amide group. J Allergy Clin Immunol 1997; 100:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/34\">",
"      Morais-Almeida M, Gaspar A, Marinho S, Rosado-Pinto J. Allergy to local anesthetics of the amide group with tolerance to procaine. Allergy 2003; 58:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/35\">",
"      Calderon AL, Diot N, Benatir F, et al. Immediate allergic cross-reactivity to levobupivacaine and ropivacaine. Anaesthesia 2013; 68:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/36\">",
"      Dower JS Jr. A review of paresthesia in association with administration of local anesthesia. Dent Today 2003; 22:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/37\">",
"      Fiset L, Milgrom P, Weinstein P, et al. Psychophysiological responses to dental injections. J Am Dent Assoc 1985; 111:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/38\">",
"      Cawson RA, Curson I, Whittington DR. The hazards of dental local anaesthetics. Br Dent J 1983; 154:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/39\">",
"      Chernow B, Balestrieri F, Ferguson CD, et al. Local dental anesthesia with epinephrine. Minimal effects on the sympathetic nervous system or on hemodynamic variables. Arch Intern Med 1983; 143:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/40\">",
"      Latronica RJ, Goldberg AF, Wightman JR. Local anesthetic sensitivity. Report of a case. Oral Surg Oral Med Oral Pathol 1969; 28:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/41\">",
"      Wells JP, Beckett H. Articaine hydrochloride: a safe alternative to lignocaine? Dent Update 2008; 35:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/42\">",
"      Lin FL, Woodmansee D, Patterson R. Near-fatal anaphylaxis to topical bacitracin ointment. J Allergy Clin Immunol 1998; 101:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/43\">",
"      Schroer BC, Fox CC, Hauswirth DW. Skin testing after anaphylaxis to a topical Neosporin preparation. Ann Allergy Asthma Immunol 2008; 101:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/44\">",
"      Sharif S, Goldberg B. Detection of IgE antibodies to bacitracin using a commercially available streptavidin-linked solid phase in a patient with anaphylaxis to triple antibiotic ointment. Ann Allergy Asthma Immunol 2007; 98:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/45\">",
"      Nasser SM, Ewan PW. Opiate-sensitivity: clinical characteristics and the role of skin prick testing. Clin Exp Allergy 2001; 31:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/46\">",
"      Nagel JE, Fuscaldo JT, Fireman P. Paraben allergy. JAMA 1977; 237:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/47\">",
"      Aldrete JA, Johnson DA. Allergy to local anesthetics. JAMA 1969; 207:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/48\">",
"      Johnson WT, DeStigter T. Hypersensitivity to procaine, tetracaine, mepivacaine, and methylparaben: report of a case. J Am Dent Assoc 1983; 106:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/49\">",
"      Luebke NH, Walker JA. Discussion of sensitivity to preservatives in anesthetics. J Am Dent Assoc 1978; 97:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/50\">",
"      Macy E, Schatz M, Zeiger RS. Immediate hypersensitivity to methylparaben causing false-positive results of local anesthetic skin testing or provocative dose testing. The Permanente Journal 2002; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/51\">",
"      Schatz M. Adverse reactions to local anesthetics. Immunol All Clin N Am 1992; 12:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/52\">",
"      Barer MR, McAllen MK. Hypersensitivity to local anaesthetics: a direct challenge test with lignocaine for definitive diagnosis. Br Med J (Clin Res Ed) 1982; 284:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/53\">",
"      Ravindranathan N. Allergic reaction to lignocaine. A case report. Br Dent J 1975; 138:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/54\">",
"      Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol 2011; 21:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/55\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/56\">",
"      deShazo RD, Nelson HS. An approach to the patient with a history of local anesthetic hypersensitivity: experience with 90 patients. J Allergy Clin Immunol 1979; 63:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/57\">",
"      Chandler MJ, Grammer LC, Patterson R. Provocative challenge with local anesthetics in patients with a prior history of reaction. J Allergy Clin Immunol 1987; 79:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/58\">",
"      Sindel LJ, deShazo RD. Accidents resulting from local anesthetics. True or false allergy? Clin Rev Allergy 1991; 9:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/59\">",
"      Gall H, Kaufmann R, Kalveram CM. Adverse reactions to local anesthetics: analysis of 197 cases. J Allergy Clin Immunol 1996; 97:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/60\">",
"      Fisher MM, Bowey CJ. Alleged allergy to local anaesthetics. Anaesth Intensive Care 1997; 25:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/61\">",
"      Lorenzi P, Marsili M, Manetta G, et al. Prevention of anaphylactic-anaphylactoid reactions to anesthetics in high-risk allergic patients. Anesth Pain Control Dent 1993; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/62\">",
"      Troise C, Voltolini S, Minale P, et al. Management of patients at risk for adverse reactions to local anesthetics: analysis of 386 cases. J Investig Allergol Clin Immunol 1998; 8:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34792/abstract/63\">",
"      Wasserfallen JB, Frei PC. Long-term evaluation of usefulness of skin and incremental challenge tests in patients with history of adverse reaction to local anesthetics. Allergy 1995; 50:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2084 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34792=[""].join("\n");
var outline_f33_62_34792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CATEGORIES OF LOCAL ANESTHETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTACT DERMATITIS OR DELAYED LOCAL SWELLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other possible culprits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Patch testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      URTICARIA AND ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Case reports",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8361454\">",
"      Cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mimics of allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Psychomotor reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Vasovagal syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sympathetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Systemic toxic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other potential allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Skin testing and challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H669002\">",
"      Testing procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H668976\">",
"      Skin test interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Future use of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Patients with past nonallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/47/18171\" title=\"table 1\">",
"      Classification local anesthetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/11/13500\" title=\"table 2\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/3/11323\" title=\"table 3\">",
"      Skin testing protocol LA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/26/29099\" title=\"table 4\">",
"      Protocol sq incremental chal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/442?source=related_link\">",
"      Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34793="Prenatal diagnosis of gastrointestinal atresia and obstruction";
var content_f33_62_34793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal diagnosis of gastrointestinal atresia and obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Dorothy I Bulas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/62/34793/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/62/34793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24138444\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atresia refers to narrowing of the lumen of a hollow viscus. The ability to diagnose gastrointestinal (GI) atresia prenatally is influenced by the site of obstruction, the presence of associated anomalies, and the gestational age at the time of imaging. This topic will discuss prenatal evaluation and obstetrical management of fetal esophageal,",
"    <span class=\"nowrap\">",
"     small/large",
"    </span>",
"    bowel, and anorectal atresia. Postnatal clinical manifestations, diagnosis, evaluation, and management are reviewed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138451\">",
"    <span class=\"h1\">",
"     TECHNIQUES FOR IMAGING THE FETAL GI TRACT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138459\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3677343\">",
"    <span class=\"h3\">",
"     Normal findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physiologic midgut herniation &ndash;",
"      </strong>",
"      Rapid growth of the intestines and liver occurs during the fourth to fifth week of development. During the sixth week of development (or eight weeks from the last menstrual period), the abdominal cavity temporarily becomes too small to accommodate all of its contents, resulting in protrusion of the intestines into the residual extraembryonic coelom at the base of the umbilical cord. This temporary herniation is called physiologic midgut herniation and is sonographically evident between the 9th to 11th postmenstrual weeks (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54907 \" href=\"mobipreview.htm?34/20/35141\">",
"       image 1",
"      </a>",
"      ). Reduction of this hernia occurs by the 12th postmenstrual week; beyond the 12th week, a midgut herniation is no longer physiological [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Esophagus &ndash;",
"      </strong>",
"      The normal fetal esophagus is collapsed and typically not visualized. Swallowing occurs by 11 to 14 weeks of gestation; therefore, a fluid-filled stomach should be detectable sonographically in most second and third trimester fetuses. Absence of the stomach on serial fetal ultrasound examinations suggests either mechanical obstruction (eg, esophageal atresia, neck mass compressing the esophagus), decreased fetal swallowing due to neuromuscular dysfunction, or severe oligohydramnios [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bowel &ndash;",
"      </strong>",
"      The bowel lumen appears collapsed in the first trimester. Fluid may be seen in the lumen after 13 weeks of gestation, and is usually seen by 20 weeks of gestation. Peristalsis can be observed as early as 18 weeks of gestation and separate loops of small bowel are distinguishable after 28 weeks of gestation. The colon is best visualized after 24 weeks of gestation as hypoechoic regions along the periphery of the abdomen.",
"      <br/>",
"      <br/>",
"      The bowel is variably echogenic, at times similar in echogenicity to adjacent liver, spleen, and kidneys. High resolution linear transducers can be helpful in differentiating these organs. Meconium accumulates in the bowel throughout the second and third trimesters and can be echogenic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/2-6\">",
"       2-6",
"      </a>",
"      ]. By term, the colon becomes filled with meconium and can measure up to 28 mm in diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Excessively echogenic bowel (which should be as bright as bone to be deemed &ldquo;echogenic bowel&rdquo;), however, may be a marker for an abnormality, such as cystic fibrosis, trisomy 21, congenital infection with cytomegalovirus (CMV) or parvovirus, or severe intrauterine growth restriction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36166?source=see_link\">",
"       \"Fetal echogenic bowel\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32456?source=see_link\">",
"       \"Overview of echogenic masses and calcification in the fetal abdomen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3678109\">",
"    <span class=\"h3\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;On ultrasound, obstruction is suggested by the presence of dilated bowel loops, which develop proximal to the obstructed site. Vigorous peristalsis also may be noted. Observational studies have found that normal small bowel loops generally do not exceed 7 mm in diameter or 15 mm in length, while the colonic diameter increases during pregnancy, achieving diameters up to 23 mm at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Tables of normal lumen diameters across gestation are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prenatal sonographic diagnosis of fetal gastrointestinal obstruction is challenging since some obstructions may not become evident until the late second trimester, later than the typical time of a fetal anatomic survey. In addition, it can be difficult to differentiate dilated small bowel loops from colon or megaureters sonographically.",
"   </p>",
"   <p>",
"    The performance of ultrasound for prenatal diagnosis of gastrointestinal obstruction was illustrated in a study of routine ultrasonographic examination in an unselected population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/8\">",
"     8",
"    </a>",
"    ]. The overall prenatal detection rate of gastrointestinal obstruction (atresia, stenosis, absence, or fistula) was 34 percent, of which 40 percent was detected at &le;24 weeks of gestation. The detection rate was 52 percent (33 out of 64) for duodenal obstruction, 40 percent (27 out of 68) for small intestine obstruction, 29 percent (28 out of 95) for large intestine obstruction, and 25 percent (31 out of 122) for esophageal obstruction. The detection rate for anal atresia was much lower, 6 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have also reported poor sensitivity in prenatal ultrasonographic diagnosis of large bowel lesions and misdiagnosis between small and large bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to low sensitivity, ultrasound is not able to accurately identify the number and location of obstructions, and has limited ability for assessing the viability of unobstructed distal bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138466\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limitations of prenatal sonography for diagnosis of gastrointestinal atresia, some experts have proposed the use of magnetic resonance (MR) imaging to help in characterizing gastrointestinal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. Fetal bowel is well visualized by MR imaging and easily differentiated from adjacent liver, spleen, kidneys, bladder, and gallbladder.",
"   </p>",
"   <p>",
"    However, MR has a limited role in identifying the level of a gastrointestinal obstruction since most obstructions can be diagnosed with ultrasound alone. Suspected anal atresia is rarely confirmed prenatally, and there is no evidence that MR improves upon sonographic diagnosis. MR may be helpful in cloacal atresia because the etiology of the obstruction and the associated abnormalities are not completely characterized by ultrasound.",
"   </p>",
"   <p>",
"    Swallowed amniotic fluid in the gastrointestinal tract is T2 hyperintense and T1 hypointense. The esophagus, stomach and duodenum should always be filled with T2 hyperintense fluid. The jejunum is also filled with amniotic fluid and should be high T2 and low T1 signal after 33 weeks of gestation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66951 \" href=\"mobipreview.htm?7/31/7668\">",
"     image 2",
"    </a>",
"    ). The distal small bowel is more variable in signal, depending on gestational age. Before 32 weeks, the distal small bowel is high signal on T1w in over half of cases due to slow protein rich meconium progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. In bowel atresia, T1 high signal may remain in proximal dilated loops due to lack of progression of meconium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meconium in the lumen is low signal on T2w and high signal on T1w. Meconium increases gradually throughout the colon as gestational age increases. The descending colon fills with meconium by 24 weeks of gestation, while the ascending colon is filled with meconium in 50 percent of fetuses before 31 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After 20 weeks of gestation, the rectum is normally high T1 signal and low T2 signal due to meconium that accumulates near the functionally obstructed anal canal. The rectum is posterior to the bladder and at least 1 cm below the bladder neck. The rectal anteroposterior diameter increases with gestational age, measuring 4 to 8 mm at 24 weeks and 9 to 15 mm by 35 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12\">",
"     12",
"    </a>",
"    ]. Normal colonic luminal volume by MR imaging increases exponentially with gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/17\">",
"     17",
"    </a>",
"    ]. Based on three-dimensional reconstructions, colonic luminal volumes at 20 to 37 weeks of gestation range from 1.1 to 65 mL, with greater variation in later gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138474\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal atresia refers to a congenitally interrupted esophagus; one or more fistulae may be present between the malformed esophagus and the trachea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link&amp;anchor=H16#H16\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheoesophageal fistula and esophageal atresia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are five types of tracheoesophageal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A &ndash; Esophageal atresia without tracheoesophageal fistula (10 percent)",
"     </li>",
"     <li>",
"      Type B &ndash; Esophageal atresia with a tracheoesophageal fistula to the proximal esophageal segment (&lt;1 percent)",
"     </li>",
"     <li>",
"      Type C &ndash; Esophageal atresia with a tracheoesophageal fistula to the distal esophageal segment (85 percent)",
"     </li>",
"     <li>",
"      Type D &ndash; Esophageal atresia with tracheoesophageal fistula to both the proximal and distal esophageal segments (&lt;1 percent)",
"     </li>",
"     <li>",
"      Type E &ndash; Tracheoesophageal fistula with no esophageal atresia (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138490\">",
"    <span class=\"h2\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated (Type A) esophageal atresia is readily diagnosed prenatally when polyhydramnios, absent stomach, and a dilated proximal esophageal pouch in the neck or mediastinum are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, over 85 percent of esophageal atresias are associated with a tracheoesophageal fistula (TEF), and the diagnosis in these cases is often missed prenatally because fluid can course into the stomach via the fistula. Thus, the amniotic fluid volume may not be increased, the proximal pouch may not be dilated or may be transiently dilated, and the stomach may not be small (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77438 \" href=\"mobipreview.htm?39/16/40197\">",
"     image 3",
"    </a>",
"    ). Even in cases of esophageal atresia without TEF, polyhydramnios may not develop until the late second trimester. Polyhydramnios is present in about one-third of fetuses with esophageal atresia plus distal TEF and in 100 percent of fetuses with esophageal atresia without TEF by the third trimester.",
"   </p>",
"   <p>",
"    Visualization of the fetal stomach is important in screening fetuses for possible",
"    <span class=\"nowrap\">",
"     TEF/esophageal",
"    </span>",
"    atresia. Nonvisualization can be due to a recently emptied stomach so repeated examination is necessary. Failure to visualize the fetal stomach despite serial examinations strongly suggests the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/21\">",
"     21",
"    </a>",
"    ]. A collapsed stomach or slightly filled stomach (gastric juices) can sometimes be detected by observation of two parallel echogenic lines in the upper abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/22\">",
"     22",
"    </a>",
"    ]. The diagnosis should still be suspected if the stomach is visualized but small, especially if polyhydramnios is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/8,21,22\">",
"     8,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3102107\">",
"    <span class=\"h3\">",
"     Associated anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 50 percent of fetuses with esophageal atresia have additional anomalies. Cardiac malformations are the most common (25 percent) and result in the highest morbidity and mortality. TEF is often associated with the VACTERL (vertebral, anal atresia, cardiac, tracheoesophageal fistula, renal, limb) association, which includes vertebral, anorectal, cardiac, tracheal, esophageal, renal, and limb anomalies and a two vessel cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138497\">",
"    <span class=\"h2\">",
"     MR findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR may be useful in selected cases to identify associated anomalies that are suspected, but not definitively diagnosed by ultrasound, such as pulmonary atresia or anal atresia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138504\">",
"    <span class=\"h2\">",
"     Differential diagnosis of a small/absent stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several causes of a small or empty stomach besides esophageal atresia. Severe oligohydramnios can result in a small or absent stomach because there is no or minimal fluid for the fetus to swallow.",
"   </p>",
"   <p>",
"    When a normal appearing fluid-filled stomach cannot be identified in the left upper quadrant, the fetus should be examined for displacement of the stomach into the chest due to diaphragmatic defect or externally due to an abdominal wall defect or to the right due to situs inversus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42169?source=see_link\">",
"     \"Congenital diaphragmatic hernia: Prenatal diagnosis and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal abdominal wall defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41205?source=see_link\">",
"     \"Overview of the development of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neck and pharynx should be examined for masses that could obstruct swallowing, resulting in a small or empty stomach, as well. Sonographic observation of swallowing and normal fetal tone helps to exclude a neuromuscular cause. Microgastria is another rare cause of a small or empty stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138511\">",
"    <span class=\"h2\">",
"     Obstetrical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus should be assessed for associated anomalies. Sonographic evaluation for VACTERL (vertebral, anal, cardiac, tracheal, esophageal, renal, limb) association includes careful assessment of the spine, heart, kidneys, skeleton, and umbilical cord. We suggest echocardiography, given the increased prevalence of cardiac malformations. (See",
"    <a class=\"local\" href=\"#H3102107\">",
"     'Associated anomalies'",
"    </a>",
"    above.) The finding of a ventricular septal defect or pulmonary stenosis, which may not be seen on a four chamber view, helps to confirm that VACTERL association is present. We also offer amniocentesis to determine the fetal karyotype, as there is a 6 to 10 percent risk of chromosomal abnormalities, including trisomy 21 and 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polyhydramnios develops in up to 60 percent of cases of esophageal atresia, typically in the third trimester. The clinical manifestations and outcome of pregnancies complicated by polyhydramnios varies according to the severity, and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether prenatal diagnosis of esophageal atresia with or without TEF improves the prognosis. However, early prenatal diagnosis provides an opportunity for parental counseling and preparation, screening for associated anomalies, pregnancy termination or delivery at an appropriate setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delivery should be planned at a center that has appropriate neonatal support. Esophageal abnormalities alone are not an indication for altering the route of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138518\">",
"    <span class=\"h2\">",
"     Postnatal management and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors affecting postnatal prognosis include the gestational age at delivery, the presence of associated anomalies, and the type of tracheoesophageal defect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138532\">",
"    <span class=\"h1\">",
"     DUODENAL ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal atresia and stenosis are the most common types of intestinal obstruction detected in the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/25\">",
"     25",
"    </a>",
"    ]. Atresia accounts for up to 75 percent of intestinal obstructions and has three phenotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 1 &ndash; Membranous mucosal atresia with an intact muscular wall (69 percent)",
"     </li>",
"     <li>",
"      Type 2 &ndash; Short fibrous cord which connects the two ends of the atretic duodenum",
"     </li>",
"     <li>",
"      Type 3 &ndash; Complete separation of the two ends of the duodenum plus biliary tract anomalies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138548\">",
"    <span class=\"h2\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic findings suggestive of duodenal atresia include a dilated fluid filled stomach adjacent to a dilated proximal intestinal segment (fetal &ldquo;double bubble&rdquo;) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70937 \" href=\"mobipreview.htm?35/48/36609\">",
"     image 4",
"    </a>",
"    ); the distal segment is empty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/27\">",
"     27",
"    </a>",
"    ]. The diagnosis can be made in the early second trimester, but more commonly is made in the third trimester when the duodenum becomes more dilated. Polyhydramnios develops in up to 50 percent of cases, but is not typically present until the mid to late second trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis can be missed at the time of the second trimester anatomic survey if performed early in the second trimester, before the stomach and duodenum become visibly dilated. The diagnosis can also be missed prenatally if the duodenum does not become dilated because it is stenotic (incomplete obstruction) rather than atretic or when fetal swallowing is inhibited, such as with coexisting esophageal atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/19,31-33\">",
"     19,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3102552\">",
"    <span class=\"h3\">",
"     Associated anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than one-half of fetuses with duodenal atresia have associated anomalies. Trisomy 21 is the most frequent, occurring in up to 30 percent of cases (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link&amp;anchor=H21#H21\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Trisomy 21 (Down syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duodenal atresia and stenosis can be part of the VACTERL association (vertebral, anal atresia, cardiac, tracheoesophageal fistula, renal, limb). In these cases, hemivertebra, radial ray anomalies and renal anomalies may be identified. Twenty to 30 percent of fetuses with duodenal atresia have congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Duodenal atresia is also associated with annular pancreas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138562\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis includes annular pancreas with extrinsic compression, intestinal malrotation with Ladd&rsquo;s bands, gastrointestinal duplication cysts, preduodenal portal vein, and choledochal cyst. Documenting that the fluid filled structure is contiguous with the stomach helps to differentiate duodenal",
"    <span class=\"nowrap\">",
"     atresia/stenosis",
"    </span>",
"    from a duplication or choledochal cyst, which would not be contiguous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138569\">",
"    <span class=\"h2\">",
"     Obstetrical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus should be assessed for associated anomalies. We suggest echocardiography, given the increased prevalence of cardiac malformations. (See",
"    <a class=\"local\" href=\"#H3102107\">",
"     'Associated anomalies'",
"    </a>",
"    above.) We also offer amniocentesis to determine the fetal karyotype, as there is a 30 percent risk of trisomy 21.",
"   </p>",
"   <p>",
"    Polyhydramnios develops in up to 50 percent of cases of duodenal atresia, typically in the third trimester. The clinical manifestations and outcome of pregnancies complicated by polyhydramnios varies according to the severity, and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early prenatal diagnosis provides an opportunity for parental counseling and preparation, screening for associated anomalies, pregnancy termination or delivery at an appropriate setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/35\">",
"     35",
"    </a>",
"    ]. Several observational series have concluded that prenatal diagnosis of duodenal atresia reduces morbidity and shortens hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delivery should be planned at a center that has appropriate neonatal support. Duodenal abnormalities alone are not an indication for altering the route of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138576\">",
"    <span class=\"h2\">",
"     Postnatal management and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors affecting postnatal prognosis include the gestational age at delivery, the presence of associated anomalies, and the type of duodenal defect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31608?source=see_link\">",
"     \"Intestinal atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138590\">",
"    <span class=\"h1\">",
"     JEJUNAL AND ILEAL ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jejunal and ileal atresias are complete obstructions of the small bowel lumen; they are more common than small bowel stenosis. Atresias can occur anywhere in the small bowel, but most commonly present in the proximal jejunal (30 percent) and distal ileum (35 percent). Multiple atretic sites occur in up to 6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/38\">",
"     38",
"    </a>",
"    ]. Ischemia can result in a jejunal or ileal atresia with secondary complications of volvulus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meconium peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31608?source=see_link\">",
"     \"Intestinal atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal atresias are classified as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 &ndash; Intraluminal diaphragm in continuity with the muscular coats of the proximal and distal segments (32 percent).",
"     </li>",
"     <li>",
"      Type 2 &ndash; Fibrotic cord connecting two blind ending bowel segments (25 percent).",
"     </li>",
"     <li>",
"      Type 3a &ndash; Complete separation of blind ending loops (15 percent).",
"      <br/>",
"      Type 3b &ndash; Mesenteric defect and associated apple peel deformity. The terminal ileum is perfused from single ileocolic artery (11 percent).",
"     </li>",
"     <li>",
"      Type 4 &ndash; Multiple atresias (6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138615\">",
"    <span class=\"h2\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fetal bowel obstruction is rarely made before 18 weeks of gestation and can be difficult before 24 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/40\">",
"     40",
"    </a>",
"    ]. In the third trimester, bowel loops become progressively more dilated with vigorous peristalsis and thus easier to see.",
"   </p>",
"   <p>",
"    The presence of dilated loops (&gt;15 mm in length and 7 mm in diameter)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mural thickness greater than 3 mm is suggestive of fetal bowel obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63793 \" href=\"mobipreview.htm?28/30/29153\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/2\">",
"     2",
"    </a>",
"    ]. The abdomen may be distended with asymmetric increase in the abdominal circumference. If meconium ileus is present, increased bowel echogenicity may be noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few dilated loops suggest a jejunal obstruction, whereas multiples loops suggest a more distal obstruction. However, differentiating an isolated atresia from multiple atresias is difficult sonographically.",
"   </p>",
"   <p>",
"    The prevalence of polyhydramnios decreases as the site of gastrointestinal obstruction becomes more distal. Polyhydramnios is seen in fewer than 50 percent of cases of jejunal obstruction and rarely with more distal obstruction. Its presence with dilated bowel loops suggests more severe obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perforation at the site of obstruction may leak fluid and meconium, resulting in ascites, meconium peritonitis, and meconium pseudocysts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73435 \" href=\"mobipreview.htm?6/44/6855\">",
"     image 6",
"    </a>",
"    ). Scattered peritoneal calcifications with posterior acoustical shadowing may be noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32456?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of echogenic masses and calcification in the fetal abdomen\", section on 'Meconium peritonitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32456?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of echogenic masses and calcification in the fetal abdomen\", section on 'Meconium pseudocyst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103159\">",
"    <span class=\"h3\">",
"     Associated anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional gastrointestinal anomalies are present in up to 45 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study, these included malrotation (23 percent), meconium peritonitis (8 percent), microcolon (3 percent), duplication cysts (3 percent), and esophageal atresia (3 percent). Volvulus has also been associated with atresias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small bowel atresia is secondary to meconium ileus in 10 percent of cases. In these cases, obstruction of the terminal ileum occurs from impacted thick meconium. Perforation with secondary ileal atresia and meconium peritonitis may develop. Up to 15 percent of fetuses with cystic fibrosis present with meconium ileus and up to 50 percent of these cases will be complicated by an atresia, volvulus, perforation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meconium pseudocysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link&amp;anchor=H11#H11\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Meconium ileus and distal ileal obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22503?source=see_link\">",
"     \"Cystic fibrosis: Prenatal genetic screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastroschisis has been associated with bowel atresia due to ischemic injury from bowel kinking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=see_link&amp;anchor=H8#H8\">",
"     \"Prenatal sonographic diagnosis of fetal abdominal wall defects\", section on 'Gastroschisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placental vascular abnormalities have also been associated with small bowel atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138622\">",
"    <span class=\"h2\">",
"     MR findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR has been used as an adjunct in the assessment of bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12,13,47\">",
"     12,13,47",
"    </a>",
"    ] and, in one study, provided more accurate findings than ultrasound in the assessment of small bowel atresias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bowel loops proximal to the obstruction are dilated (13 to 30 mm). The signal characteristics are variable depending on the gestational age and location of obstruction. The bowel can be fluid filled high signal T2w, or meconium filled high signal T1w or intermediate in signal. Distally, the rectum may contain less meconium and thus decrease in size (2 to 7 mm) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52533 \" href=\"mobipreview.htm?38/7/39027\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The level of obstruction is suggested by the number of dilated loops and the number of nondilated loops proximal to the dilated loops. The absence of loops distal to the level of obstruction suggests multiple atresias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12\">",
"     12",
"    </a>",
"    ]. One report described dilated loops with two different signals in a case with two levels of atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As it takes time for meconium to travel to and through the colon, the presence of T1 high signal in a dilated loop of bowel is not specific for a distal ileal or colonic occlusion. In one series of 11 fetuses between 23 to 35 weeks of gestation with T1 high signal in dilated bowel, 9 had proximal jejunal atresia (5 with short bowel syndrome) and 2 had meconium ileus at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meconium peritonitis can be diagnosed by extraluminal fluid collections scattered through the abdomen. MR is better than ultrasound for distinguishing meconium cysts from adjacent bowel since meconium and bowel have different signal characteristics. Peritoneal calcifications, however, are more easily noted by ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138629\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for dilated tubular loops within the fetal abdomen includes jejunal or ileal atresia, total colonic aganglionosis, volvulus, malrotation with volvulus, meconium ileus, meconium peritonitis, intestinal duplication cysts, and fetal diarrhea. At times, megaureters and abdominal mesenteric cysts can mimic dilated bowel loops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12,51\">",
"     12,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138644\">",
"    <span class=\"h2\">",
"     Obstetrical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus should be assessed for associated anomalies. The incidence of aneuploidy and extraintestinal anomalies is low.",
"   </p>",
"   <p>",
"    We suggest follow-up ultrasound examinations to evaluate whether there has been any change in the appearance of the bowel or associated anomalies, and to assess interval fetal growth and amniotic fluid volume. Severely obstructed bowel may perforate and may be an indication for early delivery if the fetus is near term.",
"   </p>",
"   <p>",
"    Early prenatal diagnosis provides an opportunity for parental counseling and preparation, screening for associated anomalies, pregnancy termination, or delivery at an appropriate setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/35\">",
"     35",
"    </a>",
"    ]. Delivery should be planned at a center that has appropriate neonatal support. Jejunal or ileal atresia alone is not an indication for altering the route of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138651\">",
"    <span class=\"h2\">",
"     Postnatal management and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors affecting postnatal prognosis include the gestational age at delivery, the presence of associated anomalies, and the cause of the atresia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31608?source=see_link\">",
"     \"Intestinal atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138658\">",
"    <span class=\"h1\">",
"     COLONIC OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic obstruction may be due to Hirschsprung disease, anorectal malformations, or colonic atresia. It is often missed prenatally because fluid is resorbed in the small bowel and colonic loops, which allows the small bowel and colon to retain normal diameters despite distal obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209223\">",
"    <span class=\"h2\">",
"     Hirschsprung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirschsprung disease is one of the most common causes of intestinal obstruction in the newborn. Aganglionosis of a segment of colon results in a functionally obstructed distal segment with a dilated proximal segment that tapers at a transition zone. As fetuses do not stool, it takes time post-delivery for a transition zone with dilated proximal segment to develop so obstructive symptoms and constipation typically develop only after birth; therefore, prenatal diagnosis is rare. If Hirschsprung disease presents prenatally, it is typically due to total colonic aganglionosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209392\">",
"    <span class=\"h3\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total aganglionosis has been diagnosed in the third trimester based on polyhydramnios and small bowel dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Enterolithiasis may develop due to functional obstruction and precipitation of urates within the lumen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/55\">",
"     55",
"    </a>",
"    ]. Fetal Hirschsprung disease may be associated with echogenic bowel, but this finding is not pathognomonic of the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36166?source=see_link\">",
"     \"Fetal echogenic bowel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Up to 25 percent of affected fetuses have associated anomalies, with a strong association with trisomy 21. (See",
"    <a class=\"local\" href=\"#H24138716\">",
"     'Obstetrical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138681\">",
"    <span class=\"h2\">",
"     Anorectal malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the rectum and anus are thought to be due to arrest of the caudal descent of the urorectal septum to the cloacal membrane. The resulting malformations range from isolated imperforate anus to persistent cloaca. These malformations are classified as &ldquo;high&rdquo; supralevator lesions, which end above the levator sling and are typically associated with fistulas, and &ldquo;low&rdquo; infralevator lesions, which end below the levator sling and are not associated with fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209504\">",
"    <span class=\"h3\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated transient bowel dilatation has been observed as early as 12 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]; the distal colon may be dilated prenatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/58\">",
"     58",
"    </a>",
"    ]. Associated anomalies occur in up to 50 percent of cases. Anal atresia is most commonly associated with the VACTERL association (vertebral, anal atresia, cardiac, tracheoesophageal fistula, renal, limb), and occurs with increased frequency in trisomy 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a vesicourethral fistula is present, urine may mix with meconium, which calcifies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/55\">",
"     55",
"    </a>",
"    ]. Therefore, if intraluminal calcifications are identified, anal atresia with vesicorectal fistula should be suspected (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78127 \" href=\"mobipreview.htm?0/24/388\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209722\">",
"    <span class=\"h3\">",
"     MR findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the fetal cul-de-sac by MR can be helpful in distinguishing between a high anorectal malformation and cloaca [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/6,12,60\">",
"     6,12,60",
"    </a>",
"    ]. MR may reveal dilated meconium filled rectum in cases of anal atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/60\">",
"     60",
"    </a>",
"    ] and detection of abnormal fluid in the rectum suggests vesicorectal fistula (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76382 \" href=\"mobipreview.htm?42/11/43189\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209263\">",
"    <span class=\"h2\">",
"     Colonic atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic atresia is a rare cause of intestinal obstruction and accounts for less than 15 percent of all bowel atresias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/40\">",
"     40",
"    </a>",
"    ]. Similar to jejunal and ileal atresia, colonic atresia is thought to be secondary to a vascular event or a mechanical event, such as intestinal volvulus. The majority of colonic atresias occur proximal to the splenic flexure with a distal microcolon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138695\">",
"    <span class=\"h3\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, distal colonic obstruction is often missed prenatally because fluid is resorbed in the small bowel so colonic loops remain normal in caliber rather than dilating. Polyhydramnios is rare and, when present, should raise the suspicion that a more proximal obstruction is present. Perforation may occur with resulting ascites and meconium peritonitis.",
"   </p>",
"   <p>",
"    In two thirds of cases, colonic atresia occurs as an isolated defect without associated abnormalities. In the remaining cases, associated anomalies may include gastroschisis, omphalocele, Hirschsprung disease, or ocular and skeletal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/61\">",
"     61",
"    </a>",
"    ]. Cardiac anomalies and genetic defects are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138709\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When dilatation of the fetal bowel (including the colon) is observed, the differential diagnosis includes colonic atresia, meconium ileus, imperforate anus, persistent cloaca, meconium plug syndrome, fetal diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/51\">",
"     51",
"    </a>",
"    ], and megacystis microcolon hypoperistalsis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When calcifications are noted, it is important to determine if they are intraluminal or extraluminal. Intraluminal calcifications suggest a rectovesical fistula, while extraluminal calcifications may be secondary to meconium peritonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32456?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of echogenic masses and calcification in the fetal abdomen\", section on 'Bowel calcifications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32456?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of echogenic masses and calcification in the fetal abdomen\", section on 'Peritoneal calcifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138716\">",
"    <span class=\"h2\">",
"     Obstetrical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus should be assessed for associated anomalies. Sonographic evaluation for VACTERL association includes careful assessment of the spine, heart, kidneys, skeleton, and umbilical cord. We suggest echocardiography, given the increased prevalence of cardiac malformations.",
"   </p>",
"   <p>",
"    We offer amniocentesis to determine the fetal karyotype when bowel dilatation before 22 weeks of gestation is accompanied by associated anomalies.",
"   </p>",
"   <p>",
"    Offering screening for trisomy 21 is a routine part of prenatal care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/27/22969?source=see_link\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"    </a>",
"    .) The risk of trisomy 21 increases as women age and is higher when certain congenital anomalies or soft markers are noted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link&amp;anchor=H21#H21\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Trisomy 21 (Down syndrome)'",
"    </a>",
"    .) Five percent of children with trisomy 21 have gastrointestinal tract anomalies. Imperforate anus and esophageal atresia with tracheoesophageal fistula are seen less often. Conversely, trisomy 21 affects about 30 percent of patients with duodenal atresia or stenosis and 20 percent with annular pancreas. Hirschsprung disease is more common in trisomy 21 than in the general population with 2 percent of children with Hirschsprung disease having trisomy 21. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early prenatal diagnosis provides an opportunity for parental counseling and preparation, screening for associated anomalies, pregnancy termination, or delivery at an appropriate setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/62/34793/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delivery should be planned at a center that has appropriate neonatal support. Distal colonic obstruction is not typically associated with prematurity since polyhydramnios is uncommon. Colonic abnormalities alone are not an indication for altering the route of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138723\">",
"    <span class=\"h2\">",
"     Postnatal management and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal management and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31608?source=see_link\">",
"     \"Intestinal atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24138737\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of bowel atresias prenatally can be difficult. Diagnosis is typically made in the second or third trimester. Proximal obstruction is more readily diagnosed than distal obstruction because bowel dilatation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polyhydramnios are more likely to be present. (See",
"      <a class=\"local\" href=\"#H24138459\">",
"       'Ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance (MR) imaging can be a useful adjunct in delineating the contents of normal and abnormal bowel, and can aid in the evaluation of associated anomalies. (See",
"      <a class=\"local\" href=\"#H24138466\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visualization of the fetal stomach is important in screening fetuses for esophageal atresia. Nonvisualization can be due to a recently emptied stomach so repeated examination is necessary. Failure to visualize the fetal stomach despite serial examinations strongly suggests the diagnosis. (See",
"      <a class=\"local\" href=\"#H24138474\">",
"       'Esophageal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated esophageal atresia is readily diagnosed prenatally by the presence of polyhydramnios, absent stomach, and a dilated proximal esophageal pouch in the neck or mediastinum. However, over 85 percent of esophageal atresias are associated with a tracheoesophageal fistula (TEF), and the diagnosis in these cases is often missed prenatally because fluid can course into the stomach via the fistula. (See",
"      <a class=\"local\" href=\"#H24138474\">",
"       'Esophageal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sonographic findings suggestive of duodenal atresia include a dilated fluid filled stomach next to a dilated proximal intestinal segment (fetal &ldquo;double bubble&rdquo;); the distal segment is empty. Duodenal atresia is the most common atresia identified prenatally and is associated with other anomalies, particularly trisomy 21. The diagnosis can be missed prior to 24 weeks if the duodenum has not yet significantly dilated or if a TEF is also present. (See",
"      <a class=\"local\" href=\"#H24138532\">",
"       'Duodenal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyhydramnios often develops with proximal esophageal and duodenal obstructions, but typically does not develop in more distal atresias. (See",
"      <a class=\"local\" href=\"#H24138474\">",
"       'Esophageal atresia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24138532\">",
"       'Duodenal atresia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24138590\">",
"       'Jejunal and ileal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal ultrasound has low sensitivity for detection of colonic obstructions including Hirschsprung disease, anorectal malformations, and colonic atresia. A dilated meconium filled rectum, intraluminal or extraluminal calcification, and the presence of VACTERL association suggest the diagnosis. (See",
"      <a class=\"local\" href=\"#H24138658\">",
"       'Colonic obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anal atresia may be associated with rectovesical fistula. In these cases, urine can mix with meconium resulting in dilated fluid filled rectum with intraluminal calcifications easily identified by ultrasound. (See",
"      <a class=\"local\" href=\"#H24138681\">",
"       'Anorectal malformations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When calcifications are noted, it is important to determine if they are intraluminal or extraluminal. Intraluminal calcifications suggest a rectovesical fistula. Extraluminal may be secondary to meconium peritonitis. Echogenic bowel with meconium peritonitis may be related to cystic fibrosis. (See",
"      <a class=\"local\" href=\"#H2209263\">",
"       'Colonic atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early prenatal diagnosis provides an opportunity for parental counseling and preparation, screening for associated anomalies, pregnancy termination, or delivery at an appropriate setting. Delivery should be planned at a center that has appropriate neonatal support. Gastrointestinal abnormalities alone are not an indication for altering the route of delivery. (See",
"      <a class=\"local\" href=\"#H24138511\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/1\">",
"      Cyr DR, Mack LA, Schoenecker SA, et al. Bowel migration in the normal fetus: US detection. Radiology 1986; 161:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/2\">",
"      Hertzberg BS. The fetal gastrointestinal tract. Semin Roentgenol 1998; 33:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/3\">",
"      Parulekar SG. Sonography of normal fetal bowel. J Ultrasound Med 1991; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/4\">",
"      Zalel Y, Perlitz Y, Gamzu R, et al. In-utero development of the fetal colon and rectum: sonographic evaluation. Ultrasound Obstet Gynecol 2003; 21:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/5\">",
"      Barnewolt CE. Congenital abnormalities of the gastrointestinal tract. Semin Roentgenol 2004; 39:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/6\">",
"      Farhataziz N, Engels JE, Ramus RM, et al. Fetal MRI of urine and meconium by gestational age for the diagnosis of genitourinary and gastrointestinal abnormalities. AJR Am J Roentgenol 2005; 184:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/7\">",
"      Nyberg DA, Mack LA, Patten RM, Cyr DR. Fetal bowel. Normal sonographic findings. J Ultrasound Med 1987; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/8\">",
"      Haeusler MC, Berghold A, Stoll C, et al. Prenatal ultrasonographic detection of gastrointestinal obstruction: results from 18 European congenital anomaly registries. Prenat Diagn 2002; 22:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/9\">",
"      Stoll C, Alembik Y, Dott B, Roth MP. Evaluation of prenatal diagnosis of congenital gastro-intestinal atresias. Eur J Epidemiol 1996; 12:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/10\">",
"      Corteville JE, Gray DL, Langer JC. Bowel abnormalities in the fetus--correlation of prenatal ultrasonographic findings with outcome. Am J Obstet Gynecol 1996; 175:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/11\">",
"      Benachi A, Sonigo P, Jouannic JM, et al. Determination of the anatomical location of an antenatal intestinal occlusion by magnetic resonance imaging. Ultrasound Obstet Gynecol 2001; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/12\">",
"      Veyrac C, Couture A, Saguintaah M, Baud C. MRI of fetal GI tract abnormalities. Abdom Imaging 2004; 29:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/13\">",
"      Saguintaah M, Couture A, Veyrac C, et al. MRI of the fetal gastrointestinal tract. Pediatr Radiol 2002; 32:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/14\">",
"      Huisman TA, Kellenberger CJ. MR imaging characteristics of the normal fetal gastrointestinal tract and abdomen. Eur J Radiol 2008; 65:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/15\">",
"      Rubesova E. Fetal bowel anomalies--US and MR assessment. Pediatr Radiol 2012; 42 Suppl 1:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/16\">",
"      Colombani M, Ferry M, Garel C, et al. Fetal gastrointestinal MRI: all that glitters in T1 is not necessarily colon. Pediatr Radiol 2010; 40:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/17\">",
"      Rubesova E, Vance CJ, Ringertz HG, Barth RA. Three-dimensional MRI volumetric measurements of the normal fetal colon. AJR Am J Roentgenol 2009; 192:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/18\">",
"      HOLDER TM, CLOUD DT, LEWIS JE Jr, PILLING GP 4th. ESOPHAGEAL ATRESIA AND TRACHEOESOPHAGEAL FISTULA. A SURVEY OF ITS MEMBERS BY THE SURGICAL SECTION OF THE AMERICAN ACADEMY OF PEDIATRICS. Pediatrics 1964; 34:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/19\">",
"      Estroff JA, Parad RB, Share JC, Benacerraf BR. Second trimester prenatal findings in duodenal and esophageal atresia without tracheoesophageal fistula. J Ultrasound Med 1994; 13:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/20\">",
"      Kalache KD, Wauer R, Mau H, et al. Prognostic significance of the pouch sign in fetuses with prenatally diagnosed esophageal atresia. Am J Obstet Gynecol 2000; 182:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/21\">",
"      Shulman A, Mazkereth R, Zalel Y, et al. Prenatal identification of esophageal atresia: the role of ultrasonography for evaluation of functional anatomy. Prenat Diagn 2002; 22:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/22\">",
"      Sase M, Asada H, Okuda M, Kato H. Fetal gastric size in normal and abnormal pregnancies. Ultrasound Obstet Gynecol 2002; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/23\">",
"      Spitz L. Esophageal atresia: past, present, and future. J Pediatr Surg 1996; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/24\">",
"      Shaw-Smith C. Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: review of genetics and epidemiology. J Med Genet 2006; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/25\">",
"      Forrester MB, Merz RD. Population-based study of small intestinal atresia and stenosis, Hawaii, 1986-2000. Public Health 2004; 118:434.",
"     </a>",
"    </li>",
"    <li>",
"     Skandalakaies, JE, Gray, et al. The small intestines. In: Embryology for Surgeons, Skandalakis, JE, Gray, SW (Eds), Williams and Wilkins, Baltimore MD 1994. p.184.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/27\">",
"      Zimmer EZ, Bronshtein M. Early diagnosis of duodenal atresia and possible sonographic pitfalls. Prenat Diagn 1996; 16:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/28\">",
"      Kimble RM, Harding JE, Kolbe A. Does gut atresia cause polyhydramnios? Pediatr Surg Int 1998; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/29\">",
"      Lawrence MJ, Ford WD, Furness ME, et al. Congenital duodenal obstruction: early antenatal ultrasound diagnosis. Pediatr Surg Int 2000; 16:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/30\">",
"      Hancock BJ, Wiseman NE. Congenital duodenal obstruction: the impact of an antenatal diagnosis. J Pediatr Surg 1989; 24:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/31\">",
"      Chitty LS, Goodman J, Seller MJ, Maxwell D. Esophageal and duodenal atresia in a fetus with Down's syndrome: prenatal sonographic features. Ultrasound Obstet Gynecol 1996; 7:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/32\">",
"      Dave S, Shi EC. The management of combined oesophageal and duodenal atresia. Pediatr Surg Int 2004; 20:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/33\">",
"      Fujishiro E, Suzuki Y, Sato T, et al. Characteristic findings for diagnosis of baby complicated with both the VACTERL association and duodenal atresia. Fetal Diagn Ther 2004; 19:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/34\">",
"      Gilbertson-Dahdal DL, Dutta S, Varich LJ, Barth RA. Neonatal malrotation with midgut volvulus mimicking duodenal atresia. AJR Am J Roentgenol 2009; 192:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/35\">",
"      Aite L, Trucchi A, Nahom A, et al. Antenatal diagnosis of surgically correctable anomalies: effects of repeated consultations on parental anxiety. J Perinatol 2003; 23:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/36\">",
"      Bittencourt DG, Barini R, Marba S, Sbragia L. Congenital duodenal obstruction: does prenatal diagnosis improve the outcome? Pediatr Surg Int 2004; 20:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/37\">",
"      Cohen-Overbeek TE, Grijseels EW, Niemeijer ND, et al. Isolated or non-isolated duodenal obstruction: perinatal outcome following prenatal or postnatal diagnosis. Ultrasound Obstet Gynecol 2008; 32:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/38\">",
"      Baglaj M, Carachi R, Lawther S. Multiple atresia of the small intestine: a 20-year review. Eur J Pediatr Surg 2008; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/39\">",
"      Raherison R, Grosos C, Lemale J, et al. [Prenatal intestinal volvulus: A life-threatening event with good long-term outcome]. Arch Pediatr 2012; 19:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/40\">",
"      Touloukian RJ. Diagnosis and treatment of jejunoileal atresia. World J Surg 1993; 17:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/41\">",
"      Iacobelli BD, Zaccara A, Spirydakis I, et al. Prenatal counselling of small bowel atresia: watch the fluid! Prenat Diagn 2006; 26:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/42\">",
"      Estroff JA, Bromley B, Benacerraf BR. Fetal meconium peritonitis without sequelae. Pediatr Radiol 1992; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/43\">",
"      Sweeney B, Surana R, Puri P. Jejunoileal atresia and associated malformations: correlation with the timing of in utero insult. J Pediatr Surg 2001; 36:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/44\">",
"      Caspi B, Elchalal U, Lancet M, Chemke J. Prenatal diagnosis of cystic fibrosis: ultrasonographic appearance of meconium ileus in the fetus. Prenat Diagn 1988; 8:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/45\">",
"      Gaillard D, Bouvier R, Scheiner C, et al. Meconium ileus and intestinal atresia in fetuses and neonates. Pediatr Pathol Lab Med 1996; 16:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/46\">",
"      Komuro H, Amagai T, Hori T, et al. Placental vascular compromise in jejunoileal atresia. J Pediatr Surg 2004; 39:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/47\">",
"      Garel C, Dreux S, Philippe-Chomette P, et al. Contribution of fetal magnetic resonance imaging and amniotic fluid digestive enzyme assays to the evaluation of gastrointestinal tract abnormalities. Ultrasound Obstet Gynecol 2006; 28:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/48\">",
"      Wax JR, Hamilton T, Cartin A, et al. Congenital jejunal and ileal atresia: natural prenatal sonographic history and association with neonatal outcome. J Ultrasound Med 2006; 25:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/49\">",
"      Shinmoto H, Kashima K, Yuasa Y, et al. MR imaging of non-CNS fetal abnormalities: a pictorial essay. Radiographics 2000; 20:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/50\">",
"      Dirkes K, Crombleholme TM, Craigo SD, et al. The natural history of meconium peritonitis diagnosed in utero. J Pediatr Surg 1995; 30:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/51\">",
"      Colombani M, Ferry M, Toga C, et al. Magnetic resonance imaging in the prenatal diagnosis of congenital diarrhea. Ultrasound Obstet Gynecol 2010; 35:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/52\">",
"      Eliyahu S, Yanai N, Blondheim O, et al. Sonographic presentation of Hirschsprung's disease. A case of an entirely aganglionic colon and ileum. Prenat Diagn 1994; 14:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/53\">",
"      Vermesh M, Mayden KL, Confino E, et al. Prenatal sonographic diagnosis of Hirschsprung's disease. J Ultrasound Med 1986; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/54\">",
"      Cowles RA, Berdon WE, Holt PD, et al. Neonatal intestinal obstruction simulating meconium ileus in infants with long-segment intestinal aganglionosis: radiographic findings that prompt the need for rectal biopsy. Pediatr Radiol 2006; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/55\">",
"      Mandell J, Lillehei CW, Greene M, Benacerraf BR. The prenatal diagnosis of imperforate anus with rectourinary fistula: dilated fetal colon with enterolithiasis. J Pediatr Surg 1992; 27:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/56\">",
"      Gilbert CE, Hamill J, Metcalfe RF, et al. Changing antenatal sonographic appearance of anorectal atresia from first to third trimesters. J Ultrasound Med 2006; 25:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/57\">",
"      Kaponis A, Paschopoulos M, Paraskevaidis E, Makrydimas G. Fetal anal atresia presenting as transient bowel dilatation at 16 weeks of gestation. Fetal Diagn Ther 2006; 21:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/58\">",
"      Taipale P, Rovamo L, Hiilesmaa V. First-trimester diagnosis of imperforate anus. Ultrasound Obstet Gynecol 2005; 25:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/59\">",
"      Cuschieri A, EUROCAT Working Group. Anorectal anomalies associated with or as part of other anomalies. Am J Med Genet 2002; 110:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/60\">",
"      Lubusky M, Prochazka M, Dhaifalah I, et al. Fetal enterolithiasis: prenatal sonographic and MRI diagnosis in two cases of urorectal septum malformation (URSM) sequence. Prenat Diagn 2006; 26:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/61\">",
"      Etensel B, Temir G, Karkiner A, et al. Atresia of the colon. J Pediatr Surg 2005; 40:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/62/34793/abstract/62\">",
"      Livingston, J, Elicevik, et al. US findings in neonates with anorectal malformations: a review of 95 cases. Am J Obstet Gynecol 2006; 195:S63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14208 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34793=[""].join("\n");
var outline_f33_62_34793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24138737\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138444\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138451\">",
"      TECHNIQUES FOR IMAGING THE FETAL GI TRACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138459\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3677343\">",
"      - Normal findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3678109\">",
"      - Obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138466\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138474\">",
"      ESOPHAGEAL ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138490\">",
"      Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3102107\">",
"      - Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138497\">",
"      MR findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138504\">",
"      Differential diagnosis of a small/absent stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138511\">",
"      Obstetrical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138518\">",
"      Postnatal management and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138532\">",
"      DUODENAL ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138548\">",
"      Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3102552\">",
"      - Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138562\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138569\">",
"      Obstetrical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138576\">",
"      Postnatal management and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138590\">",
"      JEJUNAL AND ILEAL ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138615\">",
"      Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3103159\">",
"      - Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138622\">",
"      MR findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138629\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138644\">",
"      Obstetrical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138651\">",
"      Postnatal management and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138658\">",
"      COLONIC OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209223\">",
"      Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2209392\">",
"      - Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138681\">",
"      Anorectal malformations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2209504\">",
"      - Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2209722\">",
"      - MR findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2209263\">",
"      Colonic atresia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24138695\">",
"      - Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138709\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138716\">",
"      Obstetrical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24138723\">",
"      Postnatal management and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24138737\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14208|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/20/35141\" title=\"diagnostic image 1\">",
"      Prenatal ultrasound images of physiologic midgut herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/31/7668\" title=\"diagnostic image 2\">",
"      MRI of normal fetal bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/16/40197\" title=\"diagnostic image 3\">",
"      Prenatal ultrasound of tracheoesophageal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/48/36609\" title=\"diagnostic image 4\">",
"      Prenatal ultrasound image of duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/30/29153\" title=\"diagnostic image 5\">",
"      Prenatal ultrasound image of ileal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/44/6855\" title=\"diagnostic image 6\">",
"      Prenatal ultrasound of ileal atresia with meconium pseudocyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/7/39027\" title=\"diagnostic image 7\">",
"      Prenatal ultrasound image of jejunal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/24/388\" title=\"diagnostic image 8\">",
"      Prenatal ultrasound anal atresia with rectovesical fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/11/43189\" title=\"diagnostic image 9\">",
"      Fetal anal atresia with rectovaginal fistula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42169?source=related_link\">",
"      Congenital diaphragmatic hernia: Prenatal diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36166?source=related_link\">",
"      Fetal echogenic bowel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31608?source=related_link\">",
"      Intestinal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32456?source=related_link\">",
"      Overview of echogenic masses and calcification in the fetal abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41205?source=related_link\">",
"      Overview of the development of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal abdominal wall defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_62_34794="Forearm dorsal anatomy";
var content_f33_62_34794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Extensor muscles of right forearm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 787px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAMTAloDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5y1e18PeGvgr4Hu9K8EeGdW8Vaza6fa2kd3psUnnzSRKzu5wCeM5JYcsCTWtoFv4V8Q/C/w14q0zwtoGmas2raWkzWdhHE8Ew1GBJApA3KDzxnO1u9JpGl+F9V0TwFL4w0vxRcXXh/SYrU6ZN4cvJbXzTCqOXX7OQ5BXghsfKDVuy0zQdG02fSvCFn4o2an4i0/Ufslxod3Db2229geTYzQIsaBEJ+ZsALQB7bXnPhL4t6N4luNDSLTNXsYNbM66fcXiQiOdoc+YvySsykYP3gM9q9Gry/wV8GtE8PeFY9Mvbi41G/S3urVb8ySJ5KTlt/kxM7JEdrYJUAnGT1oA7S08X+G7yC8mtPEOjzw2a7rl4r2JlgHTLkN8o+uKwNV+LPg3T9Q0a2Gt2F2mqTPAlza3cMkMDIoJMrb/lHIHfkiuUj+CTSWawalrFhfiDSY9Ft45NOkji8hJVkDSrHcKzyZUYYMgB5xmr8Hwr1WJdCuJPF813qekalNfwS3tvJcRKkiBPICtMZNoA4JkY9etAHfr4n0BtUuNNXXNLOo26s81qLuPzYlUZYsmcgAcnI4qkPG+hT3enwabqNjqX22YQK9pfWzCNiu4ZBkDNkcgIGPfGOa4DTPghBp2qSzx6slxaiW6mthcx3LzWxuEKvtIuVi78kxZYDB7EWbX4J6bbaD4V02C8hgbSJHku7i2slikvy0bR5Yhsq2G4Y7ulAHf23i/wANXK3zW3iHR5lsVL3ZjvYmFuoOCZMN8oz3OKni8R6JNpVxqkOsabJptuSJrtbpDDGRgkM+cDqOp7ivK1+BzyaYbO78RK62+iy6JYtDYeWY4nYtvl/eHzWGe2wd8Zr0XRfB2kaX4L/4RqGztUsZbX7Pci3gWETkxhHcgfxMByeT7mgB2s+MtG0xExe2l1MxhzDFe26OqSnCOfMkUbT2wcn+EGrEvivw7DqFxYTa9pMd9bo0k1u15GJIkUbmZlzkAAEknoOa8z0n4HLY+EZdJm8RS3d9Lf2d09/La8+TahVig27+iqCAc9+lWNM+ClnZeJJb6W/iv9Oe/nvxbXiXLPG0ww6qVuVi5HG4xEkcEnjAB6I/ivw7HE0smvaSsS263bO15GAIGICyk5+4SQA3Q561sRusiK8bBkYAqynIIPcV4Nafs6wRw2EV14lnuUhuFW5BtMfabJTCyWp+fgKYQd3PLHive6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8K+IsOk6Xo/wAUvFNx4b0DV9VsNTt1hbVLFLgbTZ2I2knDY+djgEcmofhfbeHvEXi3VdF1jwX4PK29lBeQSp4d+wSyB/vfuJtzlQTjeMA/jW/4mtdL1IfEDw54ltvEkVnq+owzJPp2kXU++NbS0G5JEhdPvxMpHJ4NO8Mjw1oniKTXppfG2q6u1munpcX3h28zFbqdwjVYrVFAyM5IJ9+tAHYfCf8A5JZ4N/7Atl/6ISrWneK7G/8AGWr+GoYrlb/TIYZ5pHVRGyyglQpzknjnIH41F8Mraez+G3hO1vIZYLmDSbSOWKVCrxusKAqwPIIIIINZDeC9XtPiHq/ijRdbsIP7ThggmtrvTXn2rEMZV1nTBOT1BoA1bvx/4Vt7XUpo/EGk3L6fDJPcQW97E8qhB8w27uDnjnHPFV9F+JHhTVPC1hr7a3p9hYXnyp9uu4omR8AmNvmIDgEErnIzXGWfwbv38TQ6vrvjC61V44Ly1JlgfzGjuEZAMtMyLs3cbI1B7jvUE3wRnn0zw/BP4ijkn0izk01T9lniintXGNjrFco+7rkhwrDgrxQB6jP4p8P294tpPrulRXTKrrC95GrlWBZSFJzggEj1ArmfGHxQ0LR/BWr6/oV9pniFtOERktrPUI2OHlWMZZd2372enOKy9F+EFlputT6mLq1+0jSYdOsWSyydPkjQqJoWleRgeeASSMYLGucuPgNe3tvrX9qeMZbu81TT4bGW5ktJZGJjuEm8w+ZcNydm3apVRnIA6EA9qvdTsLGe0gvr21tprt/Kt45pVRpn/uoCcsfYVkR+MNHn1eGxtby0uVkillNxFe25RPKOHBXzN5I7kKQO5FVfiX4OHjXw6lhFfyaZf21zFeWd9HHva2mjbIcLkZ4yOo61xl/8DtPu9N0jThq08NlY6NNpTCOEB5WkYO027dgEuCSuDnJ5oA9CtPGPhm8gSe08R6NPC86WqyRX0TK0zcrGCGwXODhepxViHxJoc88MMOs6ZJNNO9tEiXUZZ5U5eNRnllzyo5HevL4vgih8P6pZXGrwf2ldC0aLU47e5aWOS3OY3YTXUgbA+UBdgAJHTAFzwH8GbXwn4ws9c/teW8jtbUrFavBtC3TxRxzXG7ceXEfK4/i6mgD1miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimllBwSM06gAopsjhAMnGTgfWsTV/EMNjMYUBkmI4UDg570BubtFcfF4rUnc38I+6CPm9Dmp7fxL5tvFKCMOCuODhsUm0ilCT6HU0VyieKV8yPeDtkB2nbkZHXPp3qSTxOkZQkKymQRnBxjJwD6d6E09hOLW509Fc8PEUYYoTGZA20KDyw4+b9aaPE0RugmAqbN3zECmFmdHRVKx1CK7Kqn3iu4j27VdoEFFFFABRRRQAUUVFLcwQzQRSzRJLOxWJGYBpCAWIUdyACeOwNAEtFFFABRRRQAUVElzA91LbJNE1xEqvJEHBdFbIUkdQDtbB77T6UJcwSXMtvHNE1xEFaSIOCyBs7SR1AODj1waAJaKKKACiojcwLdpatNELl0aRYi43sikBmA6kAsoJ7bh61LQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQTgc0Vk+KLr7JotwwJ3uPLQDqWNAGQdVM9/PcoSYIn2KMfeIGa1otTKxsXydg+Y47+lctYRi2tEViWMYLswPG4859xVq4mLvFArAjqSDguev+FapLqJlnxBr8djYtdsXJb5I1AxyePyHJrxvXfEImvpPndQyCVpWIDkDPUdBnjArZ164e98VXc88wh0vT1EC3BbIL9WCL3bPBPPSuElmi1XXzHCNlgsnnOZTuYoDwX9z6dgOmBXJVqa2R2UaPfc6LWdQaBoVZJILieOJ0RflG0fTocEVo2Oty29jME2pGr/ADPK3C5OCQPxBxmvP/E2vHXL6K5QyxWhmEaMwyDGDgE47YHFX9DufssMWox7pJLaQ27MxLDAYspA7EjK59q5KsrTPSjStDl6nSSaldTXMfnyqI4ZpG2yxFAy7TtAU9QwIwwye2OKvXK397GIry88skRn5YgEDoQeA3JB7jGOR+Op5El5bgWcMszTJvQIpbIIOKxtdmttJt7Rda1jStOkiVVlW8u0WQ4GD8mS56A8CqjKTfuo5pwgleTLMl48OyOKZ4/Lcb1I8zYzYORnAGfp2qHWry5iv7NVnadzPtY7AhdWzjK9O2Mis+K7t9Rkll0yx8Ra5HJjD2OnNDb7sEHM9wY159QDWhJYeIL65tyNG0LTJo9scZ1G+l1Cdip4Kx24SMsD2LnFaKNRu8tDJzpJJR1O/wDhlePey3AkLEx56+gO0Y9uGxXbapqun6TbfaNVv7Wxg/56XMyxL+bECvAruZbe5bSrnxf4j1jVwABovhO1htGTnpK0W4xrk8l5AeelWNM+CMmv3P2vxFaWmg2zYLW0EzahfuP9u7m3bDn/AJ5KPYiuqKsrHFN3k2dzf/GvwNBepY2GqyaxqEhxHbaVbyXTufYqNp/OvSByK53wb4K8O+DbP7P4b0q2sgRh5VXdLL/vyHLN+Jrdu5WgtZpY4nneNGZYkxucgZCjPGT0pkniui65qmj/AAwstJ0/TvE1vrUFzIJTFpU8YiRp5G3b3tZldcFeER2+bPABIgs9U8fR6ff6hJJr7a3PpNrJBYtYf6L5gd0nbPkHZIFAcLwWLfcYbVHX6T8SZrgpHqWkwWd1tuGlg+0zB4PKhWUBxLBGQWBPQFcDILCq9v8AFC7mlil/sGEac0lpA8v28mUSXFsk6hY/LwyrvwTuBwN2DyAAUfDupeNr2BXvrrU/Igtbq5/cWGya4ZHiMcLNcWsQDsDIvESgjpyCaq+Bb3xVrPiHSJvEFtqj21pqDtDNd2rRukbWUgO8/Z4BgOcZ8scnGW4Nal98U7ywtNIubvQ7bZfxQXTQQ3k800NvMyKsjBbYxr8xYfPIoO3g5OBEfi5dSf2hJaeFryW0hnNvb3DmaKORxdJb4eRofLUkuWARpOFIO00AM8Ya742svHl1FZeZb6JEqNA32WSWKVPKzIzMls4Vw2cbpowNoypByc3wxq/irW7LTro/b9Ztj/Z9ysupaQsGy5ZZTKIv3Sfuh+6xJg43cOecbF/8Rp4XlGo6XiWCO9tp7KK7SS1lljntIV/eNEGKn7UMt8oUBwVY4IuTeOb/AES9/su58O6bbw6eLOO7FpqRYQrcSmKIQIYV8wDAyDsx0XdigDmxrviz+yNNd9T8XieSF21Fl8OqXtroRgxwxJ9m+aJm3gv8+Nq/Ou7J1ob7x+Lpr+RrsyLdxW39lfZI/s5U6akjuJNm/AuSy7t+0EFTntYPxPvorfzLrw9ChukU6eF1DcJma6S2AlJjHlDfIjZG/wCUnuMVR0n4gX+jLd2+tWK3F/eahdwWSRXrSxvcrOka2ocxghfnBDbeAr/L8vIBh2WseJNFXVPFLNruoPDBpgvItR05bNrnJuElgiBiThHlRgRknpuYEZu+IW8caLPNcWa3U99PHp0WoX1vbE8CO5MhiCwTcCQxrxE5AYZ67hPqnjz+wrK6j1Kwi1tE1a7mkimkmklt447vEbqqwyIApA2l3jAKgA+novhPXLzXvt88unRWljBd3NnFJ9p8x5WhuJIWYpsAVT5YI+YnJIxgBmAOd1fVvEVv8LdPvGW/l12QQpNJp1s6upJwXMcltI4GPvDyCeeFA6c5oup/EC9sba+u59Tt5bW2sGe0OnJtu3e+njm37og+RAkbHZsxuDYUHBvP8StSWy8O6rPo/krrOnfabOyW/Qo7STWUUfmsYcp8111ViAoJKkkBKdr8QtZ0ex1lZtNtL/ULWTUtQuUl1V1hggt5FUxxSGIs5y2ANigY5xQBe8CSa3f/ABBivdc/tlp49PvoZkudP8i1tWNzDsjhkEa+YCiZyXfO3II5Feq1wPhr4hTa74vuNJg0K8WximmtjfhJiiyRfe3kxCIKSCBiRmzjKjNd9QAUUUUAFFFFABRRRQAUE4FFZHiLUFtLTylbEsowPYdzQBbTUInkZVzgHG7tWZrHiKLTrYuVLSScRIO/ufQVn6ZG03ykkRqdzcfkD7VzfimeOTXlEW5jEBGz9SW/ur647noOlTVlyIujD2krM6G18S3AX9+y5yBgrjPv+PpSDxgCu5zGic81xWpT/Z4BJcFdnC7F6Fvc96851vWptR1dNJs5FeeU4kbr5ad+n8R5rn9s0dawyep7/p3jS1u2bldmAUYdGzzn6YrQi8S2ryBMg88kGvIrHbY2qRs7MzNkk98ZwOKhk1F44gCxw+RwOf8AOaPrOtmhrB3V0z3SLVLaRdyv8vrUn26DaWLqAPevI9L1Yxxhd7Ddj5c+3+NV9V8SyW9jdSCQ5VlQqGwT0/xq414tmMsNKJ7arK6gqQQe4pa888P+Lk+xwRsCGZ9uGb6k/wBPzrr9O1mC9ZVjPJOBzWqnF7GDhKO5qUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl4vlebUrW2XhIlMpPqx4AP+e9dbXn13cLcatdThy2+QgZ6AKNo/rTirsCTcVt1OeMFtoPvWF4l1638PaZd3l2z7nzDb7Bk+YVJGfbitm5by0iTdwOAenAHI/PFcH8SHZtP0aFlhljuL7LRy/xEDg+u31HfitKkuWLfYunDnkl3MUXU58IFvOR7tnDGd0OAxPJX9ce45rE0y1t21UxXxnaxAM115UbzyeWDwhVAWZnYjO3sD2qTxLq0kt69isw+xlvK2xkguBwdxHAGeBj/AOtXSeF7aKw0/VLuzJj3ecyOhOeB5aYzzxgV5sbJX8z1uXlV1u9EYD6Ov2yW5XQdbkjkUnZqktvo1uFHAISRnkIHXIUH2rY+xXtpbNI154a0e3aSOJzYWEmpSA/wlnuCkQx/eCkdetcb4XZrjxBd3SqZIVlEMpxlmjORvHrjbuPrivVNZ0ppfDyQTMiG0TZcXDyLFGIjnaxdiFwAMDJ7Cj2nNJ2iRVptWdSb1+Rx+nXOn6zdahYanP4k1c2i7kgvdV+zwSgHDBYLcIox6Zbr+FdJo9lDYC5h8J6JpWm3UW3a9pYqJFXnLNK2Txgck4rkrFrKK6TV9ChbVDahozqEsv2PSlGNvzyyLumOOqxLzgYNbWq2H2i2jfxPeNrcO8FdNgBstMUDHPlA+ZMRkYMjfhVtyWs5WMOWne1KN/PoVp9XuNSvnKanqHiS7t1YTwaZOEtICcj9/dsREnBx8u81HfrN/ZN21/fRtbgnfo+gM9vbscH/AF90f302cAEDaM9DWB4w1KS58yyR1XT4ArW9rGojiiU/KVRFAVcEDoKv2G64M9shJNxbnywOhbdgHP8AwMflWarJP3UbPDycb1H8uh7/APC7TbbTfBOl/ZdMstN8+FZmhtIgiDdyPcnBHJJPvXWVV0y2+xabaWoORBEkYP8AugD+lWq7UeUxAQehBxxTZoo5oXimRZIpFKujjIYHggjuKcMjt3paYGAPBfhYaclgPDWiCxSXz1thYReWsmMbwu3G7HGetQ6f4G8PWOvXmsRaXZvf3GxVke3jJt0SJYhHEduVTao+XPc9uK6WigDHvfC+gXz2T3uh6VcPZKI7VprSNzAo6BMj5QMDgYriPiNB8OYbDxI2px6CurRW322+hg+zJfXCRMk2x8gswcogIYc5HtXp9eY+IfhdNrEurRHWoodOvJLy5jjFjmaKe5tXt2LShxvQB2YJtBPALYAoAt/2h4e0vwTot/faP4ZttMuj9jYWs8UllbwTNl9svlqrIdiFhgAkDrgGtOx07wDEljd2Fn4WRbONbm0mhitwII5HIWSNgPlVn3YYcE571t+INHXWBpweURizvYrzBTduKEkDrxyevbFcNdfC+6K+XYa7DbwTR+Tcq1hvLot3JcoEIkAQgyFSSGyOgFAGzda58OpFksLvVPCTKqm0kt5Li2OAzZMRUnoWXJXuR7U57XwVa6laWsN5o1g3h4yagdOglghS3/dlDNJGOVCq7fNwBuye2Mub4YRSaJPp/wDaEYaXS9T07zfsgyDeSiTzMbv4MYxnnPUVQu/hF59zrrf2zug1OK9CCZLh3tpLqNkdlX7QIcDcePKBI43Z5oA6m5tPAmssJrm38MX7QTlA8iQSmOaWUpjJzh3kBX1ZgRya1tA1XQb43lt4ev8AS7k20rNcxWM0b+VI7szFwh+VmbeTnknceua5rXfAVxf+IFvbDVYLLT3n06ee0NlvLGzm8xFRw6hAehG1sYBHcG/4D8KXnhh75ZtUjuLOYItvZW8UscFttLZKLLNKRkMowpVRsGFBJJANufQNHns4rOfSdPktIrc2kcL2yFEgO3MQUjAQ+Wny9PkX0Fc34p+Gfh3xBpVppjWsOn6bbFyLeys7VVO8ANgvEzRnA+9GUb34GO2ooAy4vDuiw6wdWi0jTk1UrsN6tsgnIxjHmY3Yxx1rE+IniLxD4atba90Hww/iG0G77XFb3GyeIcbWRNp3/wAWQOenvXX0UAeQeGvj94T1iCSW9ttZ0lYG2TPc2TSRxN/dZo923/gQWvRfD/irQPEaBtB1rTtQ4yVt7hXYfVQcj8RWR4t+H2keIL4anF5+k6/Gu2LVtOk8m4X2YjiRePusCPpXnXiLQhpj/wDFzPB+n+I9NVv+Rj0ey8u5jH96eKP94uOSWjJA9BQB7tRmvKPD/hO3vNMj1L4dfELW4bFx+7Q3C6jbJ/s7JgzL7jcCPatJpvidox+e08N+JrdeB5Ekmn3D+5Db48/iP60Aei0V55/ws+HThjxZ4Z8R6Bt+/NJZG6twf+usG8fmBXReHPGvhnxKF/sHXtNvnPPlw3CmQfVM7h+IoA3ppUhieWRgqIMkmuCa4k1TUHuW6F9sSnsK2fF14zmPT4eC/wA0h/2fSspMWls0uGGwYGOc0bajSuW7rV7TSVWyTbNfOu8Qg88/xN7e1cvdPFaia4l/18h+Y9xntx6U9FFu0uoXRCSTHcTjvjgKOpriPEuvLFdi3ghkuryTiG0iUsSx/iYjt3rjnUcmd1Kiox0MnxrrwjgVE8yaSclYlJ+ZyeOPQfoKzvhvpbW895ez4e83KWz1GSB/WpIdJv7K/wDt2sbZNTlOCFGREuSNqjoK0vAzxGXVYUb95528g8kjcD/U1lezs9+p1WbhdbdDp9VQQQSGLI8oAEjnk1yt7duvkjAHJJ49TXWa+my1ulVOM5A7nrXn91I4ltAVLZ24Bbuf85rCb943pK0DpoJsALzkYOT1qj40mjg0aIDJd7lDjkZ5yenfgU2yLPMQR82Rzx61U8c3DRR2O/DM8uEXbn5jwOKaYONze0KZ2iaXjdt2Ip/hP8Rz+VeleA4y2pKVH7pE6dvrXm+gQuYrWCJiRGNpIA5bHWvY/BWl/ZLY3DdXG1Pp3P5/yrpw8W3c4sZJJWOnoooruPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCrqkzQaddSxnDpGxX644rzS13BYXk+aMAFu1dz4zlMegyhG2tIyoPz/wBrjraJ5vLtUAaRiM47Af/rq4B0Lk0ge3eRgAQSoPfgiuF+Iy2aah4TN8u5ljuJ9rcbgCuQfbkUuneObjUtT1Gyi0T/Q7SVoYrkXAJkIJGSMYGcHoTiq/ix7HVtZsdae++wrY2pheGRwfLO4klFXIckY49QKxq1oSi0mdNKlOE1KS0PPL03P9sXd7cyos80Tuq8ARnHyA5HHTPtx613mjC00rwtNDqN/ZWcEFskTXN5OI0Zu5GeSSQeACTXn+lGKS+u5JLzzLcwtESwwSG5x7H15PSvSvDqiPR9El1G3gkvLfAc3cKSGNxlVcEjhip6j1NcuyTfc7akpcqS3uc/4I0W4tysnhPTmlSX5Rq2uBrWzwzAgxW/8ArZ+ScMdg7d66XWvDW3zbvXp5PFOrWbK6pqS7bJExgmG2T5Ex93LBz0zVjy49J8W6hHf3bvZ6rD9phkmkJKuMbuvYHkH39q2dfu5JbG31NY/MeEG3u4lYZYEYI46Z4YfUVbla6joc7Tm05O/5HiXii51C4v5pb27luowD5Id9yLCccJjhQBtYAYHBrq/h1qDax4durOVS97ZtsLFuX2jv6ZXH/fNYPi3fDefYJGP2mzJ+zN081AdxTpg4yGB9G9hVL4cailj42MEgd0u8KSOCxQZXj1KN+lYpX1Z2XskkM8a/PfG8tg3lFOgB+VXGQfrnFdR4CPnXumAuCGvFiYYxlGwy/j8tYnxIaayufsyBPK+aNlUYPDfL+lX/AIdXLSajZY+Xy7q1kJB6jftOfzrOK1VzSo7wdj6torhvi9FO+h6NNb2t3dLa65p91KlrbvO6xR3CM7bEBY4UE8A1zeveKfEl/wCN9Ki8NweI7fR5pYYpmm0x44zG7MskgWS0LKV65eVOgOxlPPqHgnrtFfP6ax8QbDw34ZhsLnXJJlsVF5PqWnTM4vVEYaGQR2cjvEPmw/yl8k+cSK3/ABRqnjWy8PzXVtPrr31xqd9DBHa2SbLeGKecQ7gLSd2DoI8NtAICfMuSzAHrkNzBPJPHBNFJJbuI5lRgTG5VW2sB0O1lbB7MD3FS1594GbWf7H8Wahe2lxbandzQ3SK0BUtJ/ZloDtUjnEiuuOeVI6g1z+nyeP7dLW6udX1m7KR6RPJayabAqyNcT7LqM7YQwESDdwQy5yxIoA9hpssiQxPJK6pGgLM7HAUDqSewrxyTxL4ynspIVOr2dza2DC5nfRZSGuRdooEZWB9xMRbDIkigHcVbacJFqviXUbcwaxJ4ps4JtNxbQppazfbJS0yuLiRbYeVwI8DbCdrZPOcAHskUiTRJJE6vG4DK6nIYHoQe4p1eI2GrePrbXhY4lsdPhtQkCSafPPH5YtMh/wB3bN+8Eo+6ZxnBXy8lSd7wRq/iS6k0RNTl8QMG1GeK4kuNNXy54xallLMYLd4Yw/QmLJcFcspBoA9QooooAKKKKACiiigAooooAKDRRQBwev8Aw2sZ9Sl1nwteT+GPED/evLBR5c564nhPySj6gH3rPXx5rHhOQW3xK0pbe1yETXtNVpbJv+uq8vCfqCue9emUjqrqyuoZWGCCMgigCvYX1rqFnDd6fcw3VpMN0c8Lh0ceoI4Nc94u8GeE9Zt57rX9A028kRS5meBRL+Egww/OsO/+G50u8m1P4d6k3hu/kJeSzCeZp9y3+3B0U8Y3Jgjng1lar45vII4tG8faePDl48iot6HL6fd+yT4Hlk9dsm3tzQBTsvCRgt0fw/4h8R6GMZSAXn262Uf9crgN+jUye48W21w2nS3PhnxH5WGaJTLpdywPIzjfFz6cV3EUKw2omldYrZIzKzlhtCKM5B6YwOvoB61x0N4TZ3WpyeaDeSvcMJRt2xn7i59lx0/OoqS5UaUoc7MPxBrlz9lm/tXR/EOgTEbTdG0Go2sKdwsluSR9Sua6Tw1oOm6H4clvLV3utSnAc3UisjyAHnAYA45HauW8HapLe67d3cZdBGoijcfLkk9B9AM4rtdbmKaxDYv9xLLKknksWBPH4VyqcW/dR1OM17rehyniMNJelyGUuonUgY47ivP/AAdc/Z/H8ihsR3aEAE+h/nivVNTTfp0UpBxtMLZHTuK8Z1yRNP8AFdndHpDcL0GMAjH9a53pM9CnrSaPXPE5aO3u92M7xgj05/8ArV5vPIv2y2ChcBQwxyM4r0/Xts+kSSBmLNjJHXkflXlmpKkd3CMsAUAbof4amXxDpX5DU0KYtOyux3feA9cd6p+KJHk13R4VG7YzPjr6DOPzq5oY/enGcbO/1qpAGu/E5djtKAAkdUXkk/jTirvQcnZanqHgPRmvLiMbQEGCzgY4HU/ieK9hRFjUKgCqBgAdqxPB+mDT9IiLLiaVQzZ6gdlrdr0qcOVHiVqjnK4UUUVoZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzPjkM9tYwqCQ0+4+2FPOfSubtr0aZo9/rEIVpbW13rE2V+YkgA9x06V0/i+4a2fT3UBsyMpUjg8d688+JmpLHpsWlW9o8xvNs8qxgjaFOMs3Zenv9OtRKqopo1pU3NpJbnEaXC7211e2tiZoZDuaN5PLi3bvm2qCMHnu2fase8YtLcXUunvHZRgW8GF81ry6YHy4YYwx3sSMknouSewPZJHpWn6M15rMhaytY99zMmUigBICpGg5ZyeFA6k/WvO/Get31hcQhLY2evTwGGztCcjRbRxyuSObmQHLv1UHaMHheOjTT96Wx6VatJP2dLc6nStCtrJrySJ4r27ErJJI0iyG3IwNg28DnPTP1Ndrp9qqXcS6kNpdBOkbn5yufvYPOM8A15z8Nba4me3tyInS12yyrBbna3IwHboGP8hXWWul6hoOq63PZ2Wk66uoXTyvdy6g1jfrvO4RyGRWjYICAuCoxjgVtSo3fM9jjrVHH3Vua3xOsZ7i90T7BAlz9nm8kxllV5EKHKDJGcgDgZPt1q68kcEEMDwywx3DfZJVYbfLkAHllgfUYH1xXLfESfxRqejmxm+F1vqMci7fMm1GG9aA9N6Rx7X3YJwVYHqKntvE2jaZ4di03Xr7WdPu4rGG3FxrelXEBaaIDbKWCsvXuW6BeT1q6tPmd0KjWtHkkc14plWGwiubdAbrT5DE7u3+tjIOA4HQY8xMewrz3e2ja7p7bGiuIL5PMIbIZc9R6fK/0r07WxYa9dTHQ9S0zUYL62KzCyvImdJR8wbZu3Abvbua828a6VqlnHBPqVlfw3ceyGRrmFk3YBAPP/AefU1zRi4vU7eaMkrM7z4lwzDV7hHCPasqypKeAXYEfN+NY/wALpt+oQuWVSQA64/iWRWH/ALMPwrW8UXR1Xwrot/vUC4sipC9SVKsPx+Vj+JpdD8Ttql4Yf7S8bwrvChj4jySDwGx5HSlFRbfM7Dm5qK5Y3PqhSCAR0PNLXm2m/D4X2n290vjPxuolQPt/tbOM9s7K3/DXg7+wdRN3/wAJH4k1LMZTydRvvOi5I527Rzx19zXoHjtW0JW8caAniN9Da7nGoJcLaNmzn8oTMgkWMzbPL3FSCBuya6WvItS+HWu3HxAvtYtpLKK2n1e11GK5Oo3G6FIoo43X7Js8l3YK6hy2QH46YrJ8U/CHVrzwnpOm6PFoEV9BaSLPeOqrMLkhQkizNbyPtAXGF8thhcMAoFAHseuarBo1lHdXSSvHJdW9oBGATvmmSFDyRwGkBPtnr0qybmMXq2u2bzWjMobyX2YBAwXxtB5Hy5yRk4wDXl0vw2ubk6tbXuk+HrgX2qR3kmrPIxu7i3F9FcNbyr5X3RGhQYkIOxOBkkQ6j8L9RaxntNPbTI7JTceTZM7rC0T30VwLdgq/LGyRsjAAgbsAEUAevU2VxHG7tnCgk4ryWy+GN6tvM1xa6AGW2vvsVgyNcWdlNLKjwhUZAGRNpOdowT8qgVk6T8Kdbs7Ew3dp4e1C1+3vdDSbmUC1Aa2WLfiO1SPcrAsAIQDu67vmoA9e8O63ba9ptte2cdykU9vDcqJ4WT5ZUDqN33WIB52k4PBpttr9pca1d6Ykd19otplgZvIZo9xiEudy5CjawGW25PAycZ8o1v4Wa9eeHLTTIzoVwFtbSCUXAViGitfKLxtLbyhfm54QMR/EhrWPw71iSAC8ntLljGFlAu5YmlP9m/ZT+8CEqTJk7sEhecE/LQB6vRXJfDHw9e+GfDslhqEWmwsbh5I47BI1RUIUDcY4YVZsgksI14IHOMnraACiiigAooooAKKKKACiiigAooooAjnlSCF5ZCAiDcSfSvMrzVGvb3VI7iKG5SXCvbTR74tno6nhuO1WPGeu3WpakumaVK0drHJsmlRTl37qD6D1rHsWhvbpo0d5IYGwI4RuPHViemc+prm9vzScYdOp0QpJLmkYLaFdadaND4SnNjZXMbefo187zaVJk8qj7hJAT/s5XsRiq3iLxBPqpTSruBtE1aRQsOnXzr5dz/tW1yD5cvYAZU+xrofFt7DBZsscTIx+UMz7m/TiuD8OySX92dLvvsl5pUzky6dcATrIoHLkHOwjnBGD0AIqXO/uzNoU3Fe0gd74a0U6La2ljOp+0hvNnyCCTjGPwGB+FWZ7oalrkNwu4IXkjDDkELxWFaWOqaMVTwneLqVgi5XQ9YmPyDP3ba7I3J6BJMr71f8AC8sV1Z3UaQajZ3cFzultNRtzHNEXHPzcrIOhDKTkdhWSp2bmndOw4VLvllozTvIlNhdRFuAd6+ma8G8cwn7TNgEiVCQTwcjp/KvoS4UC2MkvyqyYkOPw4rxH4mxNaX0O/BAJQHPQHqKhr3jsoSsmmd74Z1CLVvBMNyGDl0Bb2IGCK4nWo1juFHUoMeozitL4OEnw3eWQkUrDNIgTuBkFf5mqvidCkzMMZVgR2BNTNWdy6Mr6C6U4NwQvPy4K12/we8KDUNTutXu1zawTnCtyXkAGF+i9fqRXC6KfMuiWbgDIGemf84r6J+HVoLTwbpqbAjOhlYAd2Ysf51rho3kc+Om4xSR0tFFeOfEnSrC5+Il5caz4cv8AVo30GOCxlttNluDHc+fKRslVSIXGVO4suODmvQPJPY6K8M03VfihY6olheI0txbWQjWN7eWSC6dbPO/zVtygdpx1e4UYyNmSCatn4r8ZJ/ZkGvarrNlFdXLIzWmjyT3gxbu5RUexQMu9VwUjfAzlzwaAPd7i5gtjELieKIyuIo/McLvc9FGepODxU1eYeKDrl38PvB11qy6hb6ul1aT376dZG4mt28tt7CJUfkE9NrAE9CKp2Go+NpdHnub6XXALbSpLiOO2sIY7i7k8+dY8h4mVZDEIWaMLkNjjGVYA9bqK6uYLO2kuLuaKC3jG55ZXCqo9STwBXi+hal8QdWsJop7zWLEwyXxjuRpymSZUgt3hDebax5y7yrxEhO0gZI3VJr914k1nSfE1nqj69DeS2ZWy0620ktaSobdDuM3lMfM3l/kMinKgbT3APaap6rqmn6PZm71a+tbG1DBTNdTLEgJOANzEDJrmNLk8S2ei+LoHmuNU1GwmkXSp7uBIjdA2sUiZ2KiMPNd0yAPu4PIJriNPh8TeIda8Ofa77xC1haarFMLu60uO2lRzY3XmhkaAARq/lorlespAYkKwAPaqKKKACiiigAooooAKKKKACiiigAooooAKK8++MOmal4j0zTvDmmWK3UV/OZLwzSyQQiGIbtrSoj7SXMeBg5Ct7kYVnqHjq4htrh5NStJLCz01J7QWKvHd3Bu5obolnj3lfLjVxtYYVlboeQD16ivGpNb8U+RC1zqHiq3uH1Fo9US30ESLY2+Zdhtf9HbzgSsKlsykKxbA7WdKvvHtwtje3txqMPk/2Wsll/Z8YW5Wa5Mdw8nyFlZYiHIVgEOc8cUAeuUV4dofiT4hrLJca1FerFFcwNd2senTSvHH54WQRYtUV08snISSZ+Mg9av2XiHxhPqWgTXH9uLbXF5MstlHpbQyeUb6VI2ldrZ0CCERkqZIW2gtuYstAHsVFZPia+1TT9OE2h6P/a935gU2/wBqS3wuDltzcccce9cr/wAJT47/AOic/wDlcg/woA1viHETpVvcAEiGdS2OwPGf1FeUeLpTrHjL7N50Vvo2lW4mvZJflBZcsSzf3FBBP5DJNdjruu+Mr/TJYL74fmG3yGZxr1uuMHPUrjtXm+tx6vrGuk3PhvTv7Dhm+0ajY/8ACRWhe5nXlFmboIkHzeXjBPJzWM6fNK72OilVdNabk99fvqkMfiO9gaDSrJTLolnJGIwnGP7QnUjAYgfukOcDnBJyfF9TzqGt3E0shMsj5L/NlAejMTk5Pp19cdK9q8aaje3Gky6jqPh7yLV4jNDt161uIpXKnY3looaTnGMHjtwMV5HoVtHJ4jtrExxsyt+8GW+eQ9dx/upkk+uD1zWFS7lyndhVFQcup678OdL1Sy0H7VAkMFzdoVsbMsdkSZ+ad+O/UD8O9dNqNs1rDb2CzPNLI6Cadh80rMwBJxwM89OnFdLpVktrEJCxdzGD5j8k+n065/GspWE/iayG3cDIZCAeiouc/oBXfCPLBI82U3OTkWPE3lS3XkLypLj69Qa8y8OavqXhTxHdaRHd3MdtclZrPMjGMEnBQ+nzgdjw1ei6izPqdmpwMuzH8QeK5P4m6T5nhyHV7RT9ssX88FD96M43fpz9RWdVXWhdKSjLUqeOLu33Stf6ToOpYZT/AKZpscpCupKneFDfeBA5HX8a4uTXNG0a9lhi0G705SuUn0HWbmzVsjshZ1wR7dOtdtMqa94UiuLKANutWD/Nys0LAqOf4Spb8xXk+tIUnjicjARth3cr91lJ/AuK5VOStqd0aNOejR6FaT6fqvhW11KPxPrNtYvKU8rVtNtdQEbDg5dQj45PQ8jrVbT9Mhnu0Okat4PvJMZAM11psr85/wCWokTPHQYrmfCTAeBtftcri1v1ljG/HB4JHbuKyLBs+IkRG2Bi6KQvBO4jP5H9KHUu3dXFGh7qtJo+m9H8XeJNH023h1LwBq0trGuFn0u+t74MPUDcjH/vmrn/AAtzwxbca2usaFJ/d1TS7iED/gWwr+Oa1PhTK03gfT5H2l2B3Y6Zzz+tddXXHY82atJnO6P448K6yB/ZXiPSLtjzsivIy/4rnI/EV0IOTXPax4H8K61u/tXw5pF2x43y2cZcfRsZH51zrfCDwtbHdoh1fQpMk7tL1SeAZP8As7io/KmSeiVzsnjPQk1xtIF1NJeLMtu5itJpIY5W+7G8yoY1c5HylgeR61qaJp50rSraxa9vL4wrt+0XkgeaTnOWYAZPbpXI6foPifSLzVrLTG0ltI1G/lvftkk0q3NuJjukURBCrEEna29eMZHHIB3lFeJ6L8IrsXGlpq1l4fXT7aW1N3aQM8sd+YorhWuJVeMAyuZkyDngHLtwKmh+DzQafY2cMGjx27JZrqMa7gLryb1Jju+T5/3QdBu9QOByAD2aivGrv4QyxWtwmhJpOnTTjUo5WiDJ5sM0yvBC21QdiouwjooJ257ywfCmS7jmTVNN0CGydr6SHS4C0ltZtLFAkfl5jX+KJ5CQq4Z/lHegD2CkdlRGd2CooySTgAV5z8SfCt7r3hPw7pX2+zW7guYjJDdSoI75lhcGPMkUqser/NE/3CcDqKmnfDq8itbKC6Szkto4Yra4tZ7g3CzhYZE8128lA0ibwqjaFKrzghPLAPTreaK5t4p7eVJYJVDxyRsGV1IyCCOCCO9SV4XL8JNYki8PLHBpFnHp1pHbPb2F0kQWVH3G6jd7Nysj8Z2hG4HztWtP8K5EtZ/s9rprT3ltfRXwS4aA3by3kM0Bd/KfcERJFIZGHzbcFWJAB69RXiafCzXCNP8AOh8OF4oYoYpY8xNpRS7kmMlsscKozujqGIWEFkzjBK16R4F8NQ+GtGETQ2wv5WZrmeIZMx3MVyxAJwDgA9Og4oA6MEnPHQ4pa43W/Ao1bVbi+HijxVYiYg/Z7LUfLhTAA+VdpxnGevUmqP8AwrT/AKnXxv8A+DX/AOwoA9Aorz//AIVp/wBTr43/APBr/wDYUf8ACsIGOZvF3jeRugP9uSpj8EwKAPQKo63K1vpF7NGcPHC7A++DXHf8KvtP+hp8b/8AhQXH/wAVVTVfh1aWGm3V3/wk/jZ/IiaTafENwAcDPXNTP4Xca3KGuXLWWnWmnaRayG6Mahio6Ow65/zjNYmo2Or6ZpkUSXsNjIRjyLa088/UsxAz9BVPT9OW5tHvbnVfGdrYqQvnyeJ7kCQnoEzjcT7VhatqCW2oR2OnXXje+upmAijTxRc5YdyQM4/X8K51CCW51KU9kjmtb0zVLp2uta8QT2elxukfmyQYklkb7sccaAs7nB+UD3JArvfhhoNtokl00ujazAsqKUfUUjjuJ8E5zGrsYl7/ADkVEfDmopdabq9teXdxrlg8gXT9W1qe7iljkTY6JOR+4lx0deARzW3Y+IbTSDJJqfhvxLpMyoBEkumtdWkb9mEtvvDjHPQdKtQVtNRTqyb10Rv+IbyTT4ItL0nTFutWukaRIY51iMKADLec4Kq2MYGDywJ9+e0PV7TTdbt7DXbDVdCvbqQxWy6mqyQSlufKiuYyyE5OQDtz9az/AAx4n02DxFPqt9qGrazdyRtGlvZ6Jesw3EHgNEozkde/HQAAN8Ui68VeZYPpV74e0fVDFDcXesMqXEqxMGxb2oLMJOg8xyNo5HNNQ0s0Z81n7r1O9lVsyQuo3cjk9CK8i+L1uUggus8A5bI6n/8AWK9i1KQXkguwm3eSSueh/wA/yNea/Eyz+1aFMGGTF+9QE9uhFcltT0IT2kcZ8DLrd4o1K1kcbLhFkHOeRkH9SK3vHcLR3VvuByWJP4GvOvhjeGx8faYzfxM0OBznPevXfHds91NDHCjyTlsKqAkk9BjHNFZaaFUXapZnM+GSxkfcuDtIP4GvoKPxFpPhXwLYajr19FZ2iwIN0hyzsRwqgcsx9ACa8N0uL+zr2axsrZNX16JcS2qzbLWxB43Xc44Xv+7XLnGOK9Y8B+BrUzWviTxFe/2/rwGIJ5I9lvZKDjZbQ9IwMfePzHrkZxW+GpuCvI5cbVVR2j0L3hLWPFXiTWF1OfTo9D8LhGENreITfXZPSRgDiFR2U5Y85xxjT17xdb6Pqc9idPvbqWCzF9K8TQxxRxEuMs8siKDlMcn+IHoGI6WsfWPDek6wb06jaecby2W0mIkdS0asWUDaRtIZiQwwc9+BXUcJw938WLHUfDNzP4bsdRutRaG8KR27W0nkeQq7pWfzTEyAyxfdZs7sYJyAzUPiPpmiWDal4lt1u2sJ1hSZVtoHhZrOCZ9nmzqZCVmP+rUN1XZwC3Ry/DbwxLa+RJZ3jAvK7yHUrnzZPNVVkDyeZvdWEaZViVO0ZFP1P4deGNSMpurCYNKrJI0N7PCZEaKKFkYo4yhSCIFTwdmcZJJAH+Htfknt/FF5eStPa2F64hCoARCtvFJgdMnLMeeeawL34waJp9msup6fqdhO7RCK2u3toWlSRGdJA7TCNV2o3DOrZGMZIFdva6Hp1raX1rBb7IL5i1wu9jvJRUPJOR8qqOMdKzb7wToN6yPLaTRzIsSRz293NDLGI1ZU2yI4ZfldwcEZB5zQBkx/EzSZ7Rb20sdTuNNEVtPNeJGgjgjn27Gbc4YgbsttBICk46Zp6v8AGDw1pV7Db3ZuFMruA7PCg2LM0JkUPIGdS6NgIGYhc7cYJ65PDWlCxvrR7d5oL6Bba68+eSVpowhQBmdixO0kE5yepJNU28E6FjT/ACLe6tTYQJawPZ309u3lKcqjtG6mRQecOTySe5oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/HXi6y8GaSmoajC8sDPsOy4t4SOCf+W8sYbp0Uk+1ZsfxH0uS/iiSx1M2LmFTqPlxiBDLAJkDDf5nKkdEIB64rd8SeGdK8SLbjVoZ3NuWMTwXUtu67l2sN0bKSpHBUnB7iorfwhodvAsMVgoiV4ZArSOw3RRiOPOTzhFAx0PfJoAxfBfi268S+KL7FnfWWlHS7O7tI7xYg0nmyT/AL0bGYgMqJw5BG37ozznW/xNaGW7W70XULu0tbaS6lvrZIY1AWeaIKYmmLDmLG7JGTkhFyR1Xhrwjo3hqWaXR7eeJ5Yo4CZbuafbHGWKIvmO21V3tgLgDNQv4H0IzRzRQ3ttKiSRh7TUbm3JWR2dg3lyDd8zuwznaTxigBsXjKzfwU/ib7LcmzVSwhhlguJGG7aNrRSNG2eOj/keK53WvjBoWiWyNq9nqFld+dPDJZ3EltHJGYQjOSzTBG4kQgIzM27gHBx19r4X0i20KTR47aRrCVzLIslxJI8jlt5ZpGYuxLc5JJqtqHgvQ7+5a5lt7mG7aV5jcWl9PbS7nVFf543VgpEceVzt+UHGaAKMPxA0+aZGjsNS/s5rxLE6iyRrAsr4CZy4fBLIMhSMuAcHOMqL4v8AhuXWdK03F1HNqJg8oyNCuPPYiE7DJ5jB/lOUVgA6ltvOOru/CujXmh3+kXVoZdPv3MlzG00hMjHBLbt24HKg5BHIzTX8KaQdWh1KKK6trqJY1/0W9mgSQR/cEkaOEkAHGHB446cUAWPE8fm+HNTU/wDPu56ei5r508RyTPrUZu3tfKutjraRgb5z90Bx2TPzEnlunQV9LatGZtLvIwMl4XUfipr5k1nSYbzXbF5ruRp5wqxxpF/x7xgYaTPQtxwOa5q+514Xcn+Iupx/2Jb3AkMt5cArbKEwFA483HbkYXHYGuS+FmmLqHiaGIKredJ5cvlnaYkXqv44bOPT3rS8e3UclrdahDENk0Rt7JAxPkW8bBM+gLNjn0B9a6T9nzSDEup3cnMkDfZ9/cu2C35AL+tZUlzzVjtqtUqL7s9kuyiaZLKy43nK89ugH55rj9FeVvFdyFAKx2JJPoWYAY/8errdecRaeccYwB+HWsHwxAVtr6+PJuXCg4xhVGcfmTXpP4keQtiK83PqED5yVl6+2RV2SCKbTxAVUxlSjBunJxVa5TLHHruz+P8A9atm3txLaSAcHcQR7Hn+dR3KPIPCck+l6pf6NO+9bSRQDMP9ZE+FB9MbSB9VrzbWrSS2vRHMWZ4bgwMfUrwvH+62Pwr0r4s28mj6tpmtwoWinD2FyQ+M7/udugcH8xXIeMLY2d5qd1cAv/pUAYjsQCC2ffiuGquVnpYaSmYnggGKy8RQuBIREkgOPl4PX2+7mqkTeRrNzcNvzb3IYE9Bz29vm/WtjwSJJdQ121iBme7sv3aLGWZjkjaoHercvhpLPXb2z1i7dLmaZhDpljEby/mQEY/cofk6dZGT8ahRcm7G0pRpxtJ9/wBT6a+FP/ImW427cSyDH/AzS/EXxj/wh8Gkv5WnH+0Lz7J5uo3/ANit4f3Ukm55Nj4/1e0DHVhXH+GdL8a6zpS2dncweENDViDsdLzUX9QWx5UOQRwAzD1zXWy+AbY6To9nb63rkE+lXb3sF81wlxcNK6SIxczI6kESvxt78YruirI8eo05NouWHjHTZrCCS5ubd7mRIm2acZLyN/M3bTE6xgyr8j/Mq8bTnGKz9M+Jvhq+0zTb5pb+1S+hS4RLnT51aJHxh5CEKqmWx5hPlkg4Y4rTHhSN7+x1C71PULrUbMp5V1IIQ4UZ3phYwoWTPz4AzhcY2rjmH+D2hyf2UZ728uZNMgSztnurazuCtuhykWJIGAC84YAOc8seMUQbzfEPwws99E+oSo1n5/mF7OdVYwyCOVY2KYkZXIXahY8jjkUsvxB8Owz20Nzc3tvLOFYJPp1zEYlaTy1aUNGPKVnBAMm0Htmq8Xg/R9S0+OTT9SmkgZr9kniME6k3c5ll4dGRgGyoBBwODk81nWfwm0i0iSK31TV47dkSO6gR4Uju40maZEZFiARQzvgReXwxHSgDr9D1/Ttda5/suWWZbdzHJIbeRE3BmUqrMoViCjAhSccZxkZ1az9B0qDRdNWytXleJZJZcyEFsySNIegHGWOPbFaFAHmPjufxNYeLdQuNBuNalZ9GJsLKO2EtlJcr5uRI3lnYwGxhl1LEBfmHy1h6Rf8Aj/U7ERvqep221LyRZ000+cWSKExJJ59nCDl2kxsjGRxkkE17VRQB4frF94xv9ds5mt9XbUbO6aez08abtsQP7Nl2yPPszuMzlCpkGM4K9DWlo174y1SawtI9T8QQ2M19Ck2o3OkxW9xGv2O4eZNjwhRGJUgCuUPLY3N39eooAxfBVxqN34R0ifXFddUe2Q3IeLymMmPmJT+Ek84rRub+ztbm1t7q7t4bi6YpbxSSBWmYDJCAnLEAE4HarNeV/Ebwt4n17xNJq+k/ZIhotvE+mRTIHe6nEomkCP5iiLd5UURLq2QW6DmgD1SivIb3w34zW2vrrTrrV1v7z+1RJFLqm5VRroNarGC7JE3kghWQDbu+YjAAj1jRfFM0sJ0Kw8U2cH2cJaJc64Ha0uvOy0twTcP50RTaAu6TG1htGc0AexUV47rPhjxwtre3Gi32prqN3LqXmLNqLSRLEb1WthGhkAQmAMFKFCN2GZeMVl0v4gWOguIItcvZ5tP1Kzjga7ihktpZfJMEhZ7uXcFKS4cys43YwBQB7XUN1cw2lvJNdTRwQxjc8kjhVUepJ6V5/wCFNN8R2vj66uNQi1SXTJISDPeXh8tGwgCxRpcujDg8tDGw5yzZNa+tfDvw7r+vvq3iC1m1WT5fKtr2d5baHAA+SEnYM4ycg5OfWgDMuvitotxcPaeE7XUfFV8h2smkQeZEh7b52xGB77j9Ky9em+IN/o15fatdab4T0mKMyPBZIL+9ZccqXfES/UK2PWvUbS3htLdILWGOGBBhI41Cqo9ABwK5L4opFe+Hjpcl0bdLl1M5QZcxKwZgPdsBfxpN2Q0rs8bsdMtL+YXtvYy3l+pwdW1uZr64jz08tWwiv3ARRtyOeK1o7KHS7WZ4gLbpHLMDvcL3G/qzH0HArSmnsrR7aFgbO2HyBIskxLgnHrubuaie0TUS99q8x07RLD99PxhY1A+WP3c5zxnmuZ3k9TtSUI3I9V12y8NeG59YkiDFsW1lBMxIkZQBzjkKoJLY6nA71462veIPEWupcQ3tzDJPMoEiP5bzMSAHYL0AHRRwABwTVbxt4nk8ZeJQwjNvpsX7u1toxgQwAk9P7zdSe5/Cuz8E6cGvtPvJBtijkbKjoOMIAPXnPNWrIiTb3PWdPhuLfTvsn267ZUj8tXed2fjvknrWZ40uE17w+t3Ag+2WbByo5AZfvDH+0vI/Cr8koV5YiCpVo+/OGNeRXHimXQvFU8jvI2m3AMV1CvdV/iX3HJpp8xny2Z69omppeWdvcLIskUy/Pz/Fjn86yPGdrv0u6icfKoPK5+63B6dsVzWkX66X4gWwR2lsNQAks5Ixnng7QB3GQQB1B9q6LVtZe91D+xdDsjrWvRKVnto5Nttag97uYfdxz+7XLnGOKy9m3sb+0UNWeL6f4du7PW4tYv54dP0vT7lDPeXJKopH8CAcyOQOEUEnjoOa9S1W9v8AVE82SO78O6PIvyoCE1W/U/3jyLWI+2XI9jWivg+6W8hvtT1MX2sxKVjuliAjsRnHl2kJ+WIcf6whnPX5TT9Qi0nQ4Vm1q4i+0yEsZL6bzHf3wev4DvWtlHbcyc3Ud3sctpVwXjtNO0ywFlpsTny7W1QiNf8AaJP3mOOWYlj617J4M1K5t9LSzKxEJuZXZug9MDrzmvILnx9pzzi209JZyBhS2IUz6AHnH4CvUfh5Zya1pDT3l08ZR9pjtgFUjapxk5P5YqIK0t9Sqrbhtod5Z3DyrmQrwcHjAFWwQSQKhgtIIFAjjAxzzyf1qeuk5AooooAKKiubmC1jWS6mjhjZ0jDSMFBd2CouT3LMFA7kgd6loAKKKQkKCWIAHJJ7UALRUVtcQ3dtFcWssc1vMgkjljYMrqRkMCOCCDnIoiuYJpp4oponlgYLKisC0ZIDAMOxIIPPYigCWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBrkBSWICgck+lfKXxD8/SPE2jQGQxPcPOsTRvy6lgF46Dgk/iK+iPF198kVpE5JdgCqnG456H265r5r+PyCK80PWU8x0t7h4JGDclSAy49Oj1M6akrs1pTcJXNPxfJbpAtzBHH5NvAiRRjlJJTny1x6DBc+uB616F8IdJfS/CNhHMrLPNI91KxPLFjxz9P5V5lbifVruyillRbfTYPtE5Rd6vM+MIMcddqj2Br3zTbZbOKG2j5jghSPr2VR/hWWFhbU6cZO9olfxRMmVQkhQNzEnrTdC2toMDocoQ0gI5yGY4/QCs3xlKUMmfvMqouR3I/+uPyroNGthBpJjUEJEREg9kXFdS+I4uhlXK4gkfBzknjt1ra0na9pIQOHQEc1lzqrW77icZB4/wB6r+klVRFUFRipQ2cp8RtFj1vwpq1kyLvMRliYrko4H3gPXIFeIaPqUGvaYDqcUlwbm2iieKO4SBpJFO3PmOCqZOMkjgZr6U1KI+Z8ucsGGQcEZGf0r5k8W6edI8Z+INJWRHjdPtUIU7Qd4ycDsc81z1l7t+x1YV3ny9zoLG90+3u301tRjsVMDM9j4dLJvQEZSa/cGR8lj8sQCehFc3f+IJ7W8m0nR4bfSdIk83NtYLs81QxCmV8l5Dx/Gx69KpeHY8+MApKK3kygs3AOHGTWT4hcR69vLZCISSoGeJCCP0rD2kpabI7FQhC73fmfYXwgYN4YfB589s/XAqz8RbLVbyPSP7Oh1O6sYrotf2umXos7iaPy3C7ZPMj4DlSRvXI9ehz/AIKuj+F52RQo+0vwO3tXQ+LNcu9Hk0eDTtPjvrvU7xrONJLjyEQi3mm3M21uP3ODgE4OQCRg9VH4EebX/iM8u1vRviBca1q0mjWer2NpJp13bwBtVaTcxtCIDue7YLIJQoJWJMEE+YwJJta3pus/8LAvtK0CfxJcSW9rptxHcf2uwgtWe5uDNJMjyjeGRCAio4wuAFG3Ggfi2/8Aa1zp8Ojw3EruiWE0dzMkFwWuBB80klugABYEmPzRwRnOM1dE8b6hplpcS6pIklyH1J/Ie8aS3Mi6iIUjR1gaZiN4RNq88DZkgroYno/g+DULbw7aRawZGv13+YZJPMb77EZbJzxjvWzXj1l4+u9XvLbUFjvdPBeCxltElICyHVEtmbEsQOMMc7o0fGR8h5Ha+B/FV34hudRt9S0tdJurXY4tZJJTPsYuAzq8KLg7CAY2kUkMN3y8gHWUUUUAFFFFAHJfFjVr3Qvh5rWpaXcNbXtvGpjlSNZGTLqCQrAgnBPGDXEWfxF13RLbVk1DT7jVILFJ9RS61MjTrmTT0MahvJEQ3S7zKApWMEKvdhn1LxG1mmi3J1O0ivbP5RJBL5e1/mGM+YQnXB5PbjnFc94l1vwBc/aLjxBeeHL2TRN00nnmK4lsiHCE7eWQ79q8DO7A60AYWt/ETXLa6vLS00OxtruK9t4II9RuZ42nhe8itzJxBs2nzVOUd9u8FlJBQxS/Fi7iuNYU+GLmSDTRcRyTxNOY/OhHzKZGgEYUkMFYOWPGUXPG/br8OLm5u4bYeEZbjVojc3CRi2Zr2PJcyOBzIuQW3HI4JpNvw2W+ilx4PF5cZsY3/wBG8yXACmEHqcAqNnoQMUAZl5431iw8TnR20uCXVrryhDay6iqWsQKXDk+aIN+4pEMjDjccDABZtbwV40ufFk8T2ekrBYfZobiaeW6+dTLHuVUQId2CCCSwGMEZ6U/XNT+H1+NSi1298KXIgdFvkvZbd/LZSQglDHggswG7oScda09N1bwxHfw2Wmahoq3t1bpLFBbzRCSaEJlGVVOWQL0I4x04oA3qKyNM8TaDqrKNL1vS70vKYFFvdxyZkClyg2k/NtVmx1wCegoi8UaBNfWllFrmlveXkYltoFu4zJOhBIZFzlhgHkZ6GgDXooooAhvLmKztpJ522xoMk15LrWoz6pqjzOFUn7mfuoBn5s/7P6kiul+JerSQrBp1q4E8g8wjPJ54/kT+VeePfiQrBBiQzP5ZkA4ZwOdv+yO59awqy6I6qENOZmrpkFrclpJ5BFaWwee5unwFQDq5+g6V4R8SPHkvi7VTZ6azW3hq0Y/ZrYEjef8Ano/csevPTP4npvjpr7aXpFl4P0+RgXVbvUJFIBlJ/wBWhx7AuR7ivIrYnZGhAz60npFGkPeldmzoW17ieRmOB8nHGAACf8K+mPDenWq+GjIyFHjljYsQQQxGFB/8dr5v8D2xutQgt8K4uJ1BAGSfm6D8hX1ZZxNPpFxbRSFi0RdWYYPyYx+qnHtVNaaGTepzWv6slprKW7mKMS2Sy72kALuHwFUY5PGa8o8Z6R9u8R6VZRTmBLmZ1klCF/Kj5Z3x1OFBOO+K9L1jUpJ9Tgt0aJrYNJC6AnzIyUDK7dgrcgfnk8geZeONQniikvLF1SYLgN1ZAysrAfhkfWs436Fz2TO58M6bPqg0nRreW80DRGjaOB3wNWvoVGTkji1jKsowPnYY7HjsPEPifRfh/p3/AAjHgnQ1uryH5GtLcFI4MqD5ksmCScHJ5LHvXknw5vH0Tw/FrMIVWhtr67iWQ5GGaOOP8zGR+Fem6bp/9j+EYpY3MlzLE09xcOMtI7kliT7mtZStoYRhzPVngfin4ieK9SvLqG61JrWL5l8qzXyl6HkEfN69TWFOJJ7dZZrmWV3hVwdxOMH1PtS+Idsmsag6KAvmnGB6KRV/TLcTaXZqAQxgzwMZP1rOctDrp07Ox0XgfRrKe3e5k083FwspAJ161ssDaP4JVLN1PzA47dQa9y8E6r4m0rTZotD8EfbbdpNzP/wkNrJg7QMZVR2ArwXQtPaO8fzgUKLu/DA4r6c+CwP/AAism4gnzz+HAopzTlZInEU5RhzN/IP+Ep8d/wDROf8AyuQf4Vt+FtY8RajdTJr/AIYGiwqmY5P7QjufMbPTCjjjnNdLRXScJ8+6po2ox/GPUdSttHmluRr9nNBIujTB5YPs0cchF/8A6tIly5MZ+8UxnnFX/FOt/EHTPCek3dk/iC61u4tJLqSJNPQwrIoXbA0aWkj7jycM0QOW+cfKB7nRQB45rB8Qa3BqdleXniGLUl1q18m1TSR9kt7dNTgMc8U3k4kYRAOd0jAfPlQF4bqVz4ytBLNHFfXF3bJc2p1IaVG919nGoQrvUCMBn8je4RRtcqDtOK9looA8l0vUfGVxb3001zr7WFnbXVxbFdNhhvL8JIwiVlki2o7L/DsUnCnAyQcXTPEHje605otWfxDbWJvnjN7baSZrsxm2VkTa1pH8plLAv5AxjGcfNXulFAHgEVz4r0Dwbbw6VpusWd80NlEJbSwAbKafFlZv9FndvnBXJUYK7S6gYrSk/wCElNzJqosprTUbhkne5bSXuDBIdKUFlUIzjEny4UE5+Ug8qfbaKAOW+G17qV/4ZWbWV1H7WJnXdfoEd1B4YDyICF9N0Sn68GupoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvqDMlo7IeRjtnjNWKbKgkjZGGVYEGgDitQs7h2cttlLKWMitwi88CvB/ivFHfeEdUhA8poJBdYHzcg4I/I17jrEE+mXDo7YjcHyz/C4x0PuK8Z8XW0V3e3dmCwF8rQnABxuBAx+PNOTLic/8GL1ryPTbOL5n+2ia8dl6qoJjXPcDax/4Ea+krcsyyFjkkfn0r5v/AGe1ZZ7tJI1X7Nv356iRvlGfwU19E2rjyYWPfk5+lOmrBJt7mF4hQXGt26Ody+aDx2xg5/SussspoyZG0tvbn3OK5KXMmuAMfugsMD1P/wBeuxkUrpVqnfaP55oW9xMxyoKMhHb+pqbRzkN/snk496jlUhn5HU4FWPD6qTcpkk5bGB360luDLlzHw0kh4jYSHHPHevmL4okWHxTkLOGtpI1hDscHaQrDJ+gx+FfTurrKdLuxbOFmNuxjY9mwSDXyh43hmm0u21OdAzWQhmy7ZlZWY5Ru2FbeAetZVmvhZvh73cl0KngqSMeP5hMy+SLe4RST6txn8xWHrEbSeIyFcybYizdOCXZj+RNbPhq3ntdU07V7qMSreQzqqBMDajoC3vw2a56KfzdVklb/AJaQgnaR8uWH+Nc0lZndB8yv5n2J8Fcjw3eAhRi7fG3p+FbvjDVYdJ1DwzJdR2f2eXUJVknuVybZVsrqQyI38LYj2k/3Wcd6w/gsMeGrgHr9obJ9c8/yNdP4n8N2HiWG1h1PzWht5JX2I20P5lvLAytxnGyd+mDkDnsemi7wTPOxKtVkvM41NU+GZtbqdNGsj/aM6208I8PyeddO6tOoaLyd7hhEzhipB25yTVlNX+HUlvYaXBY6fNZX0UKxRQ6Q0luEuZAY1kKxlI97gHa5XJAJGa09I8BWWn6jZ6hNqWp399bTpMk908W4hLeaBIyERRtCzyHpuLHJJ5zzlx8Nr611zSItDvGg0OCSymu/OuwzTm2fcmYvI64VRuEqj1U4GdDE1oNZ8AafpVnJaWthFaSww3VrFbaWxLq0wMRSNY9xbzQGCgbtw3Y4zU850rwz4Ya+8HaJYaddanPBBCh082m+WWQRq00e1Hwu8sQcHAOMZqnB8LNOgsri1XWNVkgktlso4547SdIbdX3iNUeBlYZJGXDHHfgVq33hI2/gmz0XRZs3GnSQ3FnJdtw0kUqyAOVXhWwVO1eA3A4AoAwbv4oRWHifW9Lv/wCwbeDSG2zGbVvLvJ1FuszPDa+UdwwxAHmdVPNGsfEHXdG0C21jVfDem2dldvAkEs+tbUj811Uee3k/u8BtxK7wMHnpndHgmM6rq142raklrq7+bf6YBA9tMTCsLDJi8wAqi9HH4VXt/h7AkdhDdeINfvbWwmgmtYLiaIpF5Miug+WMFvugZcs2O4yTQBB4T+ITa9qGh2jaWsB1OC9mE0dz5seLeVIw0bbB5iPv3K+F4HQ5zW/omr3Vz4h17Sb9IhJYvFLA8SkB7eVTsLAk/MGSRTjg7QcDOKwz8N7OC/tLvSNb1nSpLM3ItltjbukMc5RniVZYnATdGCB23EA4wBteH9Gu7PXdb1PUJo5Zr0www7CSVgiU7d3AG8s8jEAYG4AZxmgC54m0n+3NEudO87yPO2/vNm7GGDdMj09a5HUfhtHeWEtuNSWKR/7VPmi2BIN7P52T83OzCr/tY/hrqPGc2pW/hm9l0Pf/AGioXydkXmkEuAfl78ZrznV9R+IGm+Nzp9lNc3lhF5Yt5bm1LR3gKEvvaG1KIwc7QTLEAFGQ2SSAXrv4WXN94hu9Wv8AWbeaS8dZ54hb3KRrMIBCHijF15Y4APzpIeSN2MAXtb+G7XyQQ2epw2ls2lw6TdobLeXhjfeDEQ6+U5Jbkhx04yAaxbPxH4gs9K0y7a58Vai8kMqX0dxoBR4bkwgxqiJbqSm8MN2XXOMuRU1jc+OrrRbm8lvtRt7xb3S7aK3OnR48uVLE3MrApuYKXuc4IC4kz90bAC1c/DTUJJLwxa3ZwwSXH2i2tktrtYrZyXJdAt4GSQ7yMxtGvLZU7uK6/CN5NXN3f69LfpOsTXX2hZxI8yWwgMqBJ1iDEDOXicgk8kYxmTar8QrPxNrFn9ovZra2hultjJYtJ56rbFoZFaO0EXmmQDIM2DkqIwcVauR4stvEGkrqGt+Jn06G8Qy3Frp0bMwktiSjpHAQ0ayrtzt+Xf8AMchWABoWXw01S1urLUU8Q2Q1ew+zRWsq6VthEUMFxCA8QlyzlblzuDAZC4XAxVnwx8OrzQL/AESW21xFgsLeKC4WC3lie92IVHmfvzERyCP3ZYYwGr0aigDgb74mWOiapPa+L9L1XQIVmaOG+uIfMtJ13EK3mx7ghIwcNjGa7XTtQs9Ts47vTbu3vLWT7k1vIsiN9GBINTyIkkbRyKrxsCrKwyCD1BFea+K/h94d0tZNY0Nr/wAN6i7qhm0SXyRKzNgb4j+7cc5OV/GgLXOU8X3MeteJbySUyeQ+9FZOGRFG0DJ6biAf+BVV8JpHdayu8HyLCEq5/hjwAx/IZ/WokfWYWuF+z6b4jQgB7jTwunX4AOQTA58mTk9EZSfrVK21LT7LwPreiaDczN4rurdoRp2ow/YLwtIcE7JDhyAWOELZrmUG5XOx1IqHLszwXxRqreJPFmq6q4wt3cvIiddqZwq/QKAPwqC2QmQfL2z06Van0q90yRrTULOa0u4yFMU8RRh25BGajZVVp2XksSiqPvZA9Pxq29S4K0Tvvg/YmfWbeUbR5SFlbph2BA/qa+kLaea3sppYLU3UkYZVh3hC4+v0P418/wDwniQoRGxE5eIIc9g2CP1r6GZpbeOURxl5TDvQHkFwMdPqvtST1MpxsjzjWr68fT9RgnsrmyuLAxSqZQuC+TuC4JBwCPzrynx3IYLW4xnzMSD3PzHj/wAer07Ubu61LP26dLh75DAzC3aFA2zBwjHJw2BnjntXmHiKGXV7vTbSE+ZeXlzFDjsxZxnB/A5qY/EaP4NTQ8TWWq2WlQ6bawhYV0+205yR8yFMSSMPYtvH4V7D4nv4/wDhGLTyPlFxHGygdlwD+XOaxvEtqdQSzmkw0rzlH7jbtkBBrn/FF8trYaPaxt5kcVv5B5xgomDxTnLQinC8kjxzUmaRbl3P3pXfGMDkGup0KJI7K2j4+WBVznjJ6msePRtU15Fj0XTb2+l3Zf7LA0gQE4BOOgxnk+hrtLfQp9OlRtZutL0lF2j/AE7UIYWGP9ktuz7AVg4uUdEdsZxhN8zsXYIFMUp2qpkxz/exx/8AXr3/AOFNt9n8KqeP3kzMCO4GB/Q14haXug3E0S2usNqcqMS0Wk6fc3jOSTwCkez/AMer1DQvFutW+k29joHw/wDEd15WR5l/5GnocknOHkLd/TNaYenKLbkjmxlaE0lBnqNYGi+LtJ1rUJrPTTfzPDJLC8p064SDfGxR1EzRiMkMCOG6jik8JXviO+juZPE2j2OknK+RDb3pumxzu3tsUDtjGe9cRongPWLFdctruzsbmC+nvZY5H168aLE8zyLutPLESlQw5U5yuQQTmus4D1JrmBbuO1aaIXMiNIkRcB2RSoZgOpALoCe24eoqWvJdU+Gl/c30FyItHur1I7+3Op3JxdAzmExXfEWPPj8tlCgqMH5WUHaKnhf4TT20On2uu2+m3NjDqSXlzatNHNDMq2lxDkRJawqGLyxk7g2QvLEgAgHstFeI3Hwp1x47OO2k0uC5j0j+zW1KSb7RLGfIeNTCGgEkeCw5WZQRnKkmtTQfhjKt7btqumaBaaSLzz5NHsneW2Ci1MJIDRqGLOQWBUDAGSxySAetUVxPi7wtcar4u0vVv7L0XWbS2gaH7NqkhQW7mRW8+L93IC+FxyFPAww5ridI+Feurdao+pPo0cV9PYyTJZEQpL5N8k7vtjgj2sUVgNzSNk8vjkAHs9zMttbSzyCRkiQuwjjaRiAMnCqCzH2AJPanxuJI0dQwVgGAZSp59QeR9DXhq/Da+1HV9fGnaPpWkW8d7dR296d8U8sLWXkpAqCPAtwzhshiPk4XPNe22ELW9jbwuQWjjVCR0yBigCeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDH8WWIv8ARJ0A/eR4ljOcYZTn/wCtXgfjO1MN/CgkQOjLI+4c5B7fga+jb/8A48bjjOI2OPwrwHx/blJhK4UNJzz/ABMT/wDWpNFxOX+E6iHXPFcUW3YmoyHH8R5I5/P+de3wEfY4mYdVwc14l8MbiAeL/FcSA7jd+YWxkEHAA+ud1ezJJ/xL4hj5gADmrgEjM02MS+JZzu4WNVA/E12moARxwR9NoUHnviuI8ISNca5qiH5vLnjTIHqgP9a7XWOZscde/rRHYTMl1Juwo6Ej+tT6ERDqY29XPP54/rUUZH21WOTh1/rWTqutf2X4p0+BSFRt6sCMnORj+f6VLdtWUlfQ1/F+r6fp2lXH9pXD29u1sS0qxuwQE4ydisRjHpXz8fDb63pl1Fo11Z6vbPFKC2nXC3DEYypdB84YEDqo/Wu71/W7y78UXklncywwRyy2tu0TlDu4dCCO5+ZfxxWHfjT9Wvbg61oun30pthcxTTwCGeMBhnMsWyTo3diciuWdSE5XfQ66MKsIvltqc/4viXRtG8BGNGEzWV3JMrcMGcxs24Y4xlhjHGPUV5foyLPdSrLtH7lEyen+sU/yFeuzatBFp0O/WdZtx9tmsfsuoxxazbxlEVgR522VAyt/C5IrLsNO0jVJvNstO0u/dgDu0PU2t5cZ/wCfS8GT06I/0qqkbr3RUari1zLqe/fA4OfCc0sgx5l07KPbjFeiV5H4G8e+FvDenppOt3d9od00hdU1uxey4IA+8cx9uzmvVbG9tdQtkuLC5gurd/uywyB1b6EcVrTjyxSOatPnqOXcnorlNF8awaq93L/ZWoWWlW089u+qXclsluXikMTdJjIAWUgEoPwq7d+MPDlnrkGjXWt6fDqc24JbvOoYsuzK9eG/eKQp5IyQCAcWZG9RWCfGPhgacdQPiPRRYCY25uft0XlCQKWKbt2N2ATjrgE1M/ijw+l5bWj65pS3VzCLiCE3cYeWIgsHVc5ZcAnI4wCaANiisKPxh4al046hF4i0Z7DcyfaVvYjFuUbmG7djIHJGeBVrV9d0nRpLaPV9V0+wkuW2QLd3CRGVsjhQxG48jgeooA06KxbXxV4fulumtte0mZbWRYpzHeRsIXZtiq+D8pLfKAep4qs3jXw46zLZa5pN7cx2zXQtre/gMjoE35GXAwVwdxIXBySBzQBq67qcWj6RdahOheK3TeyiSOPI/wB6RlQf8CYD3rjbH4o6dqdhazaPpep6hPcx3ciQQNbtt+zPGkm6QS+Xj96pDKzAjODnAPW6pptn4i0V7PU4DLZXKIzRiQqwIIZSHRsgggEFT1GQapaR4Q0bSJkls7aQyIk6eZPcSzuwnaNpdzSMxYsYozk5Py8dTkA5FPjJo1udFh1qwvNNvNSt4LnyZZ7ZjEkzbUYAS7pATnhFZgBllWtV/iXpUEZuL2x1Oz08/aVjvZ0iEUr2+8yRqBIX3YjcjKgEA4OeKu2fw/0Cya1e0j1KCS2RYo3i1W7VjGpJSNiJcuiknCNlRkgAAkU/W/BWm6npml6asccWn2epLqLROpk8xg7SEAk5XLtknnjK4weADo7OY3NpBO0MsDSormKUAOmRnawBIyOhwTU1FFABRRRQAV598WL6WNdMtLUBpS7TEZx0Xav6t+leg15N8QH+2+K5FXP+hwqAV59/1LYrOo7RNKKvI5mGKOe+WxQO6SSq0rMP4Fy3PsW/pXLfG7xfLa32l6BHbadfwxRNLdQX1ssyMGOFAJ+ZDwTlSDz1r0rSNLS1gm1O7BQBMtluEUZYk/kM/Svl3xLqj694g1PV337LqZvJZv7i/KB+AArKEXF3OqT9o7Holvq9g2g6UyXlxp9pdK/l2Gox/wBqaejISGChj58A6cozHkcetG48N6Xc2j3cVhJZQL8zaho7nVLIDqC6jFxAOn3lasC2kN54QS1EeJ7G62owXlRIpyD+Kjn3rEsJZLS8uHtLia3khtpGjkicqVIX168jNFKq5X5u/wDw34Fujyawdj0f4ZWZtkcB450ilLK6A4kwRhhkZxwTyM8ivoDV9QW1tbGXMCyO7QfvpRGhGPMJzg/wg14f8JbV5dGtUBbDyEOw5IwgKn8xivWrmXUU0ieK2sI7qZY2lDNL5ahlxhRkEklSxz04qm7SsYSV1c4jxpdTw2wFx5Ynsrze3lvuBycjacc9BXm+jv5vxG8y1UL9kiuJ0H91mLLGevYup/CvR/HD+bqUh8syfbbTJRTgCRTg/jlP1rzHwRcK+oa2xhDPMyweZ2WNAzuB9fkpR6suT0SPZrSFW07SoCDI6IhYk/eJU8n3+YmvI/EF8JdT1gR5Pk3txCo6lFPORXsuk7kuLlp+FtjsHGcAAY/nivAbe4S4ufE00o+Z5DJsPZmOAf1rJ6pm0FytDbC/tbe8W0u9NtdRimRVCXMkyomAeWWN1DcHGDke1dNpWtC3kRdK0fRNODMArW+mQhx6ZdlLfrXFaaGudXaaMArbpwoOepxXU6PbqbhQEICZ79Dn0qak3FWTN6dKM5OTV9T0Ky1vVr+dDNqF3IoGEQyttHOPu5x+navoHRrX7FpNnbd44lU+5xz+ua8K8EaYZ9as7YLglkyw5wOWP6V9BCtsNezbOHGNcySAV494o+I2t6N4fm1KS40iBpdTvrGyiaz3Bltp54/nkkuoVDMI0wASchsBt2F9horpOM8Jl8c3fibX/DwubjTLPyr0Sx6Uqv8AbCG0yWTzzJ5gxHmQqMJ2B3Z4qO6+Jt48um6CjWssF5pqRXEToRNEz2Bm3CR7lpZBnHzGLackGQsOfeqKAPC7jx7f+GdMk8i5022tormKF3u3M8pQafZy4igkuYtxzK2ViOeFxGzMSev+K+s3Gg3Gj6tYwrNcW0N3IiyK20fu1+ZgPm2qDuIHOAelei0UAePweP8AxHfxzQ6ReeHbvyWviupx2sr2t4kEUEgMaibI+aVo2O9hlCRnpUc/xP1d9bFtavo0cryNFHpEkUj3jr9ha4WfcJB8hcBANhyP4s9PZKx5fDemzeIItamS6lvoTui8y8meGJthQskJby1baSNwUH5jzycgHl+ofFu4k0+5u9Jv/Dv2WAWQe5llQgNLFK8iKHniV3DRqNnmKQN/3iMV1/ii4XWvD/hJbn57HVb61N0GiMQdDG0oVkJJAZ0RSpJ64Oea7mqWsaZaaxYtZ6hEZYC6SYDsjKyMGVlZSCpDKCCCCCKAPB4tf1IXHjhtM1KG58QW11qi2cB8SXEl0gRn2hNNIMZCgfLz2Bx2q1r17pk9poNv4F8T6trlxdahbR3Vu3iG6QSAw3DYeZSzQuxUbkGANq5Rete90UAeIeBfGUOm+INEg8T+KFgUaHLHPHqd55Wy7W6wY2Dt80iD5NxyzBc5IOa7/wCH6LbX/i2wtj/oFprDC3UDCx+ZBDNIi+3mSSHjpkjtXYVS0nS7PSLZ4NPh8qOSWSd8uzs8jsWZmZiSSST1PoOgAoAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEF+cWNz2/dt/I14b44gk1Aq21nWIhpGH8Cg/1yMV7fqxA0u8JOAIXOf+AmvKfFsK2mhtJBIBLc7VZsdFBBoKR4x8JZ1k+I3iOOGR2SSVipPRlEhyf8+tfQE5CWw/2ia+bvgY5k+Jk7RE+TIJmbHQKGz+XT86+ibyQtF5iH5VBfp60oysUxnw/CyX9/JGMFrkgnGCdqqOa6fV2H2lgT/FnArmvhm7EXjOuN15NtA9OOv45rc1GTdc8YIB7/AFq47E/aIIeJ1wMjeucV5Trt/JeeLopZ2cNb3Rji2KCVHmY7+2D9K9as033ki45Vl2mvIdSQy+LbqQsE2uZlXYSDsJHP/Al5rnxLtFHVhY802UtCMlzZF2QhY9SDkHk4EnQe2MVLq5k03TDcBSJLaWTzON3mRljvUDuNpH+RUXhFpbfw5ql2sm5o5HkBxkAhs5/rWn4yfbYPIHVhcA/KMfvPMTbkD2YCuC9z0nGz+48g1+8LaRdL5pZoNRjc7j1DwumRj/rmM/hVHwmu25Rzzmz3Y6/xgVQmuXniuY3zuNujEHqXRwD/ADatzwSQuoWZePegsCDkZB/eZrpq6QMcP/EZ9f8Aw8ghvPBMEN3DHNC5ZTHIoZSM8DB4rT8P+E/D/hy9vLnQdIstNmvAon+yxiNX25x8o4HU9BSeBY/K8LWK4AO0kgdPvGt6ummrQR5lZ3qS9Wea6J8M30q71eWObw67ahJdubptCBvFFxIzlWmMxDgBiuCmCAMjsX6l4E2C0tF1+G2t5Yr/AExEnhLzSwXflyOiyGUFpl8gkSHdkZypILHF8Uap41svD811bT6699canfQwR2tkmy3hinnEO4C0ndg6CPDbQCAnzLks2et34p1zXNFbXYNZWeG6EwsF0rFkkbabJmRpTGSXMsjIUMnGcFO9WZHT+G/huugTWF7f6rBObC7S8aZ0uCXSO1ngVXae4l27fP3ZXaBtxt5BFH/hVL3OlQ2Vr4gjg0uXTPsE7WUEiPdxmFowW/fGEjDAj90WGAA1c/Jq3jL7VpWlW2m6vHpzadHbXds1gFtxmwLExhLYBAJNq4M+QwK+WBgie9uvFOi2E50yDU7VRdR5gsNKP2i7VdPs+kn2WZMiTzVzIFyRt8xQhAAO00bwDPb6/bazq2p2t5fR3KzsLew+zxELbGBAqb22sN24tk9AAAAMbGr6BfzeKrTXdI1G1tZ47ZrOeO6szcLJEXV/kKyIUbIPPzA5GRwK6QHIBIIJ7HtS0AeWWXwru/tl1caz4jfVHne0yZ4JXLJBdpcbWDzOvzbShCKijOdvYxzfDrVNb1HXxqd5bWWmTaldXdrGlqHmdpLT7OJGkEmNgDt8m1SSoy2OK9XooAis4fs1pBBu3eUipuxjOBjNS0Vk6R4l0LWrue10fWtM1C5gGZYrW6jleMZx8wUkjnjmgDWooooAKKqWeoWt7c38FtLvlsZhb3C7SNkhjSQDkc/JIhyMjnHUEVboAKKKzV1ywfXn0aOSV9QjiE0ipBIyRqc7d8gXYpODhSQTjgUAcj/wuLwJ/wBB3/yTn/8AiK4S58aeFLnUtRuX8Q2ai5kyuLS53Bc55/dda92u5PJtJpM42IzfkK4DQry9k023kkvboySBT+8lY8t07+nNS7bFwvujgvH3jLw3q3gi+0jw94mtLe8uUEPmXFvdKojJ+fkQk5K5HTvXkS+HdEi0tLaLxXpRlVlfc6XZUHGGwBbcZ4/Kus/aC8c65aeNINL0XWtUso7S2UzLbXTxFnb5vm2kZOMVwen+NfF00yIfFeuLl9pL6jL0HX+LisqnLszoo0ptXizqNFttIttJubO/8U6NIXiKxyJb3hYcgqpJhHy5GfUHOMgkVhQeHdNhnkdfF2ilSrIp8q8yQQRz/o/vW/b+NfFbbLFtR1e6u2IWPy76ZXPp91sH8a6fWdfubvS76/HjvUNKMoEZjFzNNHFMpy/kyJgOu0HIUEKSBnpXLCrTpTtZ3fz1NpQqrdoTwPqvhvw/pENvceJ7E3EbBt0VvdFTgD1hHcGuluPHPhwXwuLTxVCqq6FY2t7oIUz+8BAi5JHAPb27v+G99q09jcE63rGpQkRtFe3MrKkgKjIVSxYY4JJ67ulbOsazqlxdxR2Op38cVsspuF8pkBO0KiiQ/e+Y54z0PauiNSE22jCUZpWZ5/r2uaFfT2723iXTFWG4E3zwXYO0/fTiHocKfzrn/DcPh7SbWZH8S6S0jm4KssF3wZCNv/LDsqgfnS+LfG3iOGwuBba5qkYErjel3IpQEZAzn16emMd6u+G/EviOTTo/M1/VpXSxXczXchJeQ5yctyRuAz2AxVOUbN2GoTulc6uTxd4Z+xagkfiWz864IKZtrnA4HX916ivJodFsE+358XaIPtGwgrFeZ4znP+j+4r2Xxl4k1bT/AA1F/wATC8juvLXe6XDAhscjg+1eK2vjTxSJb4v4n10pDCz838p5wcfxeuPyqYcjTsi5+1i9WXtG0jRrGG6EvirRzNMU+dYbzov/AGwra04aHbuXl8VaWSRj5YLv/wCMUf8ACSeIbLQrVH8Say91sVXdr6UksRk9T6n9K3PD/iLX5bmUtreqSRqMZa7kbv7ms5yp31RvCNaMU1I6PwR4w8IaHqkl1eeI7dlwQgitrkk8Y5zEK9P8OfEPwv4jvns9G1T7TcJG0zJ9nlTCDGTllA7ipPh4t0+hC5vbye6aZvkMrltqrx3PcgnPuK6euuCSVkebUk5SbZ5F4v8A2hfAnhyaa2F1e6leRHa0FpbN8p9Cz7V/ImuG8PftTWGpeLbe31bTI9F8PlX827leS4lyFJXCovGTgdD9a+gdf8N6J4hh8rXdJsNRTGALmBZCo9iRkfhXIeHPg34O8M+L7bxH4fsZ7C9gV1Ecc7NE29SpyrZxwexFUQZ//DQfww/6Gb/yQuv/AI3XZ6j4mgk+H174m0KSO5gGmy39q8iMFkAjLrlThsHA44P0roqz/EK2L6Bqa6uu7TTayi6GSMxbDv6c/dz05oA8Bk+MHie/8Hahd2lzpUksVlpl59v0y3Oy1luLiNJLSQSPIpcKzc8EegPT0TVfjJ4f0rW9V0q+tr5bvT7e4umEUltP5iQjLACOZijEcgSBCfY8VqeHNP0Dxl8M9Ksv7Fu7bw3LBbtaWl1Ltcwx7XhbdHIxx8qHls8fMOtFx8LPB1xd3NxLpDF7hbhXUXk4jAnGJtqB9qbu+0D160AY7/Gnw5BZXs99bajZS20lpGILnyEaX7UhkhKv5vlqCqsSXZduDnFa9p8TfD1z8Op/GokuE0iDcsilA0iuH8vZhSVJLEAEMQcg5xzWKNN+G13rt9pEdvJJfyTWtpNLELvy457ZMQILhfkjlRSR8rh+ecmu3l8MaVP4cn0K9hnvtMnBWSO+upblmBOeZJGZ+DgjnjAxigDzPxj8Tb68utG0nw9aazpmoya4mm6lGYrU3EAMRkCrvd4iXGCG+YYVs4OM9n4v+Imk+F/Een6HewXEt9exedHiW3gj27wmN88sas2T91SWxzirFl8PvDNk9s8OnO01vejUUmluppZWuApQO8jOWfCkjDEj2q34k8H6N4lnhk1yC5uo4thFub2dbdirblLwq4jcg85ZT0HoKAOMPx08Grq1/Yyz3KC0W5Pn/u2WQwDMgVFcyDodpdFDYOCaXUviVqyeJvA9nZ+F7+Ky157jel0bfz2jSESK8e2cqv3ssH5wCAM4B6lPAHhxJb9ksp1hvzK1zaC9nFrKZAQ5a33+Vk567c55681Gnw78OKumgw6izabL51nI+q3bvbnbsIRjKWVSowUB2kdqAOQ0r416SPD9td31vqF9KLV768ltLJIVtoFuWg8x42nY43L0VnYgZwOg2rH4saJeeJU0eOy1Rd+pPpSXjRx+Q06x+Zjh9+Cp4O364q0/wp8GNaW1qdGIt7eNoVRbudQ8ZlMxjkw/7xPMJba+4Z7Vfj8AeGY9QW9j0wLcrqB1UOJ5MC5KbC+N2Pu8bcbfagDqaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk8SzQyRSDKOpVh6gjFeOeP0ZbKO2nBjaJyvXggHg/iK9mryH4pI1vdXkmSVG6Xb148sUmVHc+evg5c/2YuqahEHa78kwQqFzlnI/TAOfwr6Pv5BDEy8MBGMk+w/xFfLvw8+eGKIKTm9ilOOMqN2ee3avovT72W/064lnRlKIBkjpkZxWal7zRtONkmbPwvJl09ZHPzyXEr5zyMuf8K27zIvXUnPzDnFYfwrSRfDNnI6hXYu/A7GR8H8iK3p1BvkPfOT78mt4/CYvcksI8XUkmSWyO/SvFPFF5JaapNdINxBuwmWyBtV26fUivb7T5baaYgFVjLn9K8N8ZSCa6tzhRE4lkk4z1OOPrkfia48U9kzvwMLybGfDCZZ9EuRMu95J5Nw25AY4O3HpzUXxPnhj02zvoC8Utq21CF4UMQcH8UH6+tHw78uC0uBHE8YS9IYcAtuU43D8hn1FZnja+SbTbmG7IBklkgiVP4cgMm769M+9ccfjsehJe4jzKUBr/AFKS3dVRYWZcDG7OCR+lbXgMGfUbCFHMTfZj3+9+9AIx9M1zqHzJIP3hMhidHyeuFOPrnP6V0/wzV21jTnRMs0kcPPpvZj+i11T1gc9PSbZ9p+FYxF4fsUHQR8Vq1S0WPytIskIwRCmR+Aq7XVFWSR5E3eTZ5doXxL+x6ZeN4kstTdorjVGhu0hiMdxHbXUieWgVs7lTYPmVc7TyTmr1z8WNGtPEKaHdWOoQ6qzLGbV3tvNDuCY08vzt7FxtIKggbwGKnIGunw88NLLeSGxnf7Us6yJLezyIomfzJfLRnKx7m5OwLmtKXwzpkmvf2wqXcN+SrSNb3s0KTFRhTJGjhJMDj5lPHFUSc+3xE067Wxm0wzvayPAZJfs3mhhLbyTiIASBlkCIpPDY3qMHJK6HhzxrZa/4YvtctbWaK2tVdijz28rNtXcf9TJIFPbaxDAjkCrVp4N0GztBbWlj5EQvJNQAjmkUid1ZWcENkcMQBnA4wBgYn0fwzpek217BaRTyLenNy91dS3Mkvy7fmeVmYjaMAZwBQB53L4w8SWN1oenS6hCZ7vSV1K4nHh+51JvMd/8AVqlsy7EUHALAk4GSSa1o/E/ie/07Xdc07+xYtJ064vLdLSeGVp3FuXRpDIHCgl0JCbOn8QrUs/h/YGz01dUu9QuL+xtRYx3lpe3Ni7wKcqr+TKNxAxknqRnA6Vau/APhy6v7q7mspt907SzxJeTpDJIV2mQwq4j3kH723PfOaAPNrX4qeI5fDlze7dOkdbzTbRbgaTcpsa5I81PspkMshRWRlKkb9w2g10mg+MdY1Cx0TULmWFSutS6Rf2qWzQb1bcIpDHJmSF/9U2wsflc57Y6XUvAHhvUViFzYSKYooIkeC7mhYLC26E7kcEsh5Vs7hk88mmReB7C1uNLWwd4LG0vX1GeGR3nlu7goUV5JnYsduc85JKpyAuCAdZXz1ofgzxvZWyi2s9Ut7yDT9QtVkuLmzVIvNlEkYtWibeCWALGXpjAPavoWvKF+K96v2JZ/D1ukupxh9OC6llWJuUgxMTEPKG6QEEB8gHjIxQBXv9B8Y23xAtzo0eqLokMrB7iTVZJ1njaB8lhJc4VhKwAVYOAoIcD5aYnhnxdYWEEIl1+9tHt9Nmv4BrJ+0yzAXAukhlaUGPn7MSA6KQCFPJrYg+JGoS3FjG2gQwRSXL2VzdzXcpto51uGg8tJY7dgckDBk8oEuq9cgZFt8WNbh0vR2vfC632oXtob94tKe5uP3AZV+VVgbEhJb5XKoMD95zgAEtp4T8QW+p3uq6Mur6dc3GpI0cN5qZmUW39mRxbpk811kYTKAWO5/kBBxycPT/D3j6Lw1cxX0niWa88+3cW8dwgDsI5RIfN/tLzNjExkhZIgCqkRkFxXX6x4+u7SRL2fT5INKt9RvbR2hukaS4+zW91K2Y2iPynyBjDq24/3R8623xD1Sa7tdO/4R+0OrXVxDFHHHqZaAJLaz3CO0vlAggW5DKFOAQRu4BALPi2w8QXWgeGlitdSlWEqdUsdL1MwXD/uWACztIhYLIQTlwWAyc9Cz4ZeGNW0rULzU/Ecl1JqdxZ2kMkjXzyRu6xAP+73bNwKgbtoJ+bHDHPoKFii7wA2OQDkA/WvKvEXx88B6FJJFPfXtxLGxRlhsZR8wzkBnCqenY0Ad341uXtPC2pSxKGcxbAD0JYhf61zVv5dhZI85EdvAvmMccAKuM+2ADXmuq/tC+HfEtu1lpmlXhiEiyF76/tbEHawI++7ZHHYZ/o2fxy3iK2ltjf/AA406CWMpImoeIpJmKngj92sYP03DilbW7KT0seAeJ9VbX/FGq6pKzMbqcspBydo6foBVzw/HOyRizike5m/doEXc+SecfpzXqy6Zpdn/wAg3xL4HebnEWj2emyso9RJd3LHHb7pPI962LCET2xE3ibWXYuAYLbxLZW424JZvLtQvHbG7qewyaxqK15N/hc66eIcYpRX4nFpaXel2y2tzNcWsk0qxXkwJDgsc/ZoQerYOXboMdfXC8Va1YTeKGljKnRrNza28EI+V4sFWAB4BOS2f9r2rt/EqLp162pl4obHSbNmsle9W7d7uQ9SxZmYjdklu68cDFeY6rprNFprvw+7bPxzE7EnDfVcGuTDxTquctbd1bf/AIH+Xc6Yycoue9vz/wCBv8j3LwHN9m8KWt7ZqvkxaOGity+AZJLkhS7+gVFBb0BrtdSu3fS2keNfs0kJlj4OQoO3Jz1yDnj0Fc/8K7SO4sNPsrmNSraDA2zb1BkkZc+oxW9qenwLY6hzKouYChQv8oMYLrtB+7kbhgcHAp4fROXds55L3rHzD4xuZBe3yPuK+Y5Ydcnpz6c54r0b4YJbzpYzagsSwyW7O5lcKihWX5iTwAAOteU+MWxez8kHJIPUkn1r2X4U28M1vaRXEEU8ENq6yCVA6NknIIPBBxWs3aOvc1im5O3YvfEbTdX1dlj0rT7i/sUIYy2Y89T167c141qWl3ljba39psp7R5J4LdRLGycMxJxn6V2fim60K0127WDwpoDRRhSDbwPasM8HDQuhHNWNF8RW7WrvDJ4o0yNrwWaR2OvylCNhZjsmEgOMAY9O/rpTUehlVdXRNGNrDiSYq+7Iy2OnfAI9sCuj8DWklxKkKMdzuoUZ7/4ZIpE1qC8LpJr94duMnVPD9lef+Pr5b/5/PrvBUOuXlytx4ch8G6jNB+9CtDeWD4B64zInXAFZ+yUpaM1lXlGFpRaPedPtls7G3t0AAjQLx7CrNcVo+v8AjOTVLe11rwVFb2zttkvrTVo5o4x/eKMqPj2AJ6fhm/ETVddh8aaBpWiza0ILmxu7iaLSFsvOZo3gCkm7G0KPMbIBzkj0rsPMPR6K858VeOtS0bStcis9NifVNL0+4vd15P8AI0ccCuGOxcNJlgGiUjA53AMhK2/xC1E+Mk8PT+HJHlikhhvZ7J7i4jgaVd6sH+zhCgBXcXZCMnCtjJAPRayfFulDXfC+raUUgc3lrJConGU3MpCluDwDg9O1cJp3xL1m80WO8HhMNcXFhZ6lbw295JcDyJy4zJsgLgrszhEkzuHvh1l8UpLq4R49Ls5dOFxDYy3MGolm+0SWwnASNolLRgMFLHa2d3yfKaAOP1X4KavJo+j2Vi2h7rfQ4NNLOzxixu1kV5Ly32x/NIxB5OxierckV6F8LvA0nhO58SXepCxuNQ1LV7m7iu4lzL9nkKEI7FQQcqSVBIz3NXB4xuoPh3L4q1DSo4AbdLmC1ju95dHVSu9yihDuYg/eAAznqBleJviFqPhm4srfVtHsHuZCjXMNle3Fw0ETyiNZMi1C4Jz/AKxoxkEAmgCbwR4Z8Q+E77ULC1Okz6FdanNqAuZJZBcosp3NGYwm0kHgPv6fw16BXnT+PdZluYIbDw9ZP9q1C9sLd7jVDEG+yvMru2IW2qRCMdTliDgAM2p8OfFR8WwXt+sdzDCy20scMzowjEltHJhdqg4+fqS2eoIBAAB2NFFFABRRRQAUUUUAFFFFABRRRQBW1S9j03TLu+nDtFbQvM4QAsVVSTjPfisfw54oXWLe3nutLvdHjuwhs/7Qlts3e5S+IxHK5yFXJBwceuDjU1ux/tPRr+w8zyvtVvJB5m3dt3KVzjjOM9K4TQPhkunaE+kTvoUVpL5Aml0jRzYXEwiDYLSCZjv3FTvABHz4+9kAHRxePPCct3eWyeJNI86ziE04N2gCRkAh8k424ZeRwMjPWrUvi3w5Eli8viDSEW+wbQtexgXGTgeX83zZPHGa5DWvhvqGrWs0E2v28aTJaO/k2Lwn7RbkbHUxzKVQgcouCDyrr0pbb4XpHot3ZSX8HnXNlNaPKkErDfJOZWk/fTSOSTjILnJGcjoADrn8XeG42v1fxBo6tYcXga9jH2bnb+8+b5OeOcc8VNF4j0SZrNYdY02Q3gVrYLdIfPDbtpTn5s7WxjOdp9DXEv8ADfUPtM80GvW9uiXkd9ZWkdnK1rDKspfc0T3DA5yQfLMQyS2M1s+CvBA8N35vZL1Lu5e3eKRlt/KG97mW4coNx2oWlwE7BRyaALuv+MdM0jWtM0cXVnPq17cpD9iF0izojKx8zy+pHy+w561LY+MdBu206A6rp8Oo38CXEFg97A07q67l2hXIbI7qSp6gkc1j3Hgi6fxbLqkOrQx6fNqUWqS2rWe6VpY4BCFE3mABNqg42Eg55wcVyOieA9d8P+IdC0vTw9zoltPZ3N3ezW8SBngslt/kYTmTB8tDsMXBZjvxwQDu9P8AiF4WvFkV9c021uIbaO7ngnvIQ0MbqrKxZWKEYZfmVmX5hzyM6Mvizw7FZwXcuv6SlpOu+KZryMJIvPKtnBHytyPQ+lcVF8Mb220uxsbXXrYRWlvpwUy6cXJuLMKEkP70Dy2C8x4z6OKu2Hw2jitNTjvtRWe41GyvLWeWK1EQVrmVpHaNdx2r82AuT0ySTQB1epeJtB0uNpNT1vS7NFZULXF3HGAzKWUZYjkqCw9QM1Jo+v6NrbTro2rafqDQY80Wlykxjz03bScZwcZrkNH+H15Drljqusa1bX1xbXiXRWKwMKMEtJbZVAMjkH94Hzk8r0GeNPwb4KTwzcWMkd4swtdIg0oqsHl7/Ldm8z7xxkueO3qc0AdfXh/7QV9/Zul39yjZk2FApOOqgY/XP4V3Wp+AP7Q1G5u/+Et8XWvnSGTybbUtkUeTnaq7eAOwrzf4gQr4Rtb+ZfEXji9Nqhcj+3PL3YAOM+UcdaBp2PG/hVEF0i6uAQ5SRP3YJG4kkY9zjOK9b0TW4IrTUrSb5ZT5kgYHsu0AH8M1zPhTxX/b9lcXJ1LxvbCGMyY/4SPfn5gv/PAetPuvFK22om0l1XxuDmQBv+Ej6henHk9+fyrl91Tb5jutOVNLk28z2jwOm3Q9M2AAG2Q+v8NaN+yw3Mk0rhI40Z2Y9AACT+lcdoPhkarpVlet4r8cQ/aYEm2f2zu27lBxnyxnrU2p+FodOs5rm58Y+N1jjAx/xN+WYnAH3O5NdeyOLW9jltd+IN3e6vZ2Phtop9GuIQJJliO925BCk4xg+2ciuX8XzvDbyMq+YkVsCXbszMW6fRR+ddFY2Uc15plzOLk7ZCWe5l8yRssrZdsDLZPJwM8+tcr4zuN9wYmXHmzCHA9vvZPsOPxry6s3OR7dCnGnHQveDTJY+H768lZT5LN856bkkJyfwNcX8R963t2OBF8rRZ4wwJH+fpXcfD678/whIkylme7uBICOoODgj6NXn/xYU2mprEXJMakqD/dcAr+PBBFEP4thy/h3OMtFZ7kOzoCAWHcYKtn8eK7j4TsDrMO2MuYnMvIPDY2qP/HjXE6JC80qDZuCxyDg452nr+f6V6z8NbCOzl0e2uwq/b7kXvzDlk4AAx23A8V0zWiOWMtX/XRn1zEuyNF9ABTqBRXUeWFFFFABRRRQAUUUUAFFFFABXnPhmw+H2k6ZDo7RaDBcaqoWS1vntGuL4GRwu8ISJcsrY69COoNejV59F8N0S3uY31FXaWCyhDG25X7PeS3OfvfxGULjtsB56AASw1P4WXEFhqVrN4PVLCX7LZzsLeM2zqxISMtgoc5YAYznI4OatanY/DW3S4t9UtfB0SW8jXc0dxHbKIpGIRpWDdGJCqWPJIArB1n4UXepJbo2vQiO1e9WBPs9xGGgupBI8cphuY2cgjGQVUjOVJwRtN8PjDpkUWnX9vbXtvqo1WCV7MyRBxH5YR03hnUKTg7wRwc8cgGv/a/g77XZ239oeH/tMxe/tYvPh3vvV90yDOTuVpMuOoLc4JrP0rUvh1pumwXWk3vhK0sBdt5M1tLbRxfadm07WU48zY5BxztbHQ1iWXwuubJo0g1q2W2aGSO7iFpMBetIJNwlQXAjMeZOF2bgoChx1qpffCO+vra2F34maaa3+0RIjreCBYJliDRALdiYjMWcNMy/Ow24CgAHok/ibQoLy8tJta0xLuziM9zA93GHgjAyXdScqoGDk4FGq+JtC0hZG1bW9MsVikEMhubuOII5XcEO4jDFSGx1xzXBz/CQXFpd6dLrEa6TIt60MUVmVlikuojG5MhkO9F3MVUqD93LHaKlvfhxrN419dzeI7NdXu7oXJvYLCeBoMQJFiLy7lSOEBO4sp6FSKAOl8ZXn7zSrWDy3aeRpDnBGxV689skV85fGnxtqOn6/DY6Vc28cSRmR1+zRPgnpncpHbjvzXvXih44fEdolzMWFppcskkrYBIJALH/AL5/Wvj/AFuV/FHi69miZYlnd3DufljjHQsfQIBWdSSirm9CHM9ToPD/AIk1rULlW1G608adEqtPJNpNrIASeFUGMgueQPqe2a2JfEj6hcyC38NeGp96KYbSXSbZlV3OF58sEkD891cPdXi31/Z6ZZDy7OAYTIwXbHzSN/tHHTsMD3rb0e8VNWMCQo73BcvITkQrjbuA9cZwa45SqXvc9FU4OPwq7L3jy9sLYi1tbDSoVs4x5kllZRWyXU6jG5hGqhwG3bQRgAE96xvA8FzqEN5JIy7Iwzzs46rtLn8c8j/DNZnjC++2G3igG21fBjXHRSSB+gA+n1rrfC9rPb+GdVKAq06rDEV6uZG2DH4Fvzrde5BJu7Jm1CSjDZfqe2fD+VYPGWm6d5gcRaLaJkH7wKOc4/L860PHsz2mh6kbWQJMkJljBwQxHX9Ca4nwvdi3+O17FGqpbQxQWIIPCmJVXH/oX5V1fxW1COztjEsAcz+YhJ+7yT/9asKGlJa/0zLlbqbHy/qix3k9q4X/AF86BtvU5JB/VT+de4eAIfsngnU7jb5e1dik9cc/4145YxRT3NgiLmYX5RvYABs/qa9sup00z4byKkgHmEhiOp444qqrskjSmruXqeQatdvPeecwQu6srA8cjJrQ0htug2LEgt9qu5iR1B2IgP6kVzsLK0kjHO3ec59CD1/Stewhnh0sSkbAsayfjJMzj/x0CrhomKrq4lqKFEZ4kdckjk+gP/1q+h/gTp6x6Pd6hsIMrCJG7FQMnH4n9K+cbDZKJGYkkuSWA7DjH64r7D8E6aNJ8KaXZiIRNHAu9R2YjLfqTToR1uRjJ2ioo3Mc1zfi2x8IXs1kni+10C4l+YWq6pHC7csinYJPVmjBx3ZR3FdJ3rC1fw//AGj4hstWW68ia0sLuzixEGZGnaE+arHoVEJGMHO/tjB6jzjMXV/AEmjtfLqHhV9KhlaI3AntzDHI6bWUtnaGZDgjqQcdKwvDuoeA5NH0jXdQ0bw3oIgtLa4tp7j7Ii2/nBnVI34ZcEMeVUHkrnnFTR/hXqumakmrf8JRHc6zHNHKs91ZzTxnbDLE25ZLlmyRLkYcBSOFwcVbX4ZX9to9tZ6d4mltnjtrK2ldIZYxOlukqkMYpkkAYyBsK4wUAO4EigC/NP4U1G9/se80DRrnTI1t7e3kdbdoDF5EkyYV8Aoqo2Am7AJbAUMRaj/4QyXSbvxN4fsfDuqPplrJElzZLC5VUjJ8kSIDtG0429g3TmsXS/hUthpWnWTapFdLZoikT2ZKTBbKe1wyiQHB8/cRnouM87hv6D4SvbDwlq2jahrLXpvRIkT7JdlsjxhNiCWWRyAQWwZDyxA2jAAA7TPFPhHUPCsTtqWgppZhFvNbm6hMMP7os0DDO0bUVsqQPlUnGAap2th8NJpVt7S08HPLp0qxrFFHbE2skj4VQAPkZmwAOCT71T0T4cTWusabqeq6paXdzZTWzBYLDyImjgtriGNdpkchgbkvvyfuqAB1FHTfhFFaJq0MuqGaG5tZ7a1kYXDTWvmSrMGG+4aL5XVW+SJMlQc9cgGr4nsvBOo3lumvLpP9m6Q895KLiS1+yCWRmRxMjHO/e5bJAG48nJxWzf6xpek+G21jQbeyvVu2hitvsjoqXUjssMQ8xQRtyVG7B2qOmBiufuPhszaZBBDqNu10lsEee4tpDunM5ne4HlTRujlyxG1wVJ6mtPVtA1OLwPYWkVzJq+rabPb3avI2xrpopVcpl2OCyhlBZjjIJJ5NAEg8bx/2rq1o2jal9l0h/Lv9RD24toD5KzMfmlEjAK68iM/SqU3xGjg0oajP4Z8RxWsphFqzxQL9qMsqRRhcy/ISZFOJNhxk44NZ938MIdQ8T63ql6NEnt9YfdKtzpAkvbdTbrCyRXIlwnCk/cOCx61PeeAtX1bQIdD8QeIbO/0uF7XbF/ZQUyrDNHJiXMjByyx7DgKvzE7T0oAfP8UbCOC2MWia1cXUr3iSWsYtw8Btdvnb2aYIcbhjazZrf0TxRFqusR2aW7RQ3OnRanZzM3M0T8MCpAKMpKZHP3x7gcVqnwiWc6ZBaXmjvpelyXRsrDVNH+2RQxz7CUx5qZ2MrFT1AYDnGTveEPC99o2t6elxNPcWOj6ONOgu53UvdPI6vI2ASVVRFGAD6kcgZIB3NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeC/tAqR4c1WUg7WSRc575GP5V71XinxpshNoes2SM6RiN3VtvAJG8j+n40ho8U+FHlzaddQq2cwSA5P3cgH+lV/GZEXiKNn3D9/NuxjOCvb25qx8IZvM0qe2ihZiT+8O3I2Ecn+f5U34nFX1YXMC4VoGcEDII3Kv8z1rzn/ABT3YK9G/kfTXhG2aHQtMtvvGK0iUnpkhQOlcn431G4uvEF3YPmO3sjBtG7h2bBLEeoHAz7+tdv4aj2W1srHLLCmT3PyivO/E0n/ABVuuxyhFlmaOaJtuSVCEbT/AN85rtru1PQ8vCx5qtia9iJ0WUxu0bxSRkbBySCpI5ryvX5Zg6yTbWmjMsjRqvIydqEAdOq/hXqVxdqlpcsyEK3zAgfeAC/zryXxLPFGJ5YnMlzJIquwO35Qu4gd+rLXnRdz1+Wxr/D/AA+kagylmSDUGfcQSNg2AnjrwTXG/FS8huL6GCIhlRWQgE5Dqev5Y/DFdX8NrxreW/giVPLiupecY+Uqp49wVH4E1xXjlV1DxEJYYkhErKTgYUOwzgn1yCPwrWC/eamLdqS8zO8P2JG+dpBtSN3P/fJH9P1r2XwNpYtPFfgSK8xJMLCIBTnhTI7Zx9GrznRtFuheWphz9na1nLZXkMIXYA/ip59q9r8C6ZNefEjwlLJkCw0IPJx97A2D8i1dUY8yucNSfJJnrnjDXm8P6ZDPBZm+vbm5itLa2EgjEkshwNzkHao5JODwOhPFZmg+NVuNXudE8QWiaXrkM3liCKZrmKZfKModJNi8FVb7yqcqRzxW14n0G28RaZ9ju5biApKk8NxbPslhlQ5V0JBGQR3BB5BBFc23w3s2Y3J1vWzrDXLXL6oZIfPcmIxbMeV5YTYSAFQY6gg81ucRJB8TvDUxnZZdRFvHDbzpc/2bcGKZZ1VohGQh3M29QE+8SSADg4t3HxA8O2wb7Vc3kDJEs0iTadco0SNuCl1MYKbihChgCx2gZLKDmp8MtPhsra0tdX1i3gtrazgjEbwkrJahRDPkxE+YAoBH3Dzlan1fwvpaWVzDreralcT6ubW0+1P5aymWJ2eFl8uMKrBjnJXb8oyOuQCW4+JPhe3gSSa9u13LM7RjTrkyRLCVEpkQR7owu9Cd4HBz05pL34jeHYDeQQ3wkurdZQGkt50t3kSIzGPzxGy52DdhdzY5CnpWLefDB59ajlj1/U47ae0vYtRulaEXV29w1vwf3OxU2QYygRhtTHen2vwwinudWGq6jd/2bNdzTWdhbugihElsLfeSY95kClwAWZRkHGaAN+Hx94ebUGsJr4xXcYbzC1vMIVZYvOZRMyBCRHlsZztBOODWh4b8T6V4k+0f2TLcsYAhkWe0mtzhwSrASopYEAkEZFcrqPh3w3cai/h55724vnkk1JrfDbP3tpJabZJFjKxqyF8AkMWGRkDFXfhr4a1nQn1S48QXoubm78mOMfaBOUjiQqMuIYQTyf4B7knmgDt6KKKACvGtQ1H4iWOjTXFrNqN9dXNqZfLlsUT7Gy3aIRHshLE+QzthlkJKZCn7p9looA8n8NS+OdctfIuNYu7BhZzvFc/2dtLS+YREJDPbR8gEZ2xJuwCMc5yta8RfEW40aw1K2s73TI72aQSQLaM0tnsjRVDKttO5DyiZs7PuhMMucn22igCpo8lxLpNlJfbPtbwI02xGVd5UbsKwDAZzwQD6irdFFABRRRQB4x8aNZGnQ+JpkAM0dhBapz08xnz/ADB/Cvl20nWG21VYSytIBG+OnljBAHuSB+Ar339o2RLUX6Y+e9uYiT2xHCv9Wr58s0K21xIGGWZcjH0rmqa3R30FZJkulYS5vLhuSi7FPv0rq/D1mz6JqtwSUeQmFJB2UALn+Zrloo/JtIt43Ft0rnHQKM8/iRXW2NuI/DOkRqzC4kYMzu/yxqVJOAO5yOtTa7Z1xa5kn6nF3Ue7WYIIkK7TuAYnKgDhfyx+Ne1eH7VG0zwvDACzT6jCNp67Vbecg9gMV53ZeGLyTVv7Z1cxaRojuxF7qUohWQHpsB+aQ9/kDV6tpjSs+m3Xh/SJ5jYxSvFf6wxsLLbjmRYiDPMAvGQqj9KdeMpR000ONVYpt9SPQ9WutZ8T3MOiazrtpcPI7jGn2l6g+YZwXjDhQWB5bOO/Gam8XapfrcSaZZ+JtI8Z6shJ/s628OmWRT33yQzBE6cliuMZxXL6trVgILaDUby51q1nkUNZ2yHTNOTIyC0SfvZu3Mjg+orpvFerW+n22oadpcNtYaNFaQTw29sgiiO4bWyo6nJ6nNUpKKUXqyPZyk7r3TldJtN19E2o6T4FtdYRt72kGq3odCeMZTzYgeCMbuCOa6/xTFf3ekRWOreHbWCCOQMJbLxNbpvOMAETxLnjoM9uorzL4awi78S/aHjdVluEUbh/CEPP06+3FdX8ZNSYW9tCFAWWMMwJ6kEfywfzqak1zcrVzWlSfLdSaMz/AIQu3nWRINL8VxtJjBtEstQC/wDfudSR9Bz26Vbu9Dt7axNvcHxFZRlYlZr7w5dRqfLjCZzGHGM8nGevevMI9169tAqhvOCxjd0B3hf6iusTV722JgsLm4tWlnZ18uZlwpfauCD0xVtpRvYjlm5WUtjW8OW2hadqenJdeLtEhijmVpDcJcQPgSAk7ZYl7ds9etfT9h4+8IX+PsXinQpycfKl/EW56cbs15L8BdU1nX9dnGoahf3enRxOxjuJmkjbnao2scAckj6V7Lf+EvDeoZ+3+H9Ius5z51lG+c/Va0ppW0MK7k5WkzTtLy1vU32dxDOnXdE4cfpXIr8R9LHiKfS7mz1C1hhvn006jMIham4SETlMhy4/d85ZQvB5rY8P+DvDnh28nutA0TT9NuJ12SPawLFuXOcEAYxmuU1D4S6VqbeJptQuZ5rvV7iW4gk3PsszJCkXyxFzGz4Q5faGKtt6VZidU/jTwsmmxag/iXRFsJZDDHcm/iETuBkqH3YJHpnNQW/j7wlPY3N4niXSFtbadrWaSW7SMRyhmXa24jGSjY/vAZGRg1y198NNUu2uLweIbS31u5naZ7+1sJoDCDFHGBCqXI28RKW3mRWIGVwMUur/AAyvb+FIl19I1ttQu760xBPGVFy8jypI0NxGz8yHBUoABghs0Adpd+JtKt7uO0jvbS4vHlSI28d1CJE3GP5irODgCWM4GSQ64B3AFYPFXh64S6a317SZVtZBFcFLyNhC5JAV8H5SSCMH0rm9L+HMGn6a9pDdRRhr6wu8xQMAqWsFvEsQLOzYPkEgliRv/iIJObo/wre0TTor3WILqHTY7O1tUTTxH+4t5vNCy/Od7nAG4BQOTtyTQB3Vzr9hBHp8/wBogeyvVaSO7W4iEQjEZk35LDcpUZygbjk4GSM6fx94RgjtZX8S6OYbm5a0ilW7RkMoQuULAkKcDuRyVHVgDH460CDxD9htZdSispil1HEjKGaXzLaSI7RuGdofdx6dutULrwNOup22o6XqdvbXdtcwXMYlszJH+7tZbYqyiRScpKSCCMEDqKAOhTxRoDtdqmuaUxtHEVwBdxkwuTgK/PykkEAGm2/ivw7cXP2e317SZbgQC68pLyNm8kqGEmAc7NpB3dMEGuD0L4QppcsIk1VbuC3lhaDzo7iSQRxzrN5Z33DR4JUD5I055x2q/qXw1kvdUvJJNSspNMlurq/Szn08u3nz27QMJJBIpeLDsdgCk8DdgCgDp4vGvhWZbVovEuiOt3IYbcrfxETSAgFU+b5myy8DnketWB4p8PmPUHGu6UU084vG+1x4tucfvDn5OeOcVxdp8OdZhuLGdvFJNxBNva4WK683ytynyFZrpsx/KeJRLy5IxwBn6d8HTp8OyHWlkktmiawmuIbiZovLnWVVkV7gxspK8iNIvUEUAekReItFmtBdRaxp0lqYftAmW6Qp5W7bv3ZxtyCM9M8U7T9d0jUdQurHT9VsLu9tDi4t4LhJJITnHzqDleeOa89vPhXfS2VxFB4ht4pr+OePUHOnFlk8y4M+YlEo8rDEjBL5B9ea6fwj4Uu9A1nUrp9TjexuSxisLaKWOGEs5YttkmkAY552BFJJO3J4AOtooooAKKKKACvP/iD4r1TRfFGi6VpkkMEV7a3NxJKdGutTcGNoVVRHburAHzDljkcAd69ArD1/wrpWvX1pe363qXdrHJFDNaX89o6o5UsuYXUkEopwc9BQBheIfiDFoulaq4028vdS02zlvZbYKsGYki3iY7mJSNj8o4ZshhtJU1EPilo0fiq18O39rd2OrTSRwvBPLbFoZJBlFZUlZmyMHcgZRuGSOcdBdeEdFu45UurSSYTJLHKZLiVjIssYjdXJbLAoqjByBtBGCAaisfBejWN/Fe2o1JLmPbuf+1Lo+dt4UygyYlIHAMm7gAdABQBzkXxa0o6L/ac+kazaxPbW15CtwLePzYZywSTeZfLRRsOfMZMceozdh+JOnSXaRHS9VW38yO3kuwIXhinkhEywlklO5ijL8yhkyyjdzWv/AMIXoi2dva28N5axwWkNjE1pf3EDrBFny03o4bA3Hvk981UtPh14Ws7uG4ttMaNogu1BdTeUWWMxq7R79jSBDt3kFsd6AJofGNq3g2XxNcWGo21gsSzRJKiGWdGVSpRVc/eLBQGIOR6YJ5i0+IU9lcazc+IIrqxtba+uFFnNbxSTRxx2kEgQNFIVyWdiPv53AZXHHdz6Dps/h0aFNahtKEC2wgLtxGoAUBs7sgAYOc8ZzmsWbwBoX9lXlpBaF3uBMxkvbie63SSxLGzOWk3N8qIPvA8cEHmgDD1v4mtYWGo3Q0TUILjTI7lrjTrtYRJIY7ZJxiVJmVF2uCThz1G3I56vw5rU+q6hqUFzaz2T2wiJtZ40EkW9ScM8crq+cZ4xjpzWB4Y+G1hp+nahBrsx1ee+lmeV3aYLskhSFkHmSyOQUQDLOx5OMDAHVaLoVhovmmxW43yhRJJcXMtw77QQuXkZmOAfWgDirT4tWNxDDcf8I74hitJYI7v7RIltsW3eTyxKQJicBuoA3Y5Ckc1PJ8SLexilN1YajeiKW7M89pbxxpbww3b25Zw0xJwU/hyWHzbV5Ub6eC9ATT1sVsMWq2iWITzpOIUbcq53Z4bnPX3p7eD9CeC7haxzHdpMkw86T5xNM00g+9xmR2bjpnAwOKAOZuPidb6elwLnTNU1FoHummlsreKNIYoruS2ywebJO5P4clh821eVGrovjNdZ1y1sUtbvT5d91Dc2l5CjSJJEsLffjlZQMTKeA+c9VxzoN4N0ErdKbDi6WVZv30nzCSdp3/i4zI7Nx0zgcYFWbbw5pVtq76nBa7b55JJWl8xzlpFjRzgnHKwxjp/Dx1OQB+qeIdF0m4WDVdY06ynZd4jublImK5IyAxBxkHn2rzD4o6lpWu6dfxaVruiSySxbF/4mVuuTt6cuO9en6p4e0XVrhZ9V0fTr2dV2LJc2ySsFyTgFgTjJJx715p8S9G0zSbaf+ytE0S3fC7G/sy3YjOf7yEHpQNHkPwu0u88Poyahd6JCrZyf7Ys24J6cS+hNReIPD0twyLFfaJcxxwrGoGsWgH3icDMoIAwv51X+G/iS61U3CapYaJdMj7So0a0RlUgjcNsQz82Kf4l8QXFvZT3VjbaLHGsjqgOi2ZLAEgHBiPfH5VwyVNVOtz1abrulpa1vM+jPDGqWN55a2uoWF1LHAhdLa6jmMZ4BzsY4HbNcP4neSLW7zaikTXPlu5HzBNrc5PQdvxrsPCNhZw6ZYXdpp9jaT3FrE8r21rHCXJUMc7FHft0rkvFMMMnie6gUEqk3ncnnftww/UVti/4ZzYH+Kc/rc4s9G8ncC5hdFD/7Kj/CvMfEVxBezyiHAcysAQcgElVIP4LxXpHisJ9j8sZP3o0HdlAAbHvzXkd03/E0lEQaO3SZjuIyWAJ6D2z+lcNNXPVm7HT+DL1v7I14xKrSx3sk4AxjKlBjPbIzXPahE1/q12jThEkChZJThYpQ25QT/D91lz/tGpvhZIJ7HXY2b97Id6ITjexB+XPvjFZ+lwFvE1pp0zF4L3ZAHByQHGEYe6kfln1rqUf3jOLn/dJs9S0+G9t/D1hHqMMkdzcXdz8p6jFrLu/DezEexr134VWm+dr98krp1rbqx+jOf5ivNPEb3EV9oMF6/my2umzebjgs4typP869b+EUWPCkMoZikiRBQ3UARIK64qyPOm29WaXj7TdR1bS7K00uW8h3X9ubl7S6NvILcOPMw6sCPlz0OfSuBPhXxjp1qW0261ueZ4b8Spcaw0uSl5E1oqb5CFZoFkG4Yzn5zk133j3WdT0TTLGbRbWyurmfULe0KXkzRJtkcITuVWIOSB0OM5wcYPDW/j7V/Dun69carpaXltBLqs8Eg1BmctbszmEqY/lTGQrAn7v3QKZmV9X07xvfMbyKw15JH1KeaGwbUUSJIWWEJ5rw3cbLgrJgKZVGXyhJUm5BoHiSW5/0qy1dtWj1Rrg6hcaksti0XmuYzFB5p2bVKceUp4Iyc87Gr/EG8i8RXGjaLo1tf3Ud4bVXmvzDG2LVbhmJEbkcMVxg8jqM8c9deP8AW9ZXQ0ttJisL2ebTr+3hXU2KXFvcicKkriIFOYjuAVx0xnpQBlaZ4c+ICeHruLVLjxI92XtyY4JkxK6iTzGWQ6iJNhJTKq0A+VcJy4ruPEdj4gufCHheNbTUTJC8LatYadqhjuXjELAoly8ilsSmMkmQFgp+Y55v+EPGc3iG6sIn06C1Fxa3UshF+kjJJBcCAqiYDPGTuYSgAY2ggFhXY0Aeb/DPwvq+m6zc6r4ja8a+l0+0gLSag8qsy+ZuVkDbWZV8sFtvJLEH5mJ9IoooAKKKKACiivM/Fmq+IG+Ji6Tpc2vGwj0uG6aLSVsMh2mkUtIboZ24UDCHPFAHplFec+IvHuqWttqMel6VYnULCeOKb7VdsITvuUiTYypl8qxLHjy2+Uhjmqv/AAtG+TU9UtZPDFw8Wmx3Cz3MDTvEk8MHmspkMAjEZIKK2/eSVzGM8AHqFFea3XxC1q1srh5fDEZubeWLzfKvJZoYoZIvMWR2jt2kHTaQIyAeS2Oaq3PxZeGxvtQGjQTadFHfC3liv9zzS2kLSuCnl/JG2xgr5J+6So3AUAeqUVzmqeKrXw5okOo+LzFpSyzeSqxs9zgncVBKp97apJwCAeAx4Jwv+FxeBP8AoO/+Sc//AMRQB5N+0tM7XCJnO6R8Z7Y2Dj8q8NhjJsLlQuMyjnphfr9a9l+LGo6B4vvmn0zxRp0S7mIFxb3SkA4PaE+lcFLoGn7Ds8U6LJ8ysY0iu8vg5wMwAAn3I+orncXds76c4KKVzA1bfHYTKiDcIkiHqM4z/MV3dnctpl7aqLyWxjt4C8txDDHJJHwM7PMUqrYHDAZG7jmuFvfMmE0UeNxu1RfQYYCt5XNxLrMkjt8lsSPNO4tuOMf+OgD2qYaRudTS15uyX5l7w94o/tLxI50awWC/G1jqd/Kb++fHX99JwnH/ADzVcV6o95Amt+INXuzJcM1tBpq7iWI85TI35ArXi/wltUm8ZEPw6yNjjPI7fjz+Veu2is9zIzEeS+uKhCdxHb4P0IxXHmcr0mvT/P8AQ56MFFI808Tolpa6U8ewwRLGzZGCSGKEflWhpGn3PiPVv7JjcC2Mbpdzf884FYn8D0C+5FVvGsXmaTalZ1ngkRvLdOmN77c/7QyAffNel/DfR49K8AJqErFr3VcTv/eSEE7V6887n/4EorpoLnSfYvEVOTTuch4Eggn8c3hs1CWtveMsKoeFSMCNQPwx+PNc58RL0TaqIpmbZBJJE2TzjPHP0IrpPhn/AKFLq15KhCWs0pcd/wDWHHseBXn3jSRpNWvZJDnkk56896HrUZVN8tJehB4csm+zfbR8v2FJ5ic8YVcj/wAfK1LZMyiD5VXyolDEjkkIeB6ctVy3h8vwzqLh8yPEluqYxlppFP8A6DHTIoi13bwKBvlm2MMdMHn68Ct6i0SOWi9Wz6T/AGetGfTtCv525jkkWKNiuC23JJ+mWx+Br1qsPwVpR0bwzY2T/wCsVNz/AO8xyf5/pW5WsVZHLN3k2FeYavd+N7fWb+702a9uYft9zaW+nSWcYg8pbB5Ypd+wPzOqpuL7fm29cV6fRTJPG/CGo+PdXeytdRv9QtIprnbNcf2ewmgX7PIxBaa0ijx5iptIRxk4LNkVJrWrfEOGy1iOziujJpci232gWwzeJJPu8+MCJ8mOAIDsRxud/kYqBXsFFAHntlq/iNPhRPqF4l9da2u8J9jtnjuCvm7VbZLbKSwXkkQYOCVQ5ArkbTVviLe+Hrq4+0atbXVjY6hdQqNNVmvZI3Q28biS3RjuUsMLHGzY4AIr3CigDyrT5dc1D4o2b6p/bHl2d9eosDafssobfyyIZFn8v52cYz+8OCSNowKPEOveLYfibHZ6Vbav/ZAk8qUPa77dlNszeZGy22ABJsGWuCd2R5eCDXqtFAHit/L44sEs9QTU/EV5ql1oJmishp8f2UXm0ExyBYT5ZGcjewJI2gkfLWh4PvfGurCxt9Q1G+t4JLqYSXP9nssyxrEjKGM9pCuS+4BhFjBxksMj1qigDhPhlqniDVptT/t6T93pj/2XkIgF1PGzeZcZUcBlMYCjABD8end1DaWtvZxGK0gigiLtIUiQKCzMWZsDuWJJPckmpqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzP4rkhjgfwJz/wKvTK8q+KEqzX7op3GMxqcdjkH+tA0fPHwmDWut3q5+ctIpUddyNkfy/WrnjXT5G0Wa62qtl5knkkdTyWB/WjwnIth8R9at3fyAblirBdwUtyA3oOnPrXUfGJPI0y3tbfbBElu0rRg4ILk9vT7/6VwVVad/M9ejL92kuzPZvhpLJd+AvDc0xLu2nxb299o5riPFMzW+u6p8zF5JmKlf4R5XX9K0v2fNXWbwlZWTTb/IjjXkcg7BkVm+MbU/8ACVXtuG2xl3B47FMj+tbYmSlTVjmwcXGq0+xxHi29DpHHPOgkLvJkjOBuUYA9gDXnGooYlubiJ3ZI7f5pMkgu65yPbLAfWu38T28LQyIQRcKxUhuSPNckj8FauN8SstsrWsbK6SyqGIBwQXL/AKAAVzUt7I9Cs3ytkfw6aWK31zySwe3t47j5euElAY/kxrrPB8VhqfimwXUYFeK2uljtZYDj5GbzIuO67lcHv8w9KwfBP2fTPEulS3ETG2vbdoLnGSNsu5Dkd/4Tiu4+F0Vxba60U8P7qO0M7bgCOHHlkehVhIPXBrphaU+ZHDWi4U+Rmv4quGudclllCqUtbs5A7bCMfrXuPw0hMPgrTN2MvCj/APjo/wAK8E1je2vzgnciwXmQTyc7OK+kfDaCLQrFFXaBEoA9K6bWRwNljVNOstWsZbLVLO2vbOXHmQXMSyRvg5GVYEHkA1CmiaUkIhTTLFYl34QQIFG8YfjH8Q6+veuM+LnxCXwL/Y4SXTle4leadbyTbm1iAMgj5GZTuUKOc88HFVofiMmla14kXXor2TR7fU/IttQijjaCBPsMM/lthvMJJ8xt20j5gNw4FBJ2umeGdB0oINL0TS7IIxdBb2kce1iu0kbQMEr8ufTikvfC3h++thbXuhaVcW4jjhEU1nG6iOPd5aYIxtXc20dBuOOprlNA8dzXXiW4g1Kw1Kyt7ue0trG3uEh3o0kM0pdijthSIu5LA44HNTxfEiC+tLufRdB1fUEtbU3UzoYI0iO1yqMXlBLHZ/CGxuGcZoA6600jTbKS3ez0+zt3t4DbQtFAqGKIkExqQOFyqnaOOB6VergbX4mWzC2F7oOs2hZLZ7t28h47MXD7Ii7LISQx5+QMQCCwXpXS+GNfTxDayXVtY3ttahtsctyqKJsEhtoDFsAjGSBntkc0AbNFFFABRXn/AIq1/X/B/iKHUdSktL7wde3MNq+yIxz6az4RXJyRJGXIyTgjdxwK9AoAK4P4lz+DLBra78S6b4d1DWSY4rODUFh+0SKZQuI94LEAuTgCu8rh/Fngi61rXLi+stWhs4ry3tra7jls/OYrBM0q+W/mLsyXIbIbIAxgjNAElzqHgh4YrbWl8PWZnkubOG1vpLXMw88rKqqGIIaRASvXdgMAwIFC2uvhwNcS2uLLw1Ya0sE0Ecc0dqJTbxF4GVWUkbNsbrszkKCGVcEDnPEPgPXbPVZY/D4e7i1acNezyW8Qjhj/ALRmu8BzOHQgTsDiOQPtXhT03tS+Gk93a3trFrUcdtfJfx3Qay3sVuLqS4XYfMAUo0mDkMGA6LngA1r+X4e63piXuoSeFNQ09pAFnna3liLoAowxyMqGA9s471Lcr4DhW51S6HhiNby1Cz3cggHn2zkRgM5+9G3C8kg9Kp6F4FmtPECa3quo215qH2l7mTyLLyIsmBIV2KXYqQqZJySc9hgVjWHwruYY7OC812G4tbIWcVtGun7CIbe6W4CuTIdzNt2lgAO+3sQDutI8UaBrVybfR9c0vULgR+aYrS7jlcJnG7CknGSOa2K4/SPBSabrVjqCXik21zqNwUEG3f8Aa5RJjO7+HAGe+B0rsKAPmf8AaC8Q67pfilI9L1vU7KH5v3dtdSRj7q9gcV5w/i7xPONNim8Q6xJBcFUlV76Uq68hgwLcg967j9qKI/2yZlDARuAW7Dci15Xbp/o9kXOfKBP5Nk/zzXLUdmejQS5dUNjR3ubdRktJd7zz0O7Of0rZ0wuum626nYzKgLNwcIhPH1LCqccHl3Fg+5SzyPtGOp2kj6f/AF6vtCY9I1tWRgqTLGuef4Vz/Ko+ydTXu69/0ND4HQl/EGoXZCkQSIzZwMZbk/lmur0Npbqy051dvLur3UJ8gYD42qG9+CfzNcV8INSi0weJZp2AiMBYZ9VOK9Fkt4tHPhm1aQIkVjeHcWwA5SJj19WY/nXLjX78afe/4RZz05XSOV1i2mi0GzM5UxJGxzj72QD+ec16d4TvoovhzpVzd3On7/sqLGJp0ii4B2oGcgbuB36g+lcDcr9q8PXIlBEcUZDZ5JOD0/Su0+GEFvqHwntbZ4rKaSOa4jzdQpOkZV2O8qwIGAeB7+9dWElzJ3HmEbcrRy3g+xNt4e1CHU9S0K3vLiZpdserWp3bi3UiTGOelcXe+FtRvbqBJLzRBEchpX1qzOwfQS5PauqstWU+CmvZdO0lrovKqSto1orfK5HKiPaOMViJr139pv5Xh0X7JbBJQP7FsxuRl3AZ8qtYxi5No55TqKCTtYW38OXMnkRXN9oogk1GOSYHWbM7YI0wuR5vPU8Ctvwb4ZsrPxnptzqmsaOunQnc0h1W0O0g5wQJM84xxmqegapd3Wt6ZaXFjohDaabq4Q6PZj5zgjpFkYDr09K9b+F2gWGsyX8+q6No09tEFjjU6VbpljyT8qDoMD8a2aTOfmlFHf8A/Ca+Ff8AoZtE/wDA+L/4qp7LxV4ev7qO2sdd0q5uZDhIobyN3bvwAcnioP8AhCvCv/Qs6J/4ARf/ABNT2PhXw/YXUd1Y6FpVtcxnKSw2caOvGOCBkVRmcL8RviDqfhvxkulWEmkFRY291FZXEbtc38klw0RihIkGGCjP3H98DkbEvxJtQUFvoOu3Jka4EIijgBlWBiszrulHCEL1wTvXaGOQOtXSbJdcfWBD/wATF7dbRpt7cxKxYLtzj7zE5xnmueuvDXhLV7OxsT5bor3L232a/kjkJZz9oCujhiu5sOuSOgI4AoAgs/iPpl7qkVtbWGpvaSzR26ahsiFu0klqt0i8vvGY2HJXAPBI4Jybb4uWeomNNF0O/wBRuft6WU0EF3ZuULxu6sHSdo2/1bDbvBGDnHGeubwhoLRPEdOj8p51uWjDsF8xbcW4OM4x5ShdvTjOM81z2i+DvCdy2s6dZ2epo2n3kFvLM+p3PmiSO3SSMxy+aXVVS428Ff4hjGKAHD4oaUFeSXTdYjt2RpLWZoYyL1FuEgZogHLcPKhwwUkMCAa1PEXiq70ez0SZPDmo3U+pXQtjaJNbrLCSjvyTJsJ+ToHx79ilv8P/AA1bzzyxae4aY52tdTMkY84TERqX2xqZFViqBQSBkGtfX9DsNftIrfUkmKRSiaNoLiS3kjcAgMrxsrA4JHB6E0AcTafGXw1eXd5bWiXk8tu6IqwmGVpg1zHbZCLIWXEkqcSBGIOVDU6f4weH7XWrjSby2v4L+3RzLBugklWRYTM0XlpKzs20EbgpQtxuzWxL4X8Paebpbe3vJ5V2366ZFqMzLujmWZGigaURp+9RSMBRnIPBILtL0Pw/r8aeItObUYl1WETsbXUbm2WTfHt3NFHIq+ZtwN2NwKjkFRgAfYeM7XUPBOo+JLa3Zbe0hml8s3EE27y03H5oJJE/Ddn2rm9d8Yapo2gW2mqL7UPECW1pc31/DDAsNsJptvzBmHB2yKoVXbC5PPJ7TTvDGl6dpF7pltDMbW9Ltcme4knkmLqFYtJIzMx2gDk9AB2rIj8AaXdWmnf28ZdQv7SCK2a5jmlthcJExaPzY0fa5U8/NkbiSAucUAULH4kWzX1lpklpc3eoXRlKNGLe1Vgs8sYVVmnBdv3ZzsLdQSF3AVUg+LdjFofh3Udb0i800azFDJEj3dmxAk2bWVfOEjrl/wCFN2ASVXpXUf8ACFaH9ps5vIu8Wkvnwwfb7jyBJ5jS7zDv8tm3sWBKkjj0GM9fhl4VVbdFsrwRwIsUaf2ndbRGrbkjK+ZgxqRlUOVXsBQBp+B9QutT0W5nvpfNlTU9Rt1baFxHFeTRxjgDoiKM9TjJyea6Cqumafa6ZbvBYxeVE80twy7i2ZJZGkkPJPV3Y46DOBgcVaoAKKKKACiiigAooooAKKKKACiivNvCvxRttYlvJL5tCs7a1M/mQw6s1zfRiOUx75LZYQUTjcW3EKCCeMkAHpNFcle/EHQbLWTp873o2wzzyXS2UrW8awvsk3SBcAA5yfujGCQSAUb4i+GltVma6vctN5Ag/s258/f5fmf6ny/MwU+YHbggZBoA66iuV/4WB4ay7LfyvBHbLdyXKWkzW8UTReapeYJ5akoQwUsCdy4GSMkPj/w7NGjR3V15jzG3W3NhcCfzAquV8kx+YDtZW+7yDnpk0AdVRWPqniTTdN1a20y4e5e/uFDpDbWc1wVQttDv5aNsXPG5sDg88Gs//hPfDy/aRPc3dtJbtEkkV1YXEEn71ikZVHjDMGZSAygjI60AdRRXD3nxN8Ox2t61vcyi5t4J5gt7Z3VtGWhjMjxs5hOHVQSUAZwAflPSu3XOMtgHuBQAteP/ABCkVb27kRlDiQuTj0IX+leuXMvkwSS7HcopbagyWwOgHrXini3S9YnjLWmm33zAMcWzuc5zzgepoKieU6dEq/FHUmm+SIWsctwvqu0BiPpwce1bHxxszBaWTSswu5LNHmz32qQFJHGMlj+NR6j4W1uD4vWl9L4c1a601ohHJJFZSlQOVOW24zj3rW+OujSw+HtDguHY3KW4gcnI3bD1GeegzXLVhrfzR3YapsvJlH4Y6o+keF9O1KMkrkmVcYBGCMD8s123iq8gk8QvqNu4aC6jEqSYz8hTOf515n8OwZvh+VkfCM8qZz1XDHAHrk1paFqkdxozxzTljYD7OqOvOFGzb+RFc03pKPmdlOF5Rmuxia3c5JdS0tw9os6ORwF2qu8+5P8AKua8QQIYtOVghklllAxx/q0RQc+5zXXeK4YLe4S2iyJG8pMBuACxYj/x4Vg3mmNP4t020ZQ621q0sqxjP3ndun5UodzSo9Ld2HjW2js47SG2lUSxxqV29ijuSPwOPyr2PwHHEfAtrPKi7ru5LLIF2syMDgH8QW/HjrWBrGpzae9wqap43mMXT/iosZJCYB/cnGd/v0ro9B08av4U0/Wo/E3jVPtT7DD/AG7u2EOy8N5XP3c9B1rsw8Yp+67nnYupOXxxscXqjoPEF8jYDrDIM5/3QRX1Dpq7dPtl9I1/lXzvcXvk6zNYNrfjf92u7zD4gxn5lXp5P+1+leoJ8NdyK3/CaeNxkZ/5Cv8A9hXSzhex2M2jWE+pTX81uHuprX7G7M7EGHJbbtzgZLHJAyeMngY4/WPBng7w3pd5q9zpl1Na2kPmSW5vJ5o22wCDd5LyeWX8oBNxGcd65bxr8Pr/AFHWLPSbO3GsIui3MC6trs7u9rK8ylZVdYzulQE7RlDhfvCnXHws1iS61co2krJcrf8A/Ey82T7VfCdw0cdwNmAsY4GGb7q4C80hHR6F4Z8IalDdafa2OsKY7lg00t5dl1e2dogVuPMJTG5gqhwSpPGAcamn+CvDNnqAgsLG+tpLa2SNljuLqOCWLLhVf5hHMRl+G3FQRnAIrl9c+HOrXwvzHNpzrNJcyeRLI4SdZL6K4EUmFyEZI2RsZxu6MKi1r4b3uo2twsOiaBZRSW9nFHptpdhLaJ4Zbx2b57R0cH7Sh2tFjduPBUEgHXwfDrwzBNaSrZ3Tva+WE83ULmQOI2LxiQNIRIEY5UPu29sV0mmWFtpdjFZ2MXlW8edqbi2Mkk8kk9Sar+G7O40/w7pdne/ZftVvaxQy/ZI/LhDKoB8tf4VyOBxgelaVABRRRQB5/wDHv/kk2u/9sP8A0fHXoFef/Hzj4ReIn7RRxyt9FlRj+gNegUAFFFFAGJ45vrjS/BPiC/sZPKu7XTrieGTaG2usbMpwcg4IHB4rjtB8S6vovhyLVPEMHiC6glMfmNqJsfMAaNjugjtR843YyHwQp3dFavRr6O2msriO/SGSzeNlmSYAxshHzBgeCMZznjFed+ENU8D/ANtXVv4Y0jw7HaQzhFv9NNqImb7Ozsx2kHIUuvy7jgnOBmgCtf8AxH1zS5dVa/0PT5oIbi0tLZLO8mmkaaaKN9rBIGLINzneik8ABDnNTj4k6m0NvMfC7wIltHc3qXdy9vLCrXLwfJG8IZ/ub13eXlSMhTxVm4vPhtLZfbILbwrqGntGbC4ubf7JJHFDHE03lvzkoFhyEUMRtB24UkanhSXwhq0LW3hmy0ebTVtImV7NbcwtG0khCbFO5cOkhwygbi2MkNgAwz8SdQW9awl0CC31Sa9js7S0ubyWFm3eZiSRmtwoTERwYjKCTtzmtPwl43vPEuqRWtpo8UUKWkdzdzSXn+qLTXMJVAE/efNbEg/KCrZ4wA22ng7wylteW6eHNGW3vGD3MQsYgs7A5BcbcMc881zL+L7HQ9QuLWx8CeJx9nAsxNZaOvlvHEzbAjBhmMFmK9vmJAGTQB5P+03+81G7RsgKsZBx/sivKoI4zZxzZYRtCCMnvgZ/lXtPxMRfHEzyf8I942sd6KpH9g+bkr3/ANatcjB4KEelx2j6f44copVX/wCEbwO/bz/f1rnnTk9juoVoRjaTOHhuWgv9FAIkzIxOeMArg8fiat3F0w0e+MiMrtevJtPBUY7/AIKK6q48FLuspY7DxlE1qGLNL4e2q+f7zef8qjHXBrhdTkY2+rl2PN4y8cg5/wAMH86hxaikzohVjNuz0/4AzwFZfbNPu43Yj7QwizjgfvEz+leu+LUF9rultaKm2H7fCABuUHbEU49MBa8o8GhnsLGGJ0U3F6EHm8gjrz7ZFeqW++18YzrGoItpJMxjjIMcYwB2xtPeubEQvWjUfTT7zOl0Qy9gCWepwxNGRlVQ9Msy5yfSsn4cXtza6P4y0exnMc01ypV1OHRdp3kA8dgM+vPaumvrINKASMTGNjt/2f64riPBbbPHniHLHD2kr4x3B/TqavCv32jfGxfsYt9Cx4XtTceA9Ds4j807XUbMTnGVJxXJ6layrZx6dbnzJ53WBigOWJIVRyPevTPCCLF8PIniiUypKzRnkdcj2/yK860+/UeK1mcbhbGW4UgnG5FO3/x4rXbTjuzzZzvZdjpNFaG88d67dxSN5a22yLjhVMgA/Ra+lvhrZtaeELMyY3Tlp+PRj8v/AI7ivmXwDCxTXZETMjG3tVA4yxBOPqSa+udMtVsdNtbSP7sESxj8BirW5lJlmiqGu6vZaFpNxqWqStDZ24DSOsbSEZIAwqgseSOADUXh7X9O8Q208+lyyuIJjBMk0EkEkUgAJV45FVlOGU8gcEGmScL8SfA+t+JfF2k6jpzaTHb2TWzrPIES5jZJ/McB/IdypUAAJJFgls7gcVlWXwvudPu9OktfD/hBjY3d48csgOWWaRXjnK+R/rIwqgJnBAGHWvUdY1i30mXTo7lJnN9cG2j8pN2GEUkuSOuNsTDgE5I4q7bTLc20U8YkVJUDqJI2jYAjIyrAMp9iAR3oA8Q0X4Ua9Z2cq3tt4cu4Gvre8fSGkCWVzsiljcOIrVFXl43H7tzmMBicA1tX/wAL5rmS+vray0XT9TnuleIwM2ILb+zVtTbq4jU7PMBO0AArg4BG0etUUAeR2nwjg0+7trrTLPR7S6t59NlimiQq8fkkfaSDt+9IvGf4uNxrL8MfB/UrKyks9YeyvIpZrNrlmuFaO8WKbe7SRLbId7Ddy8kpOcFsc17hRQB5Zo3gQ+GNbs9YbSNHvLewS+RWRGa4tIWuZZoFt1ETFiI5BHsBXHIUsK7D4d2Nzp3grSoL+HyLoxmWWE9YmkYuUPuu7b+FdHRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcInhW18MaHexT+J9bTQ2Mhe2dbcpH5su9grLB5nJdl+8cBj0IBHd145Lo/jW+Dafe2V+1tb2l5E0819E8d3I99DJCwXzC3ywq4BcAjle4yAdbffDnS7uAW323UIbH7Pc2TWsRiEZtZyC0AzGSqKQNu0hlHGcACjwv8OtI8NPaS2k8h+yTtcpi2tLcEmJojuEEMYYbWJyec98cVzl14f8AF1ot9e2f9qXt1df2sJLWXV5BGVa6zaCMCVfLIizgoUIztZl4wngLw54ta/09fFE+sQ6dbtfSbDqLKzZe0a3WTbcSuwG244Mj4AKk7W2kAuxfCvw1q1hpUsep3l5p0Gmx2Vq8Bth5kIg8pW8+OISOCuHwXKbsHbwALlrp3hzwzr015q3iG5l1S2X7fd3upSRooSRVgTzHVEjQfJhV+UkhjzzWP4C0jxhY+I9Ek1uPV54l06CO+mvL/dFFMtqiuEVLkrKTKDkvDnJdvMI203xzp19qT+ONI0+KWXV7uTTr+0jjaNJHgjeIMYzIQhKtFIcE4BZc/eGQDe1W+8K3d3B4stvG9rp0O0WMt1a39qbe5VWLiF2kVhkbm+6VbDHnpWN4Y8A+DNF+039j4gM6JJZPNM09qADHJ5sPmNHGu5nMg+dyXcEfMeDToNP8Q2/iPRPEdzpGu619kgurRrfUJdPS8gMhiKyx+UywlSEZD8wfDHqOKzb7w34il/tuxtfDK2tvr0+nXCtDcweRp4i8oSo4yGJAiyNisDu7YoA0tM8C2HiceIX1HWb24tZr7UYktIdsaWjTI0Lthog/m7HfG4suGyAQQa7rxT4X0fxVaQ2uvWf2uCJ/MRfNdMNgjOVIPQmsrwQy3XiDxjf2oH2GfUUjjcH5ZZIoI45HH0Zdn1jNdf3oA8o8SfDLwLpdpGYdBR7mVwsaNd3ByByxwJB0Ga5G88KeGIbpUHhi1WPqS1zdZI9v3te0+Log2nxz7trQSA59Q2VI/wDHq851aIfbUbJ2h8Huc+tO10NHjnim70XR9dsobXwppd1YzylCBNeGVh/s4nx+ldr8TLOxs/h1pUkVgkcNshaO1DNiMvjJG4lictwCT94+lcR4tuF0+Hw/fYHm22qo7MOCQGbIPoa9h+LTRL4Fv7k24uXi2vCjDoxIAbjrjdkD1rOavFm1JqM1Y8h8DrjwlIinDx3NwjL/AHTsB/TP6U3w00KRX+w5SS8ZUJ5JAwCSffiqvw2a4j0zVbW4cqwu2aQtzyYsY+p/pTvDS7Rqdgm8mG9yrYwPudz25xXnSXvSPZpy9xP+upo+IjDJ4hud8JkMcsTsQ2OC2AB6dB+VUPDif2l8RdUvVuYxHa+Qu1skMihQceo45+taniKN4/7UniMZkmu7YLn+FUV2zn6qRUfwnYXXiTXCP9Y11gFkAGzOwn09cirtaDfoYufNUS82dLr8T/ZIZYwWBREcLjOVkwCT644rX+Edy8nwyjt3Q5stUktxnkgbt4/H58VHqbCATQXwVVRiWZW+7gdj3+6p+hrN+CP2iHQtft5smOO7hfdnIZiWD49sgVrhNJMxxj5oog1E7vF0/G8CEdsdZk/wr6cTOxc9cCvl25Bk8XX+U27pLeLfnnJmH+FfUYruluea9jzH4l67c+HPFEOpWS2/mppTxmW5VmhgV7y2RppApBKIrFzgjhTyOtY0/wAR/Ej6Re3mnSaBcw6dZajfyXS20rQ38dq6gGHEvyBwxG4lwCvG4V7PRUknjOvfE7WrTUtcgsJNFlubIaisektBI12n2eJnjlkIlGVkKggBBlSMMTTvEPxZlj/tK40PUvD7aVbXy28d2zJMZU+zRyN5aNcRCVt7sPkbOAAFY16bF4c06PXzrJW6lv8ADBGmvJpY4twAby42cpHkAZ2qK16AON8TFNR17wXb3S77Ka4kuijqVDyxws0YKn0JLgHoUB7V4/4r8ZeIItK8XawJtYtNK1y0uf7IuvtSCJGg/wBUbcI5dC8SyuxKrkgdetfQuqaXZ6oLX7bEZDazrcwsrsjRyLnDAqQehII6EEg5BIq7QB4fYapf+EvHGinxTqt3onh67l1BrW11rVllaOMRWwUSymRlY+Z5rKC7FQ2M9h33hJ4V8beKotPkSTT5ks78GM5TzpUcOVPT5ljibjqWz3rsqp6fpdnp017LaQ7Jb2Y3Fw5Ys0j7QuSST0VVAHQAAACgDkPjtEZvg94tVSARYSPz6L839K7e2lFxbxTKCFkQOAeoBGa5r4q232v4Y+LYMAl9JugueBu8psfritHwbc/bPCGh3OWPnWMEmW6nMann86ANiiiigDM8UaPH4g8N6ro80rwxahay2rSR/eQOpXI9xmuB1T4Z3mpWupPrGsR3M9zHKrJp9gLYbTZvbBYw0rAHDbuWxnjgdO68YTX1t4S1ufRxI2pxWM72ojj8xjKI2KYXB3HdjjBzXBWK+NLTWojdavq+oWSXtpC8M2n26pLDLFmYsUhU4RjwQRjGG3UAR+G/Buu6zLc33ikrp8v24SxRJbxxs8YsJbXGxJpVTmYsPnbOzouQB1/hDw1e6Ley3epalb31w+nWmnfuLQ26hYHnZWwZH5InAPPVc98DifCr+MYdP8PSs99aW8EOkQy6YmmRRRESRqLkkCMMmwnOFKhMEEY4FPQYvHD2NlFFe6no9vG9hbC1ttJt440SRP374aE4Kn0wqnqCOKAPa6K8++Hj65PrUk3iC3lMyWBgN3NZLDJKUvLhVywQdYxG+0fL824AbufQaAPHfj9aCe3ibftItXbAHUK65/nXz3ozqNNv9w4itthwP9vGfyxX0/8AGa3W80qCKFZ3usSKBDC7nayH0B4yBXzfoHh3V0OpQTQBPMtQnMq5DBxwRnI981yVYu56OFmlGzIdSkE2peHBIwZCXDN16gDp9KyL1oo9M1QnCu13I3HGPl4H05Nbs+hatNdaRJ5UY2Nlt0yDqR789O3rWZ4l0a4sNNv5bqNUDShVCuGz8vJ46DjvUwWln/WpvVkuZuP9aDPCiCHRtFu2+6upL16YCnn88V7HdyW3/CUywBQk882Q3TGY2yR+leU6RGY/h7pT4yTdsQPbKnn+VekeIoifGnhm4jyrSyTtwOv7sHaT9AazqpVLp9GKEbWfoarypmMKxLRs4LkZwApBJ9OcVwmgweT8TJ4ori9t0exlcy2s/kzBgwPytg7emM46V6PBZrJfzxsD8zoVbGT1BP5gV57o0nk/EvUpZid5sbpk9eGAAx+BqcL/ABDbG/wmjsrtxbeFNO1ltf8AG7Nd2oufI/t77uScDd5XPTrgVx+l+NXv4bthe+N0eDZhf+Elzu3Ejk+RxjFa/iycwfCvw2zHG7SYOPqCcfrXnmjRtHoc0yRmNppsKx6kKP5Dn869NaniWR6r4NuX8S3VnANZ8cWxubt7ZSdf34VFyz/6kfl+tenf8K0/6nXxv/4Nf/sK8++BEAlv/DxAOI7Ge5Of7zvjNfQNJCkrHL+NfDc+t+A7rQLS5ZppIoohPcysGbaykszqM7iFPIHX0rgfEnwv1m40e80bTjo95p0t/JepNqREl0fMj2/PJNBPlkIAD43MmBuUrlvZqKYjxvS/hnrVvrWn3d9Hol3cwSLLJq0k0jXhX7CbcwDMf+rEh3Z3jPUrmpYPh54itzbWitpUthvsrmeT7XLFLvgs1t2RAIzwSoYPkEf3a9fooA4n4U+Frzwno95Z3lvpltHJOHhisghIXaB+8kSCEO2R1KZxjJY8121FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUtaijm0q6WZN6BCxX/d5H6ivLNdZGRZQhLs4xg8e306V69IodGRhlWGCK8p1KGKW2DxkEA5AIxghT/hTRSPC/iIs8+iIjROYxdRtnbwrl2HP1Br2vUbu7f4bG8t1WW9bSg4DcgMI+W+owT9a8p+I0YitISq7hI6Alm6Eyr/AIHFeyeFmQeFdLMgAUQvGVPPAJ496i+rRo17tz558ExXVndauhVswyLIyZySxgY4J9f61JoSS2d3q0UDFfMW3I80fMSY2DfQ5/lUHhG6uJPEXi61uW8y5eSSTeB/Ghdc+wOf5Vd02+La9IJMH7TBHKWcYJbzMZPp9/8AWuCt7k2ethbTpps7C8t/7R+Hd3cSkoZZIHDAY3Heg6/SQ/Wud+Cl0supanEWfy5LosyBAQVZiAc9ueP/ANdei+HLKC++FxS7Aa3WKS4Vl4B2PlT9Mp+leLfC3ULiCRvKAMm9pEQk7ZBn5l6/Qg9jz2rWcbU7+hy0pXqtep7H8UbVxBvWPDTwudo+VXKN/UfpU/wzTfYakLdAtldQmVFJ3bZFKsACB0OZO5+7Sa7cT6hoGUdJJrIC6QFg/moTzyODxkHFZvw2uIxoOq6fazb4rW4W9sZM7CUOdynjgA7lI7bvpVUbKd0TXT9nZ9DNdwfF0sTEjztQswnuWlY/0r6gr5fu41fxrZSxkNE+qaeQ2chlyxGPzFfUHeutu5ws4D4oarrNlqfhax0ObU0OoXU0cyaYtqbiRUgdwFNyPLGCoJzg4zjmpJfFepacYtKbTpZdUa1WaJ9QuI0LjypGbzjChjWQNGRsTO4HcvCvt0PH0/hRIbCHxjp9vqKTSMLW3k0x79i4UliqKjnIUEk46A1kW3ibwGiw2WjR6cWZYprXydOYW4k8jfCPMCeWsnlAFVLBtuMDpSJMix+Ker+bolpd+GTdXt3Y2t/c/wBmNcTqkU7FVZcQEAjazESMgAGA7HNaEfxF1ZxPs8LiYyQ3c1ilvetK84t7mOCTeoiynMqv8vmHaG4zgHB8OX3hieKzfXPDXhO0tbcRXEcn2IJ9nLWKXcjoNjDIbceSnAzliMHor/xB4MubaFb/AEq1/siS1uZCt/pM8UjL51uWEcDwfvFeSWEnByz7MByCVAKVr8VZp5AV0i0eC2e3j1B475w8DzXDQKscckCO7KyfOriMg5UBiK7Twdrd54g0439zp8VlbOxEAFz5ruAzKxYbQF5HGCcg846VDo2heF7210vULHw7YwC0BFkZ9K+zS2oDHIRJEV4/myegznPfNb9rbw2kCw2sMcMK52xxqFUZOTgD3NAEtFFFAFbU7UX2m3doxwtxC8RPpuBH9a5D4IXZvPhJ4UZuHhsUtWHo0X7oj8ChFdxXnHwpnj0fWPFfg+dljn0/Upb20iJxutLk+apX1Cu0inHQj3oA9HorE03xXoOp6i9jYaraT3S7MIkmRJuQuNh6P8oJ+UnAHOKi+IdvNd+APE1vaxST3E2mXMccUalmdjEwCgDkknjAoA6CivGvBcWoaP4diHhnT7WDUi8YktoPC0+kRzYifIneXJcjqHUj5gFPD8QahqHjCy/t6fSL7xPeXEyWctvHeadsjSBkhE0q4tm2zA78xAMeWPlMRmgD2yivG9O1Dx9dWK3Ul9fq1rbRzLHFppAu2N3IpSTzraN93lBc7Ej7MAAeWza74yW71aLz9ektkvYw95baScW9sZiG8iGS1VncLgZDXAxlvQUAezUCvN/h9ceLdU1UPrt5qNvp9vaRyRLNYxwNeE3N4gMuUyjGFLd2RdpBK/dBKnofFPjnRPCt7Fb6697brLGJFuEsZpYepGC6KQDxnBxxQA/4hwvP4P1AI7KVVXyvoGBP6V8kaGps/Fl7aNGOYnUt0HB619U23j7wb4isZ7fTfE+izvPGyCNrtFY5GOUJBx+FfOmreFtYsPHlvdSaXfGxmYK1wkJaI7hg4YcDn3rnrJ7nZhJK9mcNrkbWsmgpg7lkk6jg/OMfypPEW2IatE+FLNG23p0J7fjT/GRkjmhWfIeCbbg9R8x/wFVfGpdtSvCUypiRzxjsDkf99VFPdHTU0TfmdO4kh+E9iFAYjM+SOg3D+WBXV+KtQ8i+8KXMhBQ3yMGXpscbT/6Fmse0hF18PdLtc8zWM0YGP4iMrn8Vp/iNWl8CeF7/ACWWM27k/wB3aErJu7+Zok1H5HrEEgt76LhT912/DCt/OvLNVIsPHF2+0bZtJu1HP8QY/wBMV6hqgCXZCgZdCVHX3I/IfpXmfjWwuxq2g3skRRLuS40sFOjb1BT+Z/Kpwq94ePl7vrY3fi/aDS/Buh2AIzbWdvExzgYWMZrzkubXwpYxOQsjxvOQRyCxOP5LXrf7QdpJ5Ea26mR0URomM5J+UD9BXlfi841BrEHe8EaQKB3I+U9uxFekzyFse2/AS1aDUvKk5a10mCNeOgY5P6ivba8n+C5Rtf8AEqqBugS2Qn6h/wDCvWKSFLcKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXmfizVfEDfExdJ0ubXjYR6XDdNFpK2GQ7TSKWkN0M7cKBhDnipvEXj3VLW21GPS9KsTqFhPHFN9qu2EJ33KRJsZUy+VYljx5bfKQxzQB6NRXl138Ury11bVLN/DFxMmmJIl1PbtO8cc6W/nMPM8gRiPOEDFw+SD5YBqe6+IWtWtlcPL4YjNzbyxeb5V5LNDFDJF5iyO0du0g6bSBGQDyWxzQB6VRXlWpfFmSytr2+XRra40yH7VFFNFqGZJZ4LRrlh5fl/LGwRgHyT90lQCK67XdW1Cy8O213e25srmTUbO28q2uFkISa7iiG5njI+6/wAygeoV+j0AdPRXmB+J99Fb+ZdeHoUN0inTwuobhMzXSWwEpMY8ob5EbI3/ACk9xism08d6po0sh1KJrm8mu7+NbVL8NbLILy0t40Mrxbwim5+8NoUBsoxxtAPZaK861Xxfr+lajfRSaGby+htbOV7S0uXnt4RLJdKXDJbGY8QLnCNyygKoDM3Tv4o0618HW/iPUrqCHTngineaAvPGBJtA2kKGYZYAHaD3IFAG9XmmvxCDVLuIY2B2bAGMA8/1NWx8YvAnfXf/ACUn/wDiK5rxH8Q/Beo3pnttegTdEEbfa3AJOfaP6UJ2GjyL4wu8LRtEcW7uFZMcYDLtx+Wa9j0KX/ihLNkJwHccf73NeVePZdE8Q6Sbez8VaWk/mK+Zba6AOD6iAnpXaab4v8J2nhKHSz4itBcI7MXW2udvJz/zyz+lTb3rmnMuWx5J4Iif/hZGrSR7SZLm4g69y4PT6ZqG8lePxVLnaDEskePZZF6j6DNdL4V07TxrsJt/EVhd3t1qfmpHbx3KkK7Y4LxKOAxJyR0wM1h+MbQ6f8QtYt7tdmNQmTzCPvq4Yjj34rlqQcm2zvoVoxsk/M9m8NI0HgKC2n+RW06ZAq8lgPNbj6henvXlnwSnFxpMlhFf+I7Vll8110nVPs6lWwNxjKHLjAGcjIxxxz6r4Wc/8I7okbLuVrL5VzndvSfv+FeT/AhXuLiT7PESI1Cnb1Zt2VwfUcjB9q2m3GCsc1OMZzkpHdeMrh/C13bC71vxtLYz5CXS+IOCw7Y8k+2fSo9CvhqmqxWx13xrHazhzb3KeIN6zFcHAHkjB55Gcj9a6XxrDHqmgSxR28NyskbF7UtjofvIezcD/wCtXiXgDWY/DWuyWWqTCOyE6ss8kPmrCc/LvXqFPHzLypGOhpU5uT1Y50YqN0j0/UZXsfEVnpcmueNsXV7b2scp8QYysoY78eT229M8+tel/wDCtP8AqdfG/wD4Nf8A7CuD1KwE/jbw5I5G2HUEXGM5+bMZz6Dn/vqvfK6JLscjPPPE/h5/7R8E6dD4j1C0ngluFS7Zllu5v3D5wzxOmcHksBx0OcVNY/C7RrGSBLO91SLTomilOniVDC80cAhSViU37tirn5gpKgkE0nxR0e+1K+8OXFnp2qahBZzzPPHpl8tpOA0LKpEhljIG4jOGzjsRxXNP4X8dt4R1Ey6lqD+IFisY4Ct+wRlEcIutqrIgLsVkALFDnlWTcWpCOqf4Y6FLZm0nkvpbcxeSyNIo3L9k+yYOFB/1fPH8XPTilj8IWmsWgkl8T6jqzxQXOnrdSrZzbVeSHzEKiDy2KtbAfMpIJfPONvMaT4f8brb6TC97qogu3e31A3NyEks4VmEqMmLiYklfNi3eYz/OhJwnE0OkeMI/Fum3Eser3NsL+4aQSX+22iga+ndG+S5VmbyWj+R4pVwEUbMNgA7HRI9F8DaZY6Ab91UR3FyjXAUbY1YvI7bFWOKNd4A4VFBVR2FSDx74PNm12PFegG1SQRNMNRh2K5BIUtuxkhWIHsfSub8fWk11rmuWESB7rWPDNxZ6cjMFEky+YXjBOACRJGeT0QnoDjAPh3xhqFp4VjjGrQ3Wm6jHK8uupYTRwRi1mjYolq6F13MowzbuQegagD03/hLPDv8AaVvp/wDb+k/b7lUaC2+2R+bKGGVKrnLAjkYHNXdJ1Sz1e2efT5vNjjlkgfKMjJIjFWVlYAggg9R6HoQa8Kl+G3iDRdUmsNEttSu7KNtMe1maSzWzlkt23M9wrHzgFOSqx+wOa9S+H7rc3/i2/th/oF3rDG3YHKyeXBDDI6+3mRyDjrgnvQB2Fea+C7ePxJ8TvFXim4AddLl/sDT8j7gjAadvqZGK59EIr0iWRYonkkO1EBZj6AVwXwHjf/hVuj3cw/0jUTNqMpPVmmmeTJ/BgPwoAi8H/CrTfDHjXUfElrf3ct3eY3hwuXypD7zjByxDfIqYwByMg9vrmp2uiaNfapqDlLOyge4mYDJCKpY4HfgVdqpq0Fnc6XeQamkb2EkLpcLL90xlSGB9sZoA4vxF8TbPwzpNtqPiPRNU0uGdmGy6uLJZFVQp3bPtG587j8qBn+U5UcZtaj8QILS9NtDoWtXrG/OmI8CwBZLgKz7FLyrxtUnd931IOQOTubL4f3en6db6jY+Kne9sHlitvM1O7nNnIVUrIYWciNtikRscD+6Dmr3i6fwdfXkdg+p3tmun6u1/ey2kV2EacQyBo/tMeBG+GztV8/LjbzQB1XhHxZD4m1GcWYlS3Wxt7oQzW+ySNnluI2VnDkEhrdgQFAGMhm3fLi654/in0a1bRhdW91dJDdRvLGhAi+2RQOp5PJ3nseOcg1Zi1Lwn4StGvNLt5iRo8Vx5duju5sInYh8OcfKZ3Y/xnceGIAq7ZeAPC8UslzbWUj+eBgm9mkQL5qzAIpcqi+YqthQB+BOQCnB8SbCU3e/S9TgjhhuZ4pbhreKO5SCZYZSjtKAuHdf9YUBByKh0n4nabrlvAdGsNQuJZknb5BBKkIikVHdnWXYygsG+RjuHTJ4rbvfBHh69tEtrmwLQpHNGgE8ilRNMk0mCGBBMkUbA5ypXgipNH8IaJpLM9lazCR0ljeSa6lmdxKytJuZ2JJJVTknPHWgDkdH1nwr481GLS9U8O2moXhtIriWe8tbVQ26NXysLytMF+bghWXII3nGa82+LWh6N4C1BLnSvDsdpbSScTadfXFk65Hby3257cqele76Z4Q0bTNQtr21iu/OtYhBbrNfTzRQJtCYSN3KIdoAyACefU1zHx08PJrvge/4PnxRNJGQM4Zfm/oRUTuldF07c1meH6v4ksYYP9I1nxNJCYkkMd+lpq6FSOmJ41PY5+bNc58Qr3TZ9BLrcaHfXdxCrwyR6TNY3IXI5ASRoSABggj6c1j6hMLzw3bTcF4m8hh6jqP5n8q53VrgS6NpbMS5SN4jk9MZx/Osqc5Pc7KtGEU3HY9m8Hxqvh/RySGVYWJ+gK8D9axpGeP4RT25Jf7JPIuGGMbZQB/IV0Pg5o20TRYtpUPaEqSR6isbXoki8Ga9FG5JN1IQoHYlXzn6GuK+rXmehy+6n5foegX1w02hWN+G/eRpHLuxkEcZ/qKnaIX/w+ub3yVd9I1a31FBnkQq6lmz7IXH/AAGsXw9cm48A2vy/Pbjy3Hqh4DfmM/iK6nwXZ2t3od1bSOxSUG2uCOjowbawA9Q2PqK3w6tUaOTGPmpJ9iz4+mjvb/Q7mOJbi3FyZ5GzldiIZM/oK8C2G+8dWSzH/W3e99xznb85x+INey6DOreHbqzvTuvNEs57a5OCFDmQIv5quc+jV49paTS+NxLIhXyradz7M2VH4/N0rsV+p59j3f8AZ7kE8/i2bGXN5HGzdztTH+NexV4j+zS7mHxDvJ/eXHmjJ6jcyg/+O17dTREtwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAx9Y8LeH9bvIrvWdC0rULqJQkc13aRyuigkgBmBIGST+NS3Hh/RrmAw3OkadNCUkj2SWyMuyRgzrgjozAMR3IBNadFAGEfB/ho3MVwfDujG4igFtHKbGLckQTZ5YO3IXYSu0cYOOlS6p4Y0DVlC6roel3qhlYC5tI5BlRtU/MDyBwPQVsUUAY8vhfQJr24u5dD0p7u4hNtNO1pGXkiK7TGzYyVK8bTxjitO5toLqNY7qGOaNXSQLIoYB0YMjYPcMoYHsQD2qWigDNn0HR7i2NvPpVhLbmJoDE9ujKY2YMyYIxtJAJHQkZqGPwt4fjsRZR6FpSWYjeEQLZxiPy3Kl024xtYohI6HauegrYooAwH8GeF5LAWL+G9FayAUC3NhEYwFLsvy7ccGSQj0Lt6mtqCGK2t4oLaJIYIlCRxxqFVFAwAAOAAO1S0UAAzWJ4wiupNDmNhNNFcLgho3Kkc+1bdR3CGWCRAcFlIzQB8xfFfxDrlv4dW40zXNXtiJireVeSo/K5HIau28J65qeofC/Trp9SvWuLhivnmdjIRjruJz3/SuP+NFktrolzByihleM/gcD9f0rY+Gjif4Q+HjuP334A9HIpLc0aVjz3w74p8QXj63Z6lrGp3Sx3TT263Fy8iN5UmWTk44ADY7YFa3xznil8eaDdrJtt7iK2nJxnKmYg9fY1yXhSGS7n8RyQRNNdWl+9yIh3j3MJAP+A5/IVtfGExT6d4VvFkLsdLwCpyPkdcH881jrzM6bJwilvr+R7bNbRQ31jHGqqkZTCqOgzMvT6mvmTwBrEfhzxtc29zK0FrJO8ayc5jO7AyB1B6H8xyK+ibO5knltZTtDGb5jnoou3GPyYfnXzFrduLTxRIdRiKxz3TtlhzsdmGfzU1tJJqxhD3Xc+ntZZhFHPahTODvIjOSQR94Duefx+teA+MbY3F/stiJLiRScDH75D/Xjj19iK9Y8OzyDTrODUJwC6BIZONvAGc/XIz0zjPGTXBfFTw4YrltVMTrztl2ttaNj/F9c9+h9jXAnaZ6S96md5p99fSeHbDUbnJvrVInZkOPOC4eOQAdNycEdiDX0Lp93Ff2Nvd253QzxrIh9iMivnjwZqE+o/DzTry8SPrJYvLGQVnwco+OxyWBB/vGvWfhDfG58Ipav/rLGVrc8/wAOcqfyP6V6N7q55MlZnbVwfjrx9/wjHiOx0nboUX2m0kuvtOsav9giG11XYp8p9zHdnHHANd5XNa94V/tTXrbWbTW9U0q/gtntA9kLdg8bOrEESxOOqLyMUiSHV/Hui6XpF1fzPcz/AGVJHlhtbaSWQbCqtxtGBl1IJwGB3DI5pR4/8Ofa/s0l3cwy4+YT2FxEI28syCN2ZAEkKDcI2IYjGByKpeJPC2j2+l61f6vqWoRw3VpLFqNyuzfLGfuFgsfWIZCYHG5shsmsOz8CeFdW8T3WoJrMt5rUnmJdGa2szPK0QFu7gtb+YmMKuYiqZwccnIB0kHxH8Mz23nw3d5JmRIkhXTrkzyF0aRSkXl73UojMGVSuFJzxVhvHnh1dSaxe9mS4UHdvtJlRWEXmmMuU2iQJ8xjJ347Vlar4G0TWReaYuqTLMILSO5hVLW4ZY4lkERZJonC7tzHdgHK8EYOSH4YaTFIqpqGrGxU+aLJ5kaLzvI8jziSm8vs7Ftu7nbmgDrdE1ez1uxF5pryyWrHCSPA8QcYB3LvA3KcjDDIPY1fqCwtUsbG2tIixjgiWJS3UhRgZ9+KnoA5/4h3RsfAHia7BIMGmXMvH+zEx/pTfhzafYPh94YtMY8jTLaM/URKO1ZPxwnFv8IfFzksM6dMny/7S7f612GmwfZdOtbcqqmKJE2r0GABgUAWKzPE+nyat4a1bToX2S3dpNbo2cbS6FQf1rTooA8nvvDes+IL/AEXX7PTjGo0lbOazn1m80eaGUPlgTAjFlGCOTg9RkYNatl4Y8R2NtrGhW50htC1G7u5zevLJ9pjS4Z3dPKCbWYM5w3mDgDK16HTJ3McEjrjKqSM+woA8pXQPEml6VeahrFpZXNzaeH/7Fs7TS2kuGunJHztuRdgJCDHzBRuJbAr0vQrJtO0TT7GRw721vHCzDoxVQM/pXnXgH4h3uoeGrXXPEsq/ZZ4IJZfJ0O5sorPzOrtPPIUljBIBZOgO77uSNLUPidBpt1ftqWhana6XaafbX73kjwLtE7yoishkBXJjAB7EneEAyQD0GivNY/jDok+nG9s9O1S8giiuJ7prU28q2scBXzHZ1mKsAHU/uy+QeOQRV+4+JulQ3+sWn2DUJJdNlW3Ko1uZJ5XlWFESLzfMG53ADOiocE7sYJAO7qC9gS6tZIZEDqwwVPQ+1ctpfjy21LUbbT7fSNXGoSPKk1u6RA2vlyIjmRvM24G9W+UtkdMnArsKAPiPxdoh8MeIfEfh3YzqxFzasy4+UEuB9dpI4/u153qG0WZSM7ljlP5EV9PftNeH5bebS/FFjArCBvJujk5Kk5UY9PvD/gVfMWqxJDcXcMLh4lwVYD7w7H8qwjG0zv5+ekey+GrpbbRtAZ/nVLZsYHOTjH8qf4jt1/szxcuBst2WZABxhoGwfzH6Vl+F52Og+HpE+bYjbgemAwyPyrp9WsY5fB/i68WRmuRDbQuD0AKOR+POK40rzaR2ylaEW/6uP8EyJb+GtHZ2lmsdQtDG7Y+7IAcqT+Bx7qBXoPgOz+x6TeOqOJGZZF/uuAOGT2Pp2INcB8P4l1v4Qw2bqVkgVpIOcFtpw4U+oIDCus+C+ptd+HtT0q6kL32lzh9pGC8L/wAQ/EHI7Ee9dlKymefX5uSwzVfs2l63rThcNrVtDMD/AHmhJDfoUrybwzIZtZ1llJEp8mLcOM53SHH5CvS/i+0tnoNvqEI3f2TeBpAvG6FwVJ/Alfbg+1eX+G3WaKS4iISSW4mkLf7IKxp+itW8tGcy2PaP2ffkup1QHa9kC5x/ELiUcfXNe2V4f8AJSuofZgSQunsTn1+0PXuFJCluFFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwf9o/St+iz3UPDxsN3BIwQSM/8Aj36Vm/CmXb8GfDjFvuzXGR6jzjgfzr0j41WyzeCdXLDCvZSAtjOCvzD+teWfD6ZIvgHpUu4Ap9s/HDMf8aI7lX2OQ+BGJNa166Iz5jbW44wXJP8AOuk+M3hprfwXpNzF5a2kFtcxg9+TuQD24Nc/+z7I/wBjuEjtpDIzcynIQD1yRjPsMn2r0n4m6feat8OLTS5rtYZEIZzAhlMpwRtGcYBzzxxWSi23c25rWsbOk6SU0+0kZssWBY9sl4JCfzzXD+I7OOHQ7fULqVHhS6uLJo08O2moMhW7kVSWlYMBhlwPYnua6bTrC4k06N9Q1rUy8qhp0V0Cu5VQeiDA+ReB0x7msr+zIVi1FbU3M7TyGYs8zPlyckjoFz6gfWtTO1yvoEk+saek9l4nVIFO1UfwvYrtJyCAA59T+dZ1/qhuLQvqGvSyxhCypN4TsW3RDI3rlyCmRj+eKbp0v2HVNQazh22bhWhSNcKckAn14OeT15rqNQ8LsfAGjafrH7nU7G2MXnxH5opVznB7g8EjoRWKUm2jT3VY47w14iguHOmaV4ge0EsuXt18Kaei7xjDELJg56BuenUV3PheLXri/Sz0nxo9lJdIJSR4ctIw3y5G7a/XqPwNeB6TbyW2rafetDLa34YTxRRjb9qXP34iePfaf5V69Hrf9japaag5eSKK4jmViNh8pxvyVPT/AJaritI3tqTUit4np3/CLeO/+ii/+UOD/GsL4lxa7deJ7XStHfWrm/bQ5nhbT78Wccd0JEVLiYeYoZQScqA/BxtNetRSJLEkkTq8bgMrKchgehBrgPHfie48NeK7WaNHuY308xx2jXHlRPNJd20MbO2CFAMnLYJAJ4PSqMTldS8M+Nb1tbt5Y9TnknS/WWebUka0u0dx9lSGAyHymVcAkqnRslt2av6n4d8XxrqS6Wl5HBLPdzNFbXqwvMj38UmEbcNkjQCUKxxtLclc1cm+J+pRi9A8O2zvpgmbUdupHbGIpRG3knyv3hwdwDBOhBwRyan8Urqxh1O8/sK3k063j1Jrdv7QImmayJWQNH5WEBYEA7mOMEjmgDP1nRfE8tjcf2VZ+K7a2zbG3spNVWaYlftHmCST7ajhSWjOUmz9wYIUqPVNEW5TRbBb6MRXa28YmjErShX2jcN7ElsHPJJJ6muG8R/Ee50zUNUgstFjubXTrgQ3N9JcSiCFfIjlLyGKGVkH7wjJG0BGLMvSt7xTPNP4h8L6dDczQW9zcyXEzQSFDKsUZZY8jnaWKkjuFweCaAOoorwVfFfiyP4dX+vz3/iSOU7EjupLfTntRm9jjPkxxoZi+wsAHUjrxnbXSeAPEXiW68ew6VrNzdyaa9jfXFsb2zW2uJ447iBIpZE2KUbDyDG1cjBKg0Aa3x9yfg/4mQdZYFiHsXkVQf1r0CvFviXPcJ4C+I2mTXMtzBZ31q8DSyF3RJWgkMZJ5wGZ8eiso6AV7TQAUUUUAFNkCtG4cEqQQQO4p1FAHJeGPB3h+x02xOlxastiixSW9teX14yRBRlB5MznZjj5SowQOMgYzb3QfCR1s6PPp2otLBYWsGIprl4zA8swhVgjnPlursHYYjyCGXtgab8Krq30/SnlfTl1qwg0uCK/j3GSFbeIJN5bFQQG+bA43DG7HaLwx8MtV00oWtdB09lGmLI9jK7NcvbTO8k8hMSnzHDjru5HLd6AO5m8K6BHH/Z91b6ldi/trjT2a4urq6JhkUGRGlZmKAhBglhzwpycF+o+BPD+p3V1c6jbXd3NcKyEz39xIIgXSQ+SC+IfmjjOY9uCi46CuD0v4Z6hbaRaWUuk6BFNbxTR3N7Z3kkU+qF7aaLzJnEG5HLSBicyY3MRnAB7b4Y+Hr3wz4dksNQi02FjcPJHHYJGqKhCgbjHDCrNkElhGvBA5xkgGlonhbR9Emjm021eOdElTzZJ5JXYSOHcuzsS7FlB3MSeOtZPiLw/4qn1eW/8O+MWsY3C/wDEvu7CO5t8hQOCNsi5xk/MeSa7E0UAeR+Lbfx5qWgXWk+I/DGj67ZzqA02jagbaVMHIYRzrjIIBxvr588ReBLa2j33V1q2ibYzH/xPNIlji46Dz4fMQ49Tjp2r7fPNfLf7Q2max4T1r/hJvDGoX9jDcyBLo2kzR4mHdgD0YYP50mle5cZNKyOV0fSL2z8O2Z02903UIrYyNNJYX0c4A4wSqncB9VFdroaNqPg/xekgAAlsmbnJEY39fbArznTvENzrWgW95qi2Mt8LxomvxZRJcouzI/eKoY55ByTnOK9L+HcK3vhvxfbqx2PHaqCR/sv/AFBrl5F7R2O6U5exTl0Zi/BK5F74P1DRgxFzZXjvA6feGew788nHfBFXvA07aR8RJLq4ykyRPHPHvwHjyN5PqNvzgHuuK4T4Q3CaVruoRXDqlreSm18yQn5XBJUkjt2J7bhXfX8z2viy01CeCNTDL5blicOh4ZW9z27Um7VBpc1K51/xMsXltruzjQSx3ML25Ufx55X8+xrwfwOPLsbVQu6SOTZIpHI+c9vXJPNe7+KrkDQcRy759OYJknLGPrGWH0+X6r714zdiC08SXpt2jigvkW+hyPuk5yvJ4wwIrsnL3bnDTV5cp7B8CoSvi3UGOQsUVxbopGPlEysOP+BV7rXhP7PYuZLwXU65W6gnmEhHJHmoo5/4Ca92qYaoVRWlYKKKKogKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMDXPFuk6Lqcen3hv5L2SH7QIbPTrm7YR7tu4+TG2BnjnFbV1cQ2kDTXU0cMK43SSMFUZOBkn3NcB438JatqnjK21jToYri3SwNo0f9u3eluG8zfndboxcY7GqfiX4eXWrRashtdHmhvFmaG0uSTDayeajgp+7P8ArSm6Q4+VsbQfmLAHqFFeK2/ws1dPFU+qBNOtYJY3EUVpdIi2qm2MQtwPsm94Q3OPMRejbMjldW+Ek62DW2j6fovlFLVxDJMEhFxHFIkkrxPbzJKW3LyyhjjO5SAaAPaaK8ZufhfrU2o3kuNDWaZbknUo2kS4lWWzMC2rJsIWFXIYYY4CLhQcmu31fwfFL4GGg6ZDa2u6S3kl2koHZZY3kYso3F2Cn5jySck96AOtlkSGJ5JXVI0BZnY4CgdST2FQW99BcTtFAZHxEkwkEbeUytnG2TG1jweASQCCcZGfIrn4RTt4yv7uEWI0a4EiRJG8UPkRNbmLyDELYs8QJJ2CZV5ztyObem/DGd0todR0vw/a2Ai06KewtWaSGT7PLdPISDEgO/z0OCOTuB9SAet0V4nqPwt1+S40BLJ9EjttKlRoZRtWaBFvGl2K5t3cr5RRQqSRAHcDuBrQ0zwBrWlWmntZ6V4aOq6dfpeHUPtMiS6phZkJuGEBZGxLu6yc5HAoA9Mg1WCbX73SFSUXNrawXbsQNhSV5lUA5zkGB88dx15xoV5Jp/w+8QafDY3McmlT31nFp+2Jp5I45JIJrx5AX8slVK3S4O0nKnIHU0LT4P3FzBM+uwaLdXhWzWJ8u/lBL+ee4CkoCA8UoTjryDgckA9qornPAvh9vDWl3dgFt47U31xPaw2/CQwySFlQDAC4z0HA7Vhf8It47/6KN/5Q4P8AGgDS+J6xyeGvJlj81JpREyEcMrBg2f8AgJP44ryrSfDFtpPw8k0tria7so2Z4I5ABt3Ek9PvDLHrXS+J7DxRpnlxap49M6spcD+wLVgAMDnc3vWDd/2vFbn7R4sk+zjHXwzZlTnpxvoKRH4dto9KsbbT7XIijTCx55P1/wA8VP441Ce00q2t7S3kubqaQKkES72Zuw46j1FUrNtRuLuGC18SStcykqEXwvZZGO5O/gVs3Om61a3qQnxrE10ychPDtnlE65Zt2Av4/Sn0sPmNHw/o11PaJPrbRmXaMQIdyK2ORnoxGcccfWp7uSCK/FtHHJLcNxsQfKoHQM3QfSqNvp3ie6hLr42cRElQX8O2o3D1A3dKTU1t9KaCXVJjeTFsYYeWg/7Zr/jQ9ECbZi3NrNF4lTMkZtSNjybcLv3Aqm7+LADEkdM123iiG51LQ5TY3MaXcKn5JlJSVMfdOOQenPb3rmr+SfU2gvLYSBbcAxqv3UcH+6vGPYmtKS53HaHkt3IyUABOPYnIpJ7jZ5j8StPtD4L0ZZC0V1ZRwIwVfmU4AYjA+p49Kl8TaNf6xoOiv5csO2F7LULq4QryjfwhuXzhiOow/Wovi9dC18OxxwX0qTeYIzHOuWkUnnt09xW54TnfVvh3I7sBKr/fwTyFBP0z3GO/WjcZ6/8ACtv+KKsoQpWK3zDEC27Ea/d5+mK6HUNK07UlkXUbC0uxJE0DieFZN0bEEocjlSQCR04Fcn8HpEbwkqRkkJIcknJJIGa7nIpIze5l2/h3Rbay+x22j6dDaeUYPIjtUVPLJ3FNoGNpJJx0zWJafD/R4fF974jlzcXd1HJE0b29uke2TbuDFIleThcfvGfAJ9TXXEZGK5PxXrOqxeI9F8P6CbGC71CG4uXur2J5UijhMYIEauhZiZV/iGACeaYi1/wgvhHyIof+EW0HyYn8yNP7Ph2o5AG4DbwcKoz7D0rQ1nR4dVl06WSWeCewuRdQywkBg21lZTkEFWVmUj0PGCARy8vj9NHney12yuJbm1eK3vr2xjX7JHPIu6OMb3EmWBTopALgFqr2HxTs7uW2Enh7xBawTfZGNxOlvsjS6k8uB22zFsM3GACRjkAUAdJbeC/C1rNPNa+GtEhlnGJXjsIlaT5w/wAxC8/Mqtz3UHqKm1zwzoOvyxSa7oel6k8QKxte2kcxQE8gFgcZ9q5Cb4tWMUU058OeImtIobm6NwsdvsMFu+yaUDzt21Tjgjcc8A1c1H4n6TYPetNp+qtZ27XESXaRxmO4lgUmWOMb924BW5ZVU7TgmgDB8QeHr/WNSuvCmnaXfx6Pc6nFqGt6zelFW4VfLkWGALgtwkcWdoCrHg7jzXrVc5pvigalo2s3UOmX9te6W7xTWN0IxKJBEsqrlXKHcsiEHdj5ucc15vo/jnxFHp3htrl9Sv767uLOS4tDa2qSuk9vcvsRlk8vYWhVlztZV+8xJIAB7XRXAN8UtK+yPcxaXrMsUVnHeT7IY8wq8k0QRsuMv5kDJhc8sCMjcVtW/wARdOee4trrTtTs762S6e4tZ1iLxeRHFIwJSRlO5J4ypBIOTkjFAHa0VyOg+PNP1vxHJo1pa3STJCszSTSQJwyK4xGZPNI+YDcE25Bw3FddQAUUUYoAKKKKACiiigArzn4qWlrrY/4Ry/jUW2qwNEkzKT5c4x5TcdBuwCfcD1r0avP/ABXajVdQnhLMpLCMOrYKdfmHoRSY1ufIehWk+jajqmhatGYrq2ulEibujKSp59MHrXsvwquo08LeM7kKyxRrbsVznBEDuQPTkmuV+LFt9ol0nx1EgcSSnTNXQKMefGSu847Ooz+ArS+Ht2F+GPxAkXaZd3O08Y+zkD+dQo+/zG7n+65fMxfBOm/bvCDxgBJr2TcCRzlhgfqQa2NetpdKKabqDCcKnk+fJ0kRTgCRv4WGOG9hnoc7vwp05QfDVq5yGWKR8dwg8w/+ggGurFhFqWv6iskUcqQWzyM0nIzISuPy3VnCKmncp1HTasZ2sRNDpen37vGYrmzFtPLIw2BWxsdmHXawX8Ca8E8Uxyyzm0KkyQOyKmeUPGRn8DXs+mfZ00nXPBVwguksEN3bxIcbrWUnzI/XKE5GfUeleM6vLO9x5xRDcLt3Db1dDtIP125/4FWy10Mdnc+sfhHHZGG+/ssB9OsVh062lDbt6ogZv1avQ683/Z8+yr8M7KKz2ERTzK5U53EyFgT/AMBK/hivSKpEPcKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAef/FmNxaW0iEbZD5JBGepBFcFrUk8mkwW1kkplcgKEXLtj+vFenfFiaO18A6reyFB9kQTjf7MOPrjOPeuG8DxXGoaXa6vNbvHdPGTDHkfulbnof4yOT/dBpotPS5Z8PWMOiGS2Qs2ryRg3sqDctop5WHPdznOM565wMVTuik/iKCDablI/3vkJyNw6M5HU+gPrW/czWdvpyrEqzxqTkRH90rH7xZ/4jnOT3ya5vQ9U1vV9auYI4IbDR0+7cwrmWY91QdMf7WMD3ptJAtdTqjJPO7LctDbR8HGcsPqB/U1h+INLs5pYLiaBr3y23J5gyqn129D+Oa3LS0SCabYSWAHzSvvIP48D8Kq+I2lGnEQrk9jnaCfc9cUpMET2F7DFB5Fytum5cKoYl2/CuS1m8vYLwwLFNGZOU8pPujPQs3GfoK6HwzDcWirJDaWySM2WfZlvxJq34rtzqcPmO+0ouGWLgsfoO341K94b0PMfF+nwx+HbuW4id5ivmCVn3tkcgdDx7Zp/w4uLE+HNSBiAQqpdpGIU+pHGc4PTuaveJ/s7eCtSBVFkji2ETJlSCPUc5rlfAPmt4VnCoZH8v/UrwCBn+H09+9UM9N8C2PivWNIaTw/4l0HSdNL9LPSZp3JwOrTy9cHqBjjiuj/4V9q95zrXxB8U3Dd1smgslP4Rx59Ohp/wVh8rwWh/vSnqeeABXfUjN7nBWvwn8Kx3UV1ew6lqd3E4kWbUdTuLghgQQcM+3ORnpXS+IfDel+IPsp1OGUy2rl4J7e4kt5oiRg7ZI2VwCOCAcHvWxXAfFLwhfeJ7jSJtMttNlnszIRJqEitFHuKHPkPBKsh+XqDGwxgOAxoEO8P+EPCGsWkOpWel3Ecau8PlyXUoV2hd4t7oJCruMNh2ywBHIPTf/wCEQ0PyBD9h/dCOziC+dJ921k8yAfe/hbn375Fed33wnvDYXK6XNYWF9eW19HeXEOQ1y0l7DPCHJQ7gI0ljJYHb5mAGBNY2o/CPxHPo9jZWg0WH7PJJMjSTQu9rIzowMLrYrsT5SdkaxENzuOcAA9FutK8JKbLRxafaIdRS+0gCGdmVFkDS3MbnfkEmM9PmU8DHNXJvh/4Znurq4l052a5EgkT7VN5YMgAdlj37UZgOWUBj3PJrkrX4WW8mtyDUtD8OvpJ1We/kZV3SXaSJNsSWPygMxtINvzMMZI2ng6+peD9Tu/hn4d0Gc2F/facll9rgu5H+zXxhVQ6O20naxBOShyQMr1oA2zcafaeKbrR7XTbua61Vft9/NGy+VGPLWFWcs4I3LCqARg/dyQOTWHqOl+BZNXOgztLDqen2UN75dvdXMMkUECvHGwkjYHKrKwIDbiHBIOQag+Hnw7/4R7WItT1C10k3Udm0ERt03G1LXE8nlxuyg+WscqRg8EhMYAwKpXnw61ubXLnX11dDqlzfXDPaMy/ZhayRGBVDCLzN4jWJsbtm5Tx3IBNoepfDbVbRNL08MYtVtrfTFt5re6iM8O2eaHAkUHBBncS9zn5iQK6Cf4ceGLiyFrNZXTp5ksrSHULnzpWkVVk8yXzN7hlVQVZiCFAxwK4qx+Fur6NZeD76yurfVfEGkfZUuP7QufJhEMNtNEIYWjgJCBpmYFlLH+Ik4rrPiF4f1nxX4UsbJbTRhdeest3b3DJPGFCsMRSS28ihgSvzND03D5Sc0Abdj4T0my1aHUoY7trmCPy4RNfTyxwrtCnZE7lEOABlVB6+pq6NVgOvtpGyX7StqLstgbNhcrjOc5yD2rzDSfhZfQ2mmTahJp02tWEWkRQXu52eIW0+642MVyA8eVH97ocCtT4W+Bb/AMK6m1xfWmiwH+z47OW4sZGaW+lVyzXE26NcO2eRlsHPzHsAbsnxE8Nx2+pXMlxfrZ6d5wubo6XdeQhiYpIBL5exiGBGFJyRxmopvib4WiRC15fGVnlQwLpd008ZiVWk3xCPemFdDlgOGBFcRd/DPxBP4e8VaQq2anVGvmgujr140Q8+ZpEDWnl+UuAwBZcnIJ5zVzxR8LLqbVrG/wBOmfV5ma6fUZNQ1WWwmuWljhjT57WLG1ViC7AqgjHXmgD1exu4L+yt7yzlWa2uI1likXo6MMgj2IIqesbwZpl7o3hPSNN1S6ju720to4ZZo02qxUY4HHA6ZwM4zWzQAUUUUAFeegyNcMW5lV2Bz2+avQq8i8ZTX2meM5ra0WaT7SgnjwOPmJBGfqPakxrc5DwjpI13wz4k0G+CJ9vvbmG4IONjErJBIOx2vkHpx9K5X4Yrc3vg3xzowtW/tSaURCBEwd/lFcEfwgEHJ7V0/hnwoy6vrq6lesbW+kina2hbYUPz/KzDjHzHhfzr1G0SPfJD5W0FCVVcAAd8nj1pRKkzkvhzoV3p99b3dxJaeZDp32cwLNkpJxlwemMAj8a0dNtr6C612byY5BcCBEEdxGSFXcWBBYHuKt+HUisp7mO4RtpZmXLnI9CMHpV2xsy8V5IpiJfkkofXjNJK2w3q9TyHS9L1LRPGF/ruuWjLG9y5lSNtzG3KhCM4+bjJwOBXK+L9IXTfFd3ZyuzLOv2mLJyMKdrc+42n6CvZzE0Wros2+WNmIKh9wII7rzSazoOkJrFrcDR7O7dlcfv1DiPODjnOB1oikm2OT2Od/Zu1PUYdevdMks/J0u4gaeKWTIaQowClAeq7XIz/ALIr6GrwDwHey/8AC3ka4fc7I8JOeANvAX24Fe/1SIkFFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuB8U+IPEkXjK70rQH0hIbPSE1N1vbeR2mYyyKUDrIoQYQclW5PQ1DpHxX0vUbOzu/wCzNVjs7iNP9KKRmFZ2thceRneHLbDjdt2543ZoA9EorhoviRZPq2kafJpOp282qKslu1y9tCGjY4VwHmDN3OxQzgDlRkZzrL4lWviK5ittE822ubbUrW3vI3ltrgGOXzMDfDJIgOY2BG4MMdBkZAPSqK57UfFC2viL+xrXStR1C4jgjubmS3MKx2sbsyqztJInXy3OFDHCnjpXPaV8VtH1WKUWVhfz3SXcdl9mgltZ2aR43dMPFM0eD5bA5cbT97A5oA9Corg7b4l2Mxl8zR9WtowLzyZbg26RztayFJlVjNhSCDgvsUgHng1F4U8ew+LvE+lDR3dNNks9R+0Qu0Mn7+GWzCkSRs6kBZn+65B3c8jgA9BorzOD4itpOpeIItftNRls7fUri3truKKLygI7YTeTwwfdtWQgldvIG7tWjd/EzTbHVtGsNS06/s31aSKO1M81qGbzH2ITCJjNgkryEOA3zYwQADu6K8/T4o6cR8+ja2jy4+xI0cOb4mYQ4jxIcfOR/rNnBz05qOLx1d2ni+5tdV0jVoLCRbCJVZbdhZSzyyRL5pSQk728sDYXA77eaAPRKaT1qlqus6Xo6xnVtRsrBZSQhuZ0iDkdcbiM9R+dZv8AwmvhXOf+Em0P/wAD4v8A4qgDiP2k7qS3+G8qKcRz3Mccn+7gn+Yqpos81z4Ytmvbq303QtqsvnAK86g/xZOMNxge/fNJ8cvEGjar4Qt00vUtO1NoL6KaaK3uUlKxDIZiFJIGSBn1IHesq513Rm1HR7PWrW4so7ht9pNeRLHHujUHoSSv8OAQKV1c6Z2VKFvP8zb8R6tpNrbWthBcrJqN0C1vEUMj7V6kKBgAfQU7wvFOEZrgTZyQysNq59fU15zrvjBYfG2rXmg6fLqwt7ePTba6DrFABgPIS2NzEuTxx061m23ijVX03xDBr95dWs1xEosLXSnKhZDnJMnLZzt+XOOaLq5lZtHtF5qmmaZekanqdrayFQRC8oDAZ67fvfpWTrHjPw3NoF3dQaiZbaAFnkhtpXXKnoWC+ory5PEFxpj2l34W8P2FrepDJbzz3NwbiR2O0lZG4JbKAkk9+MCs/VdY1Cfwqum2P9o6bY7JI9Q8x4yLyWQAsFAztBO4cHkY70OcSuSV9j0Hw58TvD+q31npmn3dzcXM5KJHHayEsQCeBj05/CtvVvFkGm4OoWN7Dbsyp50xSJFLNtBbkkDPtXA/Azw8ZPG8dytq4FlavJHIRsCsy+WMrjrgmtv46SKnw31cygGWaWCGPI7+YG/kppxlzRuiZLllY5vxVq2v6dd3AutOsre3kgliETuzAMeRuPTJxjOOp965fwL4jur3RtRtbC1t7QWsKzSSHLF1MmGwvAAG7p/Ou98ByzeMPh1bL4gPn3LGa2ZmHzzJGFOGP98Ag+pAz2rg/Btkvg74gXumalNF/Zc1pIr3T8ZicqVfPqGAB7DmhOw0nJ2R9SfCJrVvh7pP2KXzlVGWSQnJaTcdxP412NeA+C/FQ+Hc7WmprI3hu5YSGZRvNq7D/WcfejbjkZwfxr3awvLbULOG7sZ47i2mUPHJG2VYHuDQZtaliiiigQYAooooAKKKM0AFFcT8SvHJ8GPpaCDTXN9537zUNQ+xxr5aBsBvLfLN0Axyat2njrSzDpP9qR32l3Go28c6pdWcyxxs8fmeW02zyw4AbK7s8HigDq6K4LSfiFBq2vzwaeobTMWIglure4tXkM5nyyh4/nXESFTgKct89WZfHlndX+m2uk+b50l/FbXcN9ZT20scckUzqwSVUbkxEBsEHDDqOADtKKxtV8TaZpOqWlhqD3UM10yRxS/Y5mgLu21EMwQxqxbgKWB5HHIzi/8ACyvDratZWMLalMLoSbbmLTbhrddhUNuk2bQAW+Zui4O4rxkA7OiuSh+Inhma289L642mSONUaxuFkkMis0ZSMpucOEfayghiMAk8VqaZ4n0jU7qC2sbvzZ5hOyxiJwQIZBHJuBHy4chfmxk9M0AbNFchqHxA0XSXnTWbgwsklyFFtb3Fz+7g2eY77YvkC+YueqgHO48465GV0V0YMjDIIOQRQAtFFFABXnvxTtWW402+RgoJMMmVzkdR/WvQq5j4jW7T+GJWTP7mRJCAMkjOD/Okxrc4LTU2XKlwuOdpyMjnoAO9dGcRyRyspCo2CT6H3rmtM2oyfKI3Dbdw5P4nnmn+JPFmieHLJv7Vv41lU+X5ZO6QtjOMdAcYPOOoqSnodHrMMSKl1EihBw5K4yPWnaUZEs3KMqxyfKVPfmuQ07x3/b+lR/YtDu1a4gM0IvXCh0HVhtz25HtXI+FfFni+7uNW0XybC2u9OycENl1wWHOec8HPGeabBbHWTXgbX2jhtnYQkEycheewJAB6dq2NcWVbnTpQj7jlNqqCBn+8a+ZV8f8AjXVLkXFvqCwuzEgxwoMfmCa3obnxP4h8Oau+p+IdTu/skyKqrcHa29SQeMcfKfzpDae56Ba3MVl8X9NEk0P2iWVI0QPklz04ySM9Owr6Tr5B0PTrfQ/i7ZmCFohaXSEknJK+ZHySeehPWvr6rIYUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/EHgnQvEGpfb9VtriS4MAtX8u9nhSWIMWCSIjhXXLE4YHOaxdA0Hwv4h1C+1W20K7gjSeWBJJJmjt7h1Vrd5I4FkKghVZN7IrY6cc1T8e+BNR8QeLE1K1TS5YzBbQxXF3I6z6Y8U7SPLbgKQWdSFPzJ9xckjIqza/D6O1+F+veGLKHTrG61OO9RpbaIKhaVpPLZsAE7VZAeOAuBwBQBo+ItF8Py6l4esNTt7+ZZHEFrAl7MLYGFTMpkiEgR8eXkFlY5C+nFjRvAPh3R3D2NncBlMG0zXs82wQb/KVd7naq+Y+FHHPTgVx974F8Savcave6idHtrq/lmkEUFzJKiBtONqo3GNSfmwTx09TxWf4n+E99Pp9xp+gWvh+LTp5I5Xt5Y4xtkEHltKm+3lVWLYJIUMw/iU9QD0rWfCWj6xqa6hfQXH2oRCBmgu5oBLGCSEkWN1Ei5LfK4I+Y+pqto3gTw9o8kcllaXBkjkilR572edlaNHRMGR2OFWRwB056cDFDwN4OfRr6fUNYW0utTaG2ijuQTI6bLaOKTDMARuZCSR94bc9MDi9Q+GHiK98S+ItQMuiwRala3tsDb4hMoldDEZFS3VsqEO4vJKcnK7ckUAdXo3w58OImp22oSPql5NJdNPuu5R5CXM7T7Uj8wiE/d+ZApYpu6mug0Pwjouh3a3Wn28wugJh5091NO7eaYjIWaRmLE+RFyc/d4xk5898V/Cdrq91keHNM0Cxgvlt3FwoWOcmNwZIWBgdSkmAWY7skfMjVc0D4XRCwitfElvb3NolhPbCBphc+S8krNmPEESABWIXbGuzOF45IB1lx4B8OXOpXd9cWU8s10ZWlV7ycxbpIzE7rHv2I5QldygHBPNS3/gjQL7VYNRuLSb7VCbdh5d3NGjGB98JeNXCOUbkFgazvhLpmo2fhZL7xA8kmt6kVnuXljMb7VRY41KnlTsRSV7Mzdya7WgDm7zwR4eu7WK3nsCY4YzFEVnlRowZVlyrBgysHRWDA5GOCKmh8I6NHEyGC4mLPbOz3F3NNIzW8vmwku7ljtfnk89DkcVvUUAUNV0bS9YWNdW02yvljJKC6gWUIT1xuBx0FZv/AAhPhbH/ACLWh5/68Iv/AImuhooA4vxD4R8NQWGIdC0yBzIj5t7ZIiQjB8EqBlcquQeOleH+LruTXPiylnDxFo1uysxXJM0pyxx6YAHNe+eLJ9uQ/EXCZz2+8xPtwv5V87+HZJP+EyTWr2XMGru6b24BiB2xM3HBGB/31UVXaOh0Yen7R27G/YeHY1UTDD+b8xUnnB7n1NW49IAjbESHncC/3gB6f4V1jQYBdApfuMZIFY2pXd0by3sdIgSXVZV3jzThIU6b2+np3rzueUnZHZCDm2kcfe6Ha2XiFjdqnkakiyFXiLYlBwD/ALIOcHPcCuxttCSULvbIhQIq7VwOeMDtVDxJ4bsdJ8PXuq38s97fICz3EjlcMRghVHGOoAOaqxSa8IrGzsJYvt0lsZ5vMzss0wMbjyzMSccEdOK35ObVM0lGNlJPT/L+up3fw/ggtG1a4gZJGi22sjIRkPy2DjuARXD/AB4EMfgaAyNGkn9qQ7C5wCQrdccnvXf+BLD+x/AUQllM0080k0shUKWbpwB0HFeffFyIagvhuxcApLeNOwPqqYH/AKF+ld1uWmebe9W6M3S0tPDfhuWz1SDXtHl+2pexanJALuyjlC7SRNb7wFYckMBwec1a8T6Ba+M/D41Tw3JpuoX6RZeKwuFmVWx88Z2ncEcdM4IyM4qx8Mp5bX4ja5YW0joslkQ0isR86bP1+ZgPTmk8S6ZZC+1GbWtBs7+5tbU3kdzbIbS8YK2JCJYdpZlBBCn9c1EXdXKqQlTqWvrv96MTQ9Yt10+DSrJ/B0UMLGNbe7XVTJCxzmNmYcHORtBxnoOa6XQ9R1rwZbi20u58GWdvM42x7tTlj3N0xuyFz7YqK/0tW0+1v9P8Vrf6bPGk8K+I7ZL6Mofu/wCkDZMuOnBYg8HmmtBcw6Q1hqvhK4ubJQdt14fvBqCjPJxC+yZR3/iNBl7rV9TvdM1H4k6pZpdWE3gaaB8gMPtY6ex5FW/+Lqf9SR/5NVxHwr8SafpmrfYbXxBaXaTNsms52Nrco38LeTKFbI6ELnPvXuw5oi29xSSWxwH/ABdT/qSP/Jqj/i6n/Ukf+TVegUVRJ5//AMXT/wCpI/8AJqj/AIun/wBSR/5NV3N/532G4+zIJJ/Lby0LlAzY4G4cjnv2rxvwp4b8bXC/Z9dGs2enyahbSvGNVkEiRCGYSqJPtc0m3f5XSQZ6hV5oA9Em8NDX4dKuPFaW819awzRTQW2TbSiZNjghxuK7enIrnH+D2hTarbX97qGq3kkCqii5MEjFVQoF8wxeaBsOCFcA4yctljz11ofj46p4Yiji1IQWjWsV1dLqbHzYRcETCUfaVXcIj97ypWbP3lIGKUHhTxdYeF9P0/T9P8SRG2tLiAJDroTbe4jEVzuM5zb4Dfu+x3Exc5IB6Fp3w6srUlrjV9YvpB9mVZJ5IgyLbiQRqCka8fvWyep4Oc5JzPBnwy8N6FqU0ulalcXV1a3NuZ1zbKUkijl2CQRRqSxW5JJbLt8hJ9cc+CvE91JLNfajr3nzTam0n2fW5oo8Fs2mxFlAQdwBjHRuOKln0nxhJOkur2+uX2nm5DzWmm6qttO3+g2qhlcTR4QTJc5QOMs27BByQDc8c+CfD93rcXi/Xb28g/sw29ydscUip5EnmKVLRNIgJ4YRsu4dc1p3HgSwltdLt0vdQhjsFmi+Roz58UxBkik3IflbAGV2sOzA8153qfh/x1qOseIkFhew6Xd2d5AkEuoGaKRi6eQw8y5cAlQxO2KILkj5hg12XxS0/X7y40iTw7Dqdy0Jk8yC3uvs0DElMGV1uIZBjBxgSjBbKE7aAH+FvhfovhswfYJZsQXMVymLa1hJMaSIoZooUaQYlblyzZ5zycx2lppPgjxPrut6vKIpteu1S1igSWcrGkQLHaqkrlvNkcgbQCCTxmsLUfDHjFbfUbjTbzVvt93/AGtuR9UYxgG63WYjUuVjPlDAKgYDYbHQQ6j4U8QeKdQvr3WLHWLOJrq8a0tzq3ltFE9lAiL+5m2gGVJPlyRy2eGJIBujT/C2o2X9sC+1OO11gXWnRPJA8W83zQglVeMNgmFNjEbcEkkggjo/EWrX/h61sY9L8Pajrke0xt9kkiVotoG0sJGXOeenp71zXiXwveL8OPD+lWFnqd5LZXVnNPDFf/6TtRw0gSaSUEEc4+cY4CkADHNSeH/Hgt7cKNbLmOT7CF1dc2EhunZDdnzB9oAhManmX7rDBzuIB1o+JFwmBc+A/G0R/wBmxilGfqkp/M4pv/C1tJjXN7ofi6z4yPtGg3Iz69FPStPwtZazba7cPqYvTYNFJ9kEt0JPIBmJKS/Od7kbSr4O1RszkEv19AHnx+MXgdc+dq88GOf9I066i49fmjHHvUGq/FDwJq+iX1ra+LdGEs0TRp5tysfzEcctjHPfpXpFVruxtbsN9qtYJ8rt/exhuPTntQB83+JtW1O7htLHwdqXh2RCo+0XY1m2YsT1jULJuz3J49q5i3+HfiKGOGbTZk1O9CvCgPlzoA/LFBkgEHnPXjmu01C60yGeK11PTdGuZMs9x5mmW8xVByFP7vPp+VRQaX4S1XxNYWKeGfDk0Esck9z5VgkTRoiEj7mMc4HH9axU03ZXOt0Jxi5NXXzOj8V6dq3hXwu1/o9hc3Wq6dHbwW+IDJ5m0qpJAHIILZrnfiDp99axQeMdAsroS/ZWS5tfLYFomzlTxndG2fwql8S9M8LeDrHRpbHw1apJeTusgS7u4BHGqjJHlyjHLAelbWiaLp5g0U3Nx4i0d9SV0i+za/dooYOQijc5+VsDHOeRWqetjn5ZKKn0PDvBci2Nv5s9sZCrHcQMbP8AZOfeu2+HO+QeKbERgNqFss0AUnAeEbiq+vysf++a1vEWtT6N4wh8OPe+O57mbYLTZrcc4m3HA3LLB8pBBHUn3rJ8Q65ovh3xRoq+GxD5umzrJdlZHZZd3ySKFJwAQT0rPl5ZXO2jarFqS0S/HoV/Ftw0smn6wW+S6tfs9/tB+RhkMeOhU7W/CvqPwBrf9v8AhaxupTi6WMR3AJBPmAYJ47HqPY14Lf6GgvpdOjVDa3sX2izlzgM4GQgB7sgP1KGtr4X+I4/B9uYtRlKWW9Ig0gABRs7en8SncvuMVpc4dz6DoqG1uYbu2juLaRZYZBuR1OQRU1MkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvLvEnjXxDpep+MLu3XSpNF8NNA01q9vILieN4UkcrKJNqsNxwPLOcYyOteo1zN94F8PX2uTatd2c0t3PJHNMhvJvIleNQqM8G/y2KhRjKnpnrQBkt8TtJQzvLp+rR2qrM1vcmFCl2IZVik8oBy2QzDhlXIyRmpP+FjWi61caVPpGo299BbPcyxXFxZxFVVC+AGnBbIwNygoCwDMuG234/AHhqO6up105t9xvDKbmYxpvkEj+WhbbHudQx2Bckc5qXXvBOheILx7jWbe6vCysvkyX0/krujaMssW/YrbGYblUH5jzk0AYXhz4gW/izVdIbRHeOza5urW7iZoZcvHCkgxJEzoRh1OUc9cHkEVrXHjSKO71eODSNRuLTSiyXN8JLaKBZFjDmMGWVDnDKM42gnlhg4uaL4Q0XRpxPY29wbjz3uTNcXc1xI0jxpGzFpHYnKRoOT2qDUvA2gald6hPdW1zm/H+lRxX08UUx2hd7Ro4TeAq4fG4bQQcgUAZOi/E/Stbgs30uw1G6luZZ4hFC1vJsMPl7yZFlMZXbIrAq5B5H3sKYbX4q6ZNo7ajLpOqWkRsoNRhW8ktIPOt5ThXV3nEa4PUOyt0wDkV0Ol+DdF0pvMsLeZbgGZhNPdTTuWlCB2ZpHJYkRp1J6cdTWHoHwt0DTPDllpt0Ly9uYLe2he9N7cJLugHyGJvMLQrksQkbBRuxQBP4G8Xr4s128nsJXOkNpVldQROqbkkee8jkyykg/6lBwxX5cjrk1D8VtFXU9S09rW9a7sZIY2igktrhn8y4S3UgRSsV+eRCVfa2DwCeK6jw94Y0jw8WOkWrQM0KQMWmkkJRZJZFBLsf4p5Tnqd3PQYzLP4e+GbS5M8FjPv3o6q97O6RlZ0uFCIzlUUSxq21QBxjGCRQBieJfHt2fDniKTSNG1e1uNNgcS3kgtmjt5xGr+WR5rF2AZRlVZcnr1rrvDGvx69FfEWN7YXNlc/Zbi2vAgkjfy0kH3GZSCkiHIJ6+uaq3vgrQr29v7qe3uQ9+pW6ijvZ44Z8qE3NErhC20AbtueBzxWxZ6fa2Vzfz20WyW+mFxcNuJ3yCNIweTx8kaDAwOM9STQBlt4y8Mxu6S+JNFV1Ygqb6IFSOxG7rSf8ACa+Ff+hm0T/wPi/+Kp0ng3wxLI8kvhzRXdiWZmsYiWJ6knbUbeDPCqqSfDWiYHP/AB4Rf/E0AcZ4w8Q6bqOiarFa67octw8U626rqkALM3C8lwBx/OvPPES7tIstN0a/8PqYUjX7SdVtPkIABIBkHQZ+tbkyWV5aaRaaXoOhi/1F8ecdLt2ESAne2NmCBwB61V8UwQWcFzbafpujfabaQAzHSrQllK/xL5eAc4PHrWUnGTuzvw8alOS5bXlte+nmbct5b2loxs/FugXUgiICTX8Clmx0zvx1/rTPA5tlV5pru2uNbul8y5+zXCSquP4YipIKgYzznNWPBUGia/4dtb6Tw9oiySr8w/s2DOQSM42YxxW+uiaVe2Atf7Ls40j3GMQQLDsYjOV2AY5A6dawlyP3VoxqrP4Z7Psclq6v4n1NdNtt50yzmD3U2Dt3r0jHr7+xzWqrRW+oeIh+7Fysdui4+95e1iPw3bql8IRQW3hjTYoAQuGkkPdpCx3k+pz39qZcW/m6zMqBXSSxJkIHIHmYHPf/AOuamnJczgjWs7uUOi/z3+Z0NmGi8I6Zb4HmLCN3HQnn+tef+O02X+jXUo3/AGcXMu3scCMD8c4/OvSpJLVbcbJFaOIIrjPC8DA/KuD8aT2eoaPPNEm+WCCWNQp4dnYYX0P3RXXWl+7sjhw8eaou1zJ+FdqIro65fTF5L1nkTH/PIbhz7scn8qv/ABHkRtPjNteBbras8aoxDPGyFZFB+hBwfSofCLNceHNO8nascEckHHQhXI4/Kud1m+gtiLzUP3duYsxyNJ8rYzwPwX+lc0KjTcUdda8qrqP+rGF8L9YS21G48EasySaZPuksZX5EBbqp/wBhu47E+5rbubS+0C/l0qOWe3gd2Nuykt5MijIRs9jg4HpxXH3+mu3jfS7ayRzqY0/ebULl5N8XKj1YZ5H1x0r0W01GPWZG8P6xbTRaugcQeax33ESHpu6h17H0Hr13bUvde5FSPJNzjsXLy+bXfDKvqel2Orzwrtktr+ISqG/2CwJAIGQQwqPwHY2upFF8G67rXhSbJjFslz9qtUkAzjyJt64PONrj6DtnaVctpOqm11CfJwfnPAmi5w2P7ykcjsc9jUd5A2ha5JcxKwik+aRo+AoyDuGO65znuMelEpNRv2MoU41JNbX2PUvtvxK0HAvNL0bxVarx5thMbG5I9THJuQn2Dj/GS3+LPh2GZbfxJHqXhi7Y4Ees2rQIx/2ZRmMj33V1HhTVhrGiwXDMDMv7uXH98dT+PX8a1bmCG6geG5ijmhcYeORQysPQg9a0TuczTTsyOwvbXUbVLnT7mC6tn5WWCQOjfQjg1Yrgr/4T+Fpbp7zR4Lrw9qDf8vOiXLWbfiq/IfxU1X/sf4i6Fk6R4i0zxFar0t9ZtjBMFHYTw8E+7JTEeic46UZ5Ned/8LJu9JAHjXwhrmjKOXu7aMahaqPUyQ5YD6oK7Hw54g0nxLpi6hoN/Bf2ZYp5sLZAYdVPcHkcHnmgDnPD/wARtP1i4sEk03VdOt9QaWOyu7xIvJuHj3b1BSRipwjkBwuQpxmtuLxf4blsGvovEGjvZLI0RuFvYjGHVS7Lu3YyFVmI7AE9BXFWnwsuZdHttG1vX0utHsxdNaw2tj9nkEk6yoXkcyPuKrPIAAFGTk5xVrw74GWXUdP1i61ux1OSzvY3zaWYjhYW9vcWypt8x8SK0zFmz1jC7VxwAdM3jbwqsV1KfEuiCO0YJcMb+LELEkAOd3ykkEAH0NTaX4hg1LxBeafaCOW3hsLW/ju45Q6TLO86gLjjA8jOQTnd2xzxrfDnWkt72Gx8VtYQTTpLHbWkV1HAiguWXH2reu7cM+U8Qyo45Od3wD4K/wCESx/p/wBrxp1tp/8Aqin+pluH35LMeftGMHptzk54AL0/jfwtAbrz/EuiRfZZBFPvv4l8lznCvlvlJ2twfQ+lWLrxV4fszF9r13SoPNRZI/NvI13qwLBhluQVBIPoCa4yHwTqzeHl8O6Z4vtY7LS7hUVbe2mjmC7S3k3DxXKMWIkjfKmMnAJDBsVUn+Gl1pPga+07TLmLUL+SwsbCIyQBBiCQkscvyCGyVyPu9TmgDuP+E08L+RZz/wDCSaL5F47R20n2+LbOykBlQ7sMQWUEDOMj1q3oWr/2r/aH7jyfsl5Jaff3b9mPm6DGc9K8t1P4dS+LbLXLO08dWkk11cXH9rRWMTrCs7pGg/dRXIKsqxAbJWkByxK5Nep6FpP9lf2h++837XeSXf3duzdj5epzjHX9KANSiisu98RaLYn/AE7V9OtuM/vrlE9u5oA1Ka+7awXhiOPrXG3vxU8B2f8ArvF+ht/1yvEl/wDQSapf8Lh8GSYFlfX1+x6LZ6ZdTZ+hWPHv1oA4sWbabp9016A95LJJ57MckHJzg+lRfCvRUN1qGpl8yXG2JVyeIyd7dfRVA49aj16/i1n7R5Oh+N2gncs5i0Mxbgx7NM6Adev5YNbOjalrdlpqw6d8P9XeMb2Mt7qFnbffxnI3sR8oA6e3vXPShKMrvY7KldOnyrqcb8SrOPX/AB5BBOPMtNNswzRh9u2SVi7fT5dg5rqbDS7O++GvhprPzTCjzrEzE7lPmtggnnhuh+lcn4pvL2K01W6n0jR7C51Ilt0uv/aZZWZflREjhCn5QFAzjpzjmvQfCenzad8M/CtvM5kmjXzJOchmaQsfwya1W7MZfAjhvEl2PFngex8aWcezW9L89blIvvCQArKn0wRIB7kV5z8OfD9trujXV3eMN80hy2BuAUEcZ7c9O5+ldh8KdSfQviR4j8PXJJs7+/mjiOPl+0CQ7eO2RlT/AMBqppXhn/hHPHl3pMk0o08f6RaK3CujsTtJ/wBknB+lTVdlc0pSkkodHqjrbnTZp/AM1tHPNc6lobE29zL953jHmxkH3AK+uDisrxpYrr/gIazpiLJb3tutyI4myFOV82PPqpB/Fa7jw1Ay6ndQx7WhNruk45Yq/GfwLD6Vz3wp22i654buQgsPtNybWMjPlyRsdyfRkKt+BohNTjdGc04zbJP2dPGd0LmTwxq8vmZLNayE/dIGShPfIyR9DX0BXx1Aj+G/E0E9nJJmyuQeAN23hk+vGVr690+7iv7G3u7c7oZ41lQ+xGRSpS3i+heIha011LFFFFbHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFcP8W9ZvdF0TSpNPvryxNzqtvazTWdstxMInJ3BIyj7m44wpPtXNeCfiPrs+o2ehaxoGoXN5FMsF5efZpUdFkLNDI6JEYk/dmNnDSIQWbC8YoA9dorxLUPHOs3U2h+Jb7Svs2iJoUmtizg1mRHfPk7TIFjVXwX2hWbbtYscEba6q38f6lJqD6XLodkmqxXDwzY1Mm2jVYEm3+b5QJG1+RsyCPQ5oA9DoryOy+Kesas32fStE077Yt1ZJme7uY4J4LkS7Xjd7ZHPMR+YIykEEFulWm+IepWNpcumki/jtHvZruWe+WNo4ob2S3IjCwgOcJlQdvAwWJ5IB6lRXDaF44utV8TQ2J0q3h024nvre3uftpaZmtZPLkLQ+WAoLZx85OMEgZqpq/xJ/s7xnJoo06O6tv30a3UMs3yzR2zXBjkzCIlOFIwsrMMqSoycAHolFeVXvxI17Tpby81Dw/p6aRBpMWphIr+SS6xIzqg2iLaSWCgqD8oJIZ/u1p6N481fVprCzXwzJaX11LcIftcs1vGEiETGRPNgWRlIlwMxj51I6fMAD0KivI/DvxVu746TaWvh/VNTL2VnLczorvIrz26yjJjgEGBuUMxaPqSEwK7XwH4luPEljdSX9jFp95byiOS0WSZniyoYbxLDEQeewKkchjmgDp6pa1N9n0m9mJx5cLtn/gJrkLj4ueB7e4lhm1vbLGxRl+yTnBBwR9yqOp/FvwRc6ddQQ68okliZFLWlxgEjHP7vpQByXwpgjuIrnUyWaW0mexQMeABtZiPqTXPfEl3s9avFCEtcsMsp+6uBk/njj3rT8FeKfCeh6DNY3fiG0eSa6e4YxW9yRhgOOYQe1c/4u1TQtZl1B7TxJpdv5+4rmG75OMKTiD5SPbjn6VzOMr7Hp0a8I1+dvS/4HYfBWMx+F9NjdiZZI5J5ix6sxJz7cYx2r0DVpHtLa3mtYiwJO9wfu8fKTjtnArxfQfHOgeCtGaaTVTrFyttHBHZadbz7nZVA+/KihVznJ/IdqdJ4m0bxKIb/wAY+JLCV4zvtdDjt7oWNoRyrSYiJuJAcfewo5wDTVNt8zRyTmr+6zsPDmv2IsZUup44poZJHdG67Nx7fU4/EVo6Ro+rak0usf2jLpizhVtrfyw/7pTwXzyN3PA6Zrzqy1fw9FqKXk/iTS3dLlLgD7LdEdfm+Uw4HBOB649K9E/4Wd4OBJXxFGrYwCLW44/8h1MafK723OqriIRb9k9/6a+85zxe17oMMzvNYztNJtZI9ysGPQ7ehHFc/wCKbdD4Uk1K7vZWEio8cMYMa8noRjJztHHGc85xVLxVrem31zayWGtWl+6XvmrGkM6sqEck74wOMetW9d8u+1XQ9Nt5A8YljmOO6Kq9B7kD86q9nqb0mpcrT2326Hc2Wlvp3gOCCzLC5tbZQM9Sw5JI9ya8d8VX5tPC6ypBDIyXiXixkBo1ziTZj0BRgfXNe+6/HNPY6lHCSJGt8JtOBvUZ/nivmvVZ0XWJIdQiU28szeagbACSA8jv8rFh+NYr3ajOamvaU3cl0u4Gs+PNQvNatLO+i1AhHE8ZKKDsYbGUhkbJGGUg8++K7iWI30qQW102rizYeXYa7cCO6hJ5xbago9gNsoxwOc1yPw1R5NSgtZ9skkckXQYyMlQw7/8ALJD+FdZ4m321xe3EMsefs/2sRR8climAPz9+DWrqOLdzV0oT12Zr6u1h4mhh00z3WjeLIlDJaasiwzysOjI33JVbvsPzdcDpT9IlOqWcmm6lF9k1jTCu+ORcsg6Z2nquMjJ4IbFcVpt6Lu1torx7W80KeUCfTb2Lzok/vvGDho253ZUqcjr2r0g6Df6ILXUPDeo2l9bIpiXTtdd5FhU9Y4LwDzEUgcLJuQ8VtGSkclWnKi9dexo/D7Um8N682mTlvszoAGY8FAcA+5U/L67StezAggEEEHoa+bPEF7b6le2VpKbjw5rgb5LHU2VN5wPnt58+VNyAMAjOemeK9i+HGsXd7YTadqtrJa6jYkJJGykAg9GUnqOPwqY+7Ll6E1Epx9onr1Oy70UnJ9KWtTnCmRxRxbvKRE3MWbaMZY9Sfen0UAFeE6TdeL9KttYtdD/tzej6xO9tcaQRDA7XbvbtBI0YMrOHLYDOMHouK9M1vxrbaVd6nAdNv7hdNjWW6nWS3hhjVhlcvNKi889+Mc4yM8lr3xXt77wTfXvhS01Ga/NhdXCyRi3dbPymMfmSMZCjrvGR5Zk3AEgGgCvf6t4z0/4gW+m2b67fackjRzzXNmhhkVoHcOhitQoVXKIMzlsjBQ53UxL/AMc2VhAl9f63NDPb6bc3V5FpUb3Fp5ouPtCRRpEQxVo4MqUdlEhJzxW9q3xP07w/H5msq8kT39xaLJGbeAxiOXy/9XJP5kmPWNSTjO1eBWx4f8QTjwhqeramxuDaX+pR4DRRExw3k0aLlyiDCIoyxHTJPU0Acn4bg1+18U3Wo2l7rU+m32twpNFe6csX2iA6ZCDcOPKR0YSIq8bVBUqVyeLvjLVPFVv4zW30ttTS1/0MWkNtp6zW1zulIuPPmKN5W1MEfMnr83SrukfE/TdatbV9G0zU7+5uZLiJLa2e2c7odhf94JvKxiRSCHIPIzuwDlQ/GnRoNN0KfXdPu9LudUtIb0QyXFsdkMmAsi/vQ0ikk4CqZMKSUWgDpPhTpV1o/gq1tr+4vJpjJLJtu4o42jy5+UBETgnLcgnLHnGAOm1Kzi1HT7myuGlWG4jaJzFI0bgEYJVlIKn0I5Fck/xH0uGR3vrLUbLTluLu0/tG4WNbcy2xlEighy3SFyDtwemd2VHW6bdfbtOtbswTW3nxLL5M4Akj3AHawBIBGcHBNAHD/wDCm/ArkG50V7wjveXtxcZ/77kIrUsvhr4JsiDbeEtBVh0Y2ETMOMdSCa62igCjYaRp2n4+w2FpbY6eTAqY4x2HpxV6iigD5+8XSzTePJIo0+0y2d8ss0a8nZ82wD16g4rp/wDhMGlsJ7BYfIuDGFZbhSGVACXb0J79eOKn8eWFqmtSX0sSNPBNG0UvRkLFQeR2IYjHvXC/Gl/+Ee8PPa2KTSwzwSPslfd5YDBW2sfm/iHc8ZrFwauzupzhVtGS2OfsLFtd16PVbs5s4cm3UgEA52rj2AA57knHFezWV/by6BBDMyxG1UBh0wobjvzwK5vwP/Z+peFbDUL2FbdfIRpUVdoVto4Uenp7VzvjvxZHBFLBpNskQELMJy25uCR0P0rnpSkm5SKrr2stDi/Ed1j/AITLWYEkhIuYJ7KfGNsrNuyp6g4TOPevR/Eb/wDCR+ENE8TJDJHdRwrcyQxHOAQBMvuMjcP/AK9eJT6zcaroNtp9xFNdS6neGeQIQrOSCgCdgAiD8TXuXwr1CO88OJpzkCSMbVixwCqgH3G5Np+oNdPSzKxFJwpwkumv37E/hJ0XXLabzD5czbGAPG1l2/8A16wbqeXRfiRrkWADcwpdWyE8PIsZViPfCtx6CotDZ9G1+80iRmLWcoMGTy0Lcof6Vc+KkMsOu6Bq9sVWWTzInyMgZQvj9XH4msaceVSh2M42dSPmeba1JumaSMOxkhhZCByTubn+VfT/AMJL033w80aQjDRxGFh6FGK/0r5Ov5plvFEx2bd8WOw+bKn9CK+mvgLc/aPh7bhsb45nVsevB/rVQ0qtd0FbWj6M9GooorpOEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAgu7O2vBCLu3hnEMizR+agbY6/dZc9GHYjkVTu/D+jXmq2+qXmk6fPqdvjybuW2Rpo8dNrkZH4GtOigCimkabHDHCmn2awxW/wBkRFhUKkGAPKAxwnA+XpwOOKi0zw/o2lQRQ6XpGnWUMTM0aW9skaoWGGICgYJAwfWtOigDAi8F+FobK6s4vDWiJaXRQ3EC2EQSYqSV3rtw2CSRnoSavLoekrDJCul2AikV0dBbptZXcuwIxyCxLEdySTzWjRQByeneBNLsvG1z4oV5JNRmV1A8i3jVd+3JLRxq8hwoAMjPgE461qyeGdBl1Z9Ul0TS31NwVa8a0jMzAqUIL43H5SV69CR0rXooAy7vw9ot5PbzXmkadPNbxNBDJLbIzRRspVkUkcKVJBA4IOKNI8O6Joyouj6PptgsZdkFrapEFL7QxG0DGdq59do9BWpRQBiTeEvDc8trLN4f0iSW0iEFu72UZMMYGAiEr8qgcADirmi6LpehWrW2iabZadbM28xWkCQoW9cKAM+9X6KACsfxdNLb+F9Ult3aOZLdyjoSCpxwQRWxXN/EedrbwJrkylVZbV8EnAzjFKWqHHdHAfCjWL+/8M3Vxcane3RF46LJPO7kqAOASemP51hfEfU9XTWGtdP13VLPFqxRUunUM209wevH4cetbXwxsGsfB1moQhruRrnYeCA2AvH0A/OsbxhfQajrV3YaRLFGbcLDq+rtGsqWh5/cQqQRJcsOD1CDOeenHTTcvQ71UUanNa+uxofCXXdU1KwH23UL+5ZbWN3klmcgMxBAGTzwTz6CrfxB8Q6hpt7pzpd3EcDGQOY7h0AOD8pAIBODkZ9Kj+E2z/hHZbi3haG0kdnSPcHKhmJCkgDJUBV6dj0rH+KcF02p6bNbLIzNtRoowWMqE8bQP4gcj/gVKTcXa4oxTnZrY5fRvGGrSataQrr+rTr9uRW8y7cF0OTjbnH3ht+n1r3jU9Snt4JJWuJlVUJLZPGB1x3r520bSRZ+Nrgtcx3EVndHiJ1ch41zsZhxuUuisPY175e3GzQ5r2ZDKBbeY6EcnOM4qnfRFVYxspJaHkmtXWoa7PGl7q1y9mszhYZ5WKb2GNrc44BfHcA1Q0gi78a6SiKxWG3G1hkEFdvJI7cD86Zfzxb2LB/K8oyrcZwWTkYI/vYyD34FVNBZlv3b5pjFEzod2CwziNVHr94+nSsot3bZ2xilB27HtOkyJd2E7REllLMXPOSeSB+ePwr5++IumLH458qVfLSdNhfb/q3zwfYE4z6Zr3j4dl7iykj8lokS2Ay5/eZOT8/v3/GvOPjXoYnMV/5RZCAMKM5fowPsV6e6iqa9/wBThhJRbSOE0XbZaza3JZlukiAYN0ARsjIHptZfrXqOqWUNzpc0gYBkIlBXkFQ8jD9c8V4zbS/afFllCXHmXFp9nLqMBnIJDfjwT9a9NW5l/wCEY0aKKdQZRLBKc+jbQB75elVvdnWkub0ObtYzp4gt0xKmW81iuCclAPzJY/jXpPg7Vkt9Mj06+je4kijEMgPWeMcBkPQsOuO3I715Nq91ONVt7dB8ksgyoH39rFzj227efevXbWxW68LXKoYi6QtNC5/5ZSAZDAjpVQfuxIqWnN03tf7irfJDpmrT6Rew217oWqMCsF1EJbfzWGUkAb7ok5Ukc78HOSai0a7v/D2oG28I6y9kkTiNNG1ovcWbBsYWKf8A1sI7YO5Q1FtbX+p6JqWk67CwuLcB45CMkxOec+u19rA989qasq3kFhqbpiS4RbeJiuC0pIMhweoXa3Pqa7Oa6TPNqUnTk4y3R6NpnxOsYb+LTPGdhdeFdVkO1FvyDbTt6RXA+Rvx2n2r0AEMAQQQeQRVK906z1XTGstTtILyzmQCSCeMOjD3B4NcE3w/1TwsTP8ADfW3sYRydG1NmuLFvZCTvh+qkj2qjE9Lorzqx+JcenXcVh8QNKn8K3sjbI553EtjOe2y4X5Qe+19pFegxPHPEksMiyROu5XRsqwPQg9xQBk6t4X0jVor6O+tWcXrQyTMk0kbFoiDGysrAoykAgqQeKx5/hp4VntBbS2N0YsTK5Go3IaYSvvkEjCTdIC3zYcnnmszxffatJ47bTLPxLJoVhBoj6g0ghgePzFmC5kMiE7ADyFZfqKo+F/iffanBpDXmiRRRymwt7yT7SUkjuLqJXXy4Sh3RjcuSXBHPB2k0AdPqnw88M6nK0l3YzbnMpk8q9niEnmSeY4cI4DKX52tkA9AK07jw3pE+hXejy2udOu5JpZo/NcEvLK0rsGB3KS7FhgjB6YwK4uz+IurzWPh3Ubvw3b2WmaxDBcC7kvpnSFZQmFYx27Kr5Y43lVI2/MCSq5r/EWbXdQg0+2t/sqJf2EsN5aTTmO5ge6EZGZIYsggc7N6EEjdQB3+i+ENE0edJ7G2m+0I8snmz3Us7lpQgcs0jMWJEadc9OOpqla/D3w7aLbCzh1C3+zKI4mh1W6jZYwciLIkBMYPSM/KMnAGTWH4W8c3t1c+H7S7050s9Rt0YajezOGmkZWbYnlW4hLDGMM0ZPJCnHN3WvHV1pnieaxGjxS6bb3lnYzXX20rLvucBSkPlkMFJG75wQMkZ5FAGn4g8Fabq+hxaPsji0/+0hqM0bKZPMbzzO4BJ+Xe7HPoGIAAPHU5ryFPiDe6/Dog+xDTBfzadqFs9tf+c0lrLchCkoCrsYjquWByRk4NR+DfG+qR6bo+nxRPquq3q28UX2+9EUQJt3ldjIImfOE6HeSem0ZoA9izzRXmV7471PSJLwz6X50MN9JDdXU9w5trMLFA20PDbM2394xDSKB8py4yqj0HWNTstG0y41HVLhLayt13yzOflRfU0AXKK4yP4p+A3cKPF+hAk45vUA/MmrkPxB8GTPsh8XeHZH/upqUJP/oVAHJfFdmMd/HEGExMRUj6pXKfF2H7Zpui3Mi+YkkNzE8efvEojj/0E103jzUdO1kzto2r6TdOUQfur+IkEEf7XHSud+I1jeaz4R0dNIaK4mivlW4WCeNisRQh+QeOij8aiezS7G9CSjOLfco3l5LafDa4kTEbBBtGOmSa8w8dPLb2EJ3h5Zw27b0xux/Q17Hr/hvVb/wn5Frp08ofy/3cYD8A9Mjrjj9a8k8cWOsaSIb3V9JuIljgk2/aYGVC4yM8jHBYEe+O1edSjNu0kenBws7NalX4X23n+LZZVh8u3t0Nvb4GRG5A3t9cZz9a7Vpz4I8XrfJE72MzKUlLcRHgEY9CBj8BVX4Xae2m+G4Xn3JLMn2iQ4+ZVY5LH3Pygf7tbXikw6lpr290QFdflyAfL9B9D3/Ot5Vf3hcEpJ8y0lv5dvuNP4mqlo+jeJrbJiBWKVgvPkScgn02tj/vo0/xUPt3wuS+cGWS0kEsbKeVCSDn3wjn8Kg+H91H4r8Dan4X1TeLi2Ro0YjJeBx8rg9PlOPpTfhA0upeHde8P6o2+ezkNtJn7vKmJhj/AICD+NdCV3zdzy5J0W4veLOZ8R28Ot+EJntYtt9bqrgbfnyvQe4IJr079mnUI7rwhdRfdlSYOU7qGUY/ka8t8O3E0OjxzXI8ua0le0vlPBChiqnHqpwPxrr/AIBxvofi7VLCUfuJcxQyZyGz+8UfgNwz7VjR0lqdOJ+C62Z9B+tFFFdZ5oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5d4k8a+IdL1Pxhd266VJovhpoGmtXt5BcTxvCkjlZRJtVhuOB5ZzjGR1r1GuZvvAvh6+1ybVruzmlu55I5pkN5N5ErxqFRng3+WxUKMZU9M9aAMm5+J2lW01x52nautoklxDDdiFGjuZIJBHKsYD78q2fvKoO1tucVND8QrV9fl0aXSNRtr+K3a4kjuJ7OMqAhfABn3NkY+ZQVBYBmXDYsN4I8KNrF0zWim+uBJO8BvJSF8x1Z5Ei37Y9zqNzKoyepOTVzWvBmia5eyXOrwXV2XR4zDLezmAB4miYrDv8tWKO67goPzHnJoA53w38Q7bxbrulx6I7xWwnuLe7iZ4JgzLCkikSRPIhHzj7r9cg9MVe1j4hQadr1zpUWg63fSwXUVkZrZbfy2mkiEqIC8qnlT1IAB6kcVe8L+FtAsjFqel2t8JpGMwlvp7l5ixRY8sJ2Lj5FVcN0AFaT+HNKe/lvWtc3Mt1Heu/mPzMkYjVsZxwgAx074zzQBxcvxl8NRXmm2jpdrc3qRN5TtAjxNI5jVGRpQzNvBB8sOF6kgc0wfF2ytPD2katr2i32mR6j9xZLyzYhfl+dV84PIvzdFQt8pyo4z1EHgfQba7t7mzt7u0mgxg2t/cQiQB2cCQI4EgDM3D7hhiOhxVCX4Y+FZYhE9ne+UFZNg1O6C7GIJjwJMeWCoIT7oOSAMnIAs3j63Sx1XUF0fUm0vT5JITfPNaQQzPHL5TqhlnQjDbuXCg7Dgk4Bo2nxV0i+0ltSsNO1W6to7GXUZmhWEiKKN5UfLeZtYhoWA2ls5BXIyRr3PgDw9cyXbvb3qi6m+0vHFqNzHGs28P5qIsgWN9wB3oA2c88nLJvAWkReHNW0vSY3s2v7GexNw8sk7KJWlcsd7Esd80jcnJzjOMYAMjUPitpmm6ddXWoaVqVo9s0fmQXM9nC+yRC6OC84RgwUjaGL5GCorb8G68+u6lrkiTGTT0e2ezBQKVjktopPTPJcnn1qrH8NPDf2OKGa3vZZlO5ro6ldCdz5flkGXzN5QrxsLbcdq6HRdD07REkTS7fyFkWNWG9myI41jT7xPREUfhk80AUR418Kj/mZtD/APA+L/4qsDxp4i8OazpP9nx+INBltpnAuUOoQgsgIJAy3Wt//hCvCv8A0LOif+AEX/xNZGr+FfD0F3HHB4c0MKYmY/8AEuhOSCMfw0WvoF7Hnut+NLe81QeGPDniDSrO7ZN97rBuoxFYwHoIiSA87Dpjhep56O1C18MWehaZpWh6joX2KxlDpG2qwbmyf3juxf5nbJJPr7VL4x0C5sNRsbzQvD+h3unE+Xd2v9l2wZB1EiEpk9CCCfTFST2+lTNa2Nt4e0iLUZ9gdH0u3EkBYggyAphQVzx1rKSUfdNoN35g8AXGk6H4ZmsrjXdFjmWaRY1Op25zH5jFW4cjofrWd4q8W6f4g1T/AIR7QNa0+1FnEW1DWBeQo0asP9RaM7BWmYcGTO1ATzmtHwpZadcMyanoeiSLeK81nL/ZduikK2Nq/IM5Uq3PP3vSuh1Dw7oqeHr6aLQ9DjuYYy4k/syDjAOeCmKhcqn5lT55O76nmWiIsGq2YNx4esdIsoTHa2cWsWxSNSwbB/eEtJuALOfvHn2r1iPxJ4ekt5o7jX9DYyQmMg6jBhjjnOGryfwbcJq91cST6XoxgDKiR/2Pa/3uSpEYJzjHPrmvWbPw94da5VZ/Duh7TngadD/8TUuUOa7bNq6nH3JW07XPGNQ0xEuJ7W11DQ7iyKyNDK+rWo2lgPlYeZnH09KyvD6SW/iK7s727tyjWyStLazRzKi7cOVdCwHIZQAeC1d38QbWDQ7h/s+maNDbSFljkGkWzGNsfLuzGQVJxzx715to9+17qcdzdW1vBNOgAjgtY4xsVs4VEVQctjqBmokoK6iddGVScLytb53Por4dp5lk5aONXkYlgpGc45zj8vwqr4m0pdR066sZMHzFKrkdCOR+uKtfD6JYIikZ/djdgkYLHqSfcnJNX7oGeRjgBt3H0oltFs4X8bsfKPivRbm0vdRurQNHNZsswiByQAACR7BgVz7iupsNQtr6zVfNLqm2aPAyAzIhAP4iui8VaTD/AGbazgFZJ2MUkhY7mldijBvUE7TjsVFef+GbS4sdJnW6Hk+VJ5PnEAbCpKqxzxxkflTqwclod6qxjJtkOlmS98XyXKwuttAkkcaZzk4w757dFWvb9Du4I9LSAhQ7xGNsnGVrzvwxo2nXcNz4hvNRl0nRowLdYMfvZsc8kc/NxwOua7fwe2l6jExsrHW3RJCsQnAUBcnBXnI69+aqdLmskc1Soozbt/w//A2NlLeW6u4riOZESAmK5JOAlmQc5PqCAR3rh7XVzrnjU7AU0/TlEUMYH3F4wfqeM12XjN5LHw69pATBaEbAmSzv6lm7mvO/BEawXcjqTuYFvmPJ759x1q4Q5FynNKTnqz6nj4jQc9BTzzUNq/m20MinIZFYH1yKmrc5yC9s7a+tZbW+t4bm1lXbJDMgdHHoVPBFYnhLwdo/hKS9GgRTWtrdsrG0E7tBEwzkxoSQmc84wDgeldFRQBkax4Z0HWrqG51nRNM1C5gGIpbu0jleMZz8pYEjnnippdD0mbV4dVm0uwk1SFdkV41uhmjXnhXxuA5PAPetHmigDmPEFl4L0eLTb7xDbeHbGKx2W9jcX0cMQt8DKpEz424CkgLj7vtWbeXPw48Lme8m/wCEX052eOaV444VdmLoUkbaMn5pI23dtwbI61pePfDl94l0+2tdP1mXSwkpaYIJds6FSu1jFLE4wSDw+MjkEcVg6X8NTpvhO60iDVIzdSw6fGl21p91rSOJELLvyykxbtu4Y3EZ70AadpL8PY9VS8s5PCiala2QuVniNuJobUJkSBhysWwg7vu4PpVOL/hCI/FmseJLmXSJLqFIXfVbme1ZLbBkh2I+d8ZzG4O7AJyASQwGJqHwim1C71ae61uF21KK6L5gucQ3FxbNA8kcf2rygPmJAaNm2/LvJww1fFPgO28V3LajpesLbKq2kdt9l37I3tXugQWilRsf6Qy4VkKmPr1FAGvpx8B2upRWmm/8IxDf6mUvY4bfyFluyCXSYKOXIwzBhnuQa1brwvoF3YmyutD0qazbYTBJaRtGdgwvykY4BIHpXJeHPh3daHq2mXNnq1vbW1sv+kQ2kNypuz83+sMlzIrDLZyys4xgMBXotAGHceEPDVx9m+0eHtHl+zNvg32UTeU2FGVyvynCIMjsq+grbIDAggEHgg1Ha3MF3F5trNFNEGZN8bBhuVirDI7hgQR2IIqWgClJpWnyoUksbRkPVWhUg/pVObwr4fnTZPoWlSJnO17OMj9RWzRQB5H8SNA0DTYJZIPDHh5hEA37zSoJNo43dU9K5TxjoGhWfg2PVbXwn4a+1rMquTpkSqULsvCgAZ+7zXqfi6E3NxOq4JUcqepG0dPz/SuM+IVow+GGqQytvKxhgVHYSqR+PSpmna/kaU2uZJrqcvN4T8Mv4fa7XwjoD3oiWQ4gKITgZ4DADvXlHidoLxLeHStKtbKxluFiWO0eUm4G7blg7tgAq4GMdSTnjHtepgf8Ildxx52/YxjA5yAMfyryvw9Ctz4i0SMIDthjk+ZeFZVOP/Hmrhw9WTj7z7npToRVPmS6np0cCQaFK0hVUU7WGP4gOI/dQD+dcVqFy08sshO63OYwCcDoNzf0H1rpvGd8Y1t9OgLko5UHOA2OrH/gXP4V5n4rvY0VtPs2RSQFZiSVHqc+3Jz61ha8rI7V/D16nR+AfExs/E1tdWW02PnNDcRhwGkhYYYgHqV+9tH92vUtL0ttJ+J93cwsG0/X7IoSnIFzEAyn6NHk57kV81eDZUuvHGmLaRgWkZaNfM5DHY2W+vcfQV9H+CruTRb/AEq2llefTryEPbSycmKdQQ6fQ/MR9SK9KHu2R5Vd+3bmt1+JzWtWqWPxC1q11CKOHTtXiWaMtwshZVWX8Q4yR7g07wc82ju11JiR9ObyZlZ+jR8rIO5O3r7MfSvTvEmkRXyIklrFcxZ8xI541YY7gZxgjPUHtXBW3hxIdX1KSzuJY4EmjFxbFtyvGV5GOTuGRznpUODvdBSmp0ZU5dNf0/yPddMvYdRsILy2bdDMgdT9atVwPwxvNk2oaXuzHAQ8agYCjofzPNd9W6dziejCg57DNFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkniz4e69rPxDbW7Z9HhtQWVJVCxztGbV4ikhEBkf52zkzbdoA2ZANet0UAeQ658KWkSAaLYaHb3cmkPYTagwK3EE5H+uRvLYuWyykllOGJyelP8FfC6bTbywfWrawks7eS4lNn56TxBnWAIUjS2gjXBiLEbPvYbJY8et0UAeIwfCfW4tb0O8mura4SyhtY8xXgt3gMRO9Y3NrJIUfJyFeLIJBz1rtPhR4TvPCWn39td22mW0UsitDHZlJHwFwTJKsEPmH3ZS3qzE13VFABRRRQAUUUUAAAooFFABWPrcgEoDAYWPJP1P/2NbFcV8RdesNB0173US5QOsMUEI3S3crfdhjX+J2PHtyTwKaAy/E/iG38PaUs81vNe6heyC307ToeZLuYjhR6KOrMeFHXsK47w7pOpTaVfas0tvd3gly7wuwhln8xjOkZLMdq5EYY8ErkAAA1u+D9JvBr7a/4nSKTxHcxbFjjbdFpMPGLaPPVjkl37nIHGc9H4d0+DRvD1vptohSCDzGGTklmctnPfrTtzFKTitOpw2h6tpr6fpmm3F4kOqaWqJNa3CbGGFweO4xghhmuv1aV7vw3qP2dl8yS1kYbXzztOBUHiLwPouvWyXGrQAPDlkmRzG0XsGHJ+lcNaRQWen6ld6fqN3N4estw+0ahsjhdunDFgWAJ2jI5PTNYunY2p1XzK+2n5ifCvQli1XTpZozj7OkiuN21iVyMg98Z5/wBn0r0tDvuiVyCBjmuV8I6tdW+neGbSUIN8N2Cx5LNC0YRP++Wb8q2Lm+WO4QxhnWRjyp+77fWuXER5En0Ned1JtN6jPiBpAvNISeMBlI2Op/i9AfbqPbOa8GvLObSLrSrl0QzWruksMwI8sOxMJOOcEhvXnFfRStNeQtE4/wBFc88ZL+3tXlfiLSlmh18XQeS4t7q0ik3NjCP8qrx3BXOOvIq4x51zGtCqk3Bs9T+GSztpnmXSFJGVnCn+EMcgflUr835A4Gc1b0GeG30x5tzBZcBNwxnjP9awzdsL8/LlQ+MnqTWVf3IxTMI3lKTRheP7FrfTYxYxqqrOku0ru3PvL9PUsP1o8ZeHrW+8PW8GnLGn9qanbucrx5RQSPkd+Bmt/wAZPE2hyho3kkk+REQ/MZP4QPoefwrI8O3QvvCmg/aJFeSN5lLg5+ZD5fA+ma6aexVS/LGfm1+p06eGLO18G3p8pfNNpJ5W/wCZYxgkEDpk8EnrzjtXKeB4sqGjRoSEG5TwVJ55Fepa7CG8PXsIBKm3ZcDuNtedeFH2RrGkZCouxS/3tvpnuK1e5yxky/4psDc2DBiGXAO015rDCmmX0cfklAXy2Bzj15P8smvX9TlR44w7ADPzHt+debeLxF9phNvOWQ/I6xtls+/oopSRUWex+E7pbvQLN0P3F2EEdMcAflitmuI+FEs0uhXDzzmYmc4JXAX5RwK7eqWxm9wooopiCuI+NNlJqHw41K2is5r4tNalreGBp2dBcxM42KCW+UEkAHgGu3rO8Q6tFoei3ep3EZkhtk3uolii4yB96V0Qdc5ZgKAPIoV1PSbu+uPCVjrWg+Dru+to2W00ljPABFOZpYbR42KK8n2dT+7/AL7Be9X4L3x3daDd3d5qGoabcW2n2skaLpQczSO0ivuRYZH37QjFUU7GIJBUFTuQfFTT7/R473RdJ1PUpJLe5uBBC0GFEEnlvuk83y8ZIIKswI6Z6VDP8XtGsLjSbTW7G802+v4YZzBNNbEwpK5RGwJcyAkE4jDMByyrQBzNz4n8bqfDYsbTxIZGaI3X2q0DRzqbtkfcEslIxGN3zG3IQodpbcKidfEukWsj6bDeafJhgZ49KeWZwb28Yxh1tp2UEGNuY2UBsgAuDXdN8TNKhthdXlhqlrZSQ3EtvcSxx7bgwjLxoocsXPO0FRu2nBPGe3hcyRI7I0ZZQSj4yvscEjP0NAHI3Ml/feHfCNxJY3LXT3NpLcx3lvHJNDlcszgLtRwerKFwc4x0ribTUfHtpoWnvqN9rcxvLHTbm9nTSY3uLF5Gf7QkUaRfMwAQFWR2XJOO1ez0c0AeE6L/AMJJpemiW1ttXgSRsT6h/ZCvfLC+pXTO4Tyss2xkbZsIUOWCc86FxrnjdfFkMFhc6idF2ReRcX2lTE3CGPMjyxxWeVkD5ABkh+6PlOcn2aigDz/4e6t4hm8LarNqVvqmpalbsfIF4i2v2o7AQsYe3gZFLcZdDg5wzAU3/hYWq2ny6x8PvFcDd2tI4bxR+MchP5CvQjRQB4h4r8d+H7+9sJLu/v8ARDBd+fKmpaddWrYCFQN3llfvepHT2qxea54c13wlqFhp/iTQrq4ltZUSOK/iDM5GVwrMCOcYrX8Y6ld2vjLSLe3vLiFJDcuyxylVfBUAEDrjnrU0GkadrTyprOk6Zf7sbTdWUU2CVPdlOfmXNZc6dTlNLNR5jn7jS9QHhOXyrKaU/YRGNo3/ADbQD93OTmvOvC9r9lvdKuJ4nixAsOZkKn78bYOfY1s+D/D/AIa1TRGvbrw1Y216gk3SafJNZ5ZCV/5ZOo7H86q6ZqIaK5jXV/F1hc2k4ikhi1r7RGuTlWCTo/yleeo6EfXlhCmk1F9TuVSryWcbrff0/wAjN8QagRey3oZli8lmDMMnJJ4/M15dc2lzfTwqS2y8Ztzry0gB6Dnhc9WOBXsXiS4FtpzS6t4hjuLcsY9mp+G7aYnA6F4mjY9+cd/y8103Vbe21nV7kymHJVYorVWwyY4CKckL3AzkZ6nrRTpqCc07s6ZVXVXI1Zev9di74Q8PXml+L9CtTCImvwXSZwVRgyHCqWABOMYI6k17xNZGbwgCkzW01vfJLHLt27T5ijPI6HJ+oz9a8g0bxDcC3kutG0nxVp1kuC9xp2rukTN13GGcSIxJ7DH4V6bbP4jvdBMlr4h0XWLG6jzJBrGmNaSp0yDJbMcMD1Ozgj8a64qL1PNlNxntod6uqGzjittZjjjkEuyOWI74xn+E9xnpzxWDd3MC6lI9ucJdHlm4OR8p47DAFYWu3et3VtLa634S1MJIVLzaHeQ6gGAIIIjJjkH1wT6VlWuvaDHdva33iCOwnY5EeswS2Myk9STKoX16NTszJ8ttDvfhYvmeJNYnAIAiRcdRyx7/AIV6dXDfCq0WOw1O93wubq6O0wyrKhjVQFIZSRzyfxruapEMKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryHQviVq9nomg674uOlvo+r21xN/oNtJFJaGGGSY5DSP5gKRMMjaQccHNevVyOl/DjwtpsMkMGmvLC1s9mI7u7muUjhf76IsrsEVu4XGaAK0XxEt3nWzbQNdj1ZphANOdIPOyYTMpyJfLClVbkvwQQcVUi+K2ky6Jf6qtjdLaWc6QP517Ywtlt2Mh7hfLPyj5ZNj/MMKecbfh/wn4b0+ZZtKiaW4tbhmM0l7LcyLKIvKIZ3dmOEO0KTgDoBVPUPA3hqCN7y6g1iafzonFyuoX09yjLvRNjrIZFUefJkKQoDsTxk0AP8D+KV8TXOpXtvM7aU0FrcWqyIFZFki3HOO+fc+1c7a/EW41DX7Se3t7yx0S6gs3tzeW8T/aVmuCglQJLuVWUjBfBHXYeh7vw94c0rw7beRo9p9nh8uOHb5jv8ka7UHzE9Bx796y9N+HvhrTZFe1sJQUMXliS8nkWIRPvjRFZyERW5CKAvtigDIi+JMGoWsMtnp2pWSTtZS2013BE63UFzcpAjoqzBlB35y+0gHdtbG01Ln4u2Wl+GrPWvEOiX+mW9y8igSXdkThCAWVTOHk6n5UUt8p+X7pa14V+GVppF/dz39zHdwOLZbW1gE8cVssE/nRhRJPIRhwhCqVT5cbOTm/e/DHwreRyx3FnemOVZo3RdTukUxykGSPAkAEZIB2D5QeQBQBp+DtSuL+x1Oa/mDmDUryBWIChY45mVRxjoAOT+NL/AMJr4V/6GbQ//A+L/wCKrUsNNtLCGeK1hCRzzSTyKSWDPIxZzyT1JPHSsv8A4Qrwr/0LOif+AEX/AMTQBS1r4i+ENK0q6v7jxHpTxW8ZkZILqOSRsdlUHJJ7CvO/Cup6brmpHxn4q1zRY9SMbDSNLfUoiNMiYYy2WwZ3HLMeg+Ueg9J1Dwh4Xt7R5F8M6GWHQfYIv/iaxb3w1oEZhVNA0NWIJbOnQ8+g+5xTSuBm6fq+hxXizz6/oO/By41KHPI/3ua0YvEPh8SDzPEWhlR/1EYf/iqqf8I/ovnxkaHohTPK/wBmwcjHrsq4vhvQNqqfD+ibieSdOg/+IppMbOW+JfiXTLnQ2gi8TaTaabkyXs8F7FLIIV6pGituZ3OBwK5vwuuk6xFpt/qmoaJY6VaMG0jRLjUodttj/l5uVDfPOf4UwVT611+geHbOS41LUdV0nQ1sZZnWwshpdtiOIHAkdwmSTgkDPGefa22i6PJJiHw/oYTPDHTYOf8Axyk1cEYKRaa+lR21/wCLdAuLmAytDcRahErB5MZckvnOB296zZtdFsqyarq3h9kgy0t6NVhYMgHUojF2PHQKSc16Nb+GPD6WqmfQNDd2P3v7NhGMngABevSvJ7fVbTW9bkkg8P6JpukW0rxiOLS7eSafaxGXLRkAHGcKAR9aHZKzQWcndF+DxdN4us2/s3XrHQNCA2G5a8gh1K9HT90jPi2T/abL9CBVTSrOH+wtSsNMTQrfN9E1hp1nqEE08yRBmMjsrs0juxzySRjsKuSrHJaSvDoGkqwVihTSbY5OeM5j4ByAAOTzXpHh/wAMWWnQRSy6dpQ1Ncu08FhDCYcjG1Sqg8DqevPpUx97Q0UXTtO5x2q+K7rRGD6zayW9q4GSH3iL2Yj8sjiq+meLNFuLvI1G3Eb/ADb2uFAA/E/yrs/Fsui2mgzXviO4it9JXO4suWn/ANlR1bPoOTXzzL4gsPFniOLTPBPhfTNFtcZku57WOWcKOpAI2Jx2GTnvROCnoyYuUdnue6654k0Gayg8qdJHQlUMR3YZgRx6nGf1rE8C+eukeFxLAkLXkd1eeUhJCI7gqefUEH8az9P8JWsNqYRNJLPHF5u+ZizGPIBAA4Bf5gMD1r0Gzi+2+J7GWGExQxgIgY7SyAA529gMYx9KHboaO6gru530iB42Q9GBBryXSi9rqN1bPGyvHKY8emD1/SvXK8t8SW8lh4uuVTaY7oecN3Ayev8AI/nSZlEb4mvFtrB2kKxnnGeleOrdya34lSGPCpE23Knb169PbPWu1+IF9LsMSiQllEY46E9+a5/wjYLasUb5rmUguxHK5JAH1Iz+VQzTofQvgzT49M8O2kEWSGXzCfUtzmtyqejjGl2YGPlhUfkAKuVojEKKKKYBWfr2j2OvaZJYapE0ts7I+EkeNlZGDqyuhDKQygggg5FaFFAHP6T4O0PSgRZ2b5aOeJmmuJZmdZnDy7i7EsWYAknJqtbeAtBtXtJLZdTilto1iSRNWuw7RqxZUdhLmRFLNhXJABIAAOK6migDl9Y8F6dqNpoVkI449P0q/W/WF0MhZlDlQGJyvzsCTzkAr346iiigAooooAKKKKACiiigDyX4jx/8T/TL2AKzWUsplz2jcgFvfBUfrXR6FNHJpkU0MgYGZSrKeD1xz+dYWv3K3etiWJh5YlmhLduGPH9ar+EkktLK/hJzAjpJCuPu4Y5x/Os+VOami23yNHL+BLaWy1LxBpU7DMOp3KoAP4WO4fowrm/iPbHR75b1oXeMJ9nukTjzICec+4JyD+Heu/8AEKDS/HWo3ezYt3DFdKwBAZlGxh9cBT+NcV4wuW8S65HOsB+ztPEmGbCldwJ/QE1wr3K0r9WelhnzWvtbUp+JNHGrfDsT21wJwQsyMF/ulkI/EAGvOPhzNft4ls9PtmYvcnCjp9zON3fAPPHavcPDlk1h4Ls4o2xHKs08X+yhdmTA9Nu3865rwTosFn4r1/xGkZ+zafbkW6Kcl3kJVQM9zj/x4V2ciSscjqy1Rt6xLNe+IBoeip80xSMXDEkl2ypwOmABnnpivTZ/BUei6JaDRi3n2kYEuFy1xx8zf7x5NUfhF4ba3WbWr8F7lwYoSemON7fUkAZ/2a9MqoQSWhhOTbPM44luraMACKaIFkAGMjuM+3T2zVfVZLh9OkCSGWEjebeZRIh4xgq2R1x2ra8a+X4e8vUooglnLNidlJ/dO3R8dNpP3vwPrVZ7eKR4mjZXhuEymDkKSO3rzT20JOO+Fngnw54y8KjWNQ0mLTdX894jcaSzWDqRjqISq55PUV6F4e8H6noWrQyw+MNdvtMXd5ljqZiuN+QQMS7RIMHB6nOK4P4R6m/h7xprvhm8lYWsk3n228YClhn9c4+or23vmnB3RU1ZnkHiXxNq8PxMXUbOPUn8NaPcwaZePDMgtS8ynzDIpcMWVpbXBCMF2vkjmuf074hahNfS6+1/oLXU2nWcUwWFxDo4luSGW6/eks0Yb5uY+cZABzX0BRiqIPBdH+I0vhvw5qBe90e4adtQvLKfYyR3s/8AaEqsIl8wkrtIbaGJAOckVra14+1h7XWJLbxH4c0q4sNVjt30+a1Mlza2wvo4WnmLTAeW0bbyQigK4w4PzD2MqDRt5HtQB4tefFTWLdNZeCfQr2SzttQkS1hhkEka28DSRXUh805hlKjaABxIuHbk123jXXtW8L+DBqF1daOl6b22geeaJ0tYI5bhIyzZkBOxXJLblB25wo4rs8cYyfzqnqumWmqwRQ38RljiniuUG4riSJ1kRuCOjKpx0OOcjigDx1/itrSKD5uguqCRraUQybdc23LRBLQeZ8rbVB6y/eH8PNR6fePY6g80QJZtVmgOJXj+WTxG0bcoyno54JwejAjIPuO3ryfzpSM9zQB43b+P9Q1CHSrx9T8Pvetdzh9KSWS3k08rZ3kgS6bziD80Kgl4wowxAyFI7P4WeKJ/FWg3N1eXNpc3EFyYHezhVIR8iNhWSeZJPvfeV++CqkEV2VFABRRRQAUUUUAFFFFABRRRQAUUUUAIc4O0gHsSM14n4c+FWuW9xenVjoqW93NYyz29kVjikMM7SSMEjt4gNytgBt7cYZyK9tooA8S174Q3Mpu4NE0zw7Z2J1E3ipCI4jdRGNlEUqtayoojZiVysgOTwh5rat/hpMNOb7R9lm1GNNOS2nuZ2uJIRAyGX955a8sFI3BV3cZA6D1OigDwqH4RavE+s/aja6g15uxI2oRwrck3Cyq00f2F95UAgea0w5K4w3Hrng3TbnR/C+m6ferZrcW8QR1s41jhBz0UKqjH0VQeuB0rZooAMc0UUUAFFFFAFa/s4r2AxTA46gg4KkdCPeuQhZ3uriyup/PmhY+XKBguoOCG9T34ruK8z1yRrS+lnUO/kztJ8vVgGOR+IJovbUaNZEYSlmx8vr6HHP6U1czKwb/lpx17GmaXcJqFqdQhk8y1c7EbBwccf1/Sm6jL9ntyudsjfIMdR6mtFrqG5T1O9TcsQiZ7cfKoBx0/pU9jIk/yKzI5GADz+VVrWJSv70Nt6Lk9vWtCws0N2jqmVB+90I+tKxXQj8Tzm0XTIdkph84SSmMZYKg4/wDHiKyr/wAKaXfNcXOm3A065uCzyFV/du55LFexJ6445rW8QxST63F5dwYvIiCEYBBJOf8ACoLyHUJ2WGGeMqSFYhAcep+lS1d6kp2RH4Y0KazuGN3cW9xbRYMZjXgv6nJ7VrT6jbSRXc8twosbIlbhgeGlH8APfHGffAqW8WSC1gsrVttxMfKjbH3ePmfHsOfriuN8dTQWVjBZ2yBbS0i3W69d7HIMh9wQQD6kk9qG+VaDWrPL/izq914k1qG0kRWnnO22hDEC2Tj043HOSfXjoK674eeEtJ8KQxzzrLNcsv71Qw2sRyD64rmfh5oxu9ak1GTdtUhF+Tt17813viuaK300qjfOQXJx6dM+lZXbNPIbrHjYwyCHT4obNMgMwG6Qc8AHp/Ou28AI9y7XcxYuQWJY5JJ4z/OvDdCtjeX264wztIJSM8ewFfRfgy1+z6NGxx+85wOw6Ypx3JlojerkPiRpzXOlR3kKs0tqSSq9WU9vzxXX0jqHUqwBB4IPerITsfL3inVftmqWdvgjdIFJB/Q+uK3vDdsv9j6NMy5kuZpJpMNnLb25z7YAxXUeLvhY1zq41DR5F2ElmgJ2sD7HoR+VW/D/AIfvPI0qynsJoDbRBXd14U5+bB71FtTTmVj0LRCTpVsT1K/1NX6jhiSKJI0XCoAFH04qSrMgooooA5vxH4juNH8RaDp6WUE1rqRmEtw9wyNAI4zISECNvyAf4hzVO2+JPhe5szcwXt3Iu6JUjGnXPmy+aGMZji8vfIrCNyGUEYRueDU/jTRrGeW11/VNTvrK20SG4ndYAhRkaMiQuDGznCbsBSPxNUb34d6Vf6atst5drC1jZ2BLw204eK280x5SaF1yfPbJ29lxjnIBoSeO/D0V6LSa8nim2qzeZZzosZMfmiN2KbUkKfN5bEP/ALNZeofE/RIVuhaJfymLT5NRS4lsLpLVo0DHJlETYXCk7gpB4xkkA04Pg/4et9TS+hluvP8AISB2lhtp5JNkIhDebJC0qttUfcdRnnHJze8U+FNJul0/T7vVtSshqFjLoCxweWftUbQOxVi0bbWVI3YMCoyMHOQKAL1z498OWtzfwXOovG9hHNJcOLaYxDyV3yqsmza7IOSqksMdK0dF8S6VrNpe3NlcyCKzfZcC5hkt2hOwPllkVWAKsGBxgg5BrmL34faDqt9rNm+r3zrMly8mnpPERZveRukkyjZvDMDJjeSvLYFdWugWQl1t5PNkXWCPtKM3y4ESxYXABAKqO55oA4vXviZYzWNknhe4lkvLq7ht98+kXcgijkR3WXyQqu6ssbbSCAeSDhTXVeINfl0bVvD9mbCa4TVbs2jXKyIscDCN3GQTuJOw4AGODkjgHL0f4e2GnXlrdzanqt/dWzweVLdvEWWOFJUji+SNRtAmkOfvEnJY1qeKPDQ1+70mc6tqNgdNuPtUS2ghKvJtKgt5kbnhWcYBH3j3AIAM7VPiHoVjDczAatdRQXcdlI9rpdxInmtMICEcJsfa5wQhY5BABbCnrLeZZ4IpkDhJFDqJEKNgjPKsAQfYgEVxNz8NNNudU1TUX1LUUvL545PMhjtojC0c6Tow2wjzCrxJgy+YcAjuc9FrnhvTPEOix6X4htk1W1XYzC5UfO6j75CgDPU8ADnpQBs01xuUgnGRjNcAPg74GX/U6PNb44H2fULmHj0+WQce3Sj/AIVVpEYH2LWvFtkMYPka7dDI7Zy56UAc7LbyWly7SnfDDKY5hgDBDH5wP8avWUwN7JZksftCkDLcghSR/Ko7vwbNbajJaQ+M/Gq7UUh21OKTdn2eFsfgeazdQ0fWNLVZv+E21dEXo0+l2M+Dn3jUgew/Ouf2fvJp7M1U9LNGrrix6hHaxXiyMskSEPnH5HoCPfr0NcreaSlzqlro9r5rXRkx5kQC7Vxhnb3Ckmt690PxVFaGZ/F9hcRQyGMJceHIjg4z1SVflI9BmquinxWl3ONM1LwZcTiPdIbjTruByg6jIlIAH0NOrSU5JsdKrKCdiz4xurLT7S5mJ8mxtIvK4GQEUAZx+nHU8Vm+DNKvtcjtdKkRYIztvb90UAIhJ8uMDrnCj6YzWD451F73xP4d0AsHmmlSe6SFSVKIc4y38JYEnPPy16j8DrW4i8Ftd6gS+oXt3LNO5OSSG2qPoAoAHatFqRqkd7bQRW0EcFugjijUKqr0AFS0UVZBleKbBNT8O6haSfdeJiOOhHI/UCvNPBV7I1r/AGVOyggGS1YjbgDGU9yPvD2r03xHdvZ6PcSxD94V2KfQngfqa8stB9mtrK6nRYriF1Zo5flIYH5se2Cw+lYVZcrTNqavFod8Q/D8sostb0nKX0ADOO7pnlfqDyPqRU+jfES7S3aW52SWlrtS63Da8Rzjr3PcAjsfatvW7zfYXNnaEfNu2TtgqmR/n8a8U8V6h50MVlZ7nhO0Ssw+aVwc8AelJy973QgrxtI+q0YOiuhBVhkH1FOrE8FXS3nhXS5Q2T5CqfXIGDn8q266EYsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikOexxQAoNcFqTxzXmpWjsQ5kbKtx15/HqK72uG+JWn3EcC6vYsQYhtuAFBITs4+nf2PtSew47nA6QmpQa9cWtlfmKFEYqjjfGT67CQAfUjBrWl1S+muI7fWdOWOZOl9CMwybjydp5TsMcj3rnPBWqfa/H0iOqlGs3YLnI+8uSue2Ox969N1awZ7IlFDAD5SMYpRva6Le9ijphglj2YVGHICHit7TVOxQQOGwfr9a8A8QT3nhrXBqWnzrbzD5G3rujkQ9QVzx0/Cu88HfEq4vNOga40K6dATGZ7ZhIN/8AtKTkAZGcZxVxmnuKUdDqtQdZNRuZRHuAcrn6Vp6PbhYvMYY3DvWV4eK6szmBkZgxaTgjv1wea1Zx5riyEiohBe5YnHlxD39yMfQGrT0uS+xz/ibXnsYrSJJNl/rc62FggGTHCXAeUjucHP1K1i/GlFg1rSIIUB3wbQp6Daxx/PpXn3h/xBP43+OMOqEFbKznjttPjPAWEMRk/wC0RlvxHpXoXxePn+ONNi5Hl2hOQTk5Y9PyrFvQpKzE8DWTQWyF8Bxkk+tZPj65DQzQrlpG6En5gPWup0Pba2GAGGB1POa4PxLcslyzFM+Y5wSckAnHWpL6jvCFnvuYmBckDIHr2Br6G06AWtjBCoxsQAj37/rXkXw3sfMvYTIoVg4xjHQc/wBK9lqokTCiiiqICkx70tFAAKKTjPWloAKKKKAPMvjHomva3E9tplpqd/YTaXd24t7DUBaBbpwojebMke+PG4bcsOeVOaytS0Pxs2s6k1mNXWRvtey6GqKLRrdrRlghjh8wbJRNsO/YMbWO85xXsVFAHlF5oHiWx8UabLpia5qNuLdfP+2aq626y4csQVuQSSxHymB1HG0oBWf4E8P+M11vS5/EFpeR2VtqiXax3V555gU2N3FJgvczuRvkiH3+c5Cr81ez0UAcD4l0TXtU8UlUn1GLRJLi0Lm1v2tz5ax3Pm42OGXLNDnGCePTI4y78J+MITd3FkmrNrM+kW1pFfHVMqjwzzl1lXzl3s0LoFYA4cs25CS1e4Fc9zSFAQR69aAPJfDPhzxdIkQ1K/1mFYre6e3W4uzGEuN8TQhwtzO0iDDn55GyMqwxgHEOgeOP7McRW/iqMKtt/ok2sLO81wscgnkMq3kTpCxaPCrIPmXPl44r3XYOOvFKVB69fWgDxfU9E8evda2dKTUopbi2AjnudQYxxMDFujhUXRVsqHAdo4nB5L5YmqUnh74gf2WsefEU0vkzrYhdRS1Nlcl0Mck/+lymaIDPDSSHG4bOQa912jFAGPWgDya80/xtLd3tkYtbjtUk1KRb61vYcypMc26xK0oIKAkAPsC44Pcdj8NrbVbTwysWu289vdiZ8LPcvPIUzwWLzTlSf7olYD17DqCKCARjtQBzGvxbPEFvMoJ3xYI7cH/69c94wgjuLaKCYsIpn8rcnUZUjP610/iZWF/YSKOm4Z9+Diud8YYFtYtuUEXCPyPrWckUty6UvH0lUito5uEEmx8AlRhjj3rzC8GoWl9Ki6VqBQbv3rRMByMAAg5PXvXqGnurhjtOP4SO1YHibUiiSoksuNp43mocb7mkJNaI8q0fR9UHiNNf1OSeCO2kVI/tjbppgCchR1AOe/vXo/wR8Tu+oanoN1nKzu8Qzu2NjLLn07/gfWuP05Wn1lHO8p5gLO/LA49+tdB8DfCd6PEeo+I76EwxSSyNFlcFyxIyD3AH5mqiEtVqe50UdKK1MSnq9kmo6XdWkihllQrjOOe364rgNGdLiCSK+QGdB5cyuN21hwRz716XXmniq0bw/wCI21FAf7P1F1Dc8RzdyfZhz9c1E1dFRZk+IYkMUkPmkRDrubKj/CuKvNBji0+eeVny6lRz+gxzXUw3fm+NWguFZoUtg8WR8pYkgkD1pfEqsFCZ4BOGUdMcdPpWa0NFe5qfs86m8/hu90q5kLT2Fx8gY5bymHyZPfoRn2r1ivC/gsxsfGt3b8slxbMgPoUbIz+te6VrHYzluFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGaKQgZzgZowMYxQAuRRSED0pcUAFFGBSbRgDHTpQAtJn3H50AAdBQFA7UALUc8UdxA8Uqh45AVZT0INPAHHHSlxigDwjxn4Xn8M+JNP1LT0Jto5wuemY34ZT9Cf5V1kd9FJGoaSRMpkq5+XI9fy7V3ev2EOp6Rc2tygdHQ8HsexrzfVrdH0sg5yF5Pc/4VDVi07nlHxeljmmhWBdwjy7SL/FkH9K634HwF/Bse9Gd3mkkLY6gnH8lFc3rNgZBKfvHByTjIx7V6J8Kplt/A+ms+0hotzsvTcWJz9OaS1NHsa2oaRINs+n3c1hdoPkkjAJ+hB4YZ7GuQ8VeIdVtfCeo6ZPCjXF0Cs9+g274u64z8rHJ9sHiu/nnEkY8ieJ8jOAN/f1FcT48ENxo0qTCNXGcvnge/Pem3bYmJxv7O9kZfFqXMqhV3sQMdwpxj2zXofxGYS+PQqk+ZDaL078knP4Gsj4D2SJeRumABuwQOuAR+ua0teaO68c38ssqR4lMK5PJwAMn2yDQtgfxF3cYbPDFgWGPeuP1i0866imKsUHCAYI9MmuyhQOsRmcqhOAfKI/M/wBazfE9vbQxReRMpkDZXj735UmM2/h1AFv7ZVztUO+M5xxivTs8jg15r8LGM15OzqNyQ9fTLdP0r0qrjsZy3Cge9FFMkKDRTTnGaAHUUisG9fxpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8QReZJZPuAVHbI9eP8A61cd46cBbVeFxMPlPfgkYrvNYtzPZHbu3xt5i7evH/1s15T4nuIpNTtLZN255QSCfQHp6VnMqK1OosXMdoXHVsFj9a4rxTJlJHjYeg288/lXYzME02Mr6AAA1wfid40ZkMjKXz8oPWpZcdzmru7GmaPqV+GJmERG/d0J4/A89q6/4S+M2sbNLO6cy2QAwWOWT6eteUfECdx4ZS3gbH2i5QFR3ABY/wAh+VZ3hvUpEhhYtsOQuAcAD/OaadtSrXPtaCaO4hSWF1eNxlWU5BFSV4x8N/GjQRLHcMzQMQSD2z3FeyQyLLEkkZyjAEGtE7mLVh9VtQsrfUbKW0vIllt5RtZD3qzRTEeKa54Y1Dw9rtnduDcWCloFuQeUVvuhx2wQBu6GtzVLX7Xppb7kigPwMcg4Nelzwx3ETxTIHjcYKkZBrNstEt7ZySzyqDlEboo9Pf8AGo5CuYwPAHhxdPabUpkHnTDEYKjKL6g+/FdrQOBiiqSsJu4UUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADGViOHI9xinYPrS0UANw3Pzfp0oAbPJH4U6igBADgZPNJhsdefpTqKAAe9Ic9qWjHNABRRRQAEAgg8g15jdsI7250+UhXUlSB39D+Rr06vKfjFo97aKPEGlAMI8faULbe4AYfnzSZUXqcD4phltJ90IIQnBJPWtP4Qaio8MyRHcscFxLGCOqjdnb7jnpWRcayNU03y5lIkXGQRjB+v8AWp/hjERpuoQIf+Xtm578L/hUGjPQrvUy8K/YZI3C+gAx+HavLPHGszzy/ZI2aSZsqcjn611ur6fIs+EZVJBYJgiuPfT0OoNJcKoYEMGPP+R1okNWPVfgppn2WxeRkwVQAEj+93/T9a4CXXUHjDVpVJZppZXhbHy5DnK59a9Z+HrJD4ZvLzoMsT7BVrwXVLd7i4uPKIXcxkXb2YnkkU9kSt2eiL4oV0CvI8YwNvOSPwx61xuueJTqF4bW3USz9I2CY2gkAknt6VyV1Y3rKY3un2oSAQxABx6+ldD4H0K4meMqAu9gWYNkntznvSuUe4fCOxaDw+9zIgDzOVU+qr3/ADzXdVU0izjsNMtbWFdqRRhQPwq3WiMW7sKKKKBAaTmlooAQDv3paK8f8Q/ETWovh7Y6nbC0t76+sNVmMiRk+U9vBM8bIGJH3kXO4MDQB7BRXHnx7aDWrjTjpeqKsUk8CXTCFYZpYY/MeNSZMg7ckMwVeD8wwaztH+Kmk61bo2lafqN5cvdtZLbWz20xMiw+dxIkxiIK99/B4OKAPQaK5Lx1480zwXJZDV45TFdNgSJPbqU5A+5JKsj9c4jVzweOlULn4iP9vsINN8Mazew3WqXGleeHt4l8yEXG/YHlBbm3Y87RtJ53DYQDvKK820v4yeG9Vmmi0+O8uZFeNY0gaCRpg8oiBCrISnzFeJAjYOcda6DS/Gtlf6vDpJsr621Zpnims5hH5luEiSQu+12XZiSMBlLZZwPUgA6miiigAooooAKKKKACiigkAZJwKAAjIIPSvJvHlg2ja5p19s/0PzwNy9geMH3GeK9Zqnq+nWurafNZX8Sy28q7WB7Z7g9j70pK407HBX0kYtGELbiBgK2cjmvPPEeEncyMFc/MOP0/rXW3H2nRNUj0HVpXk43Wl2Rjz09GP95e/rXN+JIZpIl24ZSTu2jJb8aye5rE4qOztda1rT9PvZfJtg8jM7AYQsAFY46DIOfrVnxn4Am0a6CNFLAv8MoQtE4x90PjH4Hms+SCawv2lOTKi/PyV+T0H419AfDDX7fX9CbTb0iWa2ATEvJkTt16kYwapIJNrY+ebRrzTiDOg2x4wVyQMDpj0wK+kvhPqMmp+EUmkGAszop9Rwf5kj8Kr698OrC+LPYMttIVIwRlTn1x1/zzXS+F9IXQ9Et7FWDFASxAwCx5OPaqSsRKSaNYfWiiiqICiiigAooozzigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqK6t4rq3kguI1khkUo6MMhgeCDUtFAHiniD4fG01CUWNz5MbHcqyLlWHbHpisnw+x0LWr6zvgURyJEfb8rfLg/TpXv0kUcq7ZUVx1wwzXI/ELwzDqmhs9pboLq2zIoQAF1x8y/1+oqWi1LucfPqNq1uZciQ9MAbiBXE6tc7b2MQrwx+X/8AVUdjY3lshksrhpEJztJZT+Garx2N1cTZljKPnhie/tUs0PZ/Dq7Ph3qBDfM0cpJPHO2vL7O1ieMuw37hjzM8Dj/GvXvC+mF/Ar2m4k3Eb4b6jANeTQ6DqFrh7ErPEwxwc4/CmyIvVmXrMFvHMgjTee5J+Xp/jXT/AA9ha71G2hORhwWP61yd9ZTLq0a3UxE7nGxhtH4etevfDPRzEHu327F+VDj7x7mpSuym7I9CooorUxCiiigAooooAK5IfDnwtvvmOmuVvIbiCSJrqYxok/8ArhEhfbFvzyYwprraKAMHUPCGhajBNDe2CzRTSTSyK0j4ZpozHIevdGI9s5GDzUej+C9D0i6S5s7a4Nys5uBNcXk9w5k8ryclpHYn938uDwAK6KjNAHNeJvCnh7xHqER1mJ5LvyGjCRXssBkh3AlXWN13qGwfmBANWLrwno9zYw2j280cUF7LqERgupYnjnkaRndXRgwyZpMjOMMRjHFcx8RiNL8dfD/Xs4jF/LpE2O63UZCZ9hJHH+fvXolAHN2XgjQrIgW8F2sKypPHbtf3DQROjh1McRcomGGcKAO3TiprLw1b23jPU/EbFHvLy1hs1xHtMcaFmOTn5izNyeOFUdq3qKAOP+MF1c2Pwx8SXNhcTW11FaM0csMjRuh45DLyD7ivMp/G2q+B9O1izur1LbWBqTeTp2ozPqCxQ+SCm25uLiAsshRmBLE53KEypr32igDwnVfHN54h1bRori40uyWO7tJ49M2ubuYPZeaZ1cSDEQaQpkIeVPzA8VJb/E28fVdD0FGtZYLyyhiuInQiaJnsjNuEj3LSyDOPmMW05IMhYc+5VznhbxTa+Jr7WI9Mimaz025+y/bCB5VzIB84jOckIflJxgnoTzQByWoeKZPCfwj8JXdvcW8FxPbWlvG1xAskZJg3YJeeBE4U/M0g9ACSBWPJ4+8Uaz4PuNW06fSdJW30qx1GaSW1ecgzb/MAzIqqoCZyc4GfqPaKKAPFZvinrMXiuXTIW0K9tYo1KXCSRQi8U23m+fCGui7JuONiRyAgN+8BBA3W8YeJrXUNCsbu206efxBFFJYvBbyiOAhg06yEud22Ftyn5MlSMDt6bVObTbSbVLXUZYt15bRyRQuWOEV9u7C5xk7F5xnqAeTkAuUUUUAc9438PL4i0cwDAuIzviY9j6V5rHFMkj2WoxvFdRZUMR/rB/LOP8a9rqteWNrfJtuoI5R/tDkfj1qXG41Kx8/azZB3OxcGLn1z6isDwpqc3h3W/M3NGrMCDjOwj39eencV7D408MfZomurVnEA5ZgMmMe/t715rq2hyy25uFy2BleRt+v/ANes3dGsWme/eHNYg13SYb236OMMv90/56VqV4Z+z5rF02r6no9zIzLFEHUNz0IH0A5/WvcxWqd0ZSVmFFBGRg0UxBRRRQAUYGc45oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjNV8MpFdSzQMPJlcuY2GQCeuKybXwlcSajG0Z2wPkzE9F9Cox+lek0UrIfMyOCJYYI4kGERQoHsKyLzw/BJM81tiJ25ZMfKT/T8K26iluYIp4YZZo0mmJEUbOA0hAydo74HPFMRx0ngK3u7+G51CVZDE4kCqvVsY59q7C1t47aFYolCqvYDAqailYdwooopiCiiigAoornPGvi2x8KWUUl0r3F5clktLKHBluGAy2M8KqjlnOFUck9MgG3e3lvY2kt1fTw21tEpZ5pnCIg9STwBXm2tfFq3eDf4UsDqEGcHUr2X7FYrzg4kcbpCDjhFPXrXDajaat4ltv+Es8aSgaYGBs7dU82EFuI1tbYjE0jEkCWX5TuyFKgGodKli1WU3U1w1u0oEX2WOYyXgAJOLif74Oc/u02IBgc1zYrF0sJDnqM3oYedeXLA1tb+IHiWOC3lutattP8w7tunaYCnsnm3TqWOP7kbVh6rrfim5nWW/v/E62ixLK8tvfRwKqsRwdsEQ6dwzHt3ralsUEctrYQR2UDoRJKiDLBhghT3b3J/Oud1LU7+0v20z7SL7UNyfZmMABjBBwzpkCSVj8sajAOCSAATXj0s6qYmXJQgr+d9u/T8z0Z5bCiuarLT+tB/iCK6i0HXUmGq/2ibf7dYyXl21y7PasLhTlpmwdsbjiMdcbs9d27XSl1aWez8UXNl9sVbtIYxqbbUlUSKMxzbOjA8YHsKo+EtN0+3vLDVtUnlv7m4by2zNv3bwVZOMF25YHPA5wFAq54RNzF4Q0q0lknln0mSfRp4UUDc9vKyKWY9B5fln8e9dDzOUaEqiSk4uz6L5bmCwa9pGMrpSV11fzIxJY3LG3T4hz29y6/ud9/qFmCfcyyMD+VaNn4c+IkDSSaR4jm1CAlQs41tJRx1G2S2YZ/Gi7ubxJXW6vNPhtlXzJUdC3lpz8zEkDOenGOtZujafLDdrrHhjUJtKkZRtYQhIbxvWSAABkxkDo3JIPAzhRz2LSdaNl3Wv6GlTLZLWDudPMvxKjVg9xq0bK2A8EOn3auMdcMYSPTvSw+JfHFtKsNzFcFxyXu/D0uwj3e2mlA/LtXb+BPEj+I9Lma7thaanZzG2vIFbcqyAA5Q90YEMD6HHanePfFVv4R8PPqE0TXNzI629nZx/furh+EiX3J/IAntXvxkpK6PLkmnZnnWveNPEGt6dF4btRbWmr6ijzTXunidzZ6epw8/lvGriRiCkagEknIPTPf8Aw9uvDH/COWWn+D7m0k06xj8pIom+eMDrvU4YMSSTkZJJ9a8Z1aC50HRdQvdXm0zUdTv3E+sG6smuI5bjI8uNHVwY44uFUjpye4rB8S3V54dEN9f2N+XtThbq3uWnNuM8tFcsPPjx/wA85fNjbJ6VEa0JS5b6m8sLVjHmt5n1dRXi3w/+MUFxahfEE/2qzTZu1ZIPKaEMPl+1wjPl5OB5qboiWHK9K9mjkWRFeN1dGAZWU5BB6EGtDnH0UUUAFFcd4s8f2PhrV5LG707U7hYbWK8uLm3ERjgiklMSlg0iux3KeEVj0raj8TaDLd31rHrelvc2Cs93Ct3GXt1X7xkGcoB3JxigDXoAwMCuN0b4haNqc+oNHdWX9mWs8sY1FL6FoGSOKGRpCSwOAZtvyhgNvzFcgVo2XivT9S1zTLLSJ7XULO+s7q6W9tbhZIwYJIEKDbkHJn6542Ywc8AHQEZHNchr/gi3vxI2nTCxkkyZFVco5Pfb2Nbi+ItFbV5NKXWNOOqRqWezF0hmUAZJKZ3AAc9Krp4v8NPYtep4h0drNHaNpxexGMMo3MpbdjIHJHYUmrjTsZ/gTwbb+ForiQOJr652+dKBgYGcKvoOa6ysubxFosFqt1PrGnR2zRNOJXuUCGNSFZwScbQWUE9ASB3q5YXtrqNnFeafcwXVpMu6OaCQOjj1VhwR9KYm7liiiigAooooAO1ICT2xS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV518WdK1i/wBQ8N3vh22e41PS5ZryBc7Ud1QfunbookXemSQPm9q9FooA+eUt/HXg/SRp+jC9QS6hezXd8trLMZZysJVyq207GN3aY8IM4xvXjNnxLL4q1eTUZL221W51C2ttUENj/Y26xVTauIGRnhPms5xlGZuTtKA8V77RQB4vrniLxxF4i8TQaPaa0tpBYah9lSSyEiLPHFm3aEi2VSGYcKZZSc4KqeK7vw8ddtR4ktNSvLvUDayj7DdT2yRvIrQIxA2KqsBIWAwM9iSRXW0UAeK3upfEXTtDURz6nfyzW2m3M072KRyWxlFx9ojjEdu+Shjg48qRlEnI5BGppsnj3VrG4YarPaXVto9vcQbdPCR3V2ZboFHM8KuMqkG9QqEFgRtBw3q1FAHiHiPxH8RJLWw1DTre90+2vzcTpC9jJI9rgosMMyR2s0mCoaRhtQ5YqJFwBXpvifxTa+F7C0u9Ygv2gl+WWays5LhIDjJZwoLKvviuiqvf3ltp9jPeX08dvawIZJZZG2qigZJJoA5I/ETRNR0We68JXlv4gv1GIdPtJl853JwAynlFzyWYcAE89K5Dwh4Tv/FWrT614wM1zE48uTzoWhW4AOfJijOGS1UgfeAaYjc3y4BydCsIPij4hmu9a0HT5tNml+1h5rdUmtbXbiBFkQLJ5sp/fHLEKgXH3xW3r2ixeC5Yo9D+IesaXO67otMvR/ayugP8ETAzBc8ZVqGCTbsij491J7nx7NDAr3UeiwpDa6fETGiTSLl5ZCflGEKqv1bAzWdoAm+16v8AabO2huZJVkkuIHB835cBWOAcqP8A0L61Wj13VW1e6utQ0rTtVubtV819Mu3sLhhGMB/sl2FLEAgEo2On4I+saArPZahqN3od1KTts9dt5NPxnPJc/I2c84kwR0wK+XzPCYmvUlKmrxdkmn09D28FXo04KMnaS7ljVNY/s7TXvvJEiOi/ZgGwZpWOFX2zw3sMmqPgnS2gR7u7Yz6reA3QkcFtoYY8xhgbWYcKh+4oxnl6qX3hrUL+bSdMnklu9Gt8Il5GuUkjIYsRIuVZljQJuH/PX2rqIYH06S9uJJFtmv5twdpPMEYQBUCg/wARGTgZAwa4pQWCounDSU9+9k9PyuzocnXqKT2W3qVt9nbXjX0dlAI45WZ7twq75WypKY6sSdueOpxmpdOM8fiPxbY2vlJJd/Y9btxId6Dzo/JnPHXEkI+tO0vTYBdwzGSa9s4IQLZpZA8bljksFHGQAADj196NVZbHxh4bubYx24ure80WQ7PlViguYCVH+3FIMe/1q8E41XUoXu5R/FaojFe5yVLWs/wIlstKOmW99d2n2y5ljGXaISSzHOcYHbP4AfSnvdHUvsmowTQ22nWbNNLdzN8jrtZW9MAZzlscjuKp+HdH8QPeXbeGdFvJIblVX7Vqxa1hifLEsqMPMKHcDtRQOOort/D3wxj80XXjS/8A7duA++O1EflWUPsIgcOfd89uK1o5TWrPmlovPz390irjadJWTuyT4WsGsNb8TXO600u+ZJLdrgeWDBEhHnkHG0Nljzj5VU9MVxVxrU+v67pvjPUYJo9KuZpNP8OJINqxgoxa6YZyJJQpVOOF9yM4vxH8ZweI/EN3YpMbnwmkaPci03CaaJFLeSVJBSN5ANzAZKqO2K9Ys9PtfH/wvtbO+ns/OeCPM2nMClrcoAQYypwCjAcA9iOhr6aFFU6XsoaJaHlOTVRVZq93c8r1uW7hvL6TTLSZ0wsV4u1JoZAyjaxTIYEA8kDkdQeKt2ou9FsYbG8tjqFlEhia7i5bZjHzxHJI7HGeO1S6Pp7f2vc2t7Fcx+IoGX7XEk7nzmVQomQDAZGAyCAMfdIBFWPEF/puhT2g1bW7GxuEmy9q0he4dSpG0QxhnJyQegFec6cnLlS2PolWpqPtJSWpzNzpo0vVUg0K3ju7QRPdS2MTqs9qGIUtbsc8NnmBwYm2kY5roPh34uvNAS3SyEmq6BcM8aWcCnzIZEGXWBWO5XA5a1Y5H3oiy8COysZ7id7vw34Mu42QvI2pa5KNMhw2SxaP5pXT6hR34NYbTatq897H4f1Y30krAXc3hyFdL02NwMfvb990sxAPRCSRnkV6NHnjG0zwcU6M5Xpbv7j33WfGfh3QtOgvtb1i006GeMSxrdP5UjKRkYjb58+2M1ieC/ibpnjXWDbeGdP1e701N2/VmtfKtQR0UM5DMxPYLxXhejeCfB+mX1prviaAa9E05Wd0WSO1t2Ut5qlXzNLImFcrMQWQsVVsYr6p08Wwsrf+z/I+x+Wph8jHl7McbccYx0xxW5xtWdmcZ4v+HNn4m8SSa3PcJFfx2UMFjL9nDvZzRyvKsysTyCWAKYAIGCeeMPUfhTqOrarfX2r+KXunnguIYla2lIi82SNwNjTtGEXy1XaiJuX7xJ5qz8Sdc8U6f4u0m38OW2rPbbrZp/LtvNtpVafbIDtt3IZUyTumiABUjccisy4v/HtnpxnN3q1wbu38yXGmRs9iBeRoxiRYwXfyGdwj7yxTIHagDVj8DX9++pXsfiyD+1ZpboPc2FoY1hlkjt4yoXzSy7fs/I3bvn6qRmrPw/8AA6+H9bku312PUrq3a8S4RVkLK9z9kfDNJNI4IFup+ZiSJAcjAzU8Ovren/DTxNdaVHqVxqxuby4s21Cz8q4myxKSGHYnJHIXauemO1cjPe+MNPg1S50CTxBNBe6uGm1G90xobpkFlCqnyls5CE8xSuRB/BgkZ3UAeg6z8O4NVa786+Ma3Oo3F87RwgOFlsXtCgbPUb9+7HbGO9UfCnwzGhahY315qUN3JZzCXeY7hmkVYJIlDNNcS4278jbtHGMdMcZqPir4j2j6jcXr/ZI4NNknXbYT/Z222RfzFLWpCP5wPEsy4A2mPJGe++Hd/rOpWesNqNzqd7Y7IjaXGoWH2OV2aPMqhPLjJQNjaSuTk8tjNAGZc/DKy1mx1S4sddZrbUZob3TZINxitk803BCtHIpZHkdnyjIcFQCNoNdn4J0D/hGvD8enGWKaQSyzSSxiYB3dy7N+9llfJJySXOTk8dK8n8A3HjK28M6NpljNriW8FnpVtMb7RxC1nKXCTxxholLosY5chsYzv5xU+p6749t9e1iy0wa/Nb29rcxRS3Vikm6VFXypU2WiRneQxwJJM5wVTgUAe31Fb3MFyrtbTRzKjtGxjYMFdThlOOhBGCO1eWX974s07UJLC/1TxB/ZEGoSxHVrLSI7i6kj+zW8kY2JA6lPMknUusfWMAkHJq54Ktde07xFue41FtKvtR1JpLWe0REjHmFo5Q2wOC3PVtpzwBigD0yiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoo5ooAKKKKACiiigAooooAKKKKACiiigAooooAK8p+O2pWkkOjeHtRlZNOvpJb7UxGMsbO1QzOue25lRQe/SvVq8X8faXF4i+LEllcS7LVNMsrSZevmebe+aU+hWAg/WgDRn1HUPCPwwtL+C1jh1vXLuHe3l7YrKS4IVSw/uxJsjGepVR3rlLNrHwzrmow32oSSXF2EunnuyXuZxjYQXxyNyjCgYB4A6V1vxVj1LVbi+05L+GPTPs8aNZyxIY5nYk7mkI3Iwwm1lPysM4PSvP/BevLZyvaatcO95JL5H26Y7WeUDiCYH/VyKOmPlfkqSc14ObzlVvGDvy7r12foengUo2cuuzOit1j1O4uLfWYpo/NCy29vOcFUHG9T1V8nkduPx5+Xw9qViUtdC8Q3cemmdLVLC6j+1QsAuXLIx2KAM/wAPb3rcvGL+KI7hbZroWts6LhlAhlcgsWJ7lQAAM4GemaW2t9UvAl3FaQWM8c8hli+1b/NBAHUKQCRg59vevDw1edHWm7XV+mnyd/y6npVaUZ3U0ZEfhyGDU5obLRk03XJS1xbTeGb6TTjdQLgSIIzmPzlyrbSNrgnBGDWxpGn+NLq5EtoUvHiDCOHxTpgs7jbxnZcW7HceOpTtzUHiHfaaZb6paJIL20v7d4B57PulEwjKfQh5FPqD3GKxtc1T7TJcanqEttINQubiax1GaUmW2tiWMKIvGz5U4O4DLEn3+goY322HUq0eZ3t01/pHlzwzVW0HZFy7gvks4bnVdQs9I0tFJa1XU84KnBXzIow77sFuMHBx1rL8ba3Y6DofhcWmgLoLzTLqx3ff86NnETbnILFhyQ+cK+CM5qCa+TXru2hsBPIPIWTNw7yvOe0ghZgNoPI810B67W4rqdF1+00ddO8GaV4civxav5s11qtwkotndixYqikbtzABVwMkAHqa6MHy0nJy0vrayVl36v7/ALkZVlOTSb5jsNR8ZXn/AAhPhu8tmeGXU1MUlzMFhKusbNgFwUXcyHDEEY5AORXHy69/ZkKy6rrWposm2WGOPUXllLYG5DhtzqTgKqjBJPIAq34j1HW7l5LPVPEtxCsyfu0sraKC3Xglt7MHbaq8kFhkDjPQcfNo0VrpdnrFm19BbTzJHYPNLK1zqr5yrbFIKQL94nG5lHG3IJ1pY2nXf7tNr8CZYacFeWhfuPCHhMW9tP4ts9ZbxTftJcHT7GUC4FuZWKNcBSI0baV3E7QW6DOa9D0Lxro2h2tnpF5pF54f01j5ENzK6PErsejurEqSTnc3BJ5Nef2Vj/aVxPNbanqMQiZkuZh+7ku522sXckYOOgwMDoDgVehh0sRPazGSSK6MlrK10zOJiu7fknjswzx9046UpYx302PQhlcXD3pa/gP1jwgdECad9q1LV7C3YRz6dpOpC0doyS3nXQUB2cr1JkVCRn5c8Y+j6nYaVa3EHhDT7C4mt3K3F5pCrZWKLkEfaLxy7buxWOSTPODmsrw1ptlqvw98SLJO2qWvhkSXC2bySJHfSNl0e4VSDIEVQo57EHgCrviJne5h0q/aKTTJdj6c8CrCti2QFEfl42KTiNsY+Yqf4yKp1VGKvezOChRlKTSsrf1/TNs6DHrEMcnie/i1qDd5sem6epg0uNs9doO+cg/xSH8Ks3zzajfR2iyNax6cqPF9nQIiFsgIq427cA5HfI6VyNx4b1LQb5ZfDV1JI85cLE7iM7gC2XONkncZKq3I+fir9h4pS8+16brNrPaNGNk8kaMPL3cAun3o+3zDcn+3WFVzqK6d0exQjSoPlnGz7vW/z/Qv6pJHpuozXTzN/ZVy0UGtQr8rRAkCK8jOPlkjbBJ5BAx/Dx03w61W48F+KG8Ga1tW0uHzYSo37pHYMwRc/dSQKxVM/KyyKMjbXN6d4b1LUzZTazYy3dlc6U0BMcTgRjgkOe7FScHjBDY60zUILOfwfDpvivxDpthqGky/Y7S8n1CGOW4tTtaOTG8ETRMFIHBJjYfxk11YZy5eSR5mYQi5e0j13PoqivLPDvxi8OPo1nFqeqRX2tKgS4TSLae8R3HBKlIz14OD0zjnqer0nxTFr2h6neW9nrGkR28bET6jp7xN90nekbDLgfTnpXSeedRRXgPhLxe2hRTSpqkesGFNP+3akuuT6hZrE90sUsjpJj7NLsZnKAlVC88A5t6h8XtSL3Umm3nh3yk+0yWUMqO0mp+XdPFHFCRKPndVU7gGGTnbg8AHt1zbw3dtLb3UUc1vMhjkikUMrqRgqQeCCDjBqRFVEVEUKijAAGABXj+q+Ndf02LW5NJGnCLTo9W1GZbxZ52lW2nCiNCZf3e4E+qr2UDis3xF8UtabV/FGlaLdWK/YrS8lhnNmoltnt5EDB0+0OzAhnwzxxA4DKGWgD3OivHoviXqf/CRCxi1Hw7qCCeOBIbWGQTXkTW/mm8iIlYCFWypHzD5G+cHAr0PwPfanqnhiw1LWHszPewx3KpaxMixq8anaSzMWOSTnjggY4yQDeooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAa4YqQrbT64zThnvRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxHxB1j+wvEHg++vb9rDRRezRXszymOAbreQRiU5xjftwW4zjvivO/C+v61FIl/aTpLf6isUME+orJKvkTardLE+NysQImQqMjjA6V73RQB4nrXxX1bShpUMp01tQa6mt7mD7MEScRXz2xeJ3uVYEiMtsVJiuRnjmvQPCms6tqWg6hq2oNYCMPcJbQwQupXypZUy7FzuztXgAYweTnjrKKAPFb34l+J9L0NZ7+DSZp57bTbxZ4IDHFaxXQuM+YJZ1U7TbgbjJGD5g6Y51NO8Z+LtZsbibS4ND8600e31N4Rm5+1O8t0hjjeKYou4W6kHc+0kg7uo9WooA8R8R/FzWba1sNQ0uz05NL1E3E9jPfNHAs0UZRERnluIlVnO99w3EIV/dtgmvVPEPiCDQdHi1C+tr+SJ2VWWytnunQsCckICccYzjGSPWtqigDz7/hbvhRCVun1q1fHCzaLeAkeoxEa4LWfHXhiTx7Jrlp4l06KymisUZbmGeJw0M7M4w0e3mN2wcg5GMd69+NeefFSa7sdR8L3q6je2WmSXcmm3xt5WRVW4jKRyNjgbJAmGPQn3NAHnfjTxb4a1nxZLqGmeJvD9zps2niFori/EJFwrNtOGHTa/X1Gewpmq/2HrEun/ZfEvhl7mOEpcyPqdrMssYAxHLHvxIpbn/ZxkEHBrY8Q+M4rX4f6Z/a1zFB4rtnaGYTplbl7aQRzIzbdoMiZdQf7y47Vi3sj/ZnSKDTL+WeRJLDztNttkkX3mGSmN23cMkj+HArxccqFGvGpNyUns1bp6npYb21Sk4Rs0u5W0dNX06AwabPpeoWMbtts31OJmbJzi3uNx3KD/DKAw+7ubGa6CLUXt7F5rgLoUbybGa8C5Eh/2gxTJAOOTnHTisPXJfD73kVnp/g/w/qV29wIpiulWwO4DcYQ20fPjAZhkRg7m7A6Ft4Rt9OR76Oz8K2EpXEwh0VGhCcFk+d8suQvzHB44xkiuPFQwFWCq1LwcvLV+bX9eRvSqYiLdONpJf1uYEUWt+OdHuLfQLldRj0mP7S93ABEZ533KkY3YQFFZnPI6J0Jp8el6lq00d7PZRxaeiLFZ2kEoJKR42srAFc4yPNHQcJ13Voaz453aO/hJYLTRBG3m3b6ZAFW4t3TeiRQ/eDyE7XHONp5O7ir4SfWPEMST6rZeIXt4PMQadb2rQTXSlgVV5mCRogAA+U7jg9BxXZKklGMcPbTXmelr9V5v8jJVNZTq/d6DrzUbJ9Bnms7GFbdpfs1u6oFSGVgDtRjy8vJLEA7QpycjBm0HTdP8lbP7fPei5IukuEhdfMlxuDGQDB2kZVTg9ScmrmsJ4svNQWSz+H8ljaxQi0so0v7dWto2OZmQA4Dv0yP7vXrT9EvdW1m/TS/B+itbyWUYhvIdSAgTT3OChYD5pBgMBs6nnPOa48Rh6lvY4dN93dff1f+ZvRrw/iVHbsiulxbz3SQa4kV3pOmxw6hdyWcWWvZXJSK28vJ/ePJnIzgjjjJxvXfhjxR4hnv9T8QX1jpDXUKx28NtGZpLSDPEZYsqgk/eIByT1wAKb4e0WwsfiVa+Hraf7UNLtpNWvpsbTc6jIQm9x0G1GO1R93f61ZvdVtbXVLp7lbrUVsbUXEb27FvNaRpI5YxHGPlYEICSdoKg/LtJr0Y0vYR9jH5nH7aUp+0XTb0K50HXrJ/K0m70jWFhUmS1Ef2WZMEjCkFk6gj5scg81xU99btoRmS8AN1dyOLd4z5lkxLecCCc/Kok6gcn0Iyng/xrcQnSNCs3iup54Hka9+0F0tLsysVV1B/eDdsOWOTuJycmq3xBC3vj68sYM2ljrNtZ3k6iHZJHLIVViy9c7EYkHnJzzSlSfK+ZnRDFzvyS1uXPBOoPHZ3Wo2Wn/2q19YT6feQzahDYrhHZ2lk83uFcYwDjc2eMGrEWm3drDcWkek+FbJIo3vpI73Ubu9YK+/L7YY0U5BIwCOg7gEcZcavJcXtxKkZTTr2SdCGkHyqUZH6YAJBTpngCvV9SltrXVLUyy20LzloWMxxvUciNecbiWH4A1r7VxppNX9S44VVZybk1te39eRzdrrd3f3ccEfimwju0P7iPT/DyOzH7pKS3MrZIBOcjcRzzzW5JphCSyXvivxdMFG52gvorFAB1O2GNT29f/r4sHh2aa1vrO8tolFvODYTY2/L2B2nI+6pz1BYkVlG/vtYGo6Pa6jBc3EsTQYug0ZfA/hI/i4+YYwfvDB3AZRxU17qsvkaxwtOKXtk3fzYarZaJZ6nbQ6r4eh1DzXJgnvr26vBegjhELy7UmGeEZSHxhWBwD1PgRdJt/HGhJaaXoDaLqyXKQtb6ZDGUkVVdAz7d24BZFwT9RkVn3FwutyDSlhs7qxubBJLlGcMtud2Dkrzu4wMEYK9jWJFYaxp3jDQ4kea/aPU7e/BC4kvYUYI74HWWMNhz/GjBjyrE9NKrKckm9V+Jz4jDQo024q8Xs+q/wCAd/aarq3hn4qadbajqVzNpMs76LJA8xZFaQGa0m2YA3MN0RIA5jb1r2vABzgZrwr9pLSnWOPV7SUwTpZvJvHB823ljkiYHsQrTgH/AGq9r0i7F/pVneKCq3EKTAHtuUH+tdp5BbqoNOtRqx1Pyv8ATjALYybj/qwxbbjOOpznGat0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVieNPDln4t8MahoepbhbXce0sv3kYEFWHuGAP4Vt0hGe+KAPmTUdB1DxR5mh6hPBa6755hM8udp1OCNVyfl4We3WKVSMZaJhyODv+JvCN34O0mxtZ9QW80ye4itrSFIyt19pblYkk+6sYYMwdgSqjGGwK6X4waNLp9yviW0uJba1k8mDUXjXd9mKPut7wDv5bnDjnMbMO2as+ITP8QPAEn2SM2vijRriO6NmT/q7uIbgmc8pIpO1wcFXB9RWGJoxrQtJXtqvU1pVpU37rscPpC2nh3U7y3nhb7W8UPlyRR5QoSVEUWfugOSeTlixZiT00NWS4utU0fz7IToEndrZ5gEDgoFc8YYgM3B9fas5tSj8Qaax0xGhudRKAyKfngRcFyTjgq29cf3vrW1BpsyXRdLqQ+VKHgNwTMQpXDoxPJBPvkdvSvicTV/e+0qv3tn91vkfRwjaCUdtx/g27t9I0C28UPbGTV/Et0Cu5MmOEbikQORgCNDj1ZvcVr6j4j1a2NpKbQTWy3CedNHOFUK0pQMPlIZSMDYTuBOScDNUPBkdyvwv0dtiz3mnRXdvsWAySmVGkjXY4zs5X7xGMY6VVvdd1aOXRZbW0dFNvGlwZS/lmMrmUEkBTKWKbTyfv5AwRX0aSdktlf/AIB4u8m33NFdaklu9Nu5NXXbNO6S2iSFUliZOZIdgOdhddxBIyCcrS+Kbt9ElsPG8SrNPo4+xatHZnf51mThxzzmJ8OMnoGyea4DSLzQdG1DT9M1C4mvLWzMka3P2RhNYfJlo3YLgybyg+XKgIAw659V8K6rYavYxmOW4uIbq35S4jC+Ym4ozOoG0sx3AkZzgVfM6TU0yZRUtEjkPC0M9rHH4/unk1K11CWe1vpIUIaG08wlZQo5wsituxyEbP8ADzD4o8Oa3rGiTQWmrRX8d9Awj1mFmKbnnMi2+xSQIcDaXOTyOo+WsrUZNa8FS6b4EgvJrLTRLPPpd9Dc+R9oiZtwhd9pw6szjsGyv40I/DzaFLcz6bf+I7IXP7yRbS8xulPZ1Axk8fN+ddNacVLmjuzXDYSpVjzR6HQeFvANp4esp9Z8RtaacqukrmV/3UKqPlGdwBbdgnIPGAOTXPtcy+IfFOoandQPbrqNylxFI4KvDBFC4iyD91trq59N9Pk8LJqEqnxRf6nqd5BJi1nu73zUGTkbF4AOeDuBztz3xWle3t3LfuLa1F04j89SqZXErffJ4z+7RDjuWAFcdadrRWrf4W1/4B2UsLKM4yqaX6fmYunWNndRXWl2QS1t1sb+4NzcMI4yFijiWRWP3QWK8njIYgkGt+PXtMutNtNTktzPPLGCyCISPb8/MX5AQKwYHvkdDis+6ME0SXl+9u1lrV1Fp8AmU7Xs4HMkzZH8EkvloG6Ywc8is+3tzoOr33h6WYRwaiysLl4gWYkbUf3ZsbWLcb1U4/eV0yinBJ7pf1/mVGrJVpSWsW7X81+nQ7EalC96ltGk22UMEmKYSQqMkBvpnBxg4OK56/Gj2er3NzNbXBvVuYpAkA3GRmG1WyeFXceSSMEe+Dq3Fhdy39vJc6ncyRQo7blVI2LsoXkqo7E9MdRUOsacJtKv4rQ4uruIRGR3znHA5PpkmuRuKPTtKSd+n+RVGmPZPLqTSi3vpEaO6MKKFO6TIPflckA88c1n+IZDpVjquu2csk9/ol/BdW0k8hYgoF3xFuDsKuQQP71a/iKe6t7SdzapqFmbdxNFkBwQvDc/eU85HUdeayL3S57yws/CUTF11yRfKlzuaGMv5k7tnG4KuSCeTkAk1pSbclY5sVGMKbvtY6r9obWYLrQGgWPdt0l7rnqrTyxRRAepIMv4LmvatJtRY6VZWijAggSIA/7Kgf0rwGTyPGvxA0LTLWL9xdXcesTllY+Xp1oGjtUYHGPNYu+OwlWvomvYPlgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK888S/EaXQvFN7p8mkwyaZYNYJdXZvdkoN3I0aFItmGClMt84OOQDg1pw/EnwtPbGaG+uZBujWONdPuTLN5gYo0Ufl7pVYI5DICMKTnigDsKK45fiNoP2u/t5k1a3azMSsZdKuR5jSKhREGzJc+Yo8vG/gnbgE02/8AiPoEWm3VxZXf2iaGxe/2Pb3Cqka+aCZSsTGIBoJFbK5UrgrkqCAdnRXKSfELwzFcXsE+otG9kszTObabyv3RAlCSbNshQkBghJHcCtldc07+yBqk9yLSwyR514rWwHzbckSBSAT0J4OQRkEEgF27giubaWC4iSWGVDG8bqGVlIwQQeoI7V4m1tffDfxTZ2UUxksZiIdImuX+SaLknTpZT911PzQu3HVScZA9R/4TXwr/ANDLof8A4Hxf/FVna7rngXX9KudN1nWvD95YTrtkilvoiD7j5sgjqCOQeRQBxer6W08s/i7wTHcXFrO7DWNE27ZfOXhnRD92df4k/jHI5wTzUniSwurS/wBU03UZTFprRySxhCNq5wyuhG4Hr1AxgYp/nXPhvxBGdF8W6TqNpI6hNSXVLcXKIowI7uJ5FS5QDgOCJAM4PAB19XtvCHji2u28S32kaDrhQRS6hpmsQGO7GBjI3ZdeB8siAjGAe9eVjcqpYmftVpL8zuw2NnRXK9Yj/CNrBqen+KPCepx3cAlml1GAJIVZ4JucrtIJIcNlTx8wB7isHxd4di1Xw3HY2tjqD6zomnq9s8/lxRx5c7oyMnLMgztORwnOSaqazPrGk39le6X4g8Ia1eWLf6NeQanDayOhxvjniZ9hRgAPlYEEAjFdxF4k8LXuh3F3rF7ZaLPIgF3EuqwSuwAxhWhkZmH5E4GRxU06VenFc616/wBb69RTnByvF6M4HTPDuozXFu66JJeTHNxI89+VPlsP9V8rZ8whQvPy4Xoe3od3eaN4MlS+1vUpYzKpis7NZHkynGFSIZLMMYJ6D2zWDq3jyG6097/wN4f+3SMzONUvI/JhDAFdy7sSSnHygAAc4z2rKtf9ESO8WY3mu6gvzXl+Nskh2FtmBwijBOxeBjHJ5pTu1723Y6qFCdbW2nf/ACF1fWtR8b+L7KQaRbWOnaVbPLFZa3Dva883925dVPyKAOOuDzg54e6aJAJI7LUtV8Oz+X5qrcMNRsCF4Kgsdyj/AIEg6fSsfXrG6mkghu9Uf7RcFFZkCpFbxZG/APLsxwoB655HFZXimxtI7S/+3eYroYbaK2373MRdiZiT0LBWG1eBxnrirhUcrQsrf1/W5vUwvsU3FtW63/QjsNbuNRivQJre9u7cA2ojmlzcszbCI1cZJGTkLkgZ+Za6aWS9inEd1rGs3GpK3+kpoHiKb7PbLgjlNhjj5GNgz+GK5bWLK7tLjRvD+mX88dtavGHuAqlraSYggSnpydxx1w3PQVc0bVL+bwwiotoraRlLrTmgMKTImAcMvBPOSoAByPWqj7l5R3/QxdCVWaVV3Wn32NOw1uwubCS4vPFHjqylQASRvew3Kgn+6WgLMvQ8gDntVy2ujrEMk2h+NNT1MIm6RXsNOnf2UK8QIPHfAPHNWdQtzJpdy+spbvaRRlo47ZTvjOAQ6ucEMPQYHPem7dT07WoY7KxttQtRbq07QwpFOGH3dzbgGzyfugfSiOJm763Zu8upx0d7CaJqN/rdu8tr4vbII3reeGrQtgjgt5ci+/THIIIBBFRPqep+XPHJrmkyMlwbYxzeG3WTfgEgCGc8AEHcOx/CsbUbeYeNbGHwsS2uX4Pm6crbxbZ+Z3kxx5RP3lJB3HcvOQfRND+GfiWXzhrWtWGnxySmSQ6XCZJpM9jJIMLgbQCFJ4HStkpz1ilYwk6NH3ZykpLs/uZzh1PVJri0sTdeCri4vWMEVstlqUcrdQfkV2YLwckgAetJf22qeH5tQivbbwZ500UOmzCPV71JSj52QITG2xnAJKg7iOfQ1r6zr2geCLJv+EWtpnuL92tf7TB8+81CUceXAWBMhDEAuR5a9gxwtbnw4+H15DqI8Q+MYLT+0VJex06E747Atgu7Mf8AWTsQN0hyfl4OMAdMIJatK559WvKpom7ebuVfDVj4w8M3ep3ll4D0m5vNSkEs9wuvlSQBhYwGg+VVHAUYAHFdD4y1bWz8IPFOo31jNoOqw6ddPGkV4JXjKxkq6yJjB78ciu/rO8R6kujeH9S1R/K2WVtJct5rMqYRSx3FVZgMDsrH0B6Voc54ovifxN4Mhc3VxHpWmX8U15ZHxLcvfSbooYf3AdZiQ0rs7KDI5AQ4Uk4FvXviZrwuNTtodQ0fS5oFhmVBbpdNbR+bCJDcMLgGMhXbIeJPZiRmvQdT+Ivh7TpNRhmmu5LmwjmeWKKymYM0Sb5I0coEZwvO0NnHJwOams/H/h+5uLK3E95DPd+WES4sLiLy2kYrGshZAI2cqQocjdxtyCMgHnd58V9bt9ev7KBNEuoLa1eSOTzIojdBbQzC5iU3JkeNmHCLGw25Pmkg1o6v4w1vRtVm+23Ok273FvprSX0yz/ZLFJ3vMtJGZtpx5KJvBj3FxuOAqjqT8TvCYsbe8GoXLWtxEbiORdPuSDEFVjLxHxGN6guflU5BIIIFyTx54fjW7c3F40VtN9naWPT7l45JfM8vy4mEZEr78rtQscg8cGgDE8CeLNe8T6pDHIum29nFp9veTssMjNOZJruIGLL4VGFujqTuIDY5zlfQ65l/HXh+K8trWe6uIJpxGcT2U8SxGQkIsrMgETMQQFkKk9hyKbpXj7w3qrxpZX8heWSKOMSWs0Rk83d5bLvQbkbY2HGVOOtAHUUVzdn420K+v7eysbi5uriYZAgsZ5FjHmPHmRlQrGC0bgFyoO0kcV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHGXPhnwtN8Qbm9v7aO91++sk2LNAJPs0MW5S0b7cxFvNIOWG7bx901Q/wCFV6a2nSWc2rancqYYbWN7uK0uPKt4t2yFVkgZCuXJLMpc4HzUa8k//CVeKbOGW7iv9S0WD7A9oyLOwjaYOsRdlXcpkVuWX/WDkdRyg034gW+i3ENvp2rGa6s3t4tuq5a3kEwYSv5t1IVLISBskkxgDjPABvwfDrw54g0u5toNV1O50+N47WSGZYZVFzabYfMIliJdwIypDbo2yTtPBG1ZfDnSbTQtV0qOa5FvqWl/2TMYooINsW64bciRRqivm6k5C4OFOM5J4Kbwt4zhu9c/sODV7CWa61Kdpm1RBb3UcspaJYYxI3lyYOfMKIQepPbT1mw8Vx2M8fhrSPE0MV3YNbxxXesxyy2s4lDeazvcucFSQCrMRjBAFAHR3Hwy0u4kvBNqOrNaTG6aK08yPyrV7lt0zx/JuySWPzMwG5sAZrs9QsrXUbSS11C2gurWTG+GeMOjYORlSCDyAfwrxXWfC/im0stYs9B0nWxNc6pcXH2xdak2mNzI0bRIL2IjBYB92OSp2yY43bPw/wCMGuINSuLvUU1NJLNdjagTb7PsirOWhD+Wf3u4/dJyMr6kA7UeCvC3fw1of/gBF/8AE0f8IV4V/wChZ0T/AMAIv/ia8m0Xw98QobOJdZbxDeQC5ga/tLe/WCW5UJMHaCc3rsAZGhYrmBSqcKCWFa9hpvxAtF0+1uotSujPJpLy3K6jGVtY4rjdcJJlwzMYtoYopD85PYgHa6n4e8E6X9lN/wCH9EhW5nS1iY6bGVMjnCqSEwuTwCcDJA6kVkeM/hra6haK/hePRtIvY+VSTR7WaCbvhw0ZcemVYYz0Ncq1lrlj4a1vT9ch1N5dSurODTpdRu/MnnnMxJxGtxNGgQAOWTyxgH5AEBr26gD531AXXhq4DeLvB2h2WwkG6h0mK40uZRjktHH50Bxnlt44zjHTprHUvh1qlhKup+G9Isbdy0LXltBDNbA+11ACIzzkFihFewMoYEMMqRgg964PXvhX4cvpWvNIjm8PatnK3+kP9ncc5IKj5WB75FAHCy/DaWKeLWfAeq2uv6acyrZ3V4W56ZilXKk9hvBxjls81zcQuNF1CQ+JdG1jTUt3ZrTz4GmihDj5wJY8qec4yeBXY3Pw+8V6Tc291ZxeHPED2j747h0k02+cd18yEhCfdhz3o0/xB4x8OXM0mseHvFz2srkpFEbfVliyc/KybJAO3zFqwnhoT1O6jj6tJrrbucFq3iXTJIvtI1DTDbW06S/ZBPie5Cnrx93nBC4Occ4zUuu6Zqfii5tdT0jTdTl0vTnRDPBasJbjzWAYxBhkhE3HI4ywxXW6j8Uba2kLXKiz1BHy/wDaPhi4RwOo+7ITkcc1XT44RKUkl1ixeHdgiLQ7rc3spaQDP1qIYWMdTStmdSrFxtuUrTwbrd3eXEkHhK7n+17ZZLnVbyOAM/q6ISev+zmul0b4PT3upXWo+LNQjjmlhSNINJaRPLZfuyGVjlm25UjaAQec4GG2PxR1C6TzIbLxFfRkkB7PwtIAPbJmIzWKuo+NtcVkht/iRKV4G+Ox0kc+5Qk/0rSFCMXcwq4yrV029Dtb34S2t3FNFJ4p8Si2lUq8fnQkbfTJizis288B+B9KZU8SeKL+5aQBBFe6uIi+Onyx7CxAOO/Wsubwz41142y3PhXTLZIj97XtduL8n32xsFP0PFadr8KNauJ2mvvE8OjggIsHhywS0CLj5gJTmQ556nj9K05IroY+2qPeTLkfi3wh4Os2XQtKjsonwv2i4QWEcuB1Mk2Hlx6qHNc3d674q8e+Tb6Bpr3tu2JGu7+CSz0kDkgqp/fXHTHPy5AJSvRtE+GXhDR7o3VvosE96xy11es1zKT/AHt0hOD9MV1+w+ZuDHbtxt7fWqstkZt3PEfh/wCFbq81ODVWW+m1ONlW41i9iEZAVmUwQwkDyYwB/Ac/Ng46D2qzgNvCIzNJKB0Z+Tj0z3qVUVRhQBznj1p1AgrP8Q6VBr2ganpF28qW2oWstpK0RAdUkQqSpIIzgnGQa0KxfG8Go3XgvX7fQzKurTafcR2Zik8txMY2CbXyNp3YwcjHXIoAoX/gfTL5ZVuJbsrLPc3DAOoyZ4Wicfd6bWOO+e56VkRfCzSV1+w1q4vru81K18rM91a2UrzeUxMeWMGUIGFzEUOFB+981c34s8L+M4TcWmgXesTaQL8Sqp1B5bhozbIuVdrmF9olDnaZVGTwpHFaFv4d8Wppeo6nLe6vc67aT2k9jbyXwhiulS1tRNG8SSGJTJIk6kMSFY7lODuYA3L34b6bcaRpWnQalq1nHYaZ/Y5kt5Iw9xa7UUxybkI52D5lCsOcEVXm+FulyXWqzi/u0bUI/JkUWliUWPeG2lDbkSfdVQ0odgBwQSSeYl8O+P4vEmiSvqOpS2oS3kne2l8xYpjKz3Cuj3USlDu2jKTYQYUKQM+z0AebxfB7w3FqFjeBppJbaOKNvPt7WYyiMkqdzwlozzj90Y8YGMYGLVv8MLCCCMLrWttdW628dndu8LSWccBYxpH+62kfOwJdWJ7k4Fd9RQBwdr8MdMgudDl/tHUZRpD+bCJEtizuZWlJaXyfNALNyquqkAAg5Oe8oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8y1PxVqehfEDW82wvdHDaXbuHvCjwNPI0YMUW0hySwLDcpwvGTxUVn8U7q5WxZdAiI1NYpdPC3+5nje4WHMv7vEbAup2gt3Gcg131x4d0S51mLV7nR9Nl1aLAjvZLVGnTHTEhG4Yye9NtvDehWlxPPa6LpkM88qzzSR2satJIp3K7EDJYHkE8g80Aea+JPiFqdpqFnf3enxWul6Vd3iXa22oNJJcyQWE0kkYj8tQYw3RmIJKqdgyMa+kfETV9TSzhTwrJBf3dy1vCt1LPbQOBAZd4eW3VyBtKnEfB6Fq7R/Dehvq0mqPo2mNqcgKvdm1jMzAqVwXxuPykr16Eim6T4Z0HR9v9kaJpdhtkMo+y2kcWHKlS3ygc7SRn0OKAOe8e+OZvDF3NFbaZFepaadJql40t4ICsCOFIjGxvMfk/Kdo6DdkiqXg3UdSh0/xlr2qxtM8N3dCGMajLKpSBnAQRMgSHhQMqCWzluQBXaatoWkaxLbSavpdhfyWrb4HurdJTC3HKFgdp4HI9BVuG0t4I5I4LeKOOR2kdUQAOzHLMQOpJJJPegDzfVvG8t9qulQ2sb2629zZ3Evl3BImWa0uJPLYADgbF65zwcDFRx/FDUBp6vdaFZwahPBZ3drai+nnNxFcrMVAEVs7+Yv2dyVCEY53cGu50/wr4e02Mx6doOk2iFxJtgs44xuAYBsAdcO4z/tH1NOvvDGgahbrb3+h6XcwKkcYjmtI3ULHu8tcEYwu99o7bmx1NAB4Q1tPEvhbStaihaBL+2S4ETHJTcAcZ749a16hsrS3sbSK1soIra1hUJHDCgREUdAqjgD2FTUAFFFFABRRRigAooooAKKKKAA80UAYooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmvEeuarZ6/pmkaHpljfXN5a3N2zXl89skaQvCpAKxSFiTOOw+6awIPHOrT6sNLgTwLJqZJAtE8VOZiRyfkFpu7elbGrBm+J+gBG2MdE1MBsZwfPsOcVwvwYjbw94R03wp4k8OarJrlrqMrSSnT3lt3cys63QuCPLwARzu3ccAnFAHo3hLW77V31m31WwtrG90y9FnIltdNcRvmCGYMGaOM9JgMbeo6mugrlfBv/Ix+O/8AsNR/+m6zrkv2lfPsPhhqWtabqGqWGpWZgWGWyv57cAPPGrZVHCtwSMsDjPGKAPV6K8nvdf8AEOjfFG08F+GY7CTSINLTVrufVZ7u6uvKNyUlEblnZ22/dU9++MCuDHx81srq72cWlX1vDpU19aztaG3IljlCFZIluZWAwc4YxtyDjHUA+lKK8Kufit4ntF8UWsieG2vdOj0+a1mnk+xRMtym9lYSzBWZQDgeYm7HbpVXU/jPr2m+G9H19LK31HS9SF1ZxsNOe3kF6oPkLgTyq0bkYyrHOCQR0oA9/orwjxB8VvF+i+LBol1pmiRT20doZvtM8Vql4ZFBlMEktymApJUALKSR8xXiiD4neN5vDviDWxB4QisLPUZdNtftNy1u7SJKBlvNkWM/u9xxvUkjsOKAPd6K+etU+NfiBNH0SfTLWxI1BbkjUNQtFtLYyRkhYhvuxGM4zvEzZB+VScivQfE3jXVbD4U2PiOzi0SHVrqOAmO71CEWys+C2yUyKknGSoEgz60AeiUV89ap8a/ECaPok+mWtiRqC3JGoahaLaWxkjJCxDfdiMZxneJmyD8qk5FdH4f+JWr614ki02/vfDfhrNvZSQpen7UdSeZAWFtIk6IyhjsBXfkkfSgD2KivmnwD4x1yPR/DNvqurLqmoP4pawuIHnuEubZSZjiTE/zA7BtWRdoAIw3UaUHxq8RvbSTfYtJlnbTdTvJrCOKQTaO9srGNbo7/AJg5UD7sZ54oA+hKK8s+GPj3W/EPigaVrcWmlJtCtNaiks4XiKecBujYM77sE8EY6dKx7/4qa9D44n0mK000eXrsekppLROb6S3Zc/bQ3mBfL7/cxjqwoA9rorxr9nS1u5vD/ijVriTT31W+1a6RrsWjCRnV2A8xjIS6AkbUyNoyMnOa4T4XeLNT8M+APDV35mh2R8R3d/Nea5qFq5SJonkKpO4lUyO7ZCksuBwAx6gH1BRXhvh/4m+N/Emt+FdP03R9GsZdR0j+1LyLUBMHVVuDG3lkH+JAGUMP4hlsdc7Qfjbr13JezatZaXp9rFbXUskP7uS7snjJ27rcXPnTDA+b93FjOc7fmoA+g6K+crb44+JJ9J1x7e00We6s77ToLaVoyscsd0G++I55QrAr1DtjPIyCK0PGHxT8beF28RRX0Hhx7nQbCyvLhIYJ3SdpphGyo5kUqAGBBKnoeKAPfaK4T4c+K9U13XvFukaylkZtEu44UmtImjWRHj3jKs7cjkZzz6CuH8O+JF8PeB/HXjK+k8vWpNdnt7iV7VroxCOURxQlBJHhVTAGXUDdknsQD3Oivl67+KHifXrrQbubVdP0S1sPET2FzeIrC0ljMQaNpglwUK4zlfNKk4Ibjn0r4yytF4v+GkscbTOmrSMqJ1ciBjgfWgD1eivnfw/8YPG+vWWovY6Z4fW9jsJ7qOyllQTwyxPkxNCLkzPlARkxxYYjgjral+NPiC68Jp4l03R7WPRr3VIrC0nnjP7iMR/vZZS0saEeZlVy8ajact0oA9+orwLw54j1DxT8TPhtqWrxafHem21aNzp91HcQuFCYYGN5AMjGV3kg96tfEz4i6r4Q8R+NptMgtpX0zTrCaEXMtw8ZMs6xtmPzQg4J5VVOepPSgD3OivDtW+K3iLSZNesbuLRvP0/XrTSjqbQyR2tvBOpYzzIZCQFxj74BLDp34v4f+Kb3RTbvYxLqr3fibW5CtrNNEtyUtxIoREk2tuIGBIJAM8c80AfUtFeHw/Fy5j8Ax6/feIfDhvZ2gRrCy09ppLCSQt+7uA10mOm3e5jUEHrkVyun/EvxL4i8TeA9QvdUsNEsxqmpabdlQ/2OV0iQp5gE+xt27CDeQGBYFgcUAfTVFeAWPxn8TzeIdRgfQ9NEVqb1W0x7iKK+UwxF4tqtOZJS5XkCBcAggtzTfg/4huPFXxobWLy+0u7uLrwnBI405CsduxnBMLZdyXUnBOR9BQB9A0V4Xr3xD1nQ/FXiS102K0Zh4i03Ska7e4mUJPCSzBDLtUg9AgUeoJ5rs/hx4x1XxB4b8T3GrxWI1DRNTvNO3WqOkU3kgEPtZmIznpuNAHoNFfPXhb43avqFpHc376RPA2iTaldNptjLK2mSo+1VmQTHcGxnGYzg9cc1Utvjj4ou7e+hsrTQ57xNV02ytppIykUkd2khy4inlCsCg5DtjJyuRigD6QorxfwRq/ieP446xpXirWtPjeTTbWVdOi83yZX8s7zah5BjDAljtJIGDjGa4b4x+I9WsviH4yt7XxBcWLWtnYy2UQ1qa2ZHJUuILZfkuHYZBRsDnNAH1DRXlV3Ktv8AG3wde6dHJDPrukXK6nDIgV/LiVHieQDo4Ziufw6V6rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBz/iHw22r6rYalbazqWk3tnDNbrJZLA2+OVomYMJopB1hQggA9fWqv/CL6v8A9D34k/78ad/8i11VFAGL4Y0AaCuos2o32pXOoXX2ue4vBEHZxFHEABEiKAFiT+H1raoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACszTdB03S9T1LULC28i61J1luirttkdRtDbM7Q2OpABPfNadFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJ4UuIJIZV3RyKUYZxkEYNPooAzvDuiaf4c0W00jRbf7Np9qpSGLez7RknqxJPJPU1o0UUAFFFFAGXFoGmxeJJ9eW3Y6tPbratO0rtiIHcEVSdqjPJ2gZPJzWpRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) In this image, the superficial layer of extensor muscles is shown. The distal extensor tendons have been removed from the dorsum of the hand without disturbing the arteries because they lie on the skeletal plane. The fascia on the posterior aspect of the forearm is thickened to form the extensor retinaculum, which is anchored on its deep aspect to the radius and ulna. (B) Here, the deep layer of extensor muscles is shown. Three outcropping muscles of the thumb* emerge between the extensor carpi radialis brevis and the extensor digitorum: abductor pollicis longus, extensor pollicis brevis, and extensor pollicis longus. The furrow from which the three muscles emerge has been opened proximally to the lateral epicondyle, exposing the supinator muscle. (C) This transverse section of the forearm shows the superficial and deep layers of muscles in the posterior compartment (pink), supplied by the radial nerve, and the anterior compartment (gold), supplied by the ulnar and median nerves.",
"    <div class=\"footnotes\">",
"     * Outcropping muscles of thumb.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34794=[""].join("\n");
var outline_f33_62_34794=null;
var title_f33_62_34795="Magnitude of effects";
var content_f33_62_34795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions for estimating magnitude of effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Size of effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Small/slight",
"       </td>",
"       <td>",
"        <strong>",
"         Pain scales:",
"        </strong>",
"        Mean 5-10 mm improvement on a 100 mm visual analogue scale (VAS), or equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Back-specific functional status:",
"        </strong>",
"        Mean 5-10 mm improvement on the Oswestry Disability Index (ODI), 1-2 points on the Roland-Morris Disability Questionnaire (RDQ), or equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         All outcomes:",
"        </strong>",
"        Standardized mean difference (SMD) 0.2 to 0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Moderate",
"       </td>",
"       <td>",
"        <strong>",
"         Pain scales:",
"        </strong>",
"        Mean 10-20 mm improvement on a 100 mm VAS, or equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Back-specific functional status:",
"        </strong>",
"        Mean 10-20 mm improvement on the ODI, 2-5 points on the RDQ, or equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         All outcomes:",
"        </strong>",
"        SMD 0.5 to 0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Large/substantial",
"       </td>",
"       <td>",
"        <strong>",
"         Pain scales:",
"        </strong>",
"        Mean &gt;20 mm improvement on a 100 mm VAS, or equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Back-specific functional status:",
"        </strong>",
"        Mean &gt;20 mm improvement on the ODI, &gt;5 points on the RDQ, or equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         All outcomes:",
"        </strong>",
"        SMD &gt;0.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34795=[""].join("\n");
var outline_f33_62_34795=null;
var title_f33_62_34796="Sources and effects of fat";
var content_f33_62_34796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources and main effects of dietary fat",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of fat",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chief food sources",
"       </td>",
"       <td class=\"subtitle1\">",
"        Leading food contributors in diets of US adults*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolic effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects on disease prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TFA, from partially hydrogenated vegetable oils",
"       </td>",
"       <td>",
"        Stick and full fat margarine; commercial baked goods; deep fried foods",
"       </td>",
"       <td>",
"        Fast food; margarines; baked goods (sweet rolls, cookies, donuts)",
"       </td>",
"       <td>",
"        Raise LDL- cholesterol. Lower HDL-cholesterol. Raise Lp(a) levels. Interfere with PUFA metabolism.",
"       </td>",
"       <td>",
"        Raise rates of coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SFA",
"       </td>",
"       <td>",
"        Dairy foods; meat; some plant oils (coconut, palm)",
"       </td>",
"       <td>",
"        Dairy foods, especially cheese, milk, ice cream; Meat, especially beef, chicken, pork",
"       </td>",
"       <td>",
"        Raise HDL-C and LDL- C levels; may promote thrombosis",
"       </td>",
"       <td>",
"        Raise rates of coronary heart disease; may raise risk of prostate, colon cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MUFA",
"       </td>",
"       <td>",
"        Vegetable sources (canola, olive oil); also from meat, dairy, partially hydrogenated oils",
"       </td>",
"       <td>",
"        Beef; margarines; chicken; olive oil",
"       </td>",
"       <td>",
"        Lower LDL-C levels slightly. Raise HDL-C levels. May interfere with oxidation processes.",
"       </td>",
"       <td>",
"        Probably lower rates of coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PUFA; n-3",
"       </td>",
"       <td>",
"        <p>",
"         For parent alpha-linoleic acid (18:3), an essential FA - canola, soybean, flaxseed, and walnut oil, wheat germ, vegetables of cabbage family",
"        </p>",
"        <p>",
"         For longer chain n-3 FA -seafood, especially fatty fish",
"        </p>",
"       </td>",
"       <td>",
"        Alpha-linoleic acid (18:3)-mayonnaise, salad dressing, margarines, beef; longer chain n-3 - tuna, other dark fish, shrimp",
"       </td>",
"       <td>",
"        Is metabolized to longer chain n-3; may decrease thrombosis; important for brain, retinal development; may decrease thrombosis",
"       </td>",
"       <td>",
"        Increased ratio of n-3:n-6 may decrease rates of coronary heart disease; n-3 may increase birth weight, probably prevent sudden cardiac death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PUFA; n-6",
"       </td>",
"       <td>",
"        Parent linoleic acid (18:2), an essential FA - many vegetable sources",
"       </td>",
"       <td>",
"        Mayonnaise; margarines; salad dressing; nuts; chicken; peanut butter",
"       </td>",
"       <td>",
"        Arachidonic acid, a metabolite, important in inflammation",
"       </td>",
"       <td>",
"        Probably reduces rates of coronary heart disease, increased amounts may promote carcinogenesis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Leading food contributors combines the fatty acid content of the food with the frequency with which individuals eat that food.",
"    <div class=\"footnotes\">",
"     TFA: trans fatty acids; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.",
"     <br>",
"      * Data from participants in the ongoing Nurses' Health Study (women) and Health Professionals' Follow-up Study (men).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34796=[""].join("\n");
var outline_f33_62_34796=null;
var title_f33_62_34797="Docetaxel and prednisone for prostate cancer";
var content_f33_62_34797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Docetaxel and prednisone for metastatic hormone-refractory prostate cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Docetaxel",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV*",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline and administer over one hour.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prednisone",
"        </strong>",
"       </td>",
"       <td>",
"        5 mg orally",
"       </td>",
"       <td>",
"        Twice daily.",
"       </td>",
"       <td>",
"        Days 1 to 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW (10 to 30 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reaction:",
"        </strong>",
"        Premedicate with dexamethasone prior to docetaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia approximately 3 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential at least every three weeks during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Renal and liver function testing at least every three weeks during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurologic function and gastrointestinal toxicities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Docetaxel should only be administered if the absolute neutrophil count is &gt;1500 cells/microL. Reduce docetaxel to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for subsequent cycles for severe prolonged neutropenia (&lt;500 cells/microL lasting seven days or more), febrile neutropenia, or an infection with life-threatening consequences",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cutaneous, mucosal, and neurologic toxicity:",
"        </strong>",
"        For severe or cumulative cutaneous reactions (erythema, desquamation), grade 3 or 4 stomatitis or &gt;grade 2 neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        <sup>",
"         [1]",
"        </sup>",
"        . Discontinue docetaxel if toxicity persists at the lower dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, docetaxel dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; ULN: upper limit of normal; CBC: complete blood count.",
"     <br/>",
"     * Some clinicians use a dose of 70 to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to minimize toxicity.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Tannock IF, et al. N Engl J Med 2004; 351:1502.",
"      </li>",
"      <li>",
"       Taxotere (docetaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 13, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34797=[""].join("\n");
var outline_f33_62_34797=null;
var title_f33_62_34798="Incidence prostate cancer";
var content_f33_62_34798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Incidence of prostate cancer: International comparisons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 475px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Netherlands Cancer Registry. Available online at www.ikcnet.nl/index.php (Accessed on March 6, 2007).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34798=[""].join("\n");
var outline_f33_62_34798=null;
var title_f33_62_34799="Lumbar radiograph in AS";
var content_f33_62_34799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Lumbar vertebrae in ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiographs of lumbar vertebrae showing progressive disease in ankylosing spondylitis. Radiograph from 1940 (left panel) reveals \"shiny coiners\" (arrows) at anterior T11 and L2 vertebral bodies, an early sign of ankylosing spondylitis. A comparison of radiographs from 1940 and 1950 (right panel) also reveals progressive squaring of lumbar vertebrae. The 1950 radiograph demonstrates early development of a \"bamboo\" spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Robbins, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_62_34799=[""].join("\n");
var outline_f33_62_34799=null;
